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Abstract 
 The present thesis is mainly dedicated to the study of the synthesis of quinolines, 
pyrolo[2,3-b]indoles and 1H-pyrimido[4,5-b]indole-2,4(3H,9H)-diones via palladium-
catalyzed cross-coupling reactions. This includes arylation of quinolines via Suzuki-
Miyaura and alkynylation of 4-trifluoromethylquinolines via Sonogashira reaction. 
Consequent synthesis of a wide range of fused pyridines and their further modifications 
were successfully performed. A number of pyrolo[2,3-b]indoles and  
pyrimido[4,5-b]indole-2,4(3H,9H)-diones were synthesized with the usage of 
Buchwald-Hartwig reaction. Certain compounds showed significant activity as alkaline 
phosphatase inhibitors. 
 
Kurzbeschreibung 
 Die vorliegende Arbeit beschäftigt sich mit der Synthese von Chinolinen, 
Pyrolo[2,3-b]indolen und 1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dionen durch 
Palladium-katalysierte Kreuzkupplungsreaktionen. Sie beinhaltet Arylierungen von 
Chinolinen mittels Suzuki-Miyaura Reaktion und Alkinylierung von  
4-Trifluoromethylchinolinen mittels Sonogashira Reaktion. Die Synthese eines breiten 
Spektrums an kondensierten Pyridinen und deren weiteren Modifikationen wurde 
erfolgreich durchgeführt. Außerdem wurden verschiedene Pyrolo[2,3-b]indole und 
Pyrimido[4,5-b]indole-2,4(3H,9H)-dione durch Buchwald-Hartwig Reaktion 
hergestellt. Einige der hergestellten Verbindungen zeigten eine signifikante Aktivität 
als Inhibitoren der alkalischen Phosphatase. 
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Introduction 
 
 
1.1 Role of palladium in cross-coupling reactions 
 
Nowadays chemistry is one of the most intensive and industrially extensive 
nature sciences spanning countless applications in the syntheses of natural products, 
polymers, agrochemicals, and pharmaceuticals. The number of new compounds every 
year extends in exponential growth. Organic synthesis with its long and outstanding 
history plays an important and influential role and one of the high developing research 
fields among them now is the chemistry of transition metals. Palladium is one of the 
most widely used precious metal in organic synthesis and especially in cross-couplings, 
which are based mostly on palladium, used as effective tools in the construction of a 
variety of complex molecules. 
There is an impressive list of a chemical transformation that can be conducted by 
using transition metal catalysis specifically that features this metal. Among them are a 
number of well-known name reactions, including the Negishi, Suzuki, Stille, 
Sonogashira, and Heck cross-couplings (Table 1.1). More importantly, palladium is an 
integral part of numerous hydrogenation and carbonylation reactions, the formation of 
carbon-carbon bonds in the synthesis of natural products, pharmaceuticals, and other 
biologically important compounds. 
Main advantages of palladium-based methods often proceed under mild 
conditions affording excellent stereo-, regio-, and chemoselectivity of reactions and 
exceptionally high yields. This influence of palladium-catalyzed reactions was 
recognized by scientific world in 2010 by awarding the Nobel Prize to Richard Heck, 
Akira Suzuki, and Ei-ichi Negishi.[1] 
 There is a wide range of methods available to construct aromatic heterocycles. 
Nevertheless, many of these rely upon relatively involved multistep processes, 
especially for the assembly of highly substituted products. In addition, these can 
sometimes suffer from harsh reaction conditions, or display limited product diversity.  
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Table 1.1 Short historical overview of palladium-catalyzed reactions. 
 
 
Reaction Reagent Year of discovery[2–13] 
Kumada R'-MgX 1972 
Heck 
 
1972 
Sonogashira 
 
1975 
Negishi R'-ZnX 1977 
Stille R'-SiR3'' 1978 
Suzuki-Miyaura R'-B(OH)2 1979 
Hyiama R'-SiR3'' 1988 
Buchwald-Hartwig Amination R'-NH2 
1994 (first examples in 
1983 by Migita  
et al.) 
 
 The variety of reactions that can be catalyzed together with the range of 
functional groups tolerated and mild reaction conditions made palladium-catalyzed 
cross-coupling reaction an ultimate tool in constructing complicated organic molecules. 
There are two main advantages of palladium in C–C bond-forming reactions: 
 ability in the transmetallation reaction of many types of organometallic reagents; 
 high activity in addition reactions. 
 Transition metal-catalyzed reactions proceed through multiple elementary steps 
and their mechanisms are often complicated. A simplified mechanism for these 
transformations (shown below Figure 1) typically initiates with oxidative addition of 
the organic halide (or pseudohalide) to a Pd(0) complex to afford intermediate I. The 
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organopalladium halide complex I can then undergo transmetalation with the main-
group coupling partner (M = Mg, Zn, Si, B, etc.) to afford the diorganopalladium 
species II. Carbon-carbon bond-forming reductive elimination from II affords the 
desired cross-coupling product III and regenerates the Pd catalyst. Unfortunately, 
many challenging reductive elimination processes limit the scope of coupling partners 
that can be used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Simplified reaction mechanism of the cross-coupling reaction. 
 
1.2 Suzuki-Miyaura coupling reaction 
 
 There are few classical cross-coupling reactions that have played a crucial role 
in the constructing novel chemical substances and became widely and fruitfully used 
by organic chemists: Suzuki-Miyaura reaction and Sonogashira coupling.  
 The first reaction uses organoboron compounds and organic halides under 
palladium catalysis and was developed by Suzuki and Miyaura at Hokkaido University 
in 1979 (Scheme 1.2).[8] Nowadays, not only aromatic halides act as a coupling partner 
in this coupling, but a various aryl pseudohalides can cross-couple readily with 
organoboron reagents, such as arylsulfonyl chlorides,[14] aryldiazonium 
tetrafluoroborates,[15] aryltrimethylammonium salts,[16] and phenolic derivatives 
(ethers,[17] carbamates[18][19] and carboxylates[20]).  
I
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X
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R
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Oxidative additionReductive elimination
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III
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Recently, a variety of organoboron reagents, e.g., trifluoroborates,[21] 
trialkoxyborates,[22] aryltrihydroxyborates,[23] has been developed. Low toxicity and 
stability toward water and air make them one of the best coupling agents to afford  
excellent yields of products. 
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B(OH)2(OR)
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OH
OHR2
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(II) (II)
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Scheme 1.2 Possible reaction mechanism of Suzuki–Miyaura reaction. 
 
However, with the development of an effective and powerful catalyst for the 
Suzuki–Miyaura cross-coupling reactions of less reactive aryl chlorides and 
organoboronic acids are no longer challenging. Nowadays, the current focus in the 
cross-coupling of aryl chlorides has switched to: 
 
 reduce the amount of catalyst loadings,  
 conduct reactions in environmentally benign conditions, 
 further expanding the scope of substrates. 
 
Although the Suzuki–Miyaura cross-coupling reaction is used predominantly for 
the syntheses of various indoles, quinolines, imidazoles, and pyridines, a number of 
particular challenges remain that significantly limit the scope of these reactions. 
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 Basically, coordination of heteroatoms from the heterocycles to the metal 
catalyst may inhibit the catalytic cycle. Moreover, heteroaromatic boronic acids 
generally have poor reactivity and are not stable. 
 As a solution to these problems, chemists have tried to develop more effective 
ligands to accelerate these coupling reactions so as to minimize decomposition of 
boronic acids as a competitive process. 
 
1.3 Sonogashira coupling reaction 
 
First reported reaction on the cross-coupling reactions of acetylene or the 
terminal alkynes with aryl or alkenyl halides in the presence of palladium catalysts and 
monovalent copper salts was made by Sonogashira and Hagihara in 1975. Nowadays, 
this reaction is accepted as the most practical method for alkynylation of various 
organic halides. They demonstrated that the reactions improved the yields of the 
products under milder conditions by using the monovalent copper salts as co-catalysts 
(Scheme1.3).  
 
 
Scheme 1.3 Possible reaction mechanism of Sonogashira reaction. 
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Most of the reported work on the Sonogashira cross-couplings relies on the use 
standard palladium catalysts, such as Pd(PPh3)4 and Pd(PPh3)2Cl2. In the original 
paper, the amine base functioned not only as a reactant but also the solvent.  
Aromatic iodides are the most commonly used organohalides under the 
Sonogashira conditions. On the contrary, unactivated aryl bromides typically require 
elevated temperatures.[24] 
 
1.2 Tasks and motivation  
 
The group of Prof. Langer has made great efforts in chemistry of  
Suzuki-Miyaura reaction and therefore I focus on further investigation and 
development of palladium-catalyzed reactions of arylboronic acids with numerous 
heterocyclic substrates. 
Due to the exceptional usefulness of cross-coupling reactions, my scientific goal 
was to develop and implement milder and more versatile reaction conditions in design 
and synthesis of new heterocycles, which are potentially interesting pharmacological 
active compounds. 
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2 Design and synthesis of novel 6H-chromeno[3,4-c]quinolin-6-ones 
 
2.1 Introduction  
 
2.1.1 Quinolines as major part of biologically important heterocyclic 
compounds 
 
 
 
 
Quinoline was first described by German chemist Friedlieb Ferdinand Runge in 
1834 by extracting it from coal tar.[25] Nowadays quinoline moiety is one of the most 
widely spread heterocyclic core fragment in naturally occurring compounds around us.  
A great number of quinoline derivatives are very important in medicinal 
chemistry and pharmacy because of their bioactive properties.[26] In addition, certain 
quinoline-based compounds show anticancer,[27] antimalarial,[28] antifungal[29] and 
antibiotic activity.[30] Some examples of quinoline-based compounds, which have found 
their use as pharmaceutical agents, are shown in Figure 2. 
In the heterocyclic chemistry arsenal of chemical transformations, there are 
certain successful synthetic methodologies were developed recently. Among them, we 
can surely admit transition metal-catalyzed cross-coupling reactions, which in recent 
decades have significantly expanded their application.  
Chromenoquinolines combine both quinoline and coumarin moieties which are 
known to possess significant biological and pharmacological properties like 
bacteriostatic activity, anti-inflammatory effects and selective progesterone and 
glucocorticoid receptor modulators.[31,32]  
Also, chromenoquinoline derivatives represent one such a unique class of 
hybrids found in the framework of several pharmacologically active compounds and 
natural products: santiagonamine,[33] schumanniophytine[34],[35] and goniothalines A,[36] 
contain this core structure (Figure 3).  
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Figure 2. Biologically important quinoline derivatives. 
 
Moreover, Zhang et al. showed structurally related 6H-chromeno[4,3-b]quinolin-
6-ones exhibit potent cytotoxic activity and selectivity against colon cancer cells.[27] 
Asis et al. in the recent paper showed 4-arylated quinoline carboxylate compounds 
exhibited activity against Plasmodium falciparum and others resulted moderately active 
against Trypanosoma cruzi.[37] Hu et al. found quinoline-3-carboxamide containing 
sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low 
blood-brain penetration.[38] 
In addition, Cappelli and co-workers designed novel AT1 receptor antagonists 
bearing substituted 4-phenylquinoline moieties instead of the classical biphenyl 
fragment and synthesized as the first step of an investigation devoted to the 
development of new antihypertensive agents.[39] Claassen et al. found that 3-acetyl-6- 
bromo-4-(2-fluorophenyl)-2(1H)-quinolinones rapidly activate the apoptotic cascade 
and can efficiently target cancer cells.[40] Also, in the research of Illig et al.[41] series 
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of 3,4,6-substituted 2-quinolones evaluated as potent kinase inhibitors in the treatment 
of certain types of cancer. 
 
Figure 3. Biologically important heterocyclic lactones. 
Thus, the structural features and the pharmaceutical applications of 
chromenoquinolines motivate intense research for the development of novel 
methodologies of their synthesis, including palladium catalysis. Currently one of the 
major issues is to find most suitable, convenient and straightforward methods of 
synthesis of novel quinoline compounds.  
 
2.2 Synthesis of starting materials 
 
Based on retrosynthetic analysis of desired ring systems, we envisaged the 
synthetic strategy depicted in Scheme 2.2:  
 
 
Scheme 2.2: Retrosynthetic approach to the 6H-chromeno[3,4-c]quinolin-6-ones. 
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 The synthesis includes, at first, preparation of ethyl 4-chloroquinoline-3-
carboxylates (A), the second step suggests Suzuki-Miyaura reaction with ortho-
methoxyarylboronic acid (B) and, finally, lactonization leading to target molecules (C). 
Several methods have been reported in the literature for the synthesis of 4‐substituted 
quinolines, which are modifications of well-known classic quinoline-forming reactions 
(Skraup, Rhiem, Conrad-Limpach, Friedländer, Knorr, and Combes).[42] Among them, 
the most efficient method was that the 4‐position substituent on the quinoline ring was 
introduced first after the formation of quinoline ring via metal-catalyzed 
reactions.[43][44] The key step of my approach involves substitution at 4‐position of the 
quinoline core using Suzuki-Miyaura reaction. To the best of my knowledge, the 
related strategy has previously successfully applied to the synthesis of 
thienochromenones in the group of Prof. P. Langer.[45] 
 With this concept in hand, I have started the investigation of the synthesis of 
starting compounds. 
 
 
Scheme 2.2.1: Synthesis of ethyl 4-chloroquinoline-3-carboxylates 1. 
Reaction conditions: (i) (2-ethoxymethylene)malonate, EtOH, reflux, 5 h; (ii) Ph2O, 
reflux 0.5-1 h;.(iii) POCl3, neat, 110 °C, 1-2 h. 
  
According to the literature data, ethyl 4-chloroquinoline-3-carboxylates were 
synthesized using a previously reported general route (Scheme 2.2.1). Briefly, 
substituted anilines were subjected to the reaction with (2-ethoxymethylene)malonate 
to yield the corresponding diethyl 2-((arylamino)methylene)malonates. In the next step 
prepared compounds were benzannulated via Gould−Jacobs cyclization in the diphenyl 
ether at 240 °C within 1 hour (prolonged heating caused lower yield).[46],[47] The final 
step includes chlorination with neat POCl3. In order to expand the products’ scope, six 
different 4-chloroquinoline derivatives 1 were synthesized. 
 
2.3 Synthesis of 4-arylated quinolines via Suzuki-Miyaura reaction 
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 Having access to the synthesized ethyl 4-chloroquinoline-3-carboxylates I 
studied the synthesis of desired 4-arylquinolines 2 via Suzuki-Miyaura cross-coupling 
reaction (Scheme 2.3). 
 As a source of Pd, I used Pd(PPh3)4, as the most common catalyst for such type 
of transformations. My initial trials included utilization of toluene or 1,4-dioxane as a 
solvent and potassium carbonate or potassium phosphate as a base, which is obligatory 
to use for hydrochloric acid neutralization and to activate the boronic acid. The 
mixture of 4-chloroquinoline-3-carboxylate (1), 1.2 equiv. of ortho-
methoxyarylboronic acid, 5 mol% of Pd(PPh3)4 and 2.5 equiv. of K2CO3 was heated in 
DMF up to 130 °C under argon atmosphere. After 10-12 hours, no further product 
formation was observed (according to TLC) and compounds 2 were isolated in the 
amount of 43-94 % overall yield (Table 2.3). 
 
Scheme 2.3: Synthesis of compounds 2. 
Reaction conditions: (i) 2-methoxyarylboronic acid (1.2 equiv.), Pd(PPh3)4 (5 mol%), 
K2CO3 (2.5 equiv.), DMF, 130 °C, 10 - 12 h. 
 
Table 2.3 Synthesis of compounds 2. 
2 R1 R2  R3  R4 R5 
Yield, 
(%)a) 
2a 6-H OCH3 - - - 94 
2b 6-H - - OCH3 - 89 
2c 6-H - - - OCH3 43 
2d 6-H OCH3 OCH3 - - 84 
2e 6-CH3 - - - - 82 
19 
 
2f 6-CH3 OCH3 - - - 94 
2g 6-CH3 - - OCH3 - 95 
2h 6-CH3 OCH3 OCH3 - - 55 
2i 6-CH3 - - F - 88 
2j 6,8-CH3 - - - - 60 
2k 6,8-CH3 - - OCH3 - 80 
2l 6,8-CH3 OCH3 - -  63 
2m 6,8-CH3 OCH3 OCH3 - - 75 
2n 6,8-CH3 - - F - 70 
2o 6-F - - - - 89 
2p 6-F OCH3 - - - 87 
2q 6-F - - OCH3 - 86 
2r 6-F OCH3 OCH3 - - 87 
2s 6-F  - - OCH3 54 
2t 6-F - - F - 87 
2u 6-NO2 - - OCH3 - 51 
2v 7-Cl - - - - 61 
2w 7-Cl OCH3 OCH3 - - 72 
2x 
7-Cl→7-(2,5-
OCH3C6H3-) - - OCH3 - 65
b) 
a) Yield of isolated products. 
b) Compound 2x is a product of substitution of both chlorine atoms. 
 
Among other methods, including 1H, 13C NMR, IR, mass spectrometry, the 
structure of 2h was independently confirmed by X-ray crystallographic analysis 
(Figure 4). Furthermore, the aryl substituent of the molecule twisted out to planar 
quinoline core with torsion angle of 76-78°. 
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Figure 4. ORTEP of ethyl 6-methyl-4-(2,3,4-trimethoxyphenyl)quinoline-3-
carboxylate 2h (50% probability level). 
 
In the 13C NMR spectra, signals of carbonyl group appeared at δ = 165-167 ppm. 
Expectedly, in the case of 2,6-dimethoxy substituents, product yield was lower due to 
the sterical reasons. 
 
2.4 Synthesis of 6H-chromeno[3,4-c]quinolin-6-ones 
 
The synthesis of condensed thienocoumarins by Suzuki-Miyaura 
reaction/lactonization tandem protocol was previously developed in a group of  
Prof. Dr. P. Langer. During my research, I studied next the transformation of ethyl 4-
arylquinoline-3-carboxylates 2 into lactones 3 by this method.  
The most commonly used reagent for sequential demethylation and lactonization 
boron tribromide was chosen for this approach. According to the literature data, among 
any other Lewis acid reagents – BBr3 – is more suitable for this reaction due to the 
ability to cleave ethoxy group in the quinoline core moiety.[48] ,[32] With slightly 
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modified conditions, the reaction proceeded smoothly at 0 °C within 6 hours and the 
compounds 3a-x were obtained in good to excellent yields. 
 
 
Scheme 2.4: Synthesis of compounds 3. 
Reaction conditions: (i) BBr3, CH2Cl2, 0 °C – 25 °C. 
 
6H-chromeno[3,4-c]quinolin-6-ones are mostly light yellow-colored compounds, 
moderately soluble in the mixture chloroform-methanol and partially in 
dimethylformamide (DMF) and dimethylsulfoxide (DMSO). By reason of low 
solubility in DMSO-d6, investigation of 
1H and 13C NMR measurements were 
performed at higher temperatures (100 °C, compounds 3a-e). 
 
Table 2.4. Synthesis of compounds 3. 
3 R1 R2 R3 R4  R5 
Yield, 
(%)a)  
3a 6-H OH - - - 88 
3b 6-H - - OH - 86 
3c 6-H - - - OH 43 
3d 6-H OH OH - - 90 
3e 6-CH3 - - - - 76 
3f 6-CH3 3-OH - - - 81 
3g 6-CH3 - - OH - 87 
3h 6-CH3 OH OH - - 90 
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In most cases, the end product could be isolated by simple filtration of the 
formed precipitate. All desired 6H-chromeno[3,4-c]quinolin-6-ones were obtained in 
moderate to good yields. 
 
2.5 Conclusions  
 
In conclusion, I described a facile and efficient method for the preparation of 
6H-chromeno[3,4-c]quinoline-6-ones by a two-step synthetic strategy starting from 
various ethyl 4-chloroquinoline-3-carboxylates via Suzuki-Miyaura reaction followed 
3i 6-CH3 - - F - 55 
3j 6,8-CH3 -  - - 79 
3k 6,8-CH3 OH - - - 82 
3l 6,8-CH3 - - OH - 86 
3m 6,8-CH3 OH OH - - 65 
3n 6,8-CH3 - - F - 89 
3o 6-F - - - - 87 
3p 6-F OH - - - 65 
3q 6-F - - OH - 78 
3r 6-F - - - OH 25 
3s 6-F OH OH - - 70 
3t 6-F - - F - 85 
3u 6-NO2 - - OH - 81 
3v 7-Cl - - - - 83 
3w 7-Cl OH OH - - 78 
3x 
7-(2,5- 
OHC6H3) 
- - OH - 72 
a) Yield of isolated product. 
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by lactonization reaction. Desired compounds were obtained under mild reaction 
conditions and with good yields. 
The products obtained during this study might be of pharmacological relevance.  
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3. Site-selective synthesis of ethyl 4,7-dichloroquinoline carboxylates 
 
3.1 Introduction 
 
 
As it was shown in the previous chapter, functionalized quinolines have various 
pharmacological and medical applications and are important in many biological 
processes. 
Continuing my initial study of 4-chloroquinolines, I turned my attention to 
polyhalogenated quinoline substrates. In order to study the possibility of successive 
halogen substitution in Suzuki-Miyaura reactions, I chose ethyl 4,7-dichloroquinoline-
carboxylate as a model substrate. However, the choice of conditions for a selective 
functionalization remains challenging task for research chemists (Scheme 3.1). 
This substrate attracts additional interest because some functionally-substituted 
quinolines are known to possess a biological activity.[49–52] Recently, series of 4-
arylated quinoline-3-carboxylic acids developed by Kühne et al. showed activity 
against atherosclerosis.[53] Barate et al. recently reported on the antioxidant activity of 
4-arylquinolines in Alzheimer’s treatment.[54] Chakraborti et al. have synthesized a set 
of new quinolines with antitubercular activity against Mycobacterium tuberculosis.[51]  
Furthermore, site-selective functionalization of 4,7-dichloroquinolines is 
interesting in my research due to the results by Milbank et al. as such compounds were 
found as orally active compounds with high affinity for the MPEP (allosteric modulator 
of the metabotropic glutamate receptor subtype 5) binding site.[55] In 2011, Wolkenberg 
and co-workers reported novel 3,6-diarylquinolines as therapeutics for the treatment of 
proliferative diabetic retinopathy and exudative age-related macular degeneration.[56] 
LaVoie et al. reported 6- and 7-substituted 3-hydroxyquinolin-2(1H)-ones as a useful 
scaffold for the development of endonuclease inhibitors that could block the cap-
snatching associated with influenza A replication.[57]  
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Scheme 3.1 Chemoselective and site-selective cross-coupling of organic dihalides. 
 
 Using a wide experience in constructing of a variety of heterocyclic systems 
(indoles, chromones, pyrroles, thiophenes and quinolones) via palladium-catalyzed 
reactions in the group of Prof. P. Langer,[58–61] I decided to explore reactivity of ethyl 
4,7-dichloroquinoline carboxylate (Scheme 3.1.1), which is available from the previous 
project (see Chapter 2). Functionalization of 4,7-dichloroquinolines by Suzuki 
reaction opens a simple route to polysubstituted quinolines with various functional 
groups in the aryl rings. Moreover, routes to 4,7-diarylquinolines have been less 
studied in the past. 
 Site-selective cross-coupling of organic dihalides has been based on the 
“substrate-controlled” strategy, in which the selectivity between the two halogen atoms 
is controlled by the structures of the substrates. There are three general pathways: 
 the reaction preferentially occurs at the less sterically hindered position;  
 the reaction preferentially occurs at the more deficient carbon atom; 
 the catalyst is directed by a coordination of a functional group to a specific position. 
 Computational and mechanistic studies on the factors influencing site-selectivity 
in polyhaloheteroaromatics have been reported, which conduct these factors with the 
strength of the carbon-halogen bonds and energy of molecular orbitals.[62]-[64] 
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Scheme 3.1.1. Suzuki functionalization of 4,7-dichloroquinolines. 
 
3.2 Site-selective one-pot synthesis of 4,7-diarylated quinolines  
 
 Having achieved an effective method to prepare 4-substituted o-methoxyphenyl 
derivatives, I turned my attention towards the site-selective Pd-catalyzed cross-
coupling reactions for the synthesis of 4,7-diarylsubstituted quinolines.  
 My investigations into Suzuki couplings (Scheme 3.2) revealed that chlorinated 
quinolines exhibited reactivity patterns typical of heteroaromatic halides. The use of 
Pd(OAc)2 as a palladium source for the coupling with arylboronic acids provided the 
desired 4,7-bisarylated quinolines in good yield (Table 3.2). The use of ligands known 
to activate aromatic chlorides towards oxidative addition afforded improved reactivity. 
The catalyst combination of Pd(OAc)2 and XPhos, with K3PO4 as the base, enabled the 
successful regioselective Suzuki-Miyaura reaction between chlorinated quinolines and 
both electron-rich and electron-deficient boronic acids (Table 3.2).  
 
 
 
 
 
27 
 
 
 
Scheme 3.2. One-pot synthesis of compounds 5. 
Reaction conditions: (i) arylboronic acid (1.1 equiv.), Pd(PPh3)4 (2 mol%), K2CO3   
(2.5 equiv.), DMF, 130 °C, 10 - 12 h; (ii) arylboronic acid (1.2 equiv.), Pd(OAc)2 
(2mol%), Xphos (4 mol%), K2CO3 (2.5 equiv.), DMF, 130 °C, 10-12 h. 
 
Table 3.2 Synthesis of compounds 5. 
5 R1 R2 Yield, %a) 
5a 3,5-OCH3C6H3- 4-EtOC6H4- 60 
5b C6H5- 4-t-BuC6H4- 62 
5c 4-EtC6H4- 4-CH3C6H4- 70 
5d 3-OCH3C6H4- 4-CF3C6H4- 77 
5e 4-CF3C6H4- 4-CF3OC6H4- 80 
5f 3-OCH3C6H4- 4-CH3C6H4- 88 
5g 3,5-CH3C6H3- 4-OCH3C6H4- 58 
5h C6H5- thiophen-3-yl 50 
5i C6H5- 2,3-OCH3C6H3- 82 
5j 4-CF3C6H4- 3-OCH3C6H4- 85 
5k 4-CH3C6H4- 3-thienyl- 84 
5l 4-i-PrC6H4- 4-OCH3C6H4- 85 
5m 2,3-OCH3C6H3- 4-FC6H4- 51 
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5n 3-FC6H4- 4-FC6H4- 57 
a) Yield of isolated products. 
 
 In the case of 5c, the structure was independently confirmed by X-ray single 
crystal analysis. Aryl rings in positions 4 and 7 are twisted to planar quinoline core. 
The torsion angle between 4-ethylphenyl substituent and quinoline moiety lies within 
82.94° – 84.70°. The values of angles of 7-p-tolyl fragment lie within 33.63° – 34.38°. 
 
 
 
 Figure 5. ORTEP of ethyl 4-(4-ethylphenyl)-7-p-tolylquinoline-3-carboxylate 5c 
(50 % probability level). 
 
3.3 Synthesis of bisarylated products 
 
 Having obtained results in the successful regioselective substitution of chlorine 
atoms, I focused my attention to the double-substituted quinolines. Having in hand 
effective catalyst and palladium source from initial studies, I implemented conditions 
for substitution chlorine atom at the position 7. Thus, the reaction of starting quinoline 
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1 with 2.2 equivalents of boronic acid, Pd(OAc)2 (2 mol%), Xphos (4 mol%), K2CO3 
(2.5 equiv.) in DMF gave desired product in good to excellent yields (Scheme 3.3, 
Table 3.3). 
  
 
Scheme 3.3. Synthesis of compounds 6. 
Reaction conditions: (i) arylboronic acid (2.2 equiv.), Pd(OAc)2 (2 mol%), Xphos (4 
mol%), K2CO3 (2.5 equiv.), DMF, 130 °C, 10 - 12 h; 
 
Table 3.3. Synthesis of compounds 6. 
6 R1 Yield, %a) 
6a 3,5-CH3C6H3- 95 
6b thiophen-3-yl 87 
6c 3-FC6H4- 86 
6d C6H5- 88 
6e 4-CF3C6H4- 56 
6f 4-EtC6H4- 83 
6g 4-CH3C6H4- 87 
6h 4-OCH3C6H4- 86 
6i 4-t-BuC6H4- 79 
6j 4-CF3OC6H4- 68 
a) Yield of isolated products 
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The position of halogen substitution, in this case, is driven by electronic effects 
in quinoline ring system. The halogen atom at the position 7 is less reactive towards 
nucleophilic substitution than at the position 4, which is more reactive in these 
reactions also due to its ortho location to the ester group with its π-acceptor effect. In 
the oxidative addition step Pd(0) acts as a nucleophile and will preferentially attack the 
most electron-deficient position (Figure 6). Since insertion step is considered to be the 
selectivity-determining one,[65,66] the site-selectivity of the reaction is realized through 
this mechanism. 
 
7 N
4
Cl
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4
Cl
Cl
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7 N
4
Cl
Cl
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Figure 6. Possible explanation for the site-selective reactions. 
 
Figure 7. ORTEP of ethyl 4,7-bis(4-tert-butylphenyl)quinoline-3-carboxylate 6i 
(50% probability level). 
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Furthermore, the structure of 6i was identified also by X-ray single crystal 
analysis (Figure 7). In the current framework, I observed a planar core of quinoline 
core unit. As seen from crystallographic data, the torsion angle between quinoline core 
and 4-t-butylphenyl substituent at position 4 is 79.50°–80.24° and position 7 –  
28.91°–28.93°, respectively. 
 It is important to mention, ethoxycarbonyl fragment at position 3 of quinoline 
core can be transformed to many other functionalities, which potentially gives wider 
spectra of compounds.[38]  
 Additional attempts to explore the further scope of 4- or 4,7-halogenated 
quinolines were done through N-oxide derivatives of 4-phenylquinoline. It gives 
another route for the biologically active class of compounds, namely, heterocyclic N-
oxides.[67]  
 Numerous examples of heterocyclic N-oxides have shown antimicrobial, 
antibacterial, antitumor, and other activities.[68] The C−H functionalization by 
transition metal catalysis provides an efficient method for the straightforward synthesis 
of complex molecules with a quinoline scaffold.[69–73] Moreover, by simple 
deoxygenation under mild conditions, the N-oxide moiety could be used to introduce a 
wide range of other functional groups.  
Following the similar procedure,[74] the initial N-oxide (7) was prepared by the 
reaction of ethyl 4-phenylquinoline-3-carboxylate with MCPBA in CH2Cl2 at 0 °C. 
 
 
 
Scheme 3.3.1. Synthesis of compounds 8. 
Reaction conditions: (i) bromoarene (0.5 equiv.), Pd(OAc)2 (5 mol%), PtBu2Me·HBF4 
(5 mol%), K2CO3 (2 equiv.), toluene, 110 °C, 10 h. 
 
With this positive result in hand, I set the reaction of corresponding N-oxide 
with 3-bromotoluene, Pd(OAc)2 (5 mol%), PtBu2Me·HBF4 (5 mol%), K2CO3 in toluene 
at 110 °C for 10 h to give desired product 8 in 97% yield (Scheme 3.3.1). 
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The C2-substitution pattern was confirmed by means of NMR spectroscopy. The 
absence of the typical signal of 2-H proton in reaction product at 9 ppm and increased 
number of aromatic protons clearly indicate the substitution with aryl fragment and 
successful C-H activation. Additionally, the singlet of methyl group from the m-tolyl 
functionality appears at 2.4 ppm (CDCl3) (Figures 8, 9). 
 
 
Figure 8. Observations from NMR experiments. 
 
Functionalization of position 2 of N-oxide proceeded via ortho-selective C-H 
activation that exhibited high regioselectivity.  
In research of Fagnou group catalytic process of N-oxide functionalization 
proposed to proceed through a 6-membered inner-sphere concerted metallation-
deprotonation (CMD) transition state, generating the palladium biaryl species that goes 
on to the reductive elimination step to give product and regenerate the Pd(0) catalyst. 
Notably, this pathway also did not involve precoordination of oxygen atom of the N-
oxide to palladium.[75] 
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 Figure 9. Comparison of 1H NMR spectra for 8 and 9 (aromatic region only). 
N
O
O
O
H
Typical singlet of 
H-2 proton at 9.05 
ppm. 
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3.4 Conclusions  
 
In conclusion, I have described a facile and efficient method for the site-
selective preparation of quinolines by a one-pot synthetic strategy starting from 4,7-
dichloroquinolines via Suzuki-Miyaura reaction. Desired products obtained with 
excellent regioselectivity, under mild reaction conditions, and with good yields.  
The scope and limitation of the method were studied and the structures of two 
products were unambiguously confirmed by a single-crystal X-ray diffraction. In 
addition, one example of 4-substituted N-oxide quinoline derivative was functionalized 
via palladium mediated C−H arylation. 
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4. Design and synthesis of 2-aryl-4-(trifluoromethyl)-quinolines and 
different substituted 2-(ethynyl)-4-(trifluoromethyl)-quinolines 
 
4.1 Introduction 
 
Recent years a reasonable interest has been focused towards the synthesis of 
various fluorinated quinoline compounds.  
 
 
 
 
 
Fluorine-containing molecules are of particular interest in the fields of 
biomedicine, agriculture, and material sciences.[76–78] Incorporation of a fluorine atom 
into heterocycles is known to enhance the biological activity and provide some other 
unique properties, like modulation of pKa, changing of hydrophobic interactions, 
solubility, hydrogen bonding, and lipophilicity. All these properties or their 
combinations can improve potency or selectivity of drug molecules.[79] The quinoline 
scaffold has been used for a long time as a basic structure for the search of synthetic 
antimalarial drugs, such as mefloquine. The antineoplastic drug Brequinar® and its 
analogs proved to be useful in transplantation medicine,[79] for the treatment of 
rheumatic arthritis[80] and psoriasis.[81] 
A new series of 8-trifluoromethyl quinolines were evaluated for antitubercular 
and antibacterial activity in a recent paper by Dalimba et al.[82] A series of  
4-trifluoromethylquinolinones synthesized by Higuchi et al. were evaluated in an 
androgen receptor transcriptional activation assay and can be used in endocrine 
therapies to treat muscle wasting and osteoporosis.[83,84] Bowers and colleagues 
reported series of fluoro- and trifluoromethylquinoline-based compounds as effective 
neuroprotective agents.[85] Gasparini et al. in his early work in 1998 have shown anti-
hyperalgesic activity of MPEP (synthetic mGluR5 antagonist  
2-methyl-6-(phenylethynyl)pyridine).[86,87] mGluR5 is a protein-coupled receptor, 
which plays important role in several disorders of the central nervous system such as 
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schizophrenia, depression, anxiety, Alzheimer, and Parkinson’s disease.[88–91] Recently, 
different kinds of mGluR5 – NAMs – such as ADX10059 and AFQ056 have been 
discovered and known to be effective for Fragile X syndrome, chronic digestive disease 
(GERD), and migraine.[92] Many of mGluR5 antagonists contain an alkyne subunit as a 
key structural component. Therefore, much effort has been focused on the synthesis of 
compounds bearing acetylene itself or its isostere (Figure 10).  
 
 
 
Figure 10. Examples of various quinoline-based drugs. 
 
Previously in a group of Prof. P.Langer was developed the synthesis of 4-chloro-
3-(trifluoroacetyl)coumarins, a novel fluorine-containing 1,3-dielectrophiles on the 
basis of commercially available 4-hydroxycoumarin by the reaction with a number of 
o-, m- and p-substituted anilines.[93]  
 
 
4.2 Synthesis of starting materials 
 
According to detailed analysis of literature concerning the chemistry of 
quinolines bearing trifluoromethyl group (CF3-), I focused my attention on the 
synthesis and modification of 4-CF3-substituted chloroquinolines via palladium-
catalyzed reactions.  
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Scheme 4.2. Synthetic routes to 2-substituted fluoroquionolines via (i) Suzuki-Miyaura 
and (ii) Sonogashira protocols. 
 
For this purpose, I used the already known 4-trifluoroquinoline-containing 
building block 9. The synthesis of 2-chloro-4-(trifluoromethyl)quinolines by 
subsequent reaction of ethyl trifluoroacetoacetate with anilines, using a related 
strategy, was previously reported.[94] 
 Condensation of anilines with ethyl trifluoroacetoacetate have been established 
to give the corresponding 4,4,4-trifluoro-3-oxobutane substituted anilides, known 
precursors in the synthesis of 4-(trifluoromethyl)quinolinones. Namely, 4-
fluoromethylquinolin-2-ones were obtained regioselectively in moderate to good yields 
by acid assisted intramolecular ring closure reaction of the corresponding N-aryl-3-
oxo-polyfluoroalkanamides. Heating of these compounds with phosphoryl trichloride 
easily affords desired 2-chloro-4-(trifluoromethyl)quinolines 9. In this manner 4 
differently substituted 2-chloro-4-(trifluoromethyl)quinolines were synthesized 
(Scheme 4.2.1). 
 
 
 
 
 
 
 
Scheme 4.2.1. Preparative route to compounds 9. 
Reaction conditions: (i) conc. sulfuric acid, 90 °C, 1h.; (ii) POCl3, reflux, 1.5 h. 
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4.3 Suzuki-Miyaura reaction of 2-chloro-4-(trifluoromethyl)quinolines 
 
The next step of my research was conducting cross-coupling reactions of 
obtained 2-chloro-4-(trifluoromethyl)quinolines with arylboronic acids. It was found 
that the Suzuki-Miyaura reaction of 9 with arylboronic acids (1.2 equiv.), in the 
presence of Pd(PPh3)4 (3 mol%) and K2CO3 (2.5 equiv.), in DMF, at 130 °C, for 10-12 
hours afforded 2-aryl-4-(trifluoromethyl)-quinolines 10 in 41–97% yields (Scheme 4.3, 
Table 4.3). 
 
 
 
 
 
 
Scheme 4.3: Synthesis of compounds 10. 
Reaction conditions: (i) substituted arylboronic acid (1.2 equiv.), Pd(PPh3)4 (2 mol%), 
K2CO3 (2.5 equiv.), DMF, 130 °C, 10 - 12 h. 
 
Table 4.3. Synthesis of compounds 10. 
10 R1 R2 Yield, (%)a) 
10a H 2,3-OCH3C6H3- 94 
10b H 2-OCH3-5-FC6H3- 73 
10c H 3-FC6H4- 91 
10d H 4-CF3C6H4- 41 
10e 6-CH3 2,3-OCH3C6H3- 86 
10f 6-CH3 2,3-OCH3C6H3- 95 
10g 6-CH3 2-OCH3-5-FC6H3- 97 
10h 6-CH3 C6H5- 94 
10i 6-CH3 3-FC6H3- 95 
10g 6-CH3 4-FC6H3- 94 
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10k 6-F 2-OCH3C6H3- 87 
10l 6-F 2,3-OCH3C6H3- 89 
10m 6-F 2,5-OCH3C6H3- 91 
10n 6-F 4-FC6H3- 89 
a) Yield of isolated products 
 
In the case of product 10d, the lower yield can be explained by strong electron 
withdrawing effect of the trifluoromethyl group in para-position of the arylboronic 
acid. 
The structures of all obtained compounds were characterized by 1H, 13C, 19F 
NMR spectroscopy, IR spectral data as well as MS and HRMS methods. The structure 
of 10a was independently confirmed by X-ray analysis (Figure 11). Torsion angle 
between quinoline core and aryl fragment lies within 41.97°–42.82°. 
 
Figure 11. ORTEP of compound 10a (50% probability level). 
 
4.4 Sonogashira reaction of 2-chloro-4-(trifluoromethyl)quinolines 
 
Continuing my research program dedicated to the design and synthesis of novel 
quinolines, the reaction of substituted 2-chloro-4-(trifluoromethyl)quinolines was 
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examined with a set of alkynes. I have chosen 2-chloro-4-(trifluoromethyl)quinolines as 
a key precursor due to its high reactivity of its chlorine at the position 2 towards 
nucleophiles in the presence of palladium catalyst (Scheme 4.4). Accordingly,  
2-chloro-4-(trifluoromethyl)quinoline 9 was treated with terminal alkynes (R = alkyl, 
aryl) in THF in the presence of 2 mol% Pd(PPh3)2Cl2, CuI (4 mol%), and triethylamine 
(3 equiv.) under an inert atmosphere. The reaction proceeded smoothly at room 
temperature to give 2-alkynyl-4-(trifluoromethyl)quinolines 11a-f in good to excellent 
yields (see Table 1.3).  
 
 
 
 
 
 
 
 
Scheme 4.4: Synthesis of compounds 11. 
Reaction conditions: (i) alkyne (1.2 equiv.), Pd(PPh3)2Cl2 (2 mol%), CuI (4 mol%), 
Et3N (3 equiv.), THF, 23 °C, 10 - 12 h. 
 
Table 4.4. Synthesis of compounds 11. 
11 R1 R2 Yield, (%)a) 
11a H 4-CH3C6H4- 91 
11b H 4-t-BuC6H4- 88 
11c CH3 C6H5- 90 
11d CH3 4-t-BuC6H4- 92 
11e CH3 n-Pr- 82 
11f F n-Bu- 80 
a) Yield of isolated products. 
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Figure 12. ORTEP of compound 11e (50% probability level). 
 
The structures of products were characterized by IR, 1H, 13C NMR spectra data 
as well as mass spectrometry analysis. Additionally, the structure of compound 11e 
was independently confirmed by X-ray crystal structure analysis (Figure 12). The 
distance between acetylenic carbons C12-С13 is 1.204 Å, which is in good agreement 
with theoretical value – 1.2 Å. 
 
4.5 Biological studies 
 
Nucleotide pyrophosphatase/phosphodiesterase (NPP) is a class of dimeric 
enzymes that release nucleoside 5′-monophosphates from nucleotides and their 
derivatives and catalyze the hydrolysis of pyrophosphate and phosphodiester bonds 
(ATP, cyclic nucleotides, dinucleotide polyphosphates and nucleotide-sugars). NPPs 
can also generate nucleotides that activate purinergic receptors, which are responsible 
for mediate relaxation of gut smooth muscle as a response to the release of adenosine 
triphosphate (ATP). 
There are seven known members of alkaline phosphatase (AP) superfamily, 
designated as NPP-1 to NPP-7. Interestingly, three of them – NPP1-3 – are involved in 
hydrolyzing nucleotides, NPP-6 and NPP-7 regulate break of phosphodiester bonds of 
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lysophospholipids or choline phosphodiesters. The role of NPP4 and NPP5 is yet to be 
identified.[95] 
NPP-1 is found in bladder, heart, kidney, liver, lung and thymus. Furthermore, 
NPP-1 is the first to be demonstrated to have a unique role in regulating mineralization 
and is responsible for supplying the larger amount of inorganic pyrophosphate (PPi). 
NPP-3 was detected in airway epithelium, in choroid plexus epithelial cells, 
hepatocytes, epithelial cells of the bile duct and human basophils.[96] 
Both NPP-1 and NPP-3 are mainly present in the plasma membranes. For optimal 
activity, both NPP-1and NPP-3 require alkaline pH and presence of divalent ions, like 
zinc (Zn2+) or magnesium (Mg2+).[97] 
 
 
4.5.1 Structure–activity relationship 
 
The studies were accomplished at the Center for Advanced Drug Research, 
COMSATS Institute of Information Technology, Abbottabad, Pakistan, as a part of a 
cooperation project (research group of Prof. J. Iqbal). 
2-Aryl-4-(trifluoromethyl)quinolines and differently substituted 2-(ethynyl)-4-
(trifluoromethyl)-quinoline derivatives 10a–n and 11a–f were tested for their 
inhibitory activity towards nucleotide pyrophosphatase/phosphodiesterases h-NPP-1 
and h-NPP-3. 
Compounds, which exhibited inhibition of either h-NPP-1 or h-NPP-3 activity 
over 50% in the initial screening, were further evaluated for the determination of IC50 
values. Variation of substituents on aromatic rings significantly affected the inhibitory 
potency and selectivity towards NPPs. As outlined in Table 4.5.1 fluorinated 
quinolines exhibited IC50 values in the range of 0.095 ± 0.001 to 0.62 ± 0.02 µM and 
0.041 ± 0.001 to 1.37 ± 0.11 µM for h-NPP-1 and h-NPP-3, respectively.  
Among all, 2-(2,3-dimethoxyphenyl)-6-fluoro-4-(trifluoromethyl)quinoline 10l 
was the lead candidate showing the highest inhibition of h-NPP-1 and h-NPP-3: an IC50 
value of 0.095 ± 0.001 µM, which is 90-fold more potent compared to suramin (IC50 ± 
SEM = 8.67±1.30 µM), which was used as reference standard inhibitor and with an 
IC50 value of 0.041±0.001 µM, which is almost 31-fold more potent compared to 
suramin (IC50 ± SEM = 8.67 ± 1.30 µM), respectively. 
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Table 4.5.1 Nucleotide pyrophosphatase/phosphodiesterase (h-NPP-1 and h-NPP-3) 
activity of synthesized compounds at 0.01mM. 
 
Compound 
h-NPP-1 
IC50 
a (µM) ±SEM 
(% inhibition) b 
h-NPP-3 
IC50 
a (µM) ±SEM 
(% inhibition) b 
10a 38.1% 0.29±0.01 
10b 41.8% 0.21±0.002 
10c 0.24±0.002 0.084±0.001 
10d 0.36±0.01 0.11±0.002 
10e 21.4% 1.37±0.11 
10h 0.27± 0.04 0.17±0.03 
10i 48.6% 0.18±0.01 
10j 39.2% 0.35±0.09 
10k 0.31±0.03 0.55±0.03 
10l 0.095±0.001 0.041±0.001 
10m 36.1% 0.12±0.03 
10n 0.34±0.03 0.16±0.02 
11a 0.13±0.01 0.24±0.05 
11b 0.38±0.01 0.84±0.09 
11c 0.62±0.02 0.41±0.06 
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11d 38.2% 0.24±0.01 
11e 0.44±0.01 0.23±0.03 
11f 31.4% 0.17±0.03 
Suramin 
(Positive control) 
8.67 ± 1.30 1.27 ± 0.08 
a)  IC50 is the concentration at which 50% of the enzyme activity is inhibited. 
b) The % 
inhibition of the enzyme activity using 0.1 mM of the tested compound. The inhibitory 
concentrations are expressed as mean ± SEM, all experiments were carried out in triplicate. 
 
 Among compounds 11a-f only four were active against h-NPP-1. Compound 11a 
having IC50 ± SEM = 0.13±0.01 µM was found as the most potent inhibitor with the 
highest activity. Furthermore, compound 11f showed highest selective activity against  
h-NPP-3 (inhibitory potential was found to be almost 7.5-fold higher than standard 
inhibitor – suramin (IC50 ± SEM = 1.27±0.08 µM)) and only partial inhibition against  
h-NPP-1. 
 
4.6 Conclusions  
 
I described a facile and efficient method for the preparation of 2-aryl-4-
(trifluoromethyl)quinolines and 2-(arylethynyl)-4-(trifluoromethyl)quinolines by a one-
step synthetic strategy starting from substituted 2-chloro-4-(trifluoromethyl)quinolines 
via Suzuki-Miyaura and Sonogashira protocols. Desired compounds were obtained with 
good yields. The scope and limitation of the method were extensively studied and the 
structures of two products were unambiguously confirmed by a single-crystal X-ray 
diffraction. 
The biological evaluation of a set of prepared compounds showed high 
nucleotide pyrophosphatase/phosphodiesterase (h-NPP-1 and h-NPP-3) activity. 
Compound 10l showed the highest activity against both h-NPP-1 and h-NPP-3 and is 
potential drug candidate.  
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5. Design and synthesis of novel 1,3-dialkyl-1,9-dihydro-2H-
pyrimido[4,5-b]indole-2,4(3H)-diones 
 
5.1 Introduction 
 
Indole and its various derivatives are attracting attention because of their wide 
range of biological, medicinal activities, a frequent occurrence in natural products, and 
multiple uses in organic synthesis. [107] 
Uracil with its derivatives plays an important role in the chemistry and the 
biology as the core constituents of the nucleic acids. In pharmaceutical chemistry, 1,3-
dimethyl-6-aminouracil is known as a starting compound for the synthesis of 
theophylline-like xanthines.[98] 5-Fluorouracil is a known medication used to treat 
different types of cancer.[99]  
 
Figure 13. Examples of pyrimidoindole-based chemotherapeutic agents (drugs). 
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Moreover, pyrimido[4,5-b]indoles show remarkable biological significance and 
have therefore been used as key building blocks in the construction of medicinal and 
functional materials. For instance, a wide range of medicinal materials using 
pyrimidoindole building blocks showed anti-cancer,[100–103] anti-inflammatory, 
antihypertensive[104] and neuroprotective activity[105],[106–108]. In a recent study of Yao 
et al., some pyrimidoindole derivatives were found to show agonistic effects on self-
renewal of hematopoietic stem cells.[107] Sauvageau and colleagues discovered  
9H-pyrimido[4,5-b]indol-4-amine (UM729) as new anti-leukemic drug through a cell-
based assays and promising candidate in stem cell transplantation and gene therapy.[109] 
Recently, pyrimido[4,5-b]indol-4-amines and -2,4-diamines have been found to be new 
antiasthmatics and as agents against neurodegenerative disorders.[110] ,[111] In addition, 
Saito et al. have shown 9H-pyrimido[4,5-b]indoles can act as extended purine bases to 
form unnatural nucleosides and can be used as a very effective probe for the detection 
of DNA damage[112] (Figure 13). 
The next step of my research was to combine both potential heterocyclic 
fragments of uracil and indole into pyrimido[4,5-b]indole. For this reason, the 
development of efficient synthetic methods in which both the indole and the uracil 
frameworks are combined simultaneously remains a challenging task. 
To date, a number of synthetic strategies toward pyrimido[4,5-b]indoles have 
been developed (Figure 14). In most of the synthetic routes reported the functionalized 
indoles have been used as starting materials. For example:  
 By condensations of 2-amino-3-(cyano/carboethoxy)-indoles with formic acid in presence 
of base provide desired compounds;[113,114] 
 By cascade reactions of 1-bromo-2-(2,2- dibromovinyl)benzenes with aldehydes and 
aqueous ammonia;[115] 
 By reaction of 2-ethoxy(3-benzylidene)indolenine tetrafluoroborate  with amidines or 
guanidines;[116,117] 
 By photolysis of 8-phenyltetrazolo[1,5-c]pyrimidines in trifluoroacetic acid;[118] 
photocyclization of 4-anilinotrichloropyrimidine;[119] or UV irradiation of 3-aryl-3H-
[1,2,3]triazolo[4,5-d]pyrimidines;[120] 
 By palladium-catalyzed intramolecular arylation reaction of 4-aryloxy- or 4-anilino-5-
iodopyrimidines;[121] 
 Thermolysis of 6-azidouracils;[122] 
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 By reaction of p-benzoquinone with 1,3-dimethyl-6-aminouracil.[123] 
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Figure 14. Known retrosynthetic disconnections to pyrimido[4,5-b]indoles. 
 
While those pioneering methods are generally efficient and reliable, they usually 
start from substrates that already have an indole or uracil moiety. Furthermore, some of 
those syntheses require harsh reaction conditions and toxic or explosive reagents and 
multistep processes. 
Nonetheless, interesting biological properties motivated me to find an efficient 
route to pyrimido[4,5-b]indoles. According to the aim of this project, I synthesized 
new condensed heterocycles, which are potentially interesting as pharmacologically 
active compounds. 
 
5.2 Synthesis of 6-(2-bromoarylamino)pyrimidine-2,4(1H,3H)-diones 
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This research is partially based on some previous works in Prof. Langer’s group 
with deazaalloxazines.[124] My synthetic concept includes the consequent reaction of  
6-chlorouracils with substituted 2-bromoanilines followed by an intramolecular 
cyclization of obtained anilinouraciles (Scheme 5.2).  
 
 
 
 
 
Scheme 5.2. Schematic presentation of proposed transformation. 
 
As a starting point, I synthesized 6-(2-bromoarylamino)-1,3-dialkylpyrimidine-
2,4(1H,3H)-diones 13 by reaction of corresponding 6-chloro-1,3-dialkylpyrimidine-
2,4(1H,3H)-dione 12 with anilines and n-butyl lithium (solution in hexanes) at -78 °C 
overnight according to the previous research106 (Scheme 5.2.1). Thus, obtained 
products were further cyclized to desired pyrimidoindoles 13.  
 
 
 
 
 
Scheme 5.2.1. Synthesis of compounds 13. 
Reaction conditions: (i) n-BuLi (2.2 equiv.), THF, -78 °C – 20 °C, 10 h. 
 
Table 5.2 Synthesis of compounds 12. 
13 R1 R2 Yield, %a) 
13a CH3 H 78 
13b CH3 CH3 85 
13c CH3 i-Pr 70 
13d CH3 Cl 81 
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13e CH3 F 90 
13f Et H 91 
13g Et CH3 92 
13h Et i-Pr 90 
13i Et Cl 67 
13j Et F 85 
13k n-Pr H 91 
13l n-Pr CH3 88 
13m n-Pr i-Pr 80 
13n n-Pr Cl 64 
13o n-Pr F 91 
13p n-Bu H 92 
13q n-Bu CH3 70 
13r n-Bu Cl 90 
a) Yield of isolated products. 
 
In most of the cases, no additional purification of obtained compounds was 
required. The structures of synthesized compounds were established by NMR, IR 
spectroscopy methods, and mass spectrometry. In the 1H NMR spectra of 2-
bromoarylated aminouraciles, the singlets of NH-group appear at 4.9-5.1 ppm (CDCl3). 
The proton signals of 5-CH bond of pyrimidine moiety appear at 6.1-6.5 ppm (CDCl3). 
 
5.3 Preparation of 1H-pyrimido[4,5-b]indole-2,4(3H,9H)-diones via 
intramolecular arylation reaction 
 
With these results in hand, I next studied cyclization of 6-(2-bromoarylamino)-
pyrimidine-2,4(1H,3H)-dione 13 into pyrimido[4,5-b]indoles 14. The first attempt of 
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cyclization using Pd(OAc)2 as palladium source, DBU (2.5equiv.) as a base in DMA at 
130 °C, 4-5 h gave 85 % yield product (Scheme 5.3, Table 5.3). Raising the 
temperature to 145-150 °C accelerates the conversion, and the almost full consumption 
of starting materials was already detected during first 3-4 hours of reaction (TLC 
control).  
 
 
Scheme 5.3. Synthesis of compounds 14. 
Reaction conditions: (i) Pd(OAc)2 (5 mol%), PCy3·HBF4 (10 mol%), DBU (2.5 equiv.), 
DMA, 145 °C, 3-4 h. 
 
Table 5.3. Synthesis of compounds 14. 
14 R1 R2 Yield, %a) 
14a CH3 H 78 
14b CH3 CH3 89 
14c CH3 i-Pr 88 
14d CH3 Cl 90 
14e CH3 F 90 
14f Et H 91 
14g Et CH3 92 
14h Et i-Pr 99 
14i Et Cl 89 
14j Et F 95 
14k n-Pr H 89 
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14l n-Pr CH3 87 
14m n-Pr i-Pr 93 
14n n-Pr Cl 71 
14o n-Pr F 82 
14p n-Bu H 83 
14q n-Bu CH3 87 
14r n-Bu Cl 43 
a) Yield of isolated products. 
 
The structures of products were characterized by IR, 1H, 13C NMR spectra data 
as well as MS and HRMS analysis. The structure of compound 14e was independently 
confirmed by X-ray crystal structure analysis (Figure 15). A planar core of 
pyrimido[4,5-b]indole was observed. 
 
 
 
Figure 15. ORTEP of 6-fluoro-1,3-dimethyl-1H-pyrimido[4,5-b]indole-
2,4(3H,9H)-dione 14e (50 % probability level). Crystal solvate with DMSO. 
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5.4 Conclusions 
 
In this chapter, new efficient and convenient method for the synthesis of  
1H-pyrimido[4,5-b]indole-2,4(3H,9H)-diones by intramolecular arylation reaction of  
1,3-dialkyl-6-((2-bromo)arylamino)pyrimidine-2,4(1H,3H)-diones was developed.  
Desired products obtained with good yields and might be of pharmacological 
interest. 
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6. Design and synthesis of novel N-substituted 1,8-dihydro-
pyrrolo[2,3-b]indoles 
 
6.1 Introduction 
 
Indole is well known for its extensive presence in natural products, especially 
alkaloids. Many of them have been evolved as promising therapeutic agents due to 
their important biological activity against cancer, inflammation, and hypertension.[125] 
 Pyrroloindoles are a key structural fragment found in a wide number of 
biologically active natural compounds (Figure 16). 
 
 
Figure 16. Representatives of pyroloindole family. 
 
 Pyrroindomycins (PYRs) are natural products, which were isolated during the 
screening of agents active against methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant Enterococcus faecium, containing pyrroloindole fragment linked 
to tetronic acid core with macrocyclic ring.[126–133] 
 Tryptophan is presumed to be the precursor for the pyrroloindole moiety 
(Figure 17). 
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Figure 17. Structure relation between alkaloids and target compounds. 
 
In 1864 Jobst and Hesse isolated alkaloid Physostigmine (also known as eserine) 
from the Calabar bean Physostigma venenosum growing in tropical forests of 
Africa.[134] 
The first therapeutic use of physostigmine was in 1877 in the treatment of 
glaucoma. Notably, this is still one of its clinical uses. Physostigmine was the first 
discovered AChE inhibitor, which led to starting the practice of AChE inhibitors in 
clinical conditions.[135]  
Physostigmine represents the first generation of cholinesterase inhibitors and has 
been a good model molecule for designing new derivatives with stronger cholinesterase 
inhibitory action. Having reversible inhibitory effect towards AChE, physostigmine has 
been used to treat myasthenia gravis, glaucoma, Alzheimer’s disease[136] and atropine-
induced coma.[137] Recently, Pal et al. proved indolo[2,3-b]indoles for the potential 
inhibition of yeast sirtuins, which are considered as promising targets for cancer 
therapeutics.[138] 
As a result, numerous innovative methodologies toward the core hexahydro-
pyrrolo[2,3-b]indole skeleton have been developed.[139–151]  
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It is an interesting challenge to find suitable synthetic routes to pyrroloindole 
core substances. The strategy I used, in this case, was the same I adopted in the 
synthesis of pyrimidoindoles (see Chapter 5) with slight modification (Scheme 6.1).  
The first step is Buchwald-Hartwig amination reaction between 1-substituted 5-
aminopyrrole-3-carbonitriles 15 and commercially available 1,2-dihalobenezenes (1,2-
dibromobenzene, 2-bromo-4-chloro-1-iodobenzene and 1,2-dibromo-4,5-
dimethoxybenzene).  
 
 
 
 
Scheme 6.1. Schematic presentation of proposed transformation. 
 
In this sense, 5-amino-1-aryl/alkyl-1H-pyrrole-3-carbonitriles seemed to be the 
suitable starting materials for constructing [2,3]-fused indole derivatives. This 
precursor can be easily synthesized in two (or three, for aryl substituent) steps starting 
from cheap succinonitrile (Scheme 6.1.1). The properties of these compounds find 
expression as enamine moiety and good 1,3-binucleophile. The relative simplicity of 
the synthesis, structure similarity to the desired pyrrolo[2,3-b]indoles and great 
reactivity towards many reactions motivated me to use them. 
Due to the instability of 1H-pyrrol-2-amines, in my research I used the N-
substituted derivatives and in combination with the electron-withdrawing cyano 
functional group maintain their stability of electron-rich aminopyrrole ring. 
 
NC
NC
O
Na+
i, ii
N
R
NC
NH2
 
Scheme 6.1.1. Preparation of precursors 15. 
Reaction conditions: (i) aliphatic or aromatic amine, EtOH-HOAc, (1:1 vol.), reflux, 45 
min., (ii) NaOMe, methanol, 1 h. 
 
The second step in my research includes conducting of intramolecular 
cyclization in order to obtain target compounds. 
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6.2 Optimization of Buchwald-Hartwig reaction for synthesis of 
aminopyrroles 
 
The Pd-catalyzed coupling of amines with aryl halides has become an important 
tool in the organic chemist’s arsenal. In particular, the coupling of heteroaryl amines 
with aryl halides has been problematic. Over the past decades, with the development of 
new ligands became possible to dramatically enhance the rate of Buchwald-Hartwig 
reaction. 
Initially, I attempted C–N bond-forming conditions using Pd(OAc)2 as the 
catalyst source and screened four different ligands (±)-BINAP (entry 1), dppf (entry 2), 
DPEphos (entry 3), PCy3·HBF4 (entry 4) to compare both monodentate and bidentate 
ligands (Figure 18). I did not have success in obtaining any appreciable amount of 
desired coupling product in case of PCy3·HBF4, likely due to ineffective in current 
Buchwald-Hartwig reaction as long as the addition of Bu4NBr for this particular 
substrate.  
 Optimization has shown the important role of bidentate ligands (DPEphos) in 
the step of approaching 5-arylaminopyrrole-3-carbonitriles.  
 
 
Figure 18. Selected examples of screened phosphine ligands. 
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The structure of the biaryl phosphine ligands is directly correlated to the 
efficiency of catalysts containing these ligands. The monodentate ligand showed to be 
ineffective in Buchwald-Hartwig reaction. Moreover, an increase of the product yield 
correlates with the increase of bite angle in the ligand row: BINAP (93°) – dppf (99°) – 
DPEphos (104°), which indicates the presence of angle effect.[152] 
Changing to a more polar organic solvent like dioxane to help solubilize the base 
and further employing a strong base such as Cs2CO3 in combination with DPEphos 
(entry 7) did provide the requisite product, with a noticeable improvement in yield. 
Results of optimization are shown in Table 6.2. 
 
 
 
Scheme 6.2 Optimization of target molecule 16. 
Reaction conditions: (i) Pd(OAc)2 (5 mol%), ligand (10 mol%), base (2.5 equiv.), 
solvent, 110 °C, 8-9 h. 
 
Table 6.2. Optimization of C−N coupling reaction conditions. 
Entry Solvent Ligand/Additive Base Yielda) 
1 toluene Bu4NBr K2CO3 -
b)  
2 toluene PCy3·HBF4 NaOt-Bu -
b)  
3 toluene (±)-BINAP Cs2CO3 58 
4 dioxane (±)-BINAP K3PO4 72 
5 dioxane dppf Cs2CO3 85 
6 dioxane (±)-BINAP Cs2CO3 80 
7 dioxane DPEphos Cs2CO3 92 
a) 
Yields of isolated products; 
b) Product was not observed. 
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6.3 Synthesis of 5-((2-bromo)arylamino)-1H-pyrrole-3-carbonitriles 
 
After the successful screening of the coupling conditions, I started synthesis of 
NH-arylated cyanopyrroles. Heating of the corresponding pyrrole with dihaloarene (1.2 
equiv.), in the presence of Pd(OAc)2 in an 5 mol% amount, DPEphos (10 mol%), and 
Cs2CO3 (2.5 equiv.) in toluene at 110 °C for 8 ‒ 9 h afforded the desired  
5-(2-bromophenylamino)-1H-pyrrole-3-carbonitriles 16 in 55–95% yield.  
 
 
 
Scheme 6.3 Synthesis of compounds 16. 
Reaction conditions: (i) Pd(OAc)2 (5 mol%), DPEphos (10 mol%), Cs2CO3 (2.5 equiv.), 
1,4-dioxane, 110 °C, 8-9 h. 
 
Table 6.3. Synthesis of compounds 16. 
16 R1 R2 R3 Yield, %a) 
16a 2,4,6-CH3C6H2- H H 67 
16b 2,4-CH3C6H3- H H 90 
16c 2,4-CH3C6H3- CH3 CH3 55 
16d 2,4-CH3C6H3- Cl H 70 
16e 4-i-PrC6H4- H H 79 
16f 4-i-PrC6H4- Cl H 72 
16g 4-OCH3C6H4- H H 92 
16h 4-OCH3C6H4- Cl H 72 
16i 3-ClC6H4- H H 75 
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16j 3-ClC6H4- Cl H 63 
16k 4-ClC6H4- H H 70 
16l 4-ClC6H4- Cl H 75 
16m Bn- H H 60 
16n 3,4-dimethoxyphenetyl- OCH3 OCH3 68 
16o Cp- H H 50 
16p n-Pentyl- H H 76 
16q t-Bu- OCH3 OCH3 68 
16r t-Bu- H H 85 
16s 2,4,6-CH3C6H2- CH3 CH3 -
* 
a) Yield of isolated product. 
 
The structures of synthesized compounds were confirmed by spectroscopic 
methods and mass spectrometry. In 1H NMR spectra, the aromatic protons of pyrrole 
functionality appear at 7.0-7.2 ppm (solvent - CDCl3) as doublets with a coupling 
constant 4J ~ 1.9-2.1 Hz. Additionally, the broad singlets of NH group were detected at 
5.5-6.1 ppm region. 
 
 
Scheme 6.3.1. 1H NMR shifts of compound 16r (in CDCl3). 
 
In addition, in the IR spectra, the typical strong intensive peaks of stretching 
vibrations of cyano group (-CN) were observed at ranges 2219-2228 cm-1. All obtained 
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products were examined in the follow-up intramolecular arylation reaction to access 
1,8-dihydropyrolo[2,3-b]indoles 17. 
 
6.4 Synthesis of 1,8-dihydropyrrolo[2,3-b]indole-3-carbonitriles 
 
With this promising result, I next studied intramolecular cyclization reaction of 
previously obtained arylated aminopyrroles. Thus, the successful reaction of initial 
compounds 16 with Pd(OAc)2 (5 mol%), PCy3·HBF4 (10 mol%) as phosphine ligand, 
DBU (2.5 equiv.) as a base in DMA at 145 °C for 3-4 hours afforded desired  
pyrrolo[2,3-b]indoles 17 in good yields (Table 14).  
 
 
 
Scheme 6.4: Synthesis of 1,8-dihydropyrrolo[2,3-b]indole-3-carbonitriles 17. 
Reaction conditions: (i) Pd(OAc)2 (5 mol%), PCy3·HBF4 (10 mol%), DBU (2.5 equiv.), 
DMA, 145 °C, 3-4 h. 
 
Table 6.4. Synthesis of compounds 17. 
17 R1 R2 R3 Yield, %a) 
17a 2,4,6-CH3C6H2- H H 78 
17b 2,4-CH3C6H3- H H 85 
17c 2,4-CH3C6H3- CH3 CH3 81 
17d 2,4-CH3C6H3- Cl H 75 
17e 4-i-PrC6H4- H H 82 
17f 4-i-PrC6H4- Cl H 80 
17g 4-OCH3C6H4- H H 60 
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17h 4-OCH3C6H4- Cl H 87 
17i 3-ClC6H4- H H 76 
17j 3-ClC6H4- Cl H 72 
17k 4-ClC6H4- H H 70 
17l 4-ClC6H4- Cl H 56 
17m Bn- H H 62 
17n 3,4-dimethoxyphenetyl- H H 60 
17o Cp- H H 65 
17p n-Pentyl- H H 53 
17q t-Bu- OCH3 OCH3 45 
17r t-Bu- H H 70 
17s 2,4,6-MeC6H2- CH3 CH3 39* 
a) Yield of isolated product. 
 
The structures of newly synthesized compounds were elucidated by NMR 
methods, mass and IR spectroscopy. In 1H NMR spectra of target materials, the signals 
of NH-proton of indole core were detected at 11.0-12.0 ppm region (DMSO-d6). 
Interestingly, the reaction of 5-amino-1-mesityl-1H-pyrrole-3-carbonitrile with 
1,2-dibromo-4,5-dimethylbenzene gave not expected in this conditions product –  
1-mesityl-5,6-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile 17s in 39% 
yield. The structure of the product was independently confirmed by X-ray crystal 
structure analysis. Unfortunately, the data is not publishable, due to the bad quality of 
the small crystal. Nevertheless, the structure could be determined and gives the 
expected result (Figure 19).  
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Figure 19. ORTEP of 1-mesityl-5,6-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-
carbonitrile 17s (50 % probability level). 
 
With regards to the mechanism of cyclization, two possible pathways are depicted in 
Scheme 6.4.  
Originally, oxidative addition generates species A, which can then either undergo a  
Heck-type process, through intermediate B or a catalytic dearomatization process via intermediate 
C. According to the previous studies of familiar reactions – electrophilic pathway preferred to Heck 
one, which seems less likely because of the high ring-strain of the trans-fused intermediate B which 
would be formed by the required syn-carbopalladation of the indole double bond.[153]  
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Scheme 6.4. Possible reaction mechanism of cyclization of 16 (ligands omitted for 
clarity). 
  
6.5 Conclusion 
 
In summary, I have demonstrated a novel synthesis of N-substituted  
pyrrolo[2,3-b]indole derivatives. The scope of the methodology was illustrated with the 
synthesis of biologically relevant N−H pyrroloindoles by employing 5-amino-3-
cyanopyrroles as coupling partners in the sequential C−N and C−C bond-forming 
reactions. 
Furthermore, this methodology can be extended to the construction of other 
pyrrole-fused aromatic compounds.  
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7. Summary 
 
In the present thesis, a series of palladium-catalyzed reactions were utilized for 
the synthesis of novel heterocyclic compounds, especially quinolines and indole-like 
molecules.  
Chapters 1 and 2 deal with Suzuki-Miyaura reaction protocols for the synthesis 
of various quinoline moieties.  
Simple reaction procedures were developed for the synthesis of novel 6H-
chromeno[3,4-c]quinolin-6-ones.  
 
 
 
 
Site-selective one-pot cross-coupling was successfully applied to ethyl 4,7-
dichloroquinoline carboxylates. The scope and limitations of the methodology along 
with some further transformations were studied. 
 
 
 
 
In Chapter 3, a simple and efficient method for synthesis of arylated and 
alkynelated 4-trifluoroquinolines was developed along with results of biological 
evaluation of synthesized quinolines as nucleotide pyrophosphatase (NPPs) inhibitors.  
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Preparative routes for the synthesis of novel 1H-pyrimido[4,5-b]indole-
2,4(3H,9H)-diones were described in Chapter 4.  
 
 
 
 
 
 
And finally, in Chapter 5, sequential Buchwald-Hartwig and intramolecular 
arylation reactions were successfully applied in the synthesis of various 1,8-
dihydropyrrolo[2,3-b]indole-3-carbonitriles. 
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Supplement 1: 
 
Experimental section 
1.1 Analytics 
 
1H-NMR-Spectroscopy:  
Bruker AVANCE 250 II (250 MHz), Bruker AVANCE 300 III (300 MHz), Bruker 
AVANCE 500 (500 MHz). The spectra were calibrated according to the solvent signals: 
7.26 ppm for CDCl3, 2.50 ppm for DMSO-d6, 206.68 ppm for Acetone-d6. Peak 
characterization: s = singlet, d = doublet, t = triplet, q = quartet, sext = sextet, h = 
heptet, dd = doublet of doublets, td = triplet of doublets, dt = doublet of triplets, m = 
multiplet.  
 
13C-NMR-Spectroscopy:  
Bruker AVANCE 250 II (62.9 MHz), Bruker AVANCE 300 III (75.5 MHz), Bruker 
AVANCE 500 (125 MHz). The spectra were calibrated according to the solvent signals: 
77.16 ppm for CDCl3, 39.5 ppm for DMSO-d6. Peak characterization: q = quartet, dd = 
doublet of doublets. DEPT method was used for determining the presence of primary, 
secondary, tertiary and quaternary carbon atoms. 
 
19F-NMR-Spectroscopy:  
Bruker AVANCE 300 III (282 MHz). 
All chemical shifts are given in ppm. All coupling constants J are indicated in Hz. 
 
Mass spectrometry (MS):  
GC 6890N/MSD 5973 (Agilent) or Finnigan MAT 95-XP (Thermo Electron). 
 
High-resolution MS (HRMS):  
Finnigan MAT 95 XP (Thermo Electron) (electron ionisation EI, 70 eV) or 6210 Time-
of-Flight LC/MS (Agilent) (electrospray ionization, ESI). Only the measurements with 
an average deviation from the theoretical mass of ± 2 μDa were accounted as correct. 
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Infrared spectroscopy (IR):  
Nicolet 380 FT-IR spectrometer with ATR sampling technique for solids as well as 
liquids. Abbreviations for signal allocations: w = weak, m = medium, s = strong. 
 
X-ray crystallography:  
Bruker-Nonius Apex X8 or Bruker Kappa Apex II diffractometers with CCD camera 
(Mo-Kα and graphite monochromator, λ = 0.71073 Å). 
 
Melting point determination (mp):  
Microscope Laborlux 12 Pol S, Mettler FP90 central Processor, SNT 12 V 100 K. The 
melting points are uncorrected. 
 
Thin layer chromatography (TLC):  
Merck silica gel 60 F254. Detection under UV light at 254 nm and 366 nm without 
dipping reagent. 
 
Column chromatography:  
Chromatography was performed using Merck silica gel 60 (0.063-0.200 mm, 70-230 
mesh). All solvents were distilled before use. 
 
All chemicals and extra dry solvents were purchased from the standard chemical 
suppliers, such as Sigma-Aldrich®, Arcos®, Merck® and others. All reactions were 
monitored by TLC using UV light to visualize the course of the reaction.  
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General synthetic procedures and product characterization 
 
General procedure for the synthesis of compounds 2a-x: 
 The mixture of corresponding ethyl 4-chloroquinoline-3-carboxylate (1),  
1.2 equiv. of ortho-methoxyarylboronic acid, 5 mol % of Pd(PPh3)4 and 2.5 equiv. of 
K2CO3 was heated in dry DMF at 130 °C for 10-12 h under argon atmosphere. The 
solvent was evaporated in vacuo. The residue was purified by column chromatography 
(EA : Heptane = 1:5). 
 
Ethyl 4-(2,3-dimethoxyphenyl)quinoline-3-carboxylate (2a): 
Starting from ethyl 4-chloroquinoline-3-carboxylate (200 mg, 
0.85 mmol), the product 2a was isolated as yellow crystals 
(270 mg, 94 %); mp = 55 – 56 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.08 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.50 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.72 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.06 (dd, 
3J = 8.2 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.16 (dd, 
3J = 8.1 Hz, 3J = 7.6 Hz, 1H, CHAr), 
7.41 – 7.52 (m, 1H, CHAr), 7.59 (dd, 
3J = 8.5 Hz, 4J = 0.9 Hz, 1H, CHAr), 7.77 (ddd, 
3J = 8.4 Hz, 3J = 6.8 Hz, 4J = 1.5 Hz, 1H, CHAr), 8.18 (d, 
3J = 8.1 Hz, 1H, CHAr), 9.40 
(s, 1H, CHAr).  
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 60.6 (OCH3), 
61.2 (CH2CH3), 112.7 (CH), 122.0 (CH), 123.3(C), 123.9 (CH), 127.2 (C), 127.3 (CH), 
127.7 (CH), 129.6 (CH), 131.1 (2*C, C+CH), 146.3 (C), 147.3 (C), 149.2 (C), 150.4 
(CH), 152.8, 166.3 (C=O); 
IR (ATR, cm-1): v~ = 2984 (w), 2962 (w), 2929 (w), 2840 (w), 1698 (s), 1601 
(w), 1574 (m), 1505 (w), 1470 (s), 1456 (m), 1442 (m), 1426 (m), 1415 (m), 1369 (s), 
1319 (m), 1301 (m), 1281 (m), 1259 (s), 1225 (s), 1166 (s), 1137 (m), 1124 (s), 1078 
(s), 1012 (s), 960 (m), 941 (m), 869 (m), 815 (m), 790 (s), 770 (s), 755 (s), 684 (m), 
676 (m), 644 (m), 604 (m), 587 (m), 562 (w), 535 (m); 
MS (EI, 70eV): m/z (%) = 338 ([M+H]+, 22), 337 (M+, 100), 306 (21), 292 (18), 
279 (14), 278 (71), 264 (14), 262 (15), 249 (13), 235 (20), 234 (18), 206 (19), 186 
(36), 151 (14); 
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HRMS (EI): calcd. for C20H19O4N (M
+) 337.13086, found 337.13079. 
 
Ethyl 4-(2,5-dimethoxyphenyl)quinoline-3-carboxylate (2b): 
Starting from ethyl 4-chloroquinoline-3-carboxylate (200 mg, 
0.85 mmol), the product 2b was isolated as yellow crystals 
(255 mg, 89 %); mp = 96 – 97 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.09 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3). 3.62 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 4.18 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.71 (dd, 
4J = 2.8 Hz, J = 0.4 Hz, 1H, CHAr), 6.96 (d, 
3J = 8.6 Hz, 1H, CHAr), 7.01 (dd, 
3J = 9.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 7.51 (ddd, 
3J = 8.3 Hz, 3J = 6.8 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.63 (ddd, 
3J = 8.5 Hz, 4J = 1.4 Hz, 
J = 0.5 Hz, 1H, CHAr), 7.80 (ddd, 
3J = 8.4 Hz, 3J = 6.8 Hz, 4J = 1.5 Hz, 1H, CHAr), 
8.24 (d, 3J = 8.4 Hz, 1H, CHAr), 9.40 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 56.3 (OCH3), 
61.3 (CH2CH3), 112.1 (CH), 114.6 (CH), 116.2 (CH), 123.7, 126.3, 127.4, 127.6 (CH), 
127.7 (CH), 129.0 (CH), 130.5 (CH), 149.8 (2*C, C+CH), 151.0 (C), 153.6 (2*C), 
166.0 (C=O). 
IR (ATR, cm-1): v~ = 3335 (w), 3055 (w), 2997 (w), 2953 (w), 2932 (w), 2912 
(w), 2834 (w), 1729 (s), 1718 (s), 1612 (w), 1573 (m), 1495 (s), 1463 (s), 1451 (m), 
1440 (m), 1410 (m), 1374 (m), 1308 (m), 1281 (s), 1216 (s), 1178 (s), 1162 (s), 1138 
(m), 1124 (m), 1101 (s), 1040 (s), 1030 (s), 1019 (s), 939 (m), 893 (m), 861 (m), 807 
(s), 772 (s), 742 (s), 734 (s), 690 (s), 668 (s), 634 (m), 583 (m), 565 (m), 540 (m), 529 
(m). 
MS (EI, 70eV): m/z (%) = 338 (22), 337 (M+, 100), 278 (38), 262 (16), 250 
(17), 149 (11), 235 (14), 234 (14), 207 (13), 206 (16), 186 (12), 151 (12). 
HRMS (EI): calcd. for C20H19NO4 (M
+) 337.13086, found 337.13082. 
 
Ethyl 4-(2,6-dimethoxyphenyl)quinoline-3-carboxylate (2c): 
Starting from ethyl 4-chloroquinoline-3-carboxylate (150 mg, 
0.64 mmol), the product 2c was isolated as yellow crystals 
(93 mg, 43 %); mp = 139-140 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.61 (s, 6H, 2*OCH3), 4.14 (q, 
3J = 7.1 Hz, 2H, 
 
 
70 
 
CH2CH3), 6.70 (d, 
3J = 8.4 Hz, 2H, CHAr), 7.42 (t, 
3J = 8.4 Hz, 1H, CHAr), 7.44 (ddd, 
3J = 6.8 Hz, 4J = 1.4 Hz, 1H, CHAr), 7.53 (dd, 
3J = 8.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 
7.74 (ddd, 3J = 8.4 Hz, 3J = 6.7 Hz, 4J = 1.6 Hz, 1H, CHAr), 8.16 (d, 
3J = 8.6 Hz, 1H, 
CHAr), 9.43 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.7 (CH2CH3), 55.8 (2*OCH3), 60.8 (CH2CH3), 
104.08 (2*CH), 114.2 (C), 124.1 (C), 126.9 (CH), 127.3 (CH), 127.5 (C), 129.6 (CH), 
130.2 (CH), 130.8 (CH), 144.8 (2*C), 149.4 (C), 150.7 (CH), 157.5 (C), 166.4 (C=O). 
IR (ATR, cm-1): v~ = 2955 (w), 2926 (w), 2855 (w), 1726 (s), 1585 (m), 1503 
(w), 1469 (s), 1430 (m), 1369 (m), 1298 (m), 1280 (s), 1252 (s), 1222 (s), 1212 (s), 
1157 (s), 1104 (s), 1027 (s), 1018 (s), 983 (m), 955 (m), 925 (m), 860 (m), 828 (w), 
805 (m), 782 (m), 771 (s), 761 (s), 741 (s), 678 (m), 608 (m), 564 (m), 531 (m); 
MS (EI, 70eV): m/z (%) = 338 ([M+H]+, 19), 337 ([M]+, 79), 292 (23), 262 (18), 
249 (26), 248 (20), 234 (22), 214 (12), 206 (21), 190 (13), 187 (12), 186 (95), 151 
(13), 149 (21), 29 (29); 
HRMS (EI): calcd for C20H19NO4 ([M]
+) 337.13086, found 337.13041. 
 
Ethyl 4-(2,3,4-trimethoxyphenyl)quinoline-3-carboxylate (2d): 
Starting from ethyl 4-chloroquinoline-3-carboxylate (300 mg, 
1.26 mmol), the product 2d was isolated as yellow crystals 
(395 mg, 84 %); mp = 95 – 96 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.13 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.57 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.95 (s, 3H, 
OCH3), 4.2 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.80 (s, 1H, CHAr), 6.81 (s, 1H, CHAr), 7.5 
(ddd, 3J = 8.4 Hz, 3J = 6.8 Hz, 4J = 1.3 Hz, 1H, CHAr), 7.7 (dd, 
3J = 8.6 Hz, 
3J = 0.8 Hz, 1H, CHAr), 7.8 (ddd, 
3J = 8.4 Hz, 3J = 6.8 Hz, 4J = 1.5 Hz, 1H, CHAr), 8.3 
(d, 3J = 8.4 Hz, 1H, CHAr), 9.4 (s, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.1 (OCH3), 60.86 (OCH3), 
60.99 (OCH3), 61.2 (CH2CH3), 107.1 (CH), 123.1 (C), 123.9 (C), 124.4 (CH), 127.5 
(CH), 127.6 (CH), 127.7 (C), 129.3 (CH), 131.3 (CH), 142.3 (C), 147.5 (C), 148.7 (C), 
150.0 (CH), 151.3 (C), 154.4 (C), 166.4 (C=O); 
IR (ATR, cm-1): v~ = 2994 (w), 2969 (w), 2956 (m), 2935 (w), 2836 (m), 1724 
(s), 1604 (m), 1573 (m), 1505 (w), 1488 (m), 1469 (m), 1462 (m), 1443 (m), 1434 (m), 
1416 (m), 1381 (m), 1367 (m), 1291 (m), 1271 (m), 1263 (m), 1223 (s), 1198 (s), 1167 
(m), 1151 (s), 1134 (m), 1120 (m), 1098 (s), 1056 (s), 1015 (s), 993 (s), 944 (m), 912 
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(m), 878 (m), 856 (m), 809 (s), 796 (s), 782 (s), 765 (s), 679 (m), 666 (m), 621 (m), 
300 (m), 581 (m), 535 (m); 
MS (EI, 70eV): m/z (%) = 368 ([M+H]+, 23), 367 (M+, 100), 322 (10), 308 (26), 
292 (23), 264 (24), 221 (12), 186 (27); 
HRMS (EI): calcd. for C21H21O5N (M
+) 367.14142, found 367.14122. 
 
Ethyl 4-(2-methoxyphenyl)-6-methylquinoline-3-carboxylate (2e): 
Starting from ethyl 4-chloro-6-methylquinoline-3-carboxylate 
(200 mg, 0.8 mmol), the product 2e was isolated as yellow 
crystals (211 mg, 82 %); mp = 123 – 124 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.42 (s, 3H, CH3), 3.67 (s, 3H, OCH3), 4.13 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.04 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.06 – 7.14 (m, 2H, CHAr), 
7.31 (s, 1H, CHAr), 7.47 (ddd, 
3J = 8.2 Hz, 3J = 6.2 Hz, 4J = 3.0 Hz, 1H, CHAr), 7.59 
(dd, 3J = 8.6 Hz, 4J =1.8 Hz, 1H, CHAr), 8.06 (d, 
3J = 8.6 Hz, 1H, CHAr), 9.31 (s, 1H, 
CHAr).  
13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 21.9 (CH3), 55.70 (OCH3), 61.0 
(CH2CH3), 110.9 (CH), 120.5 (CH), 123.7 (C), 125.8 (C), 126.2 (CH), 127.3 (C), 129.4 
(CH), 129.8 (CH), 130.3 (CH), 133.3 (CH), 137.2 (C), 146.5 (C), 148.1 (C), 149.5 
(CH), 156.8 (C), 166.7 (C=O). 
IR (ATR, cm-1): v~  = 3049 (w), 3004 (w), 2983 (w), 2961 (w), 2937 (w), 2923 (w), 2899 
(w), 2839 (w), 1939 (w), 1870 (w), 1702 (s), 1601 (s), 1570 (s), 1494 (s), 1461 (s), 1453 (s), 1437 
(s), 1422 (s), 1365 (s), 1316 (s), 1287 (s), 1257 (s), 1236 (s), 1216 (s), 1177 (s), 1123 (s), 1106 (s), 
1049 (s), 1024 (s), 1012 (s), 975 (m), 964 (m), 937 (m), 895 (w), 867 (m), 845 (m), 832 (s), 784 
(m), 756 (s), 729 (s), 708 (m), 680 (m), 632 (m), 619 (s), 599 (m), 565 (m), 545 (m); 
MS (GC, 70 eV) m/z (%): 321 ([M]+, 90), 290 (19), 277 (10), 276 (50), 275 (11), 
263 (12), 262 (63), 261 (11), 248 (27), 247 (11), 246 (26), 234 (17), 233 (60), 232 
(410, 218 (12), 216 (11), 205 (13), 204 (24), 203 (14), 201 (17), 200 (100), 190 (11), 
189 (10), 178 (11), 177 (12), 176 (18), 29 (36); 
HRMS (ESI): calcd. for C20H19NO3 (M]
+) 321.13594, found 321.13575. 
 
Ethyl 4-(2,3-dimethoxyphenyl)-6-methylquinoline-3-carboxylate (2f): 
N
H3C
O
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Starting from ethyl 4-chloro-6-methylquinoline-3-carboxylate 
(200 mg, 0.8 mmol), the product 2f was isolated as yellow 
crystals (267 mg, 94 %); mp = 103 - 104°C; 
1H NMR (300 MHz, CDCl3): δ = 1.08 (t, 
3J = 7.1 Hz, 
3H, CH2CH3). 2.43 (s, 3H, CH3), 3.62 (s, 3H, OCH3), 3.79 (s, 
3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.70 (d, 
4J = 2.7 Hz, 1H, CHAr), 6.99-
7.04 (m, 2H, CHAr), 7.35 (s, 1H, CHAr), 7.60 (dd, 
3J = 8.6 Hz, 4J = 1.9 Hz, 1H, CHAr), 
8.07 (d, 3J = 8.6 Hz, 1H, CHAr), 9.31 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 21.8 (CH3), 55.8 (OCH3), 56.2 
(OCH3), 61.0 (CH2CH3), 112.2 (CH), 114.3 (CH), 116.2 (CH), 123.6 (C), 126.2 (CH), 
126.7 (C), 127.2 (C), 129.2 (CH), 133.5 (CH), 137.4 (C), 146.5 (C), 147.8 (C), 149.3 
(CH), 151.1, 153.6 (C), 166.4 (C=O). 
IR (ATR, cm-1): v~  = 3064 (w), 3032 (w), 2991 (w), 2974 (w), 2944 (w), 2927 
(w), 2904 (w), 2830 (w), 1727 (s), 1619 (w), 1586 (w), 1569 (m), 1497 (s), 1457 (s), 
1440 (m), 1421 (s), 1389(w), 1366 (m), 1356 (m), 1300 (m), 1283 (s), 1272 (s), 1259 
(s), 1236 (s), 1222 (s), 1203 (s), 1177 (s), 1146 (s), 1130 (s), 1101 (s), 1055 (s), 1034 
(s), 1021 (s), 932 (m), 923 (m), 903 (m), 883 (m), 870 (m), 837 (s), 809 (s), 763 (s), 
751 (s), 725 (s), 699 (s), 680 (m), 640 (m), 628 (m), 606 (m), 592 (m), 556 (m), 535 
(m); 
MS (GC, 70 eV) m/z (%): 351 ([M]+, 100), 292 (38), 276 (13), 264 (14), 263 
(13), 249 (10), 248 (11), 220 (13), 200 (12), 29 (22); 
HRMS (ESI): calcd. for C21H21NO4 (M+H
+) 352.15474, found 352.15433. 
 
Ethyl 4-(2,5-dimethoxyphenyl)-6-methylquinoline-3-carboxylate (2g): 
Starting from ethyl 4-chloro-6-methylquinoline-3-
carboxylate (200 mg, 0.8 mmol), the product 2g was isolated 
as yellow crystals (268 mg, 95 %); mp = 95-96°C; 
1H NMR (300 MHz, CDCl3): δ = 1.08 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.42 (s, 3H, CH3), 3.51 (s, 3H, OCH3), 3.96 (s, 
3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.71 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, 
CHAr), 7.07 (dd, 
3J = 8.2 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.17 (dd, 
3J = 8.2 Hz, 
3J = 7.6 Hz, 1H, CHAr), 7.31 (s, 1H, CHAr), 7.60 (dd, 
3J = 8.6 Hz, 4J = 1.9 Hz, 1H, 
CHAr), 8.08 (d, 
3J = 8.6 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr). 
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13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 22.0 (CH3), 55.9 (OCH3), 60.6 
(OCH3), 61.2 (CH2CH3), 112.6 (CH), 122.0 (CH), 123.4 (C), 123.9 (CH), 126.3 (CH), 
127.2 (C), 129.1 (CH), 131.2 (C), 133.6 (CH), 137.5 (C), 146.3 (C), 146.8 (C), 147.6 
(C), 149.3 (CH), 152.8 (C), 166.4 (C=O). 
IR (ATR, cm-1): v~  = 3070 (w), 3045 (w), 3016 (w), 2993 (w), 2968 (w), 2939 (w), 2918 
(w), 2874 (w), 2838 (w), 2827 (w), 1708 (s), 1623 (w), 1600 (w), 1574 (s), 1504 (w), 1470 (s), 1452 
(s), 1422 (s), 1383 (w), 1358 (s), 1315 (s), 1297 (s), 1258 (s), 1223 (s), 1176 (s), 1143 (m), 1126 (s), 
1113 (s), 1074 (s), 996 (s), 943 (m), 887 (w), 866 (w), 830 (s), 819 (m), 788 (s), 774 (s), 755 (s), 
688 (m), 676 (m), 648 (s), 611 (m), 602 (m), 570 (m), 538 (m); 
MS (GC, 70 eV) m/z (%): 351 ([M]+, 100), 320 (24), 306 (21), 293 (18), 292 
(73), 291 (10), 278 (16), 276 (19), 264 (11), 263 (16), 262 (11), 249 (17), 248 (18), 
220 (22), 200 (44), 191 (150, 190 (13), 165 (11), 29 (35); 
HRMS (EI): calcd. for C21H21NO4 (M
+) 351.14651, found 351.14591. 
 
Ethyl 6-methyl-4-(2,3,4-trimethoxyphenyl)quinoline-3-carboxylate (2h): 
Starting from ethyl 4-chloro-6-methylquinoline-3-
carboxylate (100 mg, 0.4 mmol), the product 2h was isolated 
as yellow crystals (84 mg, 55 %); mp = 97 – 98 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.44 (s, 3H, CH3), 3.56 (s, 3H, OCH3), 3.94 
(s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 6.78 (s, 2H, CHAr), 7.35 (s, 1H, CHAr), 7.61 (dd, 
3J = 8.6 Hz, 4J =1.8 Hz, 
1H, CHAr), 8.07 (d, 
3J = 8.6 Hz, 1H, CHAr), 9.29 (s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 14.0 (CH2CH3), 22.0 (CH3), 56.2 (OCH3), 60.95 (OCH3), 
61.1 (OCH3), 61.2 (CH2CH3), 107.1 (CH), 123.4 (C), 123.9 (C), 124.4 (CH), 126.2 (CH), 127.6 (C), 
129.25 (CH), 133.4 (CH), 137.4 (C), 142.25 (C), 146.35 (C), 147.8 (C), 149.3 (CH), 151.3 (C), 
154.2 (C), 166.7 (C=O). 
IR (ATR, cm-1): v~  = 2996 (w), 2961 (w), 2936 (w), 2838 (w), 1873 (w), 1719 (s), 1599 
(m), 1571 (m), 1491 (s), 1466 (s), 1441 (s), 1412 (s), 1390 (m), 1365 (s), 1295 (s), 1268 (s), 1228 
(s), 1196 (s), 1181 (s), 1121 (s), 1093 (s), 1056 (s), 1031 (s), 1012 (s), 993 (s), 937 (m), 920 (m), 
893 (m), 865 (m), 835 (s), 820 (s), 806 (m), 795 (m), 784 (m), 776 (m), 764 (s), 728 (m), 678 (m), 
627 (m), 588 (m), 532 (m); 
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MS (GC, 70 eV) m/z (%): 382 (28), 381 ([M]+, 100), 336 (11), 322 (28), 278 
(24), 235 (13), 200 (30), 29 (29); 
HRMS (EI): calcd. for C22H23NO5 (M
+) 381.15707, found 381.15688. 
 
Ethyl 4-(5-fluoro-2-methoxyphenyl)-6-methylquinoline-3-carboxylate (2i): 
Starting from ethyl 4-chloro-6-methylquinoline-3-carboxylate 
(200 mg, 0.8 mmol), the product 2i was isolated as yellow 
crystals (239mg, 88 %); mp = 132-133 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.45 (s, 3H, CH3), 3.64 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.88 (dd, 
3J = 8.4 Hz, 3J = 3.1 Hz, 1H, CHAr), 6.97 (dd, 
3J = 9.1 Hz, 3J = 4.3 Hz, 1H, CHAr), 7.17 (ddd, 
3J = 9.0 Hz, 3J = 8.0 Hz, 3J = 3.1 Hz, 
1H, CHAr), 7.29 – 7.3 (m, 1H, CHAr), 7.62 (dd, 
3J = 8.6 Hz, 3J = 2.0 Hz, 1H, CHAr), 
8.08 (d, 3J = 8.6 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 13.8 (CH2CH3), 21.85 (CH3), 56.2 (OCH3), 61.1 
(CH2CH3), 111.75 (d, 
3JC-F = 8.3 Hz, CH), 115.6 (d, 
2JC-F = 22.6 Hz, CH), 117.1 (d,  
2J  C-F = 24.2 Hz, CH), 123.3 (C), 125.7 (CH), 126.9 (C), 126.95 (d, 
3JC-F = 8.0 Hz), 
129.0 (CH), 133.6 (CH), 137.6 (C), 147.6 (C), 149.1 (CH), 152.9 (d, 4JC-F = 2.2 Hz), 
156.77 (d, 1JC-F = 239.6 Hz), 165.9 (C=O). One Carbon signal cannot be detected. 
19F NMR (282 MHz, CDCl3): δ = -123.98 (CF). 
IR (ATR, cm-1): v~  = 3071 (w), 3030 (w), 2953 (w), 2922 (w), 2856 (w), 2833 (w), 2055 
(w), 1889 (w), 1830 (w), 1727 (s), 1616 (w), 1596 (w), 1570 (m), 1495 (s), 1478 (m), 1464 (s), 
1427 (m), 1390 (w), 1371 (m), 1361 (w), 1297 (s), 1272 (s), 1254 (s), 1241 (s), 1201 (s), 1177 (s), 
1126 (s), 1097 (s), 1071 (s), 1030 (s), 1007 (m), 963 (m), 947 (m), 904 (m), 879 (m), 866 (m), 829 
(s), 809 (s), 798 (s), 763 (s), 747 (s), 737 (s), 725 (s), 696 (s), 679 (w), 633 (m), 624 (m), 591 (m), 
547 (m), 534 (m); 
MS (GC, 70 eV) m/z (%): 339 ([M]+, 100), 308 (23), 295 (11), 294 (45), 281 
(18), 280 (89), 279 (13), 266 (35), 265 (15), 264 (28), 252 (21), 251 (62), 250 (48), 
249 (11), 236 (15), 234 (12), 223 (11), 222 (20), 221 (13), 200 (72), 195 (10), 194 
(11), 29 (47); 
HRMS (ESI): calcd. for C20H18FNO3 (M+H
+) 340.13435, found 340.13456. 
 
Ethyl 4-(2-methoxyphenyl)-6,8-dimethylquinoline-3-carboxylate (2j): 
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Starting from ethyl 4-chloro-6,8-dimethylquinoline-3-
carboxylate (200 mg, 0.76 mmol), the product 2j was isolated 
as light yellowish liquid (153 mg, 60 %);  
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.37 (s, 3H, CH3), 2.83 (s, 3H, CH3), 3.67 (s, 
3H, OCH3), 4.13 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.03 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.07 – 
7.11 (m, 2H, CHAr), 7.16 (s, 1H, CHAr), 7.41 – 7.53 (m, 2H, CHAr), 9.35 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 18.4 (CH3), 21.9 (CH3), 55.7 
(OCH3), 61.0 (CH2CH3), 110.9 (CH), 120.5 (CH), 123.5 (C), 124.2 (CH), 126.2 (C), 
127.4 (C), 129.7 (CH), 130.3 (CH), 133.7 (2*C, C+CH), 136.8 (C), 146.87 (C), 146.92 
(C), 148.2 (CH), 156.8 (C), 166.7 (C=O). 
IR (ATR, cm-1): v~  = 3976 (w), 2954 (w), 2923 (w), 2835 (w), 1707 (s), 1620 
(w), 1601 (m), 1580 (m), 1488 (s), 1456 (m), 1433 (m), 1407 (m), 1366 (m), 1318 (s), 
1291 (m), 1250 (s), 1196 (s), 1160 (s), 1141 (s), 1117 (s), 1062 (m), 1044 (m), 1023 
(s), 937 (m), 859 (m), 826 (m), 815 (m), 750 (s), 725 (m), 687 (m), 655 (m), 623 (m), 
567 (w); 
MS (GC, 70 eV) m/z (%): 336 (25), 335 (M+, 100), 290 (12), 276 (15), 262 
(14), 247 (15), 246 (13), 232 (15), 214 (12), 29 (43); 
HRMS (EI): calcd. for C21H21N3O3 (M
+) 335.15160, found 335.15138. 
 
Ethyl 4-(2,5-dimethoxyphenyl)-6,8-dimethylquinoline-3-carboxylate (2k): 
Starting from ethyl 4-chloro-6,8-dimethylquinoline-3-
carboxylate (200 mg, 0.76 mmol), the product 2k was isolated 
as light yellow crystals (176 mg, 64 %); mp = 105 – 107 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.07 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.38 (s, 3H, CH3), 2.82 (s, 3H, CH3), 3.61 (s, 
3H, OCH3), 3.78 (s, 3H, OCH3), 4.14 (q, 
3J = 7.1Hz, 2H, CH2CH3), 6.69 (dd, 
4J = 2.7 Hz, 5J = 0.7 Hz, 1H, CHAr), 6.91 – 7.05 (m, 2H CHAr), 7.18 (s, 1H, CHAr), 7.46 
(s, 1H, CHAr), 9.35 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 18.4 (CH3), 21.9 (CH3), 55.9 
(OCH3), 56.4 (OCH3), 61.0 (CH2CH3), 112.1 (CH), 114.1 (CH), 116.3 (CH), 123.3 (C), 
124.1 (CH), 127.2 (C), 133.7 (CH), 136.8 (C), 136.8 (C), 146.4, 147.0 (C), 148.2 (CH), 
151.1 (C), 153.5 (C), 166.6 (C=O). One Carbon signal cannot be detected. 
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IR (ATR, cm-1): v~  = 3052 (w), 2998 (w), 2986 (w), 2956 (w), 2936 (w), 2835 
(w), 1724 (s), 1619 (w), 1566 (m), 1504 (s), 1493 (s), 1460 (s), 1441 (m), 1429 (m), 
1408 (m), 1367 (m), 1356 (m), 1292 (s), 1262 (m), 1248 (m), 1232 (s), 1216 (s), 1194 
(s), 1174 (s), 1141 (s), 1123 (s), 1095 (m), 1059 (s), 1033 (s), 1021 (s), 951 (m), 933 
(m), 899 (m), 881 (m), 858 (s), 816 (s), 803 (m), 777 (m), 767 (m), 746 (s), 740 (s), 
716 (s), 677 (m), 659 (m), 630 (m), 601 (m), 574 (m), 562 (m), 533 (m); 
MS (GC, 70 eV) m/z (%): 366 (25), 365 (M+, 100), 306 (22), 305 (17), 29 (52); 
HRMS (EI): calcd. for C22H23NO4 (M
+) 365.16216, found 365.16188. 
 
Ethyl 4-(2,3-dimethoxyphenyl)-6,8-dimethylquinoline-3-carboxylate (2l): 
Starting from ethyl 4-chloro-6,8-dimethylquinoline-3-
carboxylate (200 mg, 0.76 mmol), the product 2l was isolated 
as yellow crystals (222 mg, 80 %); mp = 120 – 122 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.08 (t, 
3J = 7.1 Hz, 
3H, CH3), 2.37 (s, 3H, CH3), 2.83 (s, 3H, CH3), 3.51 (s, 3H, 
OCH3), 3.95 (s, 3H, OCH3), 4.16 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 6.70 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.06 (dd, 
3J = 8.2 Hz, 
4J = 1.5 Hz, 1H, CHAr), 7.12 – 7.19 (m, 2H, CHAr), 7.46 (s, 1H, CHAr), 9.36 (s, 1H, 
CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 18.4 (CH3), 21.9 (CH3), 55.9 
(OCH3), 60.6 (OCH3), 61.1 (CH2CH3), 112.5 (CH), 122.0 (CH), 123.1 (C), 123.8 (CH), 
124.3 (CH), 127.3 (C), 131.7 (C), 133.9 (CH), 136.8 (C), 136.9 (C), 146.3 (C), 146.8 
(2*C, C), 148.2 (CH), 152.7 (C), 166.6 (C=O). 
IR (ATR, cm-1): v~  = 2990 (w), 2968 (w), 2939 (w), 2828 (w), 1981 (w), 1906 
(w), 1718 (s), 1618 (w), 1599 (w), 1569 (m), 1498 (w), 1471 (s), 1428 (m), 1391 (w), 
1365 (m), 1293 (m), 1259 (s), 1248 (s), 1227 (m), 1199 (s), 1170 (s), 1145 (s), 1110 
(s), 1081 (m), 1052 (s), 1024 (s), 995 (s), 956 (m), 887 (m), 856 (m), 816 (s), 784 (s), 
761 (m), 750 (s), 710 (s), 650 (m), 623 (m), 603 (m), 561 (m); 
MS (GC, 70 eV) m/z (%): 366 (22), 365 (M+, 100), 334 (11), 320 (11), 307 
(11), 306 (29), 292 (10), 262 (11), 234 (10), 29 (47); 
HRMS (EI): calcd. for C22H23NO4 (M
+) 365.16216, found 365.16189. 
 
Ethyl 6,8-dimethyl-4-(2,3,4-trimethoxyphenyl)quinoline-3-carboxylate (2m): 
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Starting from ethyl 4-chloro-6,8-dimethylquinoline-3-
carboxylate (200 mg, 0.76 mmol), the product 2m was 
isolated as yellow crystals (225 mg, 75 %);  
mp = 98 – 100 ° C; 
1H NMR (300 MHz, CDCl3): δ = 1.10 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.38 (s, 3H, CH3), 2.82 (s, 3H, CH3), 3.55 (s, 
3H, OCH3), 3.94 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 6.78 (s, 2H, CHAr), 7.19 (s, 1H, CHAr), 7.45 (s, 1H, CHAr), 9.32 (s, 1H, 
CHAr). 
13C NMR (63 MHz, CDCl3): δ = 14.0 (CH2CH3), 18.7 (CH3), 21.9 (CH3), 56.2 
(OCH3), 60.9 (OCH3), 61.05 (OCH3), 61.1 (CH2CH3), 107.0 (CH), 123.6 (C), 
123.7 (C), 124.2 (CH), 124.4 (CH), 127.6 (C), 133.7 (CH), 136.8 (C), 136.9 (C), 142.2, 
146.3 (C), 146.90 (C), 148.2 (CH), 151.3 (C), 154.05 (C) , 166.8 (C=O). 
IR (ATR, cm-1): v~  = 2953 (w), 2838 (w), 1723 (m), 1596 (m), 1484 (m), 1459 
(s), 1404 (m), 1367 (m), 1319 (m), 1288 (s), 1268 (s), 1250 (m), 1206 (s), 1170 (m), 
1136 (m), 1085 (s), 1040 (s), 1004 (s), 956 (m), 945 (m), 923 (m), 910 (m), 891 (m), 
860 (m), 814 (s), 705 (m), 685 (m), 671 (m), 623 (m), 545 (m); 
MS (GC, 70 eV) m/z (%): 396 (27), 395 (M+, 100), 364 (11), 336 (15), 214 
(14), 29 (44); 
HRMS (EI): calcd. for C23H25NO5 (M
+) 395.17272, found 395.17262. 
 
Ethyl 4-(5-fluoro-2-methoxyphenyl)-6,8-dimethylquinoline-3-carboxylate (2n): 
Starting from ethyl 4-chloro-6,8-dimethylquinoline-3-
carboxylate (200 mg, 0.76 mmol), the product 2n was 
isolated as yellow crystals (188 mg, 70 %); mp = 97 – 98 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.10 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.39 (s, 3H, CH3), 2.82 (s, 3H, CH3), 3.63 (s, 
3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.86 (dd, 
3J = 8.4 Hz, 4J = 3.1 Hz, 1H, CHAr), 6.96 (dd, 
3J = 9.0 Hz, 4J = 4.3 Hz, 1H, CHAr), 
7.12 (s, 1H, CHAr), 7.14 – 7.20 (m, 1H, CHAr), 7.47 (s, 1H, CHAr), 9.37 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 18.2 (CH3), 21.8 (CH3), 56.2 
(OCH3), 60.9 (CH2CH3), 111.70 (d, 
3JC-F = 8.3 Hz, CH), 115.34 (d, 
2JC-F = 22.6 Hz, 
CH), 117.14 (d, 2JC-F = 24.1 Hz, CH), 122.9 (C), 123.6 (CH), 126.80, 127.5 (d,  
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3JC-F = 7.9 Hz, C), 133.7 (CH), 136.9 (C), 136.95 (C), 145.1 (d, 
4JC-F = 0.8 Hz, C), 
147.1 (C), 148.2 (CH), 152.9 (d, 4JC-F = 2.1 Hz, C), 156.7 (d, 
1JC-F = 239.4 Hz, C), 
166.2 (C=O). 
19F NMR (282 MHz, CDCl3): δ = -124.13 (CF); 
IR (ATR, cm-1): v~  = 3077 (w), 2983 (w), 2957 (w), 2940 (w), 2923 (w), 2839 
(w), 1869 (w), 1723 (m), 1709 (m), 1620 (w), 1597 (w), 1569 (m), 1490 (s), 1456 (m), 
1429 (m), 1365 (m), 1318 (s), 1294 (m), 1252 (s), 1232 (m), 1203 (m), 1179 (s), 1159 
(s), 1143 (s), 1119 (s), 1057 (m), 1026 (s), 962 (m), 936 (m), 910 (m), 880 (m), 854 
(s), 813 (s), 767 (m), 741 (s), 718 (s), 681 (m), 665 (m), 630 (m), 590 (m); 
MS (GC, 70 eV) m/z (%): 354 (23), 353 (M+, 100), 308 (12), 280 (17), 265 
(16), 264 (14), 250 (22), 29 (47); 
HRMS (EI): calcd. for C21H21FNO3 (M
+) 353.14217, found 353.14233. 
 
Ethyl 6-fluoro-4-(2-methoxyphenyl)quinoline-3-carboxylate (2o): 
Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2o was isolated as white 
solid (228 mg, 89 %); mp = 231 – 233 °C;  
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.68 (s, 3H, OCH3), 4.14 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 7.04 (d, 
3J = 8.3 Hz, 1H, CHAr), 7.09-7.11 (m, 2H, CHAr), 7.18 (dd, 
3J = 10 Hz, 3J = 2.8 Hz, 1H, CHAr), 7.48-7.51 (m, 1H, CHAr), 7.51-7.54 (m, 1H, CHAr), 
8.19 (dd, 3J = 9.2 Hz, 3J = 5.4 Hz, 1H, CHAr), 9.34 (s, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 55.7 (OCH3), 61.3 (CH2CH3), 
110.9 (d, 2JC-F = 23.3 Hz, CH), 110.9 (CH), 120.7 (CH), 121.1 (CH), 121.5 (CH), 124.4 
(C), 125.1 (C), 128.5 (d, 2JC-F = 9.6 Hz, C), 130.2 (d, 
3JC-F = 8.0 Hz, CH), 132.0 (d,  
3JC-F = 9.1 Hz, CH), 146.4 (C), 146.9 (d, 
4JC-F = 5.6 Hz, C), 149.6 (d, 
4JC-F = 2.7 Hz, 
CH), 156.6 (C), 161.0 (d, 1JC-F = 248.5 Hz, C), 166.3 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -111.64 (CF); 
IR (ATR, cm-1): v~ = 3056 (w), 2984 (w), 2961 (w), 2937 (w), 2901 (w), 2839 (w), 1702 (s), 
1623 (m), 1574 (m), 1494 (s), 1461 (s), 1437 (m), 1423 (s), 1367 (m), 1317 (s), 1286 (m), 1256 (s), 
1238 (s), 1220 (s), 1187 (s), 1109 (s), 1102 (s), 1047 (s), 1026 (s), 981 (s), 939 (s), 885 (s), 867 (m), 
847 (s), 827 (m), 786 (s), 760 (s), 733 (s), 684 (m), 631 (m), 618 (s), 565 (s), 527 (s); 
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MS (EI, 70eV): m/z (%) = 326 ([M+H]+, 19), 325 ([M]+, 100), 294 (15), 280 
(51), 279 (13), 267 (14), 266 (75), 265 (25), 252 (25), 251 (15), 250 (27), 238 (21), 
237 (66), 232 (15), 222 (22), 221 (14), 209 (17), 208 (42), 205 (14), 204 (100), 
183 (10), 182 (21), 181 (25), 29 (16); 
HRMS (EI) calcd for C19H16FNO3 ([M]
+) 325.11087, found 325.11088. 
  
Ethyl 4-(2,3-dimethoxyphenyl)-6-fluoroquinoline-3-carboxylate (2p): 
Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2p was isolated as yellow 
crystals (244 mg, 87 %); mp = 55 – 57 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.07 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.52 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.70 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.07 (dd, 
3J = 8.3 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.14-7.21 (m, 2H, CHAr), 7.53 (ddd, 
3J = 9.2 Hz, 
3J = 7.9 Hz, 4J = 2.8 Hz, 1H, CHAr), 8.17 (dd, 
3J = 9.2 Hz, 4J = 5.4 Hz, 1H, CHAr), 9.34 
(s, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 60.7 (OCH3), 
61.4 (CH2CH3), 111.0 (d, 
2JC-F = 23.3 Hz, CH), 113.0 (CH), 121.4 (d, 
2JC-F = 25.9 Hz, 
CH), 121.8 (CH), 124.0 (C), 124.1 (CH), 128.4 (d, 3JC-F = 9.6 Hz, C), 130.7 (C), 132.1 
(d, 3JC-F = 9.1 Hz, CH), 146.2, 146.4 (C), 146.6 (d, 
4JC-F = 5.8 Hz, C), 149.7 (d,  
4JC-F = 2.6 Hz, CH), 152.9 (C), 161.0 (d, 
1JC-F = 248.8 Hz), 166.2 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -111.14 (CF); 
IR (ATR, cm-1): v~ = 2990 (w), 2938 (w), 2829 (w), 1719 (s), 1569 (m), 1506 (s), 1468 (s), 
1423 (s), 1362 (m), 1315 (s), 1259 (s), 1206, 1170 (s), 1111 (s), 1074 (s), 1001 (s), 837 (m), 731 (s); 
MS (EI, 70eV): m/z (%) = 356 ([M+H]+, 22), 355 (M+, 100), 324 (13), 310 (18), 
297 (12), 296 (10), 280 (15), 267 (10), 253 (23), 252 (25), 225 (12), 224 (22), 208 
(12), 204 (30), 169 (13), 29 (16); 
HRMS (EI) calcd for C20H18FNO4 ([M]
+) 355.12144, found 355.12121. 
 
Ethyl 4-(2,5-dimethoxyphenyl)-6-fluoroquinoline-3-carboxylate (2q): 
Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2q was isolated as whitish 
crystals (241 mg, 86 %); mp = 96 – 98 °C;  
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1H NMR (300 MHz, CDCl3): δ = 1.07 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 3.62 (s, 3H, 
OCH3), 3.78 (s, 3H, OCH3), 4.16 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.66 (d, 
4J = 2.4 Hz, 
1H, CHAr), 6.98-7.03 (m, 2H, CHAr), 7.19 (dd, 
3J = 10.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 
7.53 (ddd, 3J = 9.2 Hz, 3J = 7.9 Hz, 4J = 2.8 Hz, 1H, CHAr), 8.17 (dd, 
3J = 9.2 Hz, 
3J = 5.4 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 56.3 (OCH3), 61.3 
(CH2CH3), 110.8 (d, 
2JC-F = 23.2 Hz), 112.1, 114.6, 116.1, 121.3 (d, 
2JC-F = 26.0 Hz), 124.3, 126.0, 
128.3 (d, 3JC-F = 9.6 Hz), 132.2 (d, 
3JC-F = 9.1 Hz), 146.4 (d, 
4JC-F = 5.8 Hz), 146.5, 149.7 (d,  
4JC-F = 2.7 Hz), 150.9, 153.6, 161.0 (d, 
1JC-F = 248.5 Hz), 166.2 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -111.64 (CF); 
IR (ATR, cm-1): v~ = 3034.2 (w), 2987 (w), 2933 (w), 2830 (w), 1734 (s), 1623 (w), 1575.5 
(m), 1495 (s), 1462 (m), 1409 (m), 1364.5 (m), 1290 (m), 1225 (s), 1209 (s), 1193 (s), 1180 (s), 
1111 (m), 1034 (s), 999 (m), 848 (s), 798 (s), 739.7 (s), 727 (m), 674.5 (m). 
MS (EI, 70eV): m/z (%) = 356 ([M+H]+, 22), 355 (M+, 100), 296 (35), 280 (15), 
268 (17), 253 (14), 252 (12), 225 (12), 224 (14), 169 (10), 29 (13). 
HRMS (EI) calcd for C20H18FNO4 ([M]
+) 355.12144, found 355.12155. 
 
Ethyl 6-fluoro-4-(2,3,4-trimethoxyphenyl)quinoline-3-carboxylate (2r): 
Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2r was isolated as light 
yellow crystals (264 mg, 87 %); mp = 111 – 113 °C;  
1H NMR (300 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.58 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 3.95 (s, 3H, 
OCH3), 4.18 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.8 (s, 2H, CHAr), 
7.22 (dd, 3J = 10.0 Hz, 4J = 2.7 Hz, 1H, CHAr), 7.53 (ddd, 
3J = 9.2 Hz, 3J = 7.9 Hz, 
4J = 2.8 Hz, 1H, CHAr), 8.17 (dd, 
3J = 9.2 Hz, 3J = 5.4 Hz, 1H, CHAr), 9.30 (s, 1H, 
CHAr). 
13C NMR (75 MHz, CDCl3): δ = 14.0 (CH2CH3), 56.3 (OCH3), 61.0 (OCH3), 
61.1 (OCH3), 61.44 (CH2CH3), 107.3 (CH), 110.9 (d, 
2JC-F = 23.3 Hz, CH), 121.4 (d, 
2JC-F = 26.1 Hz, CH), 122.7 (C), 124.3 (CH), 124.6, 128.8 (d, 
3JC-F = 9.5 Hz, C), 132.0 
(d, 3JC-F = 9.0 Hz, CH), 142.4 (C), 146.15 (C), 146.5 (C), 149.5 (d, 
4JC-F = 2.5 Hz, 
CH), 151.2 (C), 154.6 (C), 161.1 (d, 1JC-F = 248.8 Hz), 166.3 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -111.3 (CF); 
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IR (ATR, cm-1): v~ = 3066 (w), 2993 (w), 2972 (w), 2947 (w), 2845 (w), 1780 
(s), 1602 (w), 1491 (m), 1463.5 (m), 1411 (m), 1321 (m), 1296 (m), 1181 (s), 
1116 (m), 1092 (s), 1053 (s), 992.4 (m), 838 (m), 730.5 (m). 
MS (EI, 70eV): m/z (%) = 386 ([M+H]+, 19), 385 (M+, 100), 326 (21), 310 (23), 
282 (25), 254 (11), 239 (14), 204 (15), 183 (12), 29 (16). 
HRMS (EI) calcd for C21H20FNO5 ([M]
+) 385.13200, found 385.13172. 
 
Ethyl 4-(2,6-dimethoxyphenyl)-6-fluoroquinoline-3-carboxylate (2s): 
Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2s was isolated as yellow 
crystals (153 mg, 54.5 %); mp = 125 – 126 °C;  
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 3.6 (s, 6H, 2*OCH3), 4.15 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.70 (d, 
3J = 8.4 Hz, 2H, CHAr), 7.12 (dd, 
3J = 10.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 7.43 (t, 
3J = 8.4 Hz, 1H, CHAr), 7.51 (ddd, 
3J = 9.2 Hz, 3J = 8.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 
8.15 (dd, 3J = 9.2 Hz, 3J = 5.4 Hz, 1H, CHAr), 9.37 (s, 1H, CHAr). 
 13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 55.9 (s, 2*OCH3), 61.1 
(CH2CH3), 104.1 (CH), 110.6 (d, 
2JC-F = 23.1 Hz, CH), 113.6 (C), 121.1 (d,  
2JC-F = 26.0 Hz, CH), 124.8 (C), 128.7 (d, 
3JC-F = 9.8 Hz), 130.5 (CH), 132.0 (d,  
3JC-F = 9.2 Hz, CH), 144.3 (d, 
4JC-F = 5.6 Hz, C), 146.4 (C), 149.9 (d, 
4JC-F = 2.6 Hz, 
CH), 157.4 (C), 160.9 (d, 1JC-F = 247.6 Hz, C), 166.0 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -112.74 (CF); 
IR (ATR, cm-1): v~ = 2961 (w), 2926 (w), 2850 (w), 2840 (w), 1702 (s), 1625 
(w), 1582 (s), 1505 (m), 1485 (w), 1471 (s), 1459 (s), 1423 (s), 1390 (s), 1368 (m), 
1357 (m), 1321 (s), 1300 (m), 1248 (s), 1217 (m), 1178 (s), 1104 (s), 1032 (s), 1017 
(s), 980 (s), 957 (m), 944 (m), 904 (w), 863 (s), 835 (s), 792 (m), 781 (s), 763 (s), 743 
(s), 726 (s), 632 (m), 620 (m), 607 (m), 596 (s), 574 (m), 566 (m), 544 (m); 
MS (EI, 70eV): m/z (%) = 356 ([M+H]+, 22), 355 (M+, 100), 296 (35), 280 (15), 
268 (17), 253 (14), 252 (12), 225 (12), 224 (14), 169 (10), 29 (13); 
HRMS (EI) calcd for C20H18FNO4 ([M]
+) 355.12199, found 355.12185. 
 
Ethyl 6-fluoro-4-(5-fluoro-2-methoxyphenyl)quinoline-3-carboxylate (2t): 
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Starting from ethyl 4-chloro-6-fluoroquinoline-3-carboxylate 
(200 mg, 0.79 mmol), the product 2t was isolated as yellow 
crystals (244mg, 90 %); mp = 92 – 94 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 3H, 
CH2CH3), 3.64 (s, 3H, OCH3), 4.17 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.87 
(dd, 3J = 8.2 Hz, 4J = 3.1 Hz, 1H, CHAr), 6.97 (dd, 
3J = 9.2 Hz, 4J = 4.3 Hz, 1H, CHAr), 7.12-7.21 
(m, 2H, CHAr), 7.54 (ddd, 
3J = 9.2 Hz, 3J = 7.9 Hz, 4J = 3.1 Hz, 1H, CHAr), 8.18 (dd, 
3J = 9.2 Hz, 
3J = 5.4 Hz, 1H, CHAr), 9.36 (s, 1H, CHAr).  
13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.2 (OCH3), 61.4 (CH2CH3), 110.5 (d, 
2JC-F = 23.4 Hz, CH), 111.9 (d, 
3JC-F = 8.2 Hz, CH), 116.1 (d, 
2JC-F = 22.7 Hz, CH), 117.1 (d,  
2JC-F = 24.3 Hz, CH), 121.3 (d, 
2JC-F = 26.0 Hz, CH), 124.1 (C), 126.4 (d, 
3JC-F = 7.9 Hz), 128.05 (d, 
3JC-F = 9.7 Hz, C), 132.2 (d, 
3JC-F = 9.1 Hz, CH), 145.4 (d, 
4JC-F = 4.4 Hz, C), 146.4 (C), 149.7 (d,  
4JC-F = 2.7 Hz, CH), 152.85 (d, 
4JC-F = 2.2 Hz, C), 156.9 (d, 
1JC-F = 240.1 Hz, C), 161.1 (d,  
1JC-F = 249.1 Hz, C), 165.8 (C=O). 
19F NMR (282 MHz, CDCl3): δ = -123.70 (CF), -111.12 (CF); 
IR (ATR, cm-1): v~ = 3140 (w), 3050 (w), 2919 (w), 2849 (w), 1921 (w), 1747 (s), 1620 
(m), 1597 (w), 1562 (s), 1510 (s), 1483 (s), 1446 (m), 1421 (s), 1352 (m), 1330 (m), 1310 (m), 1287 
(m), 1261 (m), 1232 (m), 1203 (s), 1163 (s), 1151 (s), 1116 (m), 1083 (s), 1004 (s), 986 (s), 965 
(m), 890 (m), 858 (s), 837 (s), 821 (s), 753 (m), 742 (s), 727 (m), 709 (s), 682 (m), 661 (m), 648 
(m), 605 (m), 595 (s), 546 (m); 
MS (EI, 70eV): m/z (%) = 344 (20), 343 (100), 312 (13), 285 (14), 284 (87), 283 (25), 270 
(13); 
HRMS (EI) calcd for C19H15F2NO3 ([M]
+) 343.10145, found 343.10136. 
 
Ethyl 4-(2,5-dimethoxyphenyl)-6-nitroquinoline-3-carboxylate (2u): 
Starting from ethyl 4-chloro-6-nitroquinoline-3-carboxylate 
(200 mg, 0.71 mmol), the product 2u was isolated as yellow 
crystals (140 mg, 51 %); mp = 164 – 166 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.08 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 3.64 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 4.20 
(q, 3J = 7.1 Hz, 2H, CH2CH3), 6.70 (d, 
4J = 2.8 Hz, 1H, CHAr), 7.01 (d, 
3J = 9.0 Hz, 
1H, CHAr), 7.08 (dd, 
3J = 9.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 8.31 (dd, 
3J = 9.0 Hz, 
5J = 0.5 Hz, 1H, CHAr), 8.50 (d, 
4J = 2.5 Hz, 1H, CHAr), 8.52 – 8.56 (m, 1H, CHAr), 
9.5 (s, 1H, CHAr). 
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13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 56.2 (OCH3), 
61.7 (CH2CH3), 112.3 (CH), 115.4 (CH), 116.3 (CH), 124.4 (CH), 124.6 (CH), 124.6 
(C), 125.6 (C), 126.6 (C), 131.5 (CH), 146.3 (C), 149.0 (C), 150.7 (C), 151.1 (C), 
153.6 (CH), 153.8 (C), 165.6 (C=O). 
IR (ATR, cm-1): v~ = 3091 (w), 3061 (w), 2993 (w), 2959 (w), 2937 (w), 2921 
(w), 2838 (w), 1920 (w), 1850 (w), 1808 (w), 1723 (s), 1621 (m), 1573 (m), 1538 (m), 
1504 (s), 1489 (s), 1465 (m), 1454 (m), 1440 (m), 1419 (m), 1411 (m), 1375 (w), 1338 
(s), 1296 (m), 1282 (m), 1270 (m), 1210 (s), 1177 (s), 1141 (s), 1121 (m), 1076 (s), 
1032 (s), 1003 (m), 965 (m), 904 (m), 886 (m), 844 (s), 807 (s), 746 (s), 729 (m), 694 
(m), 669 (m), 640 (m), 619 (m), 592 (m), 563 (m), 551 (m), 529 (w); 
MS (EI, 70eV): m/z (%) = 383 ([M+H]+, 22), 382 ([M]+, 100), 323 (20), 249 
(20), 177 (11), 123 (11), 29 (14); 
HRMS (EI): calcd. for C20H18N2O6 (M
+) 382.11594, found 382.11575. 
 
Ethyl 7-chloro-4-(2-methoxyphenyl)quinoline-3-carboxylate (2v): 
Starting from ethyl 4,7-dichloroquinoline-3-carboxylate 
(200 mg, 0.74 mmol), the product 2v was isolated as yellow 
crystals (154 mg, 61.5 %); mp = 88 – 89 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 
1H, CH2CH3), 3.67 (s, 1H, OCH3), 4.13 (q, 
3J = 7.1 Hz, 1H, 
CH2CH3), 7.03 (d, 
3J = 8.3 Hz, 1H, CHAr), 7.07-7.12 (m,2H, CHAr), 7.41 (dd, 
3J = 9.0 Hz, 4J = 2.1 Hz, 1H, CHAr), 7.44 – 7.53 (m, 2H, CHAr), 8.17 (d, 
4J = 2.1 Hz, 
1H, CHAr), 9.38 (s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 13.7 (CH2CH3), 55.5 (OCH3), 61.1 (CH2CH3), 
110.8 (CH), 120.5 (CH), 123.75 (C), 125.0 (C), 125.7 (C), 128.1 (CH), 128.45 (CH), 
128.9 (CH), 130.0 (CH), 130.1 (CH), 137.1 (C), 147.3 (C), 149.6 (C), 151.4 (CH), 
156.5 (C), 166.1 (C=O). 
IR (ATR, cm-1): v~ = 3069 (w), 3000 (w), 2976 (w), 2933 (w), 2835 (w), 1709 (s), 1600 
(m), 1583 (m), 1561 (m), 1497 (m), 1480 (m), 1461 (m), 1453 (m), 1435 (m), 1400 (m), 1368 (m), 
1346 (w), 1318 (s), 1290 (m), 1253 (s), 1238 (s), 1207 (s), 1185 (m), 1163 (m), 1149 (s), 1122 (s), 
1108 (s), 1070 (m), 1052 (m), 1027 (s), 988 (m), 964 (m), 956 (m), 923 (m), 881 (m), 828 (m), 790 
(s), 764 (s), 712 (m), 674 (m), 624 (s), 582 (m), 571 (m), 545 (w), 533 (w); 
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MS (EI, 70eV): m/z (%) = 343 (35), 342 ([M+H]+, 22), 341 ([M]+, 100), 312 
(13), 310 (25), 298 (23), 297 (17), 296 (68), 295 (12), 284 (26), 283 (19), 282 (83), 
281 (15), 269 (10), 268 (29), 267 (13), 266 (28), 255 (21), 254 (20), 253 (59), 248 
(16), 233 (12), 232 (15), 224 (11), 222 (29), 221 (13), 220 (91), 218 (20), 204 (15), 
203 (11), 202 (12), 201 (14), 190 (39), 189 (13), 188 (12), 176 (16), 164 (14), 163 
(31), 162 (11), 29 (49); 
HRMS (EI) calcd for C19H16
35ClNO3 ([M]
+) 341.08132, found 341.08159; 
HRMS (EI) calcd for C19H16
37ClNO3 ([M]
+) 343.07837, found 343.07916. 
 
Ethyl 7-chloro-4-(2,3,4-trimethoxyphenyl)quinoline-3-carboxylate (2w): 
Starting from ethyl 4,7-dichloroquinoline-3-carboxylate 
(200 mg, 0.74 mmol), the product 2w was isolated as yellow 
crystals (196 mg, 72 %); mp = 104 – 105 °C; 
1H NMR (250 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 3.56 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 3.94 
(s, 3H, OCH3), 4.19 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.78 (s, 
2H, CHAr), 7.43 (dd, 
3J = 9.0 Hz, 4J = 2.1 Hz, 1H, CHAr), 7.56 (d, 
3J = 9.0 Hz, 1H, 
CHAr), 8.16 (d, 
4J = 2.1 Hz, 1H, CHAr), 9.35 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 14.0 (CH2CH3), 56.2 (OCH3), 61.0 (OCH3), 
61.1 (OCH3), 61.4 (CH2CH3), 107.2 (CH), 122.8 (C), 124.1 (C), 124.3 (CH), 126.1 (C), 
128.3 (CH), 128.7 (CH), 129.0 (CH), 137.2 (C), 142.3 (C), 146.9 (C), 149.7 (C), 151.2 
(C), 151.5 (CH), 154.5 (C), 166.3 (C=O). 
IR (ATR, cm-1): v~ = 3062 (w), 2975 (w), 2936 (w), 2906 (w), 2836 (w), 1699 (s), 1598 
(m), 1568 (m), 1498 (m), 1479 (m), 1462 (m), 1441 (m), 1411 (m), 1375 (m), 1366 (m), 1346 (w), 
1318 (m), 1291 (s), 1261 (s), 1222 (s), 1206 (s), 1183 (m), 1166 (m), 1150 (m), 1125 (m), 1094 (s), 
1073 (s), 1054 (s), 1013 (s), 995 (s), 947 (m), 934 (m), 917 (m), 894 (m), 877 (m), 864 (m), 846 
(m), 829 (m), 815 (m), 794 (s), 759 (m), 691 (m), 684 (m), 658 (m), 635 (m), 610 (m), 599 (m), 565 
(w), 530 (m); 
MS (EI, 70eV): m/z (%) = 402 ([M+H]+, 22), 401 ([M]+, 100), 342 (27), 326 
(25), 300 (10), 298 (26), 255 (12), 220 (18), 164 (13), 153 (14), 29 (33); 
HRMS (EI) calcd for C21H20
35ClNO5 ([M]
+) 401.10245, found 401.10205; 
HRMS (EI) calcd for C21H20
37ClNO5 ([M]
+) 403.09950, found 403.09969. 
 
Ethyl 4,7-bis(2,5-dimethoxyphenyl)quinoline-3-carboxylate (2x): 
85 
 
Starting from ethyl 4,7-dichloroquinoline-3-carboxylate (200 mg, 0.74 mmol), the 
product 2x was isolated as yellow crystals (260mg, 65 %); mp = 231 – 233 °C; 
1H NMR (300 MHz, CDCl3): δ = 1.11 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 3.6 (s, 3H, 
OCH3), 3.78 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.8 
(s, 3H, OCH3), 4.2 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 
6.7 (dd, 4J = 2.7 Hz, 5J = 0.5 Hz, 1H, CHAr), 6.92 
(dd, 3J = 8.9 Hz, 4J = 2.9 Hz, 1H, CHAr), 6.95 (s, 
1H, CHAr), 6.98 (s, 1H, CHAr), 6.99 (d, 
4J = 2.7 Hz, 
1H, CHAr), 7.04 (t, 
4J = 2.7 Hz, 1H, CHAr), 7.62 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.72 (dd, 
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 8.33 (d, 
4J = 1.5 Hz, 1H, CHAr), 9.40 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 56.0 (OCH3), 56.05 (OCH3), 
56.4 (OCH3), 56.4 (OCH3), 61.1 (CH2CH3), 112.1 (CH), 112.9 (CH), 114.4 (CH), 114.5 
(CH), 116.2 (CH), 116.7 (CH), 123.3 (C), 126.2 (C), 126.7 (C), 126.9 (CH), 129.4 
(CH), 129.6 (CH), 130.3 (C), 141.6, 146.9, 149.5 (C), 150.6 (CH), 151.0 (C), 151.1 
(C), 153.5 (C), 154.0 (C), 166.3 (C=O); 
IR (ATR, cm-1): v~ = 3067 (w), 3001 (w), 2929 (w), 2832 (w), 1728 (s), 1613 
(w), 1573 (m), 1495 (s), 1462 (s), 1454 (m), 1425 (m), 1417 (m), 1394 (w), 1378 (m), 
1365 (m), 1348 (m), 1302 (m), 1286 (m), 1273 (m), 1286 (m), 1273 (m), 1225 (s), 1213 
(s), 1179 (s), 1164 (s), 1154 (s), 1142 (s), 1134 (s), 1105 (m), 1041 (s), 1033 (s), 1019 
(s), 942 (m), 927 (m), 886 (m), 871 (m), 838 (m), 820 (s), 795 (s), 763 (m), 743 (s), 
733 (s), 728 (s), 697 (s), 682 (m), 664 (m), 637 (m), 621 (m), 601 (m), 581 (w), 547 
(m), 536 (m); 
MS (EI, 70eV): m/z (%) = 474 ([M+H]+, 22), 473 ([M]+, 100), 342 (27), 326 
(25), 300 (10), 298 (26), 255 (12), 220 (18), 164 (13), 153 (14); 
HRMS (EI) calcd for C28H27NO6 ([M]
+) 473.18384, found 473.18389. 
 
General procedure for the synthesis of compounds 3a-x: 
To a solution of 2 in anhydrous CH2Cl2 (10 mL) at 0 °C was added solution of 
boron tribromide (3 mmol). The cold bath was removed and the reaction mixture was 
allowed to warm to 23 °C. Upon removal of the cold bath, all of the boron tribromide 
went into solution to form a deep red homogenous solution, and as the temperature 
approaches 23 °C, a solid began to precipitate from solution. The mixture was stirred at 
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23 °C for 12 h and then quenched by the addition of MeOH (4 mL). Upon addition of 
MeOH solid redissolved and formed a red homogenous solution. After stirring for 15 
min organic solvents were concentrated under reduced pressure. Upon addition of 
water (10 mL), a bright yellow precipitate was formed and collected by filtration  
a n d  a d d i t i o n a l y  w a s h e d  w i t h  w a t e r  ( 5 m L )  to provide pure  
6H-chromeno[3,4-c]quinolin-6-ones 3. 
 
4-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3a): 
Starting from compound 2a (100 mg, 0.29 mmol), the product 3a was 
isolated as yellow solid (69 mg, 88 %); mp = 278 – 280 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 7.27 (dd, 
3J = 8.0 Hz, 
4J = 1.3 Hz, 1H, CHAr), 7.36 (t, 
3J = 8.1 Hz, 1H, CHAr), 7.88 (ddd, 
3J = 8.4 Hz, 3J = 7.0 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.04 (ddd, 
3J = 8.3 Hz, 3J = 6.9 Hz, 4J = 1.2 Hz, 1H, CHAr), 8.13 (dd, 
3J = 8.2 Hz, 4J = 0.9 Hz, 
1H, CHAr), 8.24 (dd, 
3J = 8.4 Hz, 4J = 0.9 Hz, 1H, CHAr), 8.95 (d, 
3J = 8.5 Hz, 1H, 
CHAr), 9.50 (s, 1H, CHAr), 10.39 (s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 113.8 (C), 117.5 (C), 118.7 (CH), 119.0 
(CH), 121.7 (C), 124.8 (CH), 127.2 (CH), 128.65 (CH), 129.9 (CH), 132.4 (CH), 140.9 
(CH), 141.5 (C), 145.8 (C), 149.05 (C), 149.7 (C), 159.5 (C=O); 
IR (ATR, cm-1): v~ = 3079 (w), 3052 (w), 2918 (w), 2834 (w), 2724 (w), 2128 
(w), 1884 (w), 1733 (m), 1621 (m), 1593 (m), 1578 (m), 1558 (s), 1514 (s), 1485 (s), 
1426 (m), 1374 (m), 1359 (s), 1320 (m), 1304 (s), 1265 (m), 1251 (m), 1236 (m), 1205 
(s), 1175 (m), 1157 (m), 1119 (m), 1104 (s), 1017 (s), 985 (m), 942 (m), 890 (w), 859 
(m), 843 (s), 824 (s), 814 (m), 790 (m), 757 (s), 745 (s), 713 (m), 688 (m), 667 (m), 
651 (m), 610 (m), 602 (s), 551 (w), 530 (m); 
MS (EI, 70eV): m/z (%) = 264 ([M+H]+, 19), 263 ([M]+, 100), 235 (44), 207 
(11), 179 (13), 178 (18), 152 (15), 151 (17), 76 (12); 
HRMS (EI) calcd for C16H9NO3 ([M]
+) 263.05769, found 263.05793. 
 
2-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3b): 
Starting from compound 2a (100 mg, 0.29 mmol), the product 3a was isolated as 
yellow solid (69 mg, 88 %); mp = 278 – 280 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 7.17 (dd, 
3J = 8.9 Hz, 4J = 2.6 Hz, 1H, 
CHAr), 7.43 (d, 
3J = 8.9 Hz, 1H, CHAr), 7.88 (t, 
3J = 7.5 Hz, 1H, CHAr), 8.01 – 8.06 (m, 
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2H, CHAr), 8.22 (d, 
3J = 8.2 Hz, 1H, CHAr), 8.87 (d, 
3J = 8.6 Hz, 1H, 
CHAr), 9.4 (s, 1H, CHAr), 9.9 (s, 1H, OH). 
 13C NMR (63 MHz, DMSO-d6): δ = 113.2, 113.8, 117.0, 118.8, 
120.4, 121.5, 126.6, 128.5, 130.4, 132.2, 139.9, 145.7, 149.3, 150.1, 
154.2, 159.8; 
 IR (ATR, cm-1): v~ = 3500 (w), 3307 (w), 2918 (br. m), 2849 (br. m), 2668 (br. 
m), 1731 (s), 1557 (m), 1434 (m), 1352 (m), 1251 (m), 1230 (m), 113 (m), 1105 (m), 
769 (s), 751 (s), 657 (m), 594 (s), 546 (m); 
 MS (GC-MS): m/z (%) = 264 ([M+H]+, 17), 263 ([M]+, 100), 235 (30), 207 (17), 
97 (11), 83 (11), 73 (12), 69 (26), 60 (16), 57 (15), 55 (18), 44 (71), 43 (42), 41 (13).  
HRMS (ESI): calcd. for C16H9NO3 (M+H
+) 263.05769, found 263.05765. 
  
1-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3c): 
Starting from compound 2c (100 mg, 0.29 mmol), the product 3c was 
isolated as yellow solid (34 mg, 43 %); mp = 269 – 270 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 7.00 (d, 
3J = 8.2 Hz, 2H, 
CHAr), 7.56 (t, 
3J = 8.2 Hz, 1H, CHAr), 7.67 (t, 
3J = 7.3 Hz, 1H, 
CHAr), 7.94 (t, 
3J = 7.3 Hz, 1H, CHAr), 8.12 (d, 
3J = 8.3 Hz, 1H, 
CHAr), 8.39 (d, 
3J = 8.3 Hz, 1H, CHAr), 9.42 (s, 1H, CHAr), 11.12 (s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 105.6 (C), 107.4 (CH), 112.55 (CH), 114.4 
(C), 121.4 (C), 125.3 (CH), 128.55 (CH), 130.4 (CH), 132.1 (CH), 133.1 (CH), 141.3 
(C), 148.2 (CH), 149.9 (C), 153.5 (C), 156.0 (C), 159.8 (C=O). 
IR (ATR, cm-1): v~ = 3043 (w), 2921 (w), 2850 (w), 2600 (w), 1749 (s), 1607 (s), 
1593 (m), 1576 (m), 1553 (m), 1507 (m), 1455 (m), 1418 (m), 1356 (s), 1301 (s), 1280 
(s), 1218 (m), 1196 (m), 1154 (m), 1125 (m), 1089 (m), 1047 (s), 1017 (m), 975 (m), 
911 (m), 870 (w), 835 (m), 798 (m), 759 (s), 731 (s), 670 (m), 642 (m), 627 (m), 592 
(m), 560 (s), 528 (m); 
MS (EI, 70eV): m/z (%) = 264 ([M+H]+, 17), 263 ([M]+, 100), 262 (62), 235 
(40), 178 (22), 152 (11), 151 (15), 76 (11); 
HRMS (ESI): calcd. for C16H9NO3 (M+H
+) 263.05769, found 263.05775; 
 
3,4-dihydroxy-6H-chromeno[3,4-c]quinolin-6-one (3d): 
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Starting from compound 2d (100 mg, 0.27 mmol), the product 3d was 
isolated as yellow solid (69 mg, 90 %); mp = 300 – 302 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 7.00 (d, 
3J = 8.8 Hz, 1H, 
CHAr), 7.82 (d, 
3J = 7.2 Hz, 1H, CHAr), 7.94 – 8.10 (m, 2H, CHAr), 
8.16 (d, 3J = 8.4 Hz, 1H, CHAr), 8.87 (d, 
3J = 8.0 Hz, 1H, CHAr), 9.41 
(d, 3J = 8.7 Hz, 1H, CHAr), 9.53 (s, 1H, OH), 10.47 (s, 1H, OH).
 
13C NMR (63 MHz, DMSO-d6): δ = 109.3, 111.7 (C), 112.8 (CH), 119.7 (CH), 
121.6 (C), 127.3 (CH), 128.2 (CH), 130.0 (CH), 132.1 (CH), 133.2 (C), 141.5 (C), 
143.0 (C), 149.3 (CH), 149.9 (C), 150.2 (C), 160.0 (C=O). 
IR (ATR, cm-1): v~ = 3036 (w), 2919 (w), 2849 (w), 2724 (w), 1715 (m), 1600 
(m), 1573 (s), 1557 (s), 1503 (s), 1449 (s), 1366 (m), 1350 (m), 1292 (s), 1266 (s), 
1186 (s), 1128 (s), 1102 (s), 1076 (s), 1039 (s), 1020 (s), 960 (m), 931 (m), 890 (m), 
869 (m), 788 (m), 765 (s), 748 (s), 718 (s), 659 (s), 605 (m), 577 (s), 527 (s); 
MS (EI, 70eV): m/z (%) = 280 ([M+H]+, 15), 279 (M+, 100), 251 (21); 
HRMS (ESI-TOF) calcd for C16H9NO4 ([M-H]
+) 278.04588, found 278.04627. 
 
11-methyl-6H-chromeno[3,4-c]quinolin-6-one (3e): 
Starting from compound 2e (100 mg, 0.31 mmol), the product 3e 
was isolated as yellow solid (62 mg, 76 %); mp = 219 – 220°C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.57 (s, 1H, CH3), 
7.47 (dd, 3J = 8.4 Hz, 4J = 1.1 Hz, 1H, CHAr), 7.49 – 7.53 (m, 
1H, CHAr), 7.71 (ddd, 
3J = 8.3 Hz, 3J = 7.2 Hz, 4J = 1.4 Hz, 1H, 
CHAr), 7.8 (dd, 
3J = 8.5 Hz, 4J = 1.6 Hz, 1H, CHAr), 8.00 (d, 
3J = 8.5 Hz, 1H, CHAr), 
8.49 (s, 1H, CHAr), 8.58 (d, 
3J = 8.2 Hz, 1H, CHAr), 9.28 (s, 1H, CHAr). 
13C NMR (63 MHz, DMSO-d6): δ = 21.5 (CH3), 113.9 (C), 116.8 (C), 117.8 
(CH), 121.50 (C), 125.1 (CH), 125.7 (CH), 128.9 (CH), 130.0 (CH), 132.5 (CH), 134.3 
(CH), 138.8 (C), 139.4 (C), 148.2 (CH), 148.6 (C), 152.5 (C), 159.7 (C=O). 
IR (ATR, cm-1): v~ = 3420 (w), 3060 (w), 2923 (w), 2852 (w), 1715 (s), 1606 (s), 
1591 (s), 1567 (s), 1550 (s), 1510 (s), 1487 (m), 1454 (m), 1421 (s), 1377 (m), 1354 
(s), 1309 (m), 1272 (m), 1241 (m), 1218 (s), 1159 (m), 1129 (m), 1118 (m), 1094 (s), 
1045 (m), 982 (s), 961 (m), 946 (m), 896 (m), 870 (m), 828 (s), 797 (m), 764 (s), 751 
(s), 725 (s), 678 (m), 661 (m), 650 (m), 626 (m), 605 (s), 590 (m), 530 (m); 
MS (GC/MS, 70eV): m/z (%) = 262 ([M+H]+, 19), 261 ([M]+, 100), 246 (15), 234 
(13), 233 (73), 232 (25), 218 (14), 204 (11), 190 (11), 176 (15), 88 (12); 
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HRMS (EI) calcd for C17H11NO2 ([M]
+) 261.07843, found 261.07839. 
 
4-hydroxy-11-methyl-6H-chromeno[3,4-c]quinolin-6-one (3f): 
Starting from compound 2f (100 mg, 0.285 mmol), the product 3f 
was isolated as yellow solid (64 mg, 81 %); mp = 299 – 301 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.6 (s, 3H, CH3), 7.23 
(dd, 3J = 8.0 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.31 (t, 
3J = 8.1 Hz, 
1H, CHAr), 7.79 (dd, 
3J = 8.5 Hz, 4J = 1.4 Hz, 1H, CHAr), 8.03 
(dd, 3J = 8.3 Hz, 4J = 2.4 Hz, 2H, CHAr), 8.55 (s, 1H, CHAr), 9.34 (s, 1H, CHAr), 10.33 
(s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 21.45 (CH3), 113.7 (C), 117.6 (C), 118.6 
(CH), 118.7 (CH), 121.6 (C), 124.70 (CH), 125.8 (CH), 129.82 (CH), 134.1 (CH), 
138.45 (C), 139.8 (C), 141.3 (C), 145.75 (C), 148.2 (CH), 148.5 (C), 159.55 (C=O).  
IR (ATR, cm-1): v~ = 3072 (w), 3041 (w), 2917 (w), 2852 (w), 2744 (w), 1741 
(m), 1719 (s), 1620 (w), 1574 (s), 1556 (m), 1512 (m), 1483 (m), 1425 (m), 1355 (s), 
1324 (m), 1299 (s), 1280 (m), 1230 (m), 1217 (m), 1196 (m), 1157 (m), 1141 (s), 1096 
(m), 1053 (m), 972 (m), 943 (m), 927 (m), 867 (m), 828 (s), 800 (m), 768 (s), 748 (s), 
729 (s), 648 (m), 633 (m), 592 (m), 559 (s); 
MS (GC, 70 eV) m/z (%): 278 (19), 277 (M+, 100), 249 (48), 248 (18), 221 
(10), 192 (10), 165 (13), 82 (12); 
HRMS (EI): calcd. for C17H11NO3 (M
+) 277.07334, found 277.07336. 
 
2-hydroxy-11-methyl-6H-chromeno[3,4-c]quinolin-6-one (3g): 
Starting from compound 2g (100 mg, 0.285 mmol), the product 
3g was isolated as yellow solid (69 mg, 87 %);  
mp = 229–230 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 2.65 (s, 1H, CH3), 7.2 
(d, 3J = 7.4 Hz, 1H, CHAr), 7.4 (d, 
3J = 8.4 Hz, 1H, CHAr), 7.9 
(d, 3J = 8.3 Hz, 1H, CHAr), 8.03 – 8.21 (m, 2H, CHAr), 8.65 (s, 1H, CHAr), 9.40 (s, 1H, 
CHAr), 9.96 (s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 21.6 (CH3), 113.2 (CH), 113.8 (C), 117.2 
(C), 118.8 (CH), 120.2 (CH), 121.6 (C), 125.45 (CH), 130.1 (CH), 134.1 (CH), 138.5 
(C), 139.2 (C), 145.65 (C), 148.4 (CH), 148.7 (C), 154.10 (C), 159.9 (C=O). 
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IR (ATR, cm-1): v~ = 3014 (w), 2918 (w), 2814 (w), 2704 (w), 2624 (w), 1733 
(m), 1621 (w), 1591 (m), 1573 (m), 1553 (s), 1512 (m), 1483 (s), 1420 (m), 1372 (m), 
1356 (s), 1323 (m), 1303 (s), 1274 (m), 1236 (m), 1216 (m), 1205 (m), 1183 (s), 1132 
(s), 1100 (m), 1027 (m), 1003 (m), 965 (m), 939 (m), 889 (w), 860 (m), 822 (s), 813 
(s), 747 (s), 712 (m), 686 (m), 663 (m), 652 (m), 602 (m), 548 (w); 
MS (EI, 70eV): m/z (%) = 278 ([M+H]+, 15), 277 ([M]+, 100), 249 (25); 
HRMS (EI) calcd for C17H11NO3 ([M]
+) 277.07334, found 277.07368. 
 
3,4-dihydroxy-11-methyl-6H-chromeno[3,4-c]quinolin-6-one (3h): 
Starting from compound 2h (100 mg, 0.26 mmol), the product 
3h was isolated as yellow solid (69 mg, 90 %); mp = 350 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3H, CH3), 
5.52 (br.s, 2H), 7.04 (d, 3J = 9.0 Hz, 1H, CHAr), 7.93 (dd, 
3J = 8.6 Hz, 4J = 1.4 Hz, 1H, CHAr), 8.08 (d, 
3J = 9.4 Hz, 1H, 
CHAr), 8.11 (d, 
3J = 8.6 Hz, 1H, CHAr), 8.64 (s, 1H, CHAr), 9.47 (s, 1H, CHAr). 
13C NMR (75 MHz, DMSO-d6): δ = 21.4 (CH3), 108.95 (C), 111.90 (C), 113.25 
(CH), 120.85 (CH), 122.05 (C), 125.9 (CH), 126.75 (CH), 133.2 (C), 135.6 (CH), 139.6 
(C), 143.1 (C), 143.3 (C), 144.1 (C), 146.5 (CH), 151.7 (C), 159.1 (C=O). 
IR (ATR, cm-1): v~ = 3578 (w), 3396 (w), 3090 (m), 2975 (w), 2924 (w), 2885 
(w), 2751 (m), 1945 (w), 1842 (w), 1730 (s), 1610 (m), 1597 (m), 1565 (s), 1493 (m), 
1445 (s), 1401 (s), 1380 (s), 1353 (s), 1309 (m), 1289 (s), 1268 (s), 1250 (s), 1205 (s), 
1149 (m), 1117 (m), 1083 (m), 1037 (m), 1013 (w), 976 (w), 954 (w), 872 (m), 827 
(m), 815 (m), 795 (m), 779 (s), 742 (s), 709 (m), 688 (s), 669 (m), 605 (m), 590 (m), 
572 (m); 
MS (EI, 70eV): m/z (%) = 294 ([M+H]+, 32), 293 ([M]+, 100), 278 (10), 265 
(39), 264 (11), 84 (20), 82 (27), 80 (26), 66 (22); 
HRMS (ESI-TOF) calcd for C17H11NO4 ([M+H]
+) 294.07608, found 294.07614. 
 
2-fluoro-11-methyl-6H-chromeno[3,4-c]quinolin-6-one (3i): 
Starting from compound 2i (100 mg, 0.29 mmol), the product 3i 
was isolated as yellow solid (45 mg, 55 %); mp = 225 – 226 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 2.67 (s, 3H, CH3), 7.6 
(dd, 3J = 7.0 Hz, 4J = 2.1 Hz, 2H, CHAr), 7.86 (dd, 
3J = 8.5 Hz, 
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4J = 1.6 Hz, 1H, CHAr), 8.12 (d, 
3J = 8.5 Hz, 1H, CHAr), 8.37 – 8.50 (m, 1H, CHAr), 
8.61 (s, 1H, CHAr), 9.42 (s, 1H, CHAr). 
13C NMR (63 MHz, DMSO-d6): δ = 20.8 (CH3), 113.3 (C), 113.9 (d,  
2JC-F = 26.3 Hz, CH), 117.4 (d, 
3JC-F = 8.8 Hz, C), 118.9 (d, 
2JC-F = 24.3 Hz, CH), 
119.1 (d, 3JC-F = 8.7 Hz, CH), 120.9 (C), 124.5 (CH), 129.6 (CH), 133.7 (CH), 137.8 
(d, 4JC-F = 2.5 Hz, C), 138.5 (C), 147.6 (CH), 148.4 (d, 
4JC-F = 2.0 Hz, C), 148.5 (C), 
157.8 (d, 1JC-F = 241.6 Hz, C), 158.7 (C=O). 
19F NMR (235 MHz, DMSO-d6): δ = -116.00 (CF). 
IR (ATR, cm-1): v~ = 3135 (w), 3088 (w), 3036 (w), 2952 (w), 2921 (w), 2851 
(w), 1881 (w), 1740 (s), 1623 (w), 1598 (w), 1569 (s), 1555 (s), 1512 (m), 1485 (s), 
1433 (s), 1417 (m), 1377 (m), 1350 (s), 1330 (m), 1307 (m), 1291 (m), 1264 (s), 1236 
(m), 1221 (s), 1172 (s), 1134 (s), 1090 (s), 1014 (s), 999 (s), 963 (m), 941 (m), 894 
(m), 869 (m), 851 (m), 834 (s), 818 (s), 752 (s), 741 (s), 728 (m), 709 (m), 684 (m), 
657 (m), 649 (m), 597 (s), 541 (m); 
MS (EI, 70eV): m/z (%) = 280 ([M+H]+, 18), 279 ([M]+, 100), 264 (14), 252 
(14), 251 (77), 250 (29), 236 (18), 194 (11); 
HRMS (EI) calcd for C17H10FNO2 ([M]
+) 279.06901, found 279.06917. 
 
9,11-dimethyl-6H-chromeno[3,4-c]quinolin-6-one (3j): 
Starting from compound 2j (100 mg, 0.298 mmol), the product 3j was isolated as 
yellow solid (65 mg, 79 %); mp = 231 – 232 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 2.59 (s, 1H, CH3), 
2.77 (s, 1H, CH3), 7.45 – 7.60 (m, 2H, CHAr), 7.64 – 7.79 (m, 
2H, CHAr), 8.42 – 8.51 (m, 1H, CHAr), 8.58 – 8.70 (m, 1H, 
CHAr), 9.40 (s, 1H, CHAr). 
13C NMR (63 MHz, DMSO-d6): δ = 17.6 (CH3), 22.3 
(CH3), 113.0 (C), 116.6 (C), 117.2 (CH), 121.1 (C), 122.8 (CH), 124.3 (CH), 128.3 
(CH), 131.7 (CH), 133.9 (CH), 133.9 (C), 136.9 (C), 137.5 (C), 146.3 (CH), 146.35 
(C), 152.0 (C), 159.0 (C=O); 
IR (ATR, cm-1): v~  = 3084 (w), 3005 (w), 2986 (w), 2947 (w), 2914 (w), 2603 
(m), 1998 (w), 1873 (w), 1730 (s), 1620 (w), 1600 (m), 1567 (s), 1480 (m), 1446 (w), 
1417 (m), 1405 (m), 1372 (m), 1349 (m), 1305 (m), 1269 (m), 1238 (m), 1205 (m), 
1197 (s), 1158 (m), 1141 (m), 1105 (s), 1035 (m), 1002 (m), 928 (w), 881 (s), 811 (m), 
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798 (m), 761 (s), 730 (m), 676 (w), 655 (m), 629 (m), 609 (m), 584 (m), 554 (m), 528 
(w); 
MS (EI, 70eV): m/z (%) = 276 ([M+H]+, 21), 275 (M+, 100), 247 (15), 232 (18); 
HRMS (ESI-TOF): calcd. for C18H13NO2 (M+H
+) 275.09463, found 275.09471. 
 
4-hydroxy-9,11-dimethyl-6H-chromeno[3,4-c]quinolin-6-one (3k): 
Starting from compound 2k (100 mg, 0.27 mmol), the product 3k 
was isolated as yellow solid (65 mg, 82 %); mp = 249 – 251 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.5 (s, 3H+solvent, 
CH3), 2.7 (s, 3H, CH3), 7.22 (d, 
3J = 7.5 Hz, 1H, CHAr), 7.29 (t, 
3J = 8.0 Hz, 1H, CHAr), 7.64 (s, 1H, CHAr), 7.95 (d, 
3J = 8.0 Hz, 
1H, CHAr), 8.33 (s, 1H, CHAr), 9.32 (s, 1H, CHAr), 10.30 (s, 1H, 
OH). 
13C NMR (63 MHz, DMSO-d6): δ = 18.2 (CH3), 21.5 (CH3), 113.4 (C), 117.7 
(C), 118.6 (CH), 118.8 (CH), 121.5 (C), 123.7 (CH), 124.6 (CH), 134.3 (CH), 137.3 
(C), 137.75 (C), 139.8 (C), 141.2 (C), 145.8 (C), 147.05 (CH), 147.4 (C), 159.6 (C=O). 
IR (ATR, cm-1): v~  = 3446 (w), 3040 (w), 2947 (w), 2847 (w), 2781 (w), 2734 
(w), 2671 (w), 2642 (w), 1693 (s), 1613 (m), 1574 (s), 1557 (m), 1509 (m), 1479 (m), 
1459 (m), 1411 (s), 1375 (s), 1351 (s), 1318 (m), 1299 (s), 1266 (m), 1251 (m), 1196 
(m), 1184 (m), 1162 (s), 1100 (m), 1089 (m), 1016 (m), 987 (w), 960 (m), 934 (m), 879 
(m), 844 (m), 810 (m), 790 (s), 775 (s), 756 (s), 724 (s), 701 (s), 601 (s), 558 (s); 
MS (EI, 70eV): m/z (%) = 292 ([M+H]+, 20), 291 ([M]+, 100), 263 (12), 248 
(12); 
HRMS (EI): calcd. for C18H13NO3 (M
+) 291.08899, found 291.08917. 
 
2-hydroxy-9,11-dimethyl-6H-chromeno[3,4-c]quinolin-6-one (3l): 
Starting from compound 2l (100 mg, 0.27 mmol), the product 3l 
was isolated as yellow solid (69 mg, 86 %); mp = 258 – 260°C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.50 (s, 3H, CH3), 
2.62 (s, 3H, CH3), 7.09 (dd, 
3J = 8.9 Hz, 4J = 2.5 Hz, 1H, CHAr), 
7.33 (d, 3J = 8.9 Hz, 1H, CHAr), 7.57 (s, 1H, CHAr), 7.86 (d, 
4J = 2.5 Hz, 1H, CHAr), 8.22 (s, 1H, CHAr), 9.21 (s, 1H, CHAr). 
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13C NMR (63 MHz, DMSO-d6): δ = 18.2 (CH3), 21.6 (CH3), 113.2 (CH), 113.3 
(C), 116.9 (C), 118.6 (CH), 120.1 (CH), 121.3 (C), 123.15 (CH), 134.2 (CH), 137.1 
(C), 137.7 (C), 139.1 (C), 145.4 (C), 146.8 (CH), 146.9 (C), 153.9 (C), 159.7 (C=O). 
IR (ATR, cm-1): v~ = 3441 (w), 3066 (w), 3021 (w), 2947 (w), 2890 (w), 2801 
(w), 2768 (w), 1985 (w), 1907 (w), 1861 (w), 1731 (s), 1622 (m), 1592 (m), 1573 (s), 
1557 (s), 1499 (w), 1483 (m), 1454 (m), 1426 (s), 1411 (m), 1386 (m), 1352 (s), 1315 
(m), 1302 (s), 1240 (s), 1202 (s), 1192 (s), 1157 (m), 1139 (s), 1108 (m), 1025 (m), 
1011 (m), 982 (m), 958 (w), 851 (s), 835 (s), 808 (m), 792 (s), 756 (m), 745 (m), 723 
(m), 669 (s), 604 (s), 560 (m); 
MS (EI, 70eV): m/z (%) = 292 ([M+H]+, 19), 291 ([M]+, 100), 281 (13), 248 
(12), 209 (11), 208 (19), 207 (75), 191 (13), 96 (11), 73 (12), 44 (35), 32 (16); 
HRMS (EI): calcd. for C18H13NO3 (M
+) 291.08899, found 291.08918. 
 
3,4-dihydroxy-9,11-dimethyl-6H-chromeno[3,4-c]quinolin-6-one (3m): 
Starting from compound 2m (100 mg, 0.25 mmol), the product 
3m was isolated as yellow solid (51 mg, 65 %);  
mp = 318 – 320 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 2.49 (s, 3H, CH3), 
2.66 (s, 3H, CH3), 6.95 (d, 
3J = 9.0 Hz, 1H, CHAr), 7.58 (s, 1H, 
CHAr), 7.88 (d, 
3J = 9.0 Hz, 1H, CHAr), 8.28 (s, 1H, CHAr), 9.23 
(s, 1H, CHAr), 9.47 (broad s, 1H, OH), 10.38 ( broad s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 18.25 (CH3), 21.4 (CH3), 109.5, 111.3 (C), 
112.6 (CH), 119.6 (CH), 121.4 (C), 123.8 (CH), 133.1 (C), 134.1 (CH), 137.1 (C), 
137.2 (C), 140.6 (C), 142.66 (C), 147.1 (CH), 147.3 (C), 149.7(C), 160.05 (C=O). 
IR (ATR, cm-1): v~  = 3477 (w), 3160 (w), 2919 (w), 2849 (w), 2850 (w), 1698 
(s), 1614 (m), 1579 (m), 1557 (m), 1501 (m), 1458 (m), 1406 (m), 1372 (s), 1350 (s), 
1313 (s), 1249 (m), 1209 (m), 1187 (m), 1158 (s), 1111 (s), 1048 (s), 1017 (m), 959 
(m), 926 (m), 860 (m), 825 (m), 784 (s), 751 (m), 722 (m), 671 (m), 606 (m), 553 (s); 
MS (GC, 70 eV) m/z (%): 307 (25), 290 (80), 290 (12), 256 (56), 229 (10), 154 
(26), 127 (49), 75 (15), 51 (10); 
HRMS (ESI): calcd. for C18H13NO4 (M+H
+) 308.09173, found 308.09209. 
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2-fluoro-9,11-dimethyl-6H-chromeno[3,4-c]quinolin-6-one (3n): 
Starting from compound 2n (100 mg, 0.28 mmol), the 
product 3n was isolated as yellow solid (74 mg, 89 %); 
mp = 247 – 248 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 2.60 (s, 1H, 
CH3), 2.78 (s, 1H, CH3), 7.52 – 7.61 (m, 2H, CHAr), 7.71 
(s, 1H, CHAr), 8.31 – 8.39 (m, 1H, CHAr), 8.40 (s, 1H, 
CHAr), 9.41 (s, 1H, CHAr). 
 13C NMR (63 MHz, DMSO-d6): δ = 17.1 (CH3), 20.8 (CH3), 113.0 (C), 113.9 (d, 
2JC-F = 26.4 Hz, CH), 117.5 (d, 
3JC-F = 8.8 Hz, C), 118.7 (d, 
2JC-F = 24.3 Hz, CH), 
119.0 (d, 3JC-F = 8.8 Hz, CH), 120.9 (C), 122.2 (CH), 133.9 (2*C, C+CH), 137.1, 137.8 
(d, 4JC-F = 2.3 Hz, C), 146.4 (CH), 147.2 (C), 148.3 (d, 
4JC-F = 2.0 Hz), 157.8 (d,  
1JC-F = 241.3 Hz, C), 158.8 (C=O). 
19F NMR (235 MHz, DMSO-d6): δ = -116.1 (CF); 
IR (ATR, cm-1): v~  = 3448 (w), 3133 (w), 3067 (w), 3035 (w), 2960 (w), 2921 
(w), 2850 (w), 1926 (w), 1872 (w), 1842 (w), 1743 (m), 1616 (w), 1596 (w), 1574 (m), 
1557 (s), 1485 (s), 1454 (m), 1431 (s), 1404 (m), 1385 (m), 1348 (s), 1310 (m), 1282 
(m), 1264 (m), 1244 (m), 1207 (m), 1167 (s), 1136 (s), 1107 (s), 1055 (m), 1010 (s), 
958 (m), 937 (m), 897 (m), 877 (w), 850 (s), 835 (s), 806 (s), 782 (m), 753 (m), 729 
(m), 694 (m), 676 (m), 663 (m), 611 (m), 599 (s), 561 (m), 554 (m); 
MS (EI, 70eV): m/z (%) = 294 ([M+H]+, 20), 293 ([M]+, 100), 265 (17), 250 
(23); 
HRMS (EI) calcd for C18H12FNO2 ([M]
+) 293.08466, found 293.08497. 
 
11-fluoro-6H-chromeno[3,4-c]quinolin-6-one (3o): 
Starting from compound 2o (100 mg, 0.3 mmol), the product 3o was 
isolated as yellow solid (71 mg, 87 %); mp = 226 – 228 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 7.50 – 7.60 (m, 2H, 
CHAr), 7.75 (ddd, 
3J = 8.0 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1H, CHAr), 
7.88 (ddd, 3J = 9.2 Hz, 3J = 7.9 Hz, 4J = 2.8 Hz, 1H, CHAr), 8.31 
(dd, 3J = 9.2 Hz, 3J = 5.9 Hz, 1H, CHAr), 8.60 (dd, 
3J = 10.9 Hz, 4J = 2.8 Hz, 1H, 
CHAr), 8.67 (d, 
3J = 8.7 Hz, 1H, CHAr), 9.46 (s, 1H, CHAr).  
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13C NMR (63 MHz, DMSO-d6): δ = 110.93 (d, 
2JC-F = 24.9 Hz, CH), 114.4, 
116.7 (C), 117.8 (CH), 121.73 (d, 2JC-F = 25.3 Hz, CH), 122.47 (d, 
3JC-F = 9.9 Hz, C), 
125.2 (CH), 128.2 (CH), 132.6 (CH), 133.20 (d, 3JC-F = 9.6 Hz, CH), 139.6, 147.7 (C), 
148.66 (d, 4JC-F = 2.6 Hz, CH), 152.6 (C), 159.3 (C), 161.3 (d, 
1JC-F = 248.2 Hz, C). 
 19F NMR (235 MHz, DMSO-d6): δ = -109.7 (CF); 
IR (ATR, cm-1): v~  = 3086 (w), 3055 (w), 2922 (w), 2851 (w), 1737 (s), 1622 
(m), 1604 (m), 1593 (s), 1572 (m), 1556 (m), 1511 (s), 1485 (m), 1450 (m), 1440 (m), 
1419 (s), 1370 (m), 1354 (s), 1310 (m), 1298 (m), 1207 (s), 1157 (m), 1116 (m), 1086 
(s), 1048 (m), 989 (s), 981 (s), 952 (m), 902 (m), 878 (m), 837 (s), 795 (w), 745 (s), 
723 (s), 679 (m), 665 (m), 648 (m), 605 (s), 540 (m); 
MS (EI, 70eV): m/z (%) = 266 ([M+H]+, 17), 265 ([M]+, 100), 264 (14), 237 
(40), 209 (11), 208 (24), 182 (17), 181 (20); 
HRMS (EI) calcd for C16H8FNO2 ([M]
+) 265.05336, found 365.05347. 
 
11-fluoro-4-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3p): 
Starting from compound 2p (100 mg, 0.28 mmol), the product 3p 
was isolated as yellow solid (51 mg, 65 %); mp = 282 – 283 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 7.23 (d, 
3J = 7.0 Hz, 1H, 
CHAr), 7.31 (t, 
3J = 8.1 Hz, 1H, CHAr), 7.92 (td, 
3J = 9.2, 
4J = 2.7 Hz, 1H, CHAr), 8.01 (d, 
3J = 7.5 Hz, 1H, CHAr), 8.24 (dd, 
3J = 9.2 Hz, 3J = 6.0 Hz, 1H, CHAr), 8.52 (dd, 
3J = 11.0 Hz, 4J = 2.6 Hz, 1H, CHAr), 
9.40 (s, 1H, CHAr), 10.36 (s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 111.3 (d, 
2JC-F = 24.9 Hz, CH), 114.25 (C), 
117.3 (C), 118.1 (CH), 119.0 (CH), 121.8 (d, 2JC-F = 25.3 Hz, CH), 122.4 (d,  
3JC-F = 10.1 Hz, C), 124.9 (CH), 133.0 (d, 
3JC-F = 9.5 Hz, CH), 139.95 (d,  
4JC-F = 5.1 Hz, C), 141.2 (C), 145.8 (C), 147.3 (C), 148.7 (d, 
4JC-F = 2.5 Hz, CH), 159.3 
(C=O), 160.9 (d, 1JC-F = 247.4 Hz, C). 
19F NMR (282 MHz, DMSO-d6): δ = -109.70 (CF); 
IR (ATR, cm-1): v~  = 3060 (w), 3035 (w), 2946 (w), 2920 (w), 2840 (w), 2727 
(w), 1723 (s), 1616 (m), 1577 (s), 1566 (s), 1516 (s), 1436 (s), 1427 (s), 1384 (m), 
1362 (s), 1326 (m), 1292 (s), 1209 (s), 1197 (s), 1184 (s), 1156 (m), 1131 (s), 1092 (s), 
1054 (s), 995 (s), 952 (m), 901 (m), 873 (s), 853 (s), 812 (m), 796 (s), 773 (s), 765 (s), 
750 (s), 721 (s), 665 (m), 649 (m), 634 (m), 600 (m), 568 (m), 562 (m), 545 (m); 
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MS (EI, 70eV): m/z (%) = 282 (18), 281 ([M]+, 100), 253 (25), 225 (22), 197 
(25), 196 (21), 170 (14); 
HRMS (EI) calcd for C16H8FNO3 ([M]
+) 281.04827, found 281.04837. 
 
11-fluoro-2-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3q): 
Starting from compound 2q (100 mg, 0.28 mmol), the product 3q 
was isolated as yellow solid (62 mg, 78 %); mp > 350 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 5.75 (br.s, 1H, OH), 7.2 
(dd, 3J = 8.9 Hz, 4J = 2.7 Hz, 1H, CHAr), 7.4 (d, 
3J = 8.9 Hz, 1H, 
CHAr), 9.4 (s, 1H, CHAr), 7.95 (d, 
4J = 2.7 Hz, 1H, CHAr), 7.97 (dd, 
3J = 2.7 Hz, 4J = 1.3 Hz, 1H, CHAr), 8.0 (d, 
4J = 2.6 Hz, 1H, CHAr), 8.28 (d, 
3J = 6.0 Hz, 1H, CHAr), 8.3 (d, 
3J = 6.0 Hz, 1H, CHAr), 8.55 (dd, 
3J = 11.1 Hz, 
4J = 2.7 Hz, 1H, CHAr). 
13C NMR (75 MHz, DMSO-d6): δ = 110.95 (d, 
2JC-F = 24.9 Hz, CH), 112.6 (CH), 
114.5, 116.8 (C), 118.95 (CH), 120.7 (CH), 122.05 (d, 2J = 25.3 Hz, CH), 122.45 (d, 
3JC-F = 10.1 Hz, C), 133.1 (d, 
3J = 9.8 Hz, CH), 139.6 (d, 4JC-F = 5.1 Hz), 147.1, 145.7 
(C), 148.8 (d, 4JC-F = 2.5 Hz, CH), 154.3 (C), 159.7 (C), 161.05 (d, 
1JC-F = 247.5 Hz, 
C). 
19F NMR (282 MHz, DMSO-d6): δ = -109.71 (CF). 
IR (ATR, cm-1): v~  = 3073 (m), 3029 (m), 2641 (m), 2598 (m), 1741 (s), 1618 (w), 1580 (s), 
1504 (s), 1494 (s), 1445 (s), 1430 (s), 1406 (s), 1359 (s), 1312 (m), 1249 (m), 1235 (s), 1224 (s), 
1203 (s), 1138 (s), 1114 (m), 1107 (m), 1019 (m), 987 (s), 935 (w), 878 (s), 863 (s), 836 (s), 781 (s), 
753 (m), 734 (s), 666 (s), 599 (s), 530 (m); 
MS (EI, 70eV): m/z (%) = 282 (39), 281 ([M]+, 100), 253 (42), 225 (19), 224 
(13), 197 (16), 196 (18), 171 (10), 170 (14), 169 (13), 78 (17), 63 (21); 
HRMS (ESI-TOF) calcd for C16H8FNO3 ([M+H]
+) 282.05610, found 282.05677. 
 
11-fluoro-1-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3r): 
Starting from compound 2r (100 mg, 0.28 mmol), the product 3r 
was isolated as yellow solid (20 mg, 25 %); mp = 309 – 311 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 7.00 (d, 
3J = 8.2, 2H, 
CHAr), 7.56 (t, 
3J = 8.2 Hz, 1H, CHAr), 7.88 (ddd, 
3J = 11.8 Hz, 
3J = 8.7 Hz, 4J = 2.8 Hz, 1H, CHAr), 8.12 (dd, 
3J = 11.4 Hz, 
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4J = 2.8 Hz, 1H, CHAr), 8.19 (dd, 
3J = 9.2 Hz, 3J = 5.9 Hz, 1H, CHAr), 9.40 (s, 1H, 
CHAr), 11.29 (s, 1H, OH).  
13C NMR (63 MHz, DMSO-d6): δ = 107.4 (CH), 112.7 (CH), 114.5 (d,  
2JC-F = 24.8 Hz, CH), 159.6 (C), 115.0 (C), 121.8 (d, 
2JC-F = 25.4 Hz, CH), 122.5 (d,  
3JC-F = 10.9 Hz), 131.3 (d, 
3JC-F = 9.2 Hz, CH), 133.2 (CH), 140.9 (d, 
4JC-F = 4.9 Hz), 
147.0, 147.8 (d, 4JC-F = 2.3 Hz, CH), 153.4 (C), 155.1 (C), 155.7 (C), 158.6 (d,  
1JC-F = 244.4 Hz); 
19F NMR (282 MHz, DMSO-d6): δ = -113.02 (CF); 
IR (ATR, cm-1): v~  = 3049 (w), 2927 (w), 2838 (w), 2658 (w), 2538 (w), 1749 
(s), 1609 (s), 1594 (s), 1580 (s), 1512 (s), 1457 (s), 1428 (s), 1353 (s), 1299 (s), 1261 
(m), 1210 (s), 1195 (s), 1172 (s), 1118 (s), 1087 (s), 1046 (s), 1019 (s), 974 (s), 871 
(m), 831 (s), 793 (s), 776 (s), 760 (s), 747 (s), 722 (s), 656 (s), 631 (s), 605 (s), 586 
(s), 553 (s), 543 (s); 
MS (EI, 70eV): m/z (%) = 282 (39), 281 (100), 253 (42), 225 (19), 224 (13), 197 
(16), 196 (18), 171 (10), 170 (14), 169 (13), 78 (17), 63 (21); 
HRMS (ESI-TOF) calcd for C16H8FNO3 ([M+H]
+) 282.05610, found 282.05653. 
 
11-fluoro-3,4-dihydroxy-6H-chromeno[3,4-c]quinolin-6-one (3s): 
Starting from compound 2s (100 mg, 0.26 mmol), the product 3s 
was isolated as yellow solid (54 mg, 70 %); mp = 321 – 323 °C; 
 1H NMR (250 MHz, DMSO-d6): δ = 4.62 (broad s, 2H, OH), 
7.03 (d, 3J = 9.0 Hz, 1H, CHAr), 7.68 – 7.88 (m, 1H, CHAr), 7.98 
(d, 3J = 9.0 Hz, 1H, CHAr), 8.14 – 8.44 (m, 1H, CHAr), 8.52 (dd, 
3J = 11.1 Hz, 4J = 2.3 Hz, 1H, CHAr), 9.39 (s, 1H, CHAr); 
13C NMR (63 MHz, DMSO-d6): δ = 108.8 (C), 110.5 (d, 
2JC-F = 24.7 Hz, CH), 
111.5 (C), 112.6 (CH), 118.4 (CH), 120.6 (d, 2JC-F = 25.2 Hz, CH), 121.9 (d,  
3JC-F = 9.5 Hz, C), 132.3 (d, 
3JC-F = 9.5 Hz, CH), 132.8 (C), 140.2 (d, 
4JC-F = 5.1 Hz, 
C), 142.6 (C), 146.9 (C), 148.2 (d, 4JC-F = 2.4 Hz, CH), 149.7 (C), 159.0 (C), 160.3 (d,  
1JC-F = 247.6 Hz, C); 
19F NMR (235 MHz, DMSO-d6): δ = -110.81 (CF); 
IR (ATR, cm-1): v~  = 3052 (br.w), 1722 (m), 1715 (m), 1610 (s), 1569 (s), 1508 
(s), 1456 (m), 1422 (m), 1345 (s), 1314 (s), 1212 (s), 1191 (s), 1153 (m), 1103 (s), 
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1074 (s), 1031 (s), 976 (m), 923 (m), 875 (m), 835 (s), 807 (m), 794 (m), 778 (s), 742 
(s), 713 (s), 667 (m), 607 (s), 588 (s); 
MS (EI, 70eV): m/z (%) = 297 (100), 263 (42), 225 (19), 224 (13), 197 (16), 196 
(18), 173 (10), 170 (14), 169 (13), 78 (17), 63 (21). 
HRMS (ESI): calcd. for C16H8FNO4 (M+H
+) 298.05101, found 298.05154; 
 
2,11-difluoro-6H-chromeno[3,4-c]quinolin-6-one (3t): 
Starting from compound 2t (100 mg, 0.29 mmol), the product 3t 
was isolated as yellow solid (70 mg, 85 %); mp = 252 – 254 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 7.56– 7.62 (m, 2H, 
CHAr), 7.92 (ddd, 
3J = 9.2 Hz, 3J = 8.0 Hz, 4J = 2.7 Hz, 1H, CHAr), 
8.30 (dd, 3J = 9.2 Hz, 3J = 5.9 Hz, 1H, CHAr), 8.38 – 8.45 (m, 1H, 
CHAr), 8.59 (dd, 
3J = 10.8 Hz, 4J = 2.7 Hz, 1H, CHAr), 9.48 (s, 1H, CHAr).  
13C NMR (63 MHz, DMSO): δ = 110.2 (d, 2JC-F = 25.1 Hz, CH), 113.6 (d,  
2JC-F = 26.4 Hz, CH), 114.0, 117.0 (d, 
3JC-F = 8.8 Hz, C), 119.1 (d, 
3JC-F = 10.1 Hz, 
CH), 119.2 (d, 2JC-F = 23.1 Hz, CH), 121.4 (d, 
2JC-F = 25.4 Hz, CH), 121.7 (d,  
3JC-F = 10.3 Hz, C), 132.7 (d, 
3JC-F = 9.6 Hz, CH), 138.1 (d, 
4JC-F = 2.9 Hz, C), 147.1 
(d, 5JC-F = 1.1 Hz, C), 148.0 (d, 
4JC-F = 2.7 Hz, CH), 148.4 (d, 
4JC-F = 2.0 Hz), 158.0 (d, 
1JC-F = 242.0 Hz, C), 158.5 (C), 160.8 (d, 
1JC-F = 248.8 Hz, C). 
19F NMR (235 MHz, DMSO-d6): δ = -109.12 (CF), -115.78 (CF). 
IR (ATR, cm-1): v~  = 3140 (w), 3119 (w), 3059 (w), 2987 (w), 1921 (w), 1749 (s), 1620 
(m), 1598 (w), 1562 (s), 1511 (s), 1483 (s), 1447 (m), 1422 (s), 1353 (m), 1330 (m), 1310 (m), 1287 
(m), 1262 (w), 1232 (m), 1205 (s), 1164 (m), 1151 (m), 1116 (m), 1084 (m), 1005 (s), 987 (s), 965 
(m), 890 (w), 859 (s), 838 (s), 822 (s), 812 (m), 790 (w), 753 (m), 742 (s), 727 (m), 709 (s), 682 
(m), 662 (m), 648 (m), 605 (m), 596 (s), 547 (w), 526 (s); 
MS (EI, 70eV): m/z (%) = 284 ([M+H]+, 20), 283 ([M]+, 100), 282 (16), 255 
(52), 226 (27), 207 (23), 200 (14), 199 (20), 44 (26), 32 (17); 
HRMS (EI) calcd for C16H7F2NO2 ([M]
+) 283.04394, found 283.04398. 
 
2-hydroxy-11-nitro-6H-chromeno[3,4-c]quinolin-6-one (3u): 
Starting from compound 2u (100 mg, 0.29 mmol), the product 3u was isolated as 
yellow solid (65 mg, 81 %); mp = 300 – 302 °C; 
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1H NMR (300 MHz, DMSO-d6): δ = 7.19 (dd, 
3J = 8.9 Hz, 4J = 2.6 Hz, 1H, CHAr), 7.42 (d, 
3J = 8.9 Hz, 1H, 
CHAr), 7.84 (d, 
4J = 2.6 Hz, 1H, CHAr), 8.35 (d, 
3J = 9.2 Hz, 
1H, CHAr), 8.65 (dd, 
3J = 9.2 Hz, 4J = 2.3 Hz, 1H, CHAr), 9.52 
(d, 4J = 2.2 Hz, 1H, CHAr), 9.54 (s, 1H, CHAr), 10.14 (s, 1H, 
OH). 
13C NMR (63 MHz, DMSO-d6): δ = 112.6 (CH), 114.95, 116.4 (C), 119.1 (CH), 
120.7 (C), 121.3 (CH), 123.35 (CH), 125.3 (CH), 132.1 (CH), 141.5 (C), 145.95 (C), 
146.0 (C), 152.0 (C), 152.7 (CH), 154.5 (C), 159.15 (C=O). 
IR (ATR, cm-1): v~  = 3323 (w), 3070 (w), 2921 (w), 2850 (w), 2724 (w), 1726 
(s), 1693 (s), 1617 (m), 1565 (s), 1530 (m), 1498 (s), 1457 (s), 1435 (s), 1424 (s), 1344 
(s), 1302 (s), 1267 (m), 1235 (s), 1218 (s), 1186 (s), 1174 (s), 1131 (m), 1110 (s), 1092 
(s), 1013 (s), 972 (m), 935 (m), 914 (m), 860 (s), 845 (s), 835 (s), 822 (s), 796 (m), 739 
(s), 711 (s), 694 (s), 663 (s), 629 (s), 603 (s), 596 (s), 546 (s);  
MS (EI, 70eV): m/z (%) = 309 ([M+H]+, 19), 308 ([M]+, 100), 307 (15), 205 
(13), 177 (19); 
HRMS (ESI-TOF): calcd. for C16H8N2O5 (M+H
+) 309.05060, found 309.05111. 
 
10-chloro-6H-chromeno[3,4-c]quinolin-6-one (3v): 
Starting from compound 2v (100 mg, 0.29 mmol), the product 3v 
was isolated as yellow solid (68 mg, 83 %); mp = 256 – 257 °C; 
1H NMR (250 MHz, DMSO-d6): δ = 7.48 – 7.57 (m, 2H, 
CHAr), 7.74 (dd, 
3J = 7.1 Hz, 3J = 1.3 Hz, 1H, CHAr), 7.81 (dd, 
3J = 9.3 Hz, 4J = 2.5 Hz, 1H, CHAr), 8.18 (d, 
4J = 2.3 Hz, 1H, 
CHAr), 8.61 (d, 
3J = 8.4 Hz, 1H, CHAr), 8.90 (dd, 
3J = 9.2 Hz, 4J = 0.5 Hz, 1H, CHAr), 
9.46 (s, 1H, CHAr),  
 13C NMR (63 MHz, DMSO-d6): δ = 113.5 (C), 116.0 (C), 117.3 (CH), 119.7 (C), 
124.6 (CH), 128.0 (CH), 128.2 (CH), 128.3 (CH), 128.4 (CH), 132.3 (CH), 136.5 (C), 
139.7 (C), 149.9 (CH), 150.4 (C), 152.2 (C), 158.6 (C=O). 
IR (ATR, cm-1): v~  = 3120 (w), 3056 (w), 2991 (w), 2921 (w), 2850 (w), 1727 (s), 1600 
(m), 1567 (m), 1553 (s), 1483 (m), 1450 (m), 1401 (m), 1374 (m), 1348 (m), 1300 (m), 1269 (m), 
1241 (m), 1220 (m), 1197 (m), 1180 (m), 1159 (m), 1137 (m), 1118 (m), 1079 (s), 1043 (m), 982 
(s), 937 (m), 887 (s), 827 (m), 790 (m), 748 (s), 690 (m), 649 (m), 638 (m), 605 (s), 547 (m); 
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MS (EI, 70eV): m/z (%) = 283 (34), 282 (22), 281 ([M]+, 100), 280 (14), 
255 (14), 253 (40), 218 (33), 190 (34), 163 (28), 81 (16);  
HRMS (EI) calcd for C16H8ClNO2 ([M]
+) 281.02381, found 281.02368. 
 
10-chloro-3,4-dihydroxy-6H-chromeno[3,4-c]quinolin-6-one (3w): 
Starting from compound 2w (100 mg, 0.269 mmol), the product 3w 
was isolated as yellow solid (66 mg, 78 %); mp > 350 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 6.9 (d, 
3J = 9.0 Hz, 1H, 
CHAr), 7.7 (dd, 
3J = 9.2 Hz, 4J = 2.3 Hz, 1H, CHAr), 7.8 (d, 
3J = 9.0 Hz, 1H, CHAr), 8.0 (s, 1H, CHAr), 8.7 (d, 
3J = 9.2 Hz, 1H, 
CHAr), 9.3 (s, 1H, CHAr), 9.5 (s, 1H), 10.5 (s, 1H, OH). 
13C NMR (63 MHz, DMSO-d6): δ = 108.8 (C), 111.7 (C), 112.8 (CH), 119.4 
(CH), 120.2 (C), 128.2 (CH), 128.6 (CH), 129.1 (CH), 133.2 (C), 136.55 (C), 141.3 
(C), 142.9 (C), 150.3 (C), 150.56 (CH), 150.58 (C), 159.6 (C=O).  
IR (ATR, cm-1): v~  = 3571 (m), 3211 (m), 3073 (m), 2920 (m), 2850 (m), 1727 
(s), 1713 (s), 1596 (s), 1563 (s), 1515 (s), 1488 (s), 1456 (s), 1395 (s), 1358 (s), 1344 
(s), 1300 (s), 1281 (s), 1263 (s), 1196 (s), 1134 (s), 1096 (s), 1062 (s), 1028 (s), 973 
(m), 926 (s), 908 (s), 888 (s), 866 (s), 845 (s), 825 (s), 775 (s), 743 (s), 657 (s), 606 
(s), 537 (m); 
MS (EI, 70eV): m/z (%) = 315 (28), 314 (16), 313 ([M]+, 100), 285 (14), 78 (18), 
63 (24); 
HRMS (EI): calcd. for C16H8ClNO4 (M
+) 313.01364, found 313.01303; 
HRMS (EI): calcd. for C16H8ClNO4 (M
+) 315.01069, found 315.01061. 
 
10-(2,5-dihydroxyphenyl)-2-hydroxy-6H-chromeno[3,4-c]quinolin-6-one (3x): 
Starting from compound 2x (100 mg, 0.29 mmol), the 
product 3x was isolated as yellow solid (50 mg, 72 %);  
mp > 350 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 4.09 (br.s, 3H, 
3*OH), 6.73 (dd, 3J = 8.7 Hz, 4J = 2.9 Hz, 1H, CHAr), 6.88 
(d, 3J = 8.7 Hz, 1H, CHAr), 6.93 (d, 
4J = 2.9 Hz, 1H, CHAr), 
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7.19 (dd, 3J = 8.9 Hz, 4J = 2.7 Hz, 1H, CHAr), 7.45 (d, 
3J = 8.9 Hz, 1H, CHAr), 8.12 
(dd, 3J = 8.7 Hz, 4J = 1.8 Hz, 2H), 8.37 (d, 4J = 1.8 Hz, 1H, CHAr), 8.90 (d, 
3J = 9.1 Hz, 1H, CHAr), 9.50 (s, 1H, CHAr).  
13C NMR (63 MHz, DMSO-d6): δ = 113.2 (CH), 113.5 (C), 116.3 (CH), 116.7 
(CH), 117.1 (C), 117.3 (CH), 118.8 (CH), 120.14 (C), 120.5 (CH), 125.8 (C), 126.0 
(CH), 129.0 (CH), 130.1 (CH), 140.0 (C), 142.7 (C), 145.8 (C), 147.3 (C), 149.3 (CH), 
149.75 (C), 150.4 (C), 154.2 (C), 159.9 (C=O).  
IR (ATR, cm-1): v~  = 3167 (m), 3093 (m), 2957 (m), 2865 (m), 2700 (m), 2590 
(m), 1683 (s), 1593 (s), 1575 (s), 1554 (s), 1493 (s), 1441 (s), 1412 (s), 1379 (s), 1347 
(s), 1299 (s), 1242 (s), 1219 (s), 1189 (s), 1168 (s), 1124 (s), 1039 (s), 1022 (s), 945 
(m), 892 (m), 876 (m), 808 (s), 799 (s), 778 (s), 751 (s), 687 (s), 664 (s), 654 (s), 607 
(s), 550 (s); 
MS (EI, 70eV): m/z (%) = 136 (43), 121 ([M]+, 100), 93 (14), 65 (13); 
HRMS (ESI-TOF) calcd for C22H13ClNO5 ([M]
+) 372.08665, found 372.08648. 
 
General procedure for the synthesis of compounds 5a-n: 
To a toluene suspension (4 mL) of 4 (100 mg, 0.37 mmol), Pd(PPh3)4 (3 mol %), 
and arylboronic acid (1.1 equiv.) was added K3PO4 (238 mg, 1.1 mmol), and the 
solution was degassed by bubbling argon through the solution for 10 min. The mixture 
was heated at 70 °C under argon atmosphere for 6 h. The mixture was cooled to 20 °C. 
To the solution was added arylboronic acid (1.1 equiv.), Pd(OAc)2 (4 mol%), XPhos  
(8 mol%), and the solution was degassed again. The reaction mixture was heated under 
argon atmosphere for 8 h at 110 °C. After cooling to 20 °C, the solution was diluted 
with water and extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were 
dried (Na2SO4), filtered, and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, heptane/EtOAc). 
 
Ethyl 4-(3,5-dimethoxyphenyl)-7-(4-ethoxyphenyl)quinoline-3-carboxylate (5a): 
According to the general procedure compound 
5a was isolated by column chromatography as 
white crystals (102 mg, 60 %),  
mp = 161-162 ºC; 
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1H NMR (300 MHz, CDCl3): δ = 1.09 (t, 
3J = 7.1 Hz, 3H, CH3, OCH2CH3), 1.45 (t, 
3J = 7.1 Hz, 3H, CH3, OCH2CH3), 3.82 (s, 6H, OCH3), 4.10 (q, 
3J = 7.1 Hz, 2H, CH2, OCH2CH3), 
4.18 (q, 3J = 7.1 Hz, 2H, CH2, OCH2CH3), 6.47 (d, 
4J = 2.3 Hz, 2H, CHAr), 6.59 (t, 
4J = 2.3 Hz, 1H, 
CHAr), 7.02 (d, 
3J = 8.8 Hz, 2H, CHAr), 7.69 (d, 
3J = 8.8 Hz, 2H, CHAr), 7.73-7.78 (m, 2H, CHAr), 
8.35 (s, 1H, CHAr), 9.33 (s, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.9 (COOCH2CH3), 15.0, 55.6 (OCH3), 61.4, 63.7 
(COOCH2CH3), 100.3 (CH), 107.4 (CH), 115.2 (CH), 122.7 (C), 125.7 (CH), 125.8 (C), 126.8 
(CH), 128.1 (CH), 128.7 (CH), 131.8 (C), 138.5 (C), 143.6 (C), 149.4 (C), 149.8 (C), 150.4 (CH), 
159.6 (C), 160.7 (C), 166.5 (C=O); 
IR (ATR, cm–1):  = 3008 (w), 2985(w), 2935 (w), 2898 (w), 2844 (w), 1696 (s), 1593 (s), 
1579(s), 1521 (m), 1492 (w), 1458 (m), 1407 (m), 1382 (m), 1366 (m), 1345 (w), 1316(m), 1281 
(s), 1236 (s), 1188 (s), 1155 (s), 1112 (s), 1049 (s), 1026 (s), 990 (m), 953 (w), 883 (m), 860 (m), 
826 (s), 789 (s), 738 (m), 705 (s), 677 (w), 662 (s), 632 (m), 579 (m), 541 (w); 
MS (EI, 70 eV) m/z (%): 458 ([M+H]+, 33), 457 ([M]+, 100), 357 (11), 29 (17);  
HRMS (ESI): calcd for C28H27NO5 457.18837, found 457.18833.  
 
Ethyl 7-(4-tert-butylphenyl)-4-phenylquinoline-3-carboxylate (5b): 
According to the general procedure compound 5b 
was isolated by column chromatography as white 
crystals (95 mg, 62 %), mp = 166-167 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.02 (t, 
3J = 7.1 Hz, 3H, CH3, CH2CH3), 1.39 (s, 9H, t-Bu), 4.13 (q, 
3J = 7.1 Hz, 2H, CH2, OCH2CH3), 7.31-7.35 (m, 2H, CHAr), 
7.51-7.56 (m, 5H, CHAr), 7.65 (d, 
3J = 8.7 Hz, 1H, CHAr), 
7.71 (d, 3J = 8.4 Hz, 2H, CHAr), 7.78 (dd, 
3J = 8.7 Hz, 4J =1.8 Hz, 1H, CHAr), 8.43 (d, 
4J = 1.8 Hz, 
1H, CHAr), 9.38 (s, 1H, CHAr);  
13C NMR (75 MHz, CDCl3): δ = 12.6 (CH2CH3), 30.3, 33.7, 60.2 (CH2CH3), 123.0 (C), 
126.2 (C), 126.2 (CH), 126.5 (CH), 127.0 (CH), 127.3 (CH), 128.1 (CH), 128.2 (CH), 128.3 (CH), 
129.0 (CH), 136.7 (C), 136.7 (C), 143.8 (C), 149.4 (C), 150.2 (C), 150.5 (CH), 151.8, 166.6 (C=O); 
IR (ATR, cm–1):  = 3058 (w), 2953 (w), 2904 (w), 2865 (w), 1950 (w), 1880 (w), 1703 (s), 
1614 (w), 1570 (w), 1484 (w), 1412 (m), 1369 (m), 1325 (m), 1295 (m), 1270 (m), 1221 (s), 1150 
(s), 1110 (s), 1025 (m), 943 (w), 911 (m), 867 (w), 845 (m), 820 (s), 798 (s), 768 (m), 700 (s), 587 
(m), 565 (m); 
MS (EI, 70 eV) m/z (%): 410 ([M+H]+, 28), 409 ([M]+, 100);  
~
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HRMS (ESI): calcd for C28H27NO2 409.20363, found 409.20335.  
 
Ethyl 4-(4-ethylphenyl)-7-p-tolylquinoline-3-carboxylate (5c): 
According to the general procedure compound 5c was isolated by column 
chromatography as white crystals (102 mg, 70 %), mp = 111-112 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.02 (t, 
3J = 7.1 Hz, 
3H, CH3, OCH2CH3), 1.34 (t, 
3J = 7.6 Hz, 3H, CH2CH3), 2.43 
(s, 3H, CH3), 2.78 (q, 
3J = 7.6 Hz, 2H, CH2CH3), 4.14 (q, 
3J = 7.1 Hz, 2H, CH2, OCH2CH3), 7.24 (d, 
3J = 8.1 Hz, 2H, 
CHAr), 7.32 (d, 
3J = 7.7 Hz, 2H, CHAr), 7.35 (d, 
3J = 8.3 Hz, 
2H, CHAr), 7.66 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.70 (d,  
3J = 8.8 Hz, 1H, CHAr), 7.76 (dd, 
3J = 8.8 Hz, 4J = 1.7 Hz, 1H, 
CHAr), 8.40 (d, 
4J = 1.7 Hz, 1H, CHAr), 9.35 (s, 1H, CHAr);  
13C NMR (75 MHz, CDCl3): δ = 13.8 (CH2CH3), 15.7, 21.3, 28.9, 61.3 (CH2CH3), 123.2 
(C), 126.3 (C), 126.5 (CH), 126.8 (CH), 127.5 (CH), 127.7 (CH), 128.2 (CH), 129.0 (CH), 130.0 
(CH), 133.8 (C), 136.9 (C), 138.5 (C), 143.8 (C), 144.5 (C), 149.5 (C), 150.2 (C), 150.5 (CH), 
166.8 (C=O);  
IR (ATR, cm–1):  = 3387 (w), 3024 (w), 2955 (w), 2921 (w), 2862 (w), 1904 (w), 1822 
(w), 1700 (s), 1615 (m), 1570 (m), 1513 (w), 1487 (w), 1446 (w), 1410 (m), 1365 (m), 1322 (m), 
1293 (m), 1250 (m), 1222 (m), 1183 (m), 1149 (m), 1111 (m), 1063 (w), 1052 (w), 1012 (m), 962 
(w), 927 (w), 913 (m), 876 (w), 863 (w), 814 (s), 796 (s), 719 (w), 700 (m), 679 (m), 658 (w), 679 
(w), 640 (w), 603 (m), 577 (w).  
MS (GC, 70 eV) m/z (%): 396 ([M+H]+, 27), 395 ([M]+, 100), 350 (27), 322 (13), 307 (12), 
29 (19);  
HRMS (ESI): calcd. for C27H25NO2 395.18798, found 395.18766;  
 
Ethyl 4-(3-methoxyphenyl)-7-(4-(trifluoromethyl)phenyl)quinoline-3carboxylate 
(5d): 
According to the general procedure compound 5d was 
isolated by column chromatography as white crystals 
(129 mg, 77 %), mp = 85-86 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3J = 7.1 Hz, 
3H, CH3, CH2CH3), 3.85 (s, 3H, OCH3), 4.16 (q, 
3J = 7.1, 2H, 
~
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OCH2CH3), 6.87 (dd, 
4J = 2.6 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.91 (dt, 
3J = 7.5 Hz, 4J = 1.2 Hz, 1H, 
CHAr), 7.06 (ddd, 
3J = 8.4 Hz, 4J = 2.6 Hz, 4J = 1.0 Hz, 1H, CHAr), 7.44 (dd, 
3J = 8.3 Hz, 
3J = 7.5 Hz, 1H, CHAr), 7.74-7.78 (m, 4H, CHAr), 7.86 (d, 
3J = 8.2 Hz, 2H, CHAr), 8.42 (t, 
4J = 1.2 Hz, 1H, CHAr), 9.38 (s, 1H, CHAr);  
13C NMR (75 MHz, CDCl3): δ = 13.9 (OCH2CH3), 55.5 (OCH3), 61.5 (OCH2CH3), 114.0 
(CH), 114.7 (CH), 121.5 (CH), 123.6 (C), 124.3 (d, 1J C-F = 234.7 Hz), 126.2 (q, 
3JC-F = 3.7 Hz, 
CH), 126.7 (C), 126.7 (CH), 127.6 (CH), 128.0  (CH), 128.6 (CH), 129.4 (CH), 130.5 (d,  
2J C-F = 32.7 Hz), 137.6 (C), 142.3, 143.3 (d, 
5J C-F = 1.2 Hz, C), 149.2 (C), 149.8 (C), 150.8 (CH), 
159.5 (C), 166.4 (C=O);  
19F NMR (282 MHz, CDCl3): δ = -62.6 (CF3);  
IR (ATR, cm–1):  = 3058 (w), 2956 (w), 2928 (w), 2871 (w), 2835 (w), 1923 (w), 1700 (s), 
1612 (w), 1564 (m), 1484 (w), 1470 (w), 1454 (w), 1400 (w), 1369 (w), 1348 (w), 1321 (s), 1284 
(m), 1324 (m), 1234 (m), 1208 (m), 1190 (w), 1160 (s), 1150 (s), 1108 (s), 1066 (s), 1044 (s), 1030 
(m), 968 (w), 891 (w), 851 (m), 826 (s), 796 (m), 788 (m), 775 (m), 744 (w), 715 (m), 699 (m), 645 
(w), 632 (w), 599 (m), 553 (w).  
MS (EI, 70 eV) m/z (%): 452 ([M+H]+, 28), 451 ([M]+, 100), 407 (25), 406 (71), 379 (14), 
378 (13), 376 (10), 364 (13), 363 (12), 335 (19), 334 (13); 
HRMS (ESI): calcd for C26H20FNO3 451.13898, found 451.13885. 
 
Ethyl 7-(4-(trifluoromethoxy)phenyl)-4-(4-(trifluoromethyl)phenyl)quinoline-3-
carboxylate (5e): 
According to the general procedure compound 5e was 
isolated by column chromatography as white crystals 
(150 mg, 80 %), mp = 124-125 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 3H, CH3, OCH2CH3), 4.16 (q, 
3J = 7.1 Hz, 2H, CH2, OCH2CH3), 7.37 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.46 (d, 
3J = 8.0 Hz, 2H, 
CHAr), 7.55 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.71-7.86 (m, 5H, CHAr), 8.41 (d, 
4J = 1.9 Hz, 
1H, CHAr), 9.46 (s, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.7 (CH2CH3), 61.6 (CH2CH3), 120.6 (d,  
1JC-F = 257.7 Hz, C), 121.7 (CH), 122.8 (C), 124.2 (d, 
1JC-F = 272.0 Hz, C), 125.3 (d, 
5JC-F = 4.3 Hz, CH), 126.0 (C), 127.1 (CH), 127.4 (CH), 128.0 (CH), 129.1 (CH), 129.4 
~
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(CH), 130.5 (C), 130.7 (d, 2JC-F = 32.7 Hz, C), 138.2 (C), 140.5 (C), 142.8 (C), 148.6 
(C), 149.5 (C), 151.0 (CH), 165.9 (C); 
19F NMR (282 MHz, CDCl3) δ = -62.6 (CF3), -57.8 (OCF3); 
IR (ATR, cm–1):  = 3046 (w), 2995 (w), 2958 (w), 2925 (w), 2852 (w), 1705 
(s), 1617 (w), 1588 (w), 1568 (w), 1512 (w), 1489 (w), 1453 (w), 1410 (w), 1370 (w), 
1324 (s), 1295 (m), 1254 (s), 1210 (s), 1158 (s), 1152 (s), 1120 (s), 1066 (s), 1021 (s), 
960 (m), 923 (m), 851 (m), 831 (s), 796 (s), 764 (m), 718(m), 627 (m), 582 (w). 
MS (EI, 70 eV) m/z (%): 506 ([M+H]+, 28), 505 ([M]+, 100) , 477 (21), 476 (17), 
461 (22), 460 (75), 432 (26), 412 (13), 320 (10), 239 (13), 69 (14);  
HRMS (ESI-TOF): calcd for ([M+H]+) C26H17F6NO3 506.11854, found 
506.11920;  
 
Ethyl 4-(3-methoxyphenyl)-7-p-tolylquinoline-3-carboxylate (5f): 
According to the general procedure compound 5f was 
isolated by column chromatography as white crystals 
(129 mg, 88 %), mp = 83-84 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.06 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 2.42 (s, 3H, CH3), 3.84 (s, 
3H, OCH3), 4.16 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.87 
(dd, 4J = 2.5 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.91 (ddd, 
3J = 7.5 Hz, 4J = 1.6 Hz, 
4J = 1.0 Hz, 1H, CHAr), 7.05 (ddd, 
3J = 8.4 Hz, 4J = 2.6 Hz, 4J = 1.0 Hz, 1H, CHAr), 
7.32 (d, 3J = 7.6 Hz, 1H, CHAr), 7.43 (dd, 
3J = 8.3 Hz, 3J = 7.5 Hz, 1H, CHAr), 7.63-
7.72 (m, 3H, CHAr), 7.71 (s, 1H, CHAr), 7.77 (dd, 
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 
8.40 (d, 4J = 1.8 Hz, 1H, CHAr), 9.36 (s, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 21.3 (CH3), 55.5 (OCH3), 61.3 
(CH2CH3), 113.9 (CH), 114.7 (CH), 121.5 (CH), 122.9 (C), 126.0 (C), 126.5 (CH), 
127.0 (CH), 127.5 (CH), 128.1 (CH), 129.3 (CH), 130.0 (CH), 136.8 (C), 137.9, 138.5 
(C), 143.9 (C), 149.4 (C), 149.8 (C), 150.5 (CH), 159.5 (C), 166.5 (C=O); 
IR (ATR, cm-1): v
~
 = 3060 (w), 2982 (w), 2923 (w), 2856 (w), 1699 (s), 1615 
(m), 1598 (m), 1585 (m), 1574 (m), 1563 (s), 1480 (m), 1463 (m), 1444 (m), 1425 (m), 
1409 (m), 1367 (s), 1324 (s), 1290 (s), 1280 (s), 1269 (s), 1233 (s), 1204 (s), 1174 (s), 
1146 (s), 1112 (s), 1079 (s), 1040 (s), 1020 (s), 993 (m), 964 (m), 951 (m), 887 (m), 
~
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860 (m), 843 (m), 837 (m), 813 (s), 792 (s), 779 (s), 711 (s), 700 (s), 683 (m), 673 (m), 
651 (m), 626 (m), 553 (m), 526 (m); 
MS (GC, 70 eV) m/z (%): 398 ([M+H]+, 31), 397 ([M]+, 100), 368 (11), 353 (15), 
352 (39), 309 (13), 281 (12), 29 (18); 
HRMS (EI): calcd. for C26H23NO2 ([M]
+) 397.16725, found 397.16794. 
 
Ethyl 4-(3,5-dimethylphenyl)-7-(4-methoxyphenyl)quinoline-3-carboxylate (5g): 
 According to the general procedure compound 5g 
was isolated by column chromatography as white 
crystals (88 mg, 58 %), mp = 114-115 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.05 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 2.40 (s, 6H, 2*CH3), 3.88 
(s, 3H, OCH3), 4.15 (q, 
3J = 7.1 Hz, 2H, OCH2CH3), 
6.93 (s, 2H, CHAr), 7.02 -7.05 (m, 2H, CHAr), 7.13 (s, 1H, CHAr), 7.67-7.76 (m, 4H, 
CHAr), 8.35 (d, 
4J = 1.8 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 21.5 (2*CH3), 55.5 (OCH3), 
61.3 (CH2CH3), 114.7 (2*C, CH), 122.9 (C), 125.8 (2*CH), 126.0, 126.7 ((2+1)*C), 
128.3 (CH), 128.8 (2*C, CH), 129.9 (CH), 132.1, 136.4 (C), 137.7 (2*C), 143.5 (C), 
149.2 (CH), 150.3 (CH), 150.6 (C), 160.2 (C), 166.7 (C=O); 
IR (ATR, cm-1): v
~
 = 3041 (w), 2986 (w), 2978 (w), 2964 (w), 2926 (w), 2907 
(w), 2859 (w), 2836 (w), 2735 (w), 1895 (w), 1696 (s), 1610 (s), 1602 (m), 1580 (m), 
1566 (m), 1559 (m), 1522 (m), 1490 (m), 1476 (m), 1461 (m), 1449 (m), 1439 (m), 
1413 (m), 1406 (m), 1368 (s), 1344 (m), 1326 (m), 1288 (s), 1261 (m), 1237 (s), 1199 
(s), 1174 (s), 1148 (s), 1127 (s), 1114 (s), 1052 (m), 1035 (s), 1022 (s), 948 (m), 886 
(m), 872 (m), 853 (s), 846 (s), 824 (s), 806 (s), 795 (s), 763 (s), 724 (m), 707 (m), 684 
(m), 673 (m), 662 (m), 649 (m), 614 (m), 563 (m), 543 (m); 
MS (GC, 70 eV) m/z (%): 366 ([M+H]+, 31), 365 ([M]+, 100), 366 (25); 
HRMS (EI): calcd. for C26H23NO2 ([M]
+) 365.05387, found 365.05391. 
 
Ethyl 4-phenyl-7-(thiophen-3-yl)quinoline-3-carboxylate (5h): 
According to the general procedure compound 5h was isolated by column 
chromatography as white crystals (70 mg, 52 %), mp = 95-96 ºC; 
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1H NMR (300 MHz, CDCl3): δ = 1.02 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 4.13 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.29 -
7.35 (m, 2H, CHAr), 7.46 (dd, 
3J = 5.1 Hz, 4J = 2.9 Hz, 1H, 
CHAr), 7.51-7.53 (m, 3H, CHAr), 7.57 (dd, 
3J = 5.1 Hz, 
4J = 1.4 Hz, 1H, CHAr), 7.62 (d, 
3J = 8.8 Hz, 1H, CHAr), 
7.69 (dd, 3J = 3.0 Hz, 4J = 1.4 Hz, 1H, CHAr), 7.76 (dd, 
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 8.41 (d, 
4J = 1.8 Hz, 1H, CHAr), 9.36 (s, 1H, 
CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 61.4 (CH2CH3), 122.6 (CH), 124.5 (C), 
125.7 (CH), 126.4 (CH), 126.4 (CH), 127.1 (CH), 128.2 (2*C, C+CH), 128.3 (CH), 128.9 (CH), 
136.6, 138.4, 140.9, 149.4, 150.1, 150.6 (CH), 166.5 (C=O), one Carbon signal cannot be detected; 
IR (ATR, cm–1):  = 3105 (w), 3074 (w), 3054 (w), 2974 (w), 2957 (w), 2923 (w), 2854 
(w), 1729 (s), 1697 (s), 1613 (s), 1561 (s), 1525 (m), 1487 (m), 1473 (w), 1455 (w), 1442 (m), 1374 
(s), 1333 (m), 1321 (m), 1283 (s), 1260 (s), 1217 (s), 1163 (m), 1151 (m), 1118 (s), 1104 (s), 1072 
(m), 1019 (s), 943 (m), 910 (m), 898 (m), 844 (s), 815 (w), 780 (s), 757 (s), 718 (m), 698 (s), 675 
(m), 665 (m), 656 (m), 627 (m), 604 (m), 575 (m), 537 (m); 
MS (EI, 70 eV) m/z (%): 360 ([M+H]+, 25), 359 ([M]+, 100), 331 (13), 315 (18), 314 (71), 
286 (29), 285 (12), 284 (11), 258 (18), 241 (10); 
 HRMS (ESI): calcd for C22H17NO2S ([M]
+) 359.09745, found 359.09777. 
 
Ethyl 7-(2,3-dimethoxyphenyl)-4-phenylquinoline-3-carboxylate (5i): 
According to the general procedure compound 5i was 
isolated by column chromatography as white crystals  
 (126 mg, 82 %), mp = 117-118 ºC. 
1H NMR (250 MHz, CDCl3): δ = 1.01 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 3.64 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 
4.13 (q, 3J = 7.1 Hz, 2H, CH2CH3), 7.00 (dd, 
3J = 7.8 Hz, 
4J = 1.8 Hz, 1H, CHAr), 7.09 (dd, 
3J = 7.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 7.18 (td, 
3J = 7.9 Hz, 4J = 0.7 Hz, 1H, CHAr), 7.34 (dd, 
3J = 6.6 Hz, 4J = 3.0 Hz, 2H, CHAr), 
7.51-7.60 (m, 3H, CHAr), 7.62 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.77 (dd, 
3J = 8.8 Hz, 
4J = 1.7 Hz, 1H, CHAr), 8.33 (d, 
4J = 1.7 Hz, 1H, CHAr), 9.38 (s, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 56.1 (OCH3), 61.0 (OCH3), 
61.3 (CH2CH3), 112.6 (CH), 122.8 (CH), 123.2 (C), 124.6 (CH), 126.2, 127.0 (CH), 
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128.2 (CH), 128.3 (CH), 129.0 (CH), 129.1 (CH), 129.6 (CH), 134.6 (C), 136.7 (C), 
141.9 (C), 146.9 (C), 149.1 (C), 150.1 (C), 150.2 (CH), 153.3 (C), 166.7 (C=O); 
IR (ATR, cm-1): v~  = 3057 (w), 2998 (w), 2927 (w), 2900 (w), 2871 (w), 2839 
(w), 2820 (w), 1710 (s), 1615 (m), 1596 (w), 1562 (m), 1504 (w), 1491 (w), 1470 (m), 
1461 (m), 1437 (m), 1424 (s), 1405 (m), 1402 (m), 1365 (s), 1346 (w), 1328 (w), 1307 
(s), 1263 (s), 1245 (s), 1218 (s), 1174 (s), 1150 (s), 1120 (s), 1106 (s), 1089 (s), 1031 
(s), 1005 (s), 960 (m), 943 (m), 925 (m), 903 (m), 894 (m), 867 (m), 850 (m), 835 (m), 
823 (m), 802 (m), 788 (s), 771 (s), 756 (s), 719 (s), 703 (s), 674 (s), 660 (m), 628 (m), 
619 (m), 606 (m), 575 (m), 550 (m), 533 (m); 
MS (GC, 70 eV) m/z (%): 414 ([M+H]+, 31), 413 ([M]+, 100), 412 (13), 368 (16), 
352 (26), 177 (11); 
HRMS (EI): calcd. for C26H23NO4 (M
+) 413.16216, found 413.16189. 
 
Ethyl 7-(3-methoxyphenyl)-4-(4-(trifluoromethyl)phenyl)quinoline-3-carboxy-late 
(5j): 
According to the general procedure compound 5j was 
isolated by column chromatography as white crystals 
(142 mg, 85 %), mp = 133-134 ºC. 
1H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 3.89 (s, 3H, OCH3), 4.15 
(q, 3J = 7.1 Hz, 2H, CH2CH3), 6.98 (ddd, 
3J = 8.2 Hz, 
4J = 2.5 Hz, 4J = 1.0 Hz, 1H, CHAr), 7.28 (t, 
4J = 2.1 Hz, 1H, CHAr), 7.33 (dt, 
3J = 7.3 Hz, 4J = 1.1 Hz, 1H, CHAr), 7.41 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.46 (d, 
3J = 7.3 Hz, 2H, CHAr), 7.52 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.76-7.82 (m, 3H, CHAr), 8.43 
(d, 4J = 1.8 Hz, 1H, CHAr), 9.45 (s, 1H, CHAr).  
13C NMR (75 MHz, CDCl3): δ = 13.7 (CH2CH3), 55.5 (OCH3), 61.6 (CH2CH3), 
113.2 (CH), 114.2 (CH), 120.1 (CH), 122.5 (C), 124.2 (d, 1JC-F = 272.3 Hz, C), 125.2 
(q, 3JC-F = 3.8 Hz, CH), 125.9 (C), 127.2 (CH), 127.5 (CH), 127.7 (CH), 129.4 (CH), 
130.3 (CH), 130.6 (q, 2JC-F = 32.6 Hz, C), 140.6 (d, 
4JC-F = 1.2 Hz, C), 140.9 (C), 144.2 
(C), 148.6 (C), 149.5 (C), 150.8 (CH), 160.3 (C), 165.9 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -62.52 (CF3). 
IR (ATR, cm-1): v~  = 3100 (w), 3071 (w), 3046 (w), 3000 (w), 2984 (w), 2961 
(w), 2917 (w), 2852 (w), 2836 (w), 1936 (w), 1710 (s), 1616 (m), 1606 (m), 1580 (m), 
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1571 (m), 1564 (m), 1499 (m), 1478 (m), 1460 (m), 1454 (m), 1442 (m), 1422 (m), 
1405 (m), 1368 (m), 1345 (m), 1324 (s), 1294 (s), 1284 (s), 1259 (s), 1216 (s), 1207 
(s), 1190 (s), 1164 (s), 1147 (s), 1117 (s), 1106 (s), 1067 (s), 1050 (s), 1032 (s), 1022 
(s), 962 (m), 950 (m), 937 (m), 915 (m), 904 (m), 880 (m), 865 (s), 844 (s), 836 (s), 
819 (s), 801 (s), 774 (s), 750 (s), 718 (s), 696 (s), 681 (s), 664 (s), 650 (m), 630 (s), 
622 (s), 599 (m), 568 (m), 532 (m). 
MS (GC, 70 eV) m/z (%): 452 ([M+H]+, 29), 451 ([M]+, 100), 423 (12), 407 (13), 
406 (46), 335 (12). 
HRMS (EI): calcd. for C26H20F3NO3 (M
+) 451.13898, found 451.13909. 
 
Ethyl 7-(thiophen-3-yl)-4-p-tolylquinoline-3-carboxylate (5k): 
According to the general procedure compound 5k was isolated by column 
chromatography as white crystals (116 mg, 84 %), mp = 139-140 ºC; 
1H NMR (500 MHz, CDCl3): δ = 1.07 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 2.48 (s, 3H, CH3), 4.16 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 7.20 (d, 
3J = 8.0 Hz, 2H, CHAr), 7.32 (d, 
3J = 8.0 Hz, 2H, CHAr), 7.45 (dd, 
3J = 5.0 Hz, 3J = 2.9 Hz, 
1H, CHAr), 7.57 (dd, 
3J = 5.0 Hz, 4J = 1.3 Hz, 1H, CHAr), 
7.66 (d, 3J = 8.8 Hz, 1H, CHAr), 7.68 (dd, 
3J = 2.9 Hz, 
4J = 1.3 Hz, 1H, CHAr), 7.75 (dd, 
3J = 8.8 Hz, 4J = 2.0 Hz, 1H, CHAr), 8.40 (d, 
4J = 2.0 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr);  
13C NMR (126 MHz, CDCl3): δ = 13.8 (CH2CH3), 21.4 (CH3), 61.2 (CH2CH3), 
122.4 (CH), 123.0 (C), 125.7 (CH), 126.2 (CH), 126.3 (2*C, C+CH), 126.9 (CH), 128.1 
(CH), 128.8 (CH), 128.8 (CH), 133.4 (C), 138.0 (C), 138.1 (C), 140.9 (C), 149.4 (C), 
150.5 (CH), 166.5 (C=O);  
IR (ATR, cm-1): v~  = 3108 (w), 3084 (w), 3068 (w), 3038 (w), 2984 (w), 2955 
(w), 2921 (w), 2852 (w), 1696 (s), 1615 (s), 1575 (s), 1530 (w), 1514 (w), 1493 (m), 
1474 (w), 1147 (m), 1416 (m), 1409 (m), 1373 (s), 1337 (w), 1320 (s), 1281 (s), 1261 
(s), 1249 (s), 1218 (s), 1210 (s), 1194 (s), 1175 (s), 1148 (s), 1119 (s), 1110 (s), 1090 
(s), 1025 (s), 1014 (s), 948 (m), 910 (w), 884 (s), 875 (m), 843 (s), 838 (s), 817 (m), 
787 (s), 724 (m), 710 (m), 697 (m), 681 (m), 668 (m), 659 (m), 631 (m), 616 (m), 608 
(m), 588 (m), 559 (m), 528 (m); 
MS (GC, 70 eV) m/z (%): 374 ([M+H]+,26), 373 ([M]+, 100), 345 (11), 344 (11), 
329 (18), 328 (69), 300 (18), 299 (13); 
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HRMS (EI): calcd. for C23H19NO2S (M
+) 373.11310, found 373.11233. 
 
Ethyl 4-(4-isopropylphenyl)-7-(4-methoxyphenyl)quinoline-3-carboxylate (5l): 
According to the general procedure compound 5l was 
isolated by column chromatography as white crystals 
(133 mg, 85 %), mp = 166-167 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.96 (t, 
3J = 7.1 Hz, 3H, CH3, OCH2CH3), 1.35 (d, 
3J = 6.9 Hz, 6H, CH(CH3)2), 3.03 (hept, 
3J = 6.9 Hz, 
1H, CH(CH3)2), 3.87 (s, 3H, OCH3), 4.11 (q, 
3J = 7.1 Hz, 2H, CH2, OCH2CH3), 7.04 (d, 
3J = 8.8 Hz, 2H, CHAr), 7.24 (d, 
3J = 8.2 Hz, 
2H, CHAr), 7.37 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.69-7.74 (m, 4H, CHAr), 8.36 (d, 
4J = 1.1 Hz, 1H, CHAr), 9.33 (s, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.5 (CH2CH3), 24.0 (CH(CH3)2), 34.0 
(CH(CH3)2), 55.4 (OCH3), 61.1 (CH2CH3), 114.7 (CH), 123.2 (C), 126.0 (CH), 126.0 
(C), 126.3 (CH), 126.7 (CH), 128.2 (CH), 128.7 (CH), 129.0 (CH), 132.1 (C), 134.0, 
143.4 (C), 149.1 (C), 149.4 (C), 150.2 (C), 150.5 (CH), 160.2, 167.0 (C=O); 
IR (ATR, cm–1):  = 3382 (w), 3051 (w), 2960 (w), 2949 (w), 2923 (w), 2866 
(w), 1909 (w), 1880 (w), 1851 (w), 1699 (s), 1605 (m), 1572 (m), 1561 (m), 1511 (m), 
1487 (m), 1449 (m), 1439 (m), 1379 (m), 1364 (m), 1324 (m), 1301 (s), 1250 (s), 1217 
(s), 1187 (m), 1172 (s), 1152 (m), 1127 (m), 1110 (s), 1037 (s), 1020 (s), 992 (m), 952 
(w), 941 (m), 931 (w), 886 (m), 869 (m), 849 (w), 834 (s), 823 (s), 800 (s), 769 (m), 
758 (m), 739 (m), 693 (m), 679 (s), 657 (m), 599 (m), 564 (m), 556 (m), 536 (m); 
MS (EI, 70 eV) m/z (%): 426 ([M+H]+, 29), 425 ([M]+, 100), 338 (17); 
HRMS (ESI): calcd for C26H20FNO3 425.19855, found 425.19774;  
 
Ethyl 4-(2,3-dimethoxyphenyl)-7-(4-fluorophenyl)quinoline-3-carboxylate (5m): 
According to the general procedure compound 5m was 
isolated by column chromatography as white crystals  
 (81 mg, 51 %), mp = 133-136 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.10 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 3.96 (s, 3H, OCH3), 3.54 (s, 
3H, OCH3), 4.19 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.74 (dd, 
3J = 7.6 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.08 (dd, 
3J = 8.3 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.13 
~
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– 7.24 (m, 3H, CHAr), 7.64 (dd, 
3J = 8.8 Hz, 4J = 0.4 Hz, 1H, CHAr), 7.70 (dt, 
3J = 8.8 Hz, 4J = 3.5 Hz, 3H, CHAr), 8.34 (d, 
4J = 1.4 Hz, 1H, CHAr), 9.43 (s, 1H, 
CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.7 (CH2CH3), 55.8 (OCH3), 60.5 (OCH3), 
61.1 (CH2CH3), 112.6 (CH), 116.0 (d, 
2JC-F = 21.6 Hz, CH), 121.8 (CH), 123.0 (C), 
123.9 (CH), 126.1 (C), 126.7 (CH), 126.9 (CH), 128.2 (CH), 129.3 (d, 3JC-F = 8.2 Hz, 
CH), 131.0, 135.9 (d, 4JC-F = 3.2 Hz), 142.6 (C), 146.2, 147.1, 149.4 (C), 150.9 (CH), 
152.7 (C), 163.0 (d, 1JC-F = 248.1 Hz, C), 166.2 (C=O); 
19F NMR (282 MHz, CDCl3): δ = -113.84 (CF). 
IR (ATR, cm–1):  = 3062 (w), 2970 (w), 2933 (w), 2829 (w), 1701 (s), 1616 
(w), 1601 (w), 1571 (m), 1516 (m), 1496 (m), 1469 (s), 1450 (w), 1441 (w), 1427 (w), 
1414 (w), 1399 (w), 1380 (w), 1366 (w), 1345 (w), 1324 (w), 1293 (s), 1261 (s), 1219 
(s), 1191 (s), 1171 (s), 1151 (s), 1130 (s), 1107 (s), 1077 (s), 1012 (s), 1003 (s), 940 
(m), 912 (m), 899 (m), 863 (m), 840 (m), 825 (s), 812 (s), 795 (s), 771 (s), 751 (s), 720 
(m), 700 (m), 678 (m), 608 (m), 554 (m); 
MS (EI, 70 eV) m/z (%): 432 ([M+H]+, 30), 431 ([M]+, 100), 400 (22), 386 (16), 
373 (18), 372 (67), 371 (10), 356 (14), 343 (16), 329 (12), 328 (14), 300 (20), 280 
(26), 272 (11), 271 (11), 29 (36);  
HRMS (EI): calcd for ([M]+) C26H17F6NO3 431.15274, found 431.15223;  
 
Ethyl 4-(3-fluorophenyl)-7-(4-fluorophenyl)quinoline-3-carboxylate (5n): 
According to the general procedure compound 5n was 
isolated by column chromatography as white crystals 
(82 mg, 57 %), mp = 96-98 ºC; 
1H NMR (250 MHz, CDCl3): δ = 1.10 (t, 
3J = 7.1 Hz, 3H, CH3, CH2CH3), 4.18 (q, 
3J = 7.1 Hz, 
2H, CH2, CH2CH3), 7.06-7.17 (m, 1H, CHAr), 7.19-7.36 
(m, 4H, CHAr), 7.41-7.58 (m, 3H, CHAr), 7.64 (dd, 
3J = 8.8 Hz, J = 0.6 Hz, 1H, CHAr), 
7.74 (dd, 3J = 8.8 Hz, 4J = 1.9 Hz, 1H, CHAr), 8.40 (d, 
4J = 1.7 Hz, 1H, CHAr), 9.40 (s, 
1H, CHAr). 
13C NMR (65 MHz, CDCl3): δ = 13.8 (CH2CH3), 61.4 (CH2CH3), 114.4 (d,  
2JC-F = 22.4 Hz, CH), 115.0 (d, 
1J = 21.1 Hz, CH), 115.3 (d, 1JC-F = 22.0 Hz, CH), 
123.1 (d, 4JC-F = 3.2 Hz, CH), 123.3 (C), 126.5 (C), 126.7 (CH), 127.4 (CH), 127.9 
(CH), 130.6 (d, 3JC-F = 7.8 Hz, CH), 130.6 (d, 
3JC-F = 8.2 Hz, CH), 132.2 (d,  
~
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4JC-F = 3.7 Hz, C), 141.8 (d, 
3JC-F = 7.3 Hz, C), 142.4 (d, 
4JC-F = 2.3 Hz, C), 148.6 (C), 
149.4 (C), 150.8 (CH), 162.8 (d, 1JC-F = 247.7 Hz, C), 163.3 (d, 
1JC-F = 246.7 Hz, C), 
166.3 (C=O); 
IR (ATR, cm-1): v~  = 3057 (w), 2979 (m), 2926 (w), 2900 (w), 2867 (w), 1702 
(s), 1608 (m), 1501 (s), 1291 (m), 1218 (s), 1018 (m), 782 (vs), 696 (m), 556 (m). 
MS (GC-MS): m/z (%) = 390 ([M+H]+, 26), 389 ([M]+ 100), 361 (20), 360 (11), 
345 (23), 344 (83), 317 (12), 316 (42), 315 (16), 314 (14), 288 (29). 
HRMS (EI): calcd for ([M]+) C24H17F2NO2 389.12219, found 389.12194;  
 
General procedure for the synthesis of compounds 6a-j: 
To a toluene suspension (4 mL) of 4 (100 mg, 0.37 mmol), arylboronic acid (2.2 
equiv.), Pd(OAc)2 (3.3 mg, 4 mol %), XPhos (14 mg, 8 mol %), K3PO4 (2.5 equiv) and 
was degassed by bubbling argon through the solution for 10 min. The reaction mixture 
was heated under argon atmosphere for 8 h at 110 °C. After cooling to 20 °C, the 
solution was diluted with water and extracted with CH2Cl2 (3 × 25 mL). The combined 
organic layers were dried (Na2SO4), filtered, and the filtrate was concentrated in vacuo. 
The residue was purified by column chromatography (silica gel, heptane/EtOAc). 
 
Ethyl 4,7-bis(3,5-dimethylphenyl)quinoline-3-carboxylate (6a): 
According to the general procedure compound 6a was isolated by column 
chromatography as white crystals (147 mg, 97 %), mp = 115-117 ºC 
1H NMR (300 MHz, CDCl3): δ = 1.05 (t, 
3J = 7.1, 3H, CH2CH3), 2.40 (s, 6H, 2*CH3), 2.42 (s, 
6H, 2*CH3), 4.16 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 6.94 
(s, 2H, CHAr), 7.07 (s, 1H, CHAr), 7.13 (s, 1H, CHAr), 
7.38 (s, 2H, CHAr), 9.34 (s, 1H, CHAr), 7.70 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.76 (dd, 
3J = 8.8 Hz, 
4J = 1.8 Hz, 1H, CHAr), 8.39 (d, 
4J = 1.8 Hz, 1H, 
CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.7 (CH2CH3), 21.3 (CH3), 21.4 (CH3), 61.1 
(CH2CH3), 123.0 (C), 125.4 (CH), 126.2 (C), 126.55 (CH), 126.6 (CH), 126.95 (CH), 
128.05 (CH), 129.8 (CH), 130.0 (CH), 136.2 (C), 137.6 (C), 138.6 (C), 139.6 (C), 
144.1 (C), 149.0 (C), 150.15 (CH), 150.4 (C), 166.6 (C=O); 
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IR (ATR, cm-1): v~  = 2975 (w), 2917 (m), 2858 (w), 2731 (w), 1705 (s), 1615 
(m), 1601 (s), 1566 (s), 1498 (w), 1444 (m), 1402 (m), 1367 (s), 1344 (m), 1303 (s), 
1269 (s), 1236 (s), 1209 (s), 1192 (s), 1150 (s), 1119 (s), 1079 (w), 1048 (s), 1016 (m), 
942 (w), 890 (m), 851 (s), 831 (s), 798 (s), 778 (m), 762 (w), 706 (s), 679 (w), 662 (m), 
653 (s), 600 (w), 577 (w), 540 (w); 
MS (GC, 70 eV) m/z (%): 410 (31), 409 (M+, 100), 380 (13), 365 (12), 364 
(41), 321 (11), 29 (17); 
HRMS (EI): calcd. for C28H27NO2 (M
+) 409.20363, found 409.20372. 
 
Ethyl 4,7-di(thiophen-3-yl)quinoline-3-carboxylate (6b): 
According to the general procedure compound 6b was 
isolated by column chromatography as white crystals 
(127 mg, 94 %), mp = 94-95 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.12 (t, 
3J = 7.1 Hz, 
3H, CH2CH3), 4.19 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.15 (dd, 
3J = 4.9 Hz, 4J = 1.3 Hz, 1H, CHAr), 7.31 (dd, 
4J = 3.0 Hz, 4J = 1.3 Hz, 1H, CHAr), 7.46 
(dd, 3J = 5.0 Hz, 4J = 2.9 Hz, 1H, CHAr), 7.51 (dd, 
3J = 4.9 Hz, 4J = 2.9 Hz, 1H, CHAr), 
7.57 (dd, 3J = 5.1 Hz, 4J = 1.4 Hz, 1H, CHAr), 7.69 (dd, 
4J = 2.9 Hz, 4J = 1.4 Hz, 1H, 
CHAr), 7.74 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.79 (dd, 
3J = 8.8 Hz, 4J = 1.7 Hz, 1H, CHAr), 
8.39 (d, 4J = 1.7 Hz, 1H, CHAr), 9.30 (s, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 14.0 (CH2CH3), 61.5 (CH2CH3), 122.6 (CH), 
123.8 (C), 124.5 (CH), 125.7 (CH), 125.8 (CH), 126.4 (CH), 126.5 (CH), 126.5 (C), 
127.1 (CH), 127.9 (CH), 129.2 (CH), 136.0 (C), 138.4 (C), 140.9 (C), 145.1 (C), 149.5 
(C), 150.4 (CH), 166.7 (C=O); 
IR (ATR, cm-1): v
~
 = 3394 (w), 3101 (w), 3075 (w), 2981 (w), 2958 (w), 2923 
(w), 2851 (w), 1704 (s), 1615 (m), 1569 (s), 1527 (m), 1494 (w), 1479 (w), 1470 (w), 
1446 (m), 1424 (m), 1391 (w), 1374 (m), 1364 (m), 1352 (m), 1317 (s), 1281 (s), 1248 
(s), 1221 (s), 1206 (m), 1190 (s), 1170 (s), 1147 (s), 1111 (s), 1089 (m), 1070 (m), 
1020 (s), 1005 (m), 959 (w), 948 (w), 877 (w), 860 (m), 844 (s), 824 (s), 800 (s), 769 
(s), 704 (m), 687 (s), 665 (s), 636 (m), 614 (m), 606 (m), 596 (m), 566 (m), 535 (m); 
MS (GC, 70 eV) m/z (%): 365 ([M]+, 100), 337 (16), 336 (19), 321 (22), 320 
(59), 293 (12), 292 (32), 291 (13), 264 (15), 247 (10), 45 (16), 29 (28); 
HRMS (EI): calcd. for C20H15NO2S2 ([M]
+) 365.05387, found 365.05331; 
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Ethyl 4,7-bis(3-fluorophenyl)quinoline-3-carboxylate (6c): 
According to the general procedure compound 6c was 
isolated by column chromatography as white crystals 
(124 mg, 86 %), mp = 102-103 ºC; 
1H NMR (250 MHz, CDCl3): δ = 1.1 (t, 
3J = 7.2 Hz, 3H, CH2CH3), 4.2 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 7.00 – 7.17 (m, 3H, CHAr), 7.18 – 7.26 (m, 1H, 
CHAr), 7.38-7.58 (m, 4H,CHAr), 7.63 (dd, 
3J = 8.8 Hz, 4J = 0.6 Hz, 1H, CHAr), 7.74 
(dd, 3J = 8.8 Hz, 4J = 1.9 Hz, 1H, CHAr), 8.39 (d, 
4J = 1.9 Hz, 1H, CHAr), 9.41 (s, 1H, 
CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.9 (CH2CH3), 61.5(CH2CH3), 114.5 (d,  
2JC-F = 22.3 Hz, CH), 115.3 (d, 
4JC-F = 1.8 Hz, CH), 115.4 (d, 
4JC-F = 2.0 Hz, CH), 
116.3 (d, 2JC-F = 22.5 Hz, CH), 123.1 (C), 123.3 (d, 
4JC-F = 2.9 Hz, CH), 124.8 (d,  
4JC-F = 3.1 Hz, CH), 126.2 (C), 126.9 (CH), 127.5 (CH), 128.0 (CH), 130.0 (d,  
3JC-F = 8.3 Hz, CH), 130.8 (d, 
3JC-F = 8.4 Hz, C), 138.7 (d, 
3JC-F = 8.0 Hz, CH), 141.9 
(d, 3JC-F = 7.7 Hz, C), 142.6 (d, 
4JC-F = 2.3 Hz), 148.3 (d, 
4JC-F = 2.0 Hz), 149.6 (C), 
151.0 (CH), 162.7 (d, 1JC-F = 247.4 Hz, C), 163.4 (d, 
1JC-F = 246.5 Hz, C), 166.2 
(C=O); 
IR (ATR, cm-1): v~  = 3044 (w), 2979 (w), 2929 (w), 2909 (w), 2869 (w), 1704 
(s), 1612 (s), 1582 (m), 1564 (s), 1489 (m), 1479 (m), 1431 (s), 1404 (m), 1381 (m), 
1366 (m), 1345 (m), 1325 (m), 1292 (s), 1265 (s), 1225 (s), 1203 (s), 1173 (s), 1156 
(s), 1140 (s), 1117 (s), 1073 (m), 1044 (m), 1018 (s), 1001 (m), 943 (m), 933 (m), 897 
(s), 865 (s), 837 (m), 822 (s), 800 (s), 780 (s), 716 (s), 700 (s), 692 (s), 674 (s), 653 
(s), 636 (m), 603 (m), 584 (m), 546 (w); 
MS (GC, 70 eV) m/z (%): 390 (28), 389 ([M]+, 100), 361 (21), 344 (81), 317 
(12), 316 (51), 315 (18), 314 (19), 296 (11), 286 (13), 268 (10), 29 (31); 
HRMS (EI): calcd. for C24H17F2NO2 (M
+) 389.12219, found 389.12199. 
 
Ethyl 4,7-diphenylquinoline-3-carboxylate (6d): 
 According to the general procedure compound 6d was isolated by column 
chromatography as white crystals (115 mg, 88 %), mp = 104-105 ºC; 
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1H NMR (300 MHz, CDCl3): δ = 1.02 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 4.13 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 7.3 – 7.36 (m, 2H, CHAr), 7.40 – 7.46 (m, 1H, 
CHAr), 7.47 – 7.55 (m, 5H, CHAr), 7.66 (d, 
3J = 8.8 Hz, 
1H, CHAr), 7.73 – 7.8 (m, 3H, CHAr), 8.41 (d, 
4J = 1.6 Hz, 
1H, CHAr), 9.38 (s, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.8 (CH2CH3), 61.3 (CH2CH3), 123.1 (C), 
126.3 (C), 126.9 (CH), 127.2 (CH), 127.6 (CH), 128.2 (CH), 128.2 (CH), 128.3 (CH), 
128.4 (CH), 129.0 (CH), 129.2 (CH), 136.7 (C), 139.8 (C), 143.8 (C), 149.7 (C), 149.8 
(C), 150.8 (CH), 166.7 (C=O); 
IR (ATR, cm-1): v~  = 3055 (w), 3042 (w), 2987 (w), 2925 (w), 2908 (w), 2870 
(w), 2854 (w), 1705 (s), 1614 (m), 1599 (m), 1579 (m), 1562 (m), 1482 (m), 1470 (m), 
1444 (m), 1434 (m), 1402 (m), 1365 (s), 1322 (s), 1292 (s), 1276 (s), 1261 (s), 1242 
(s), 1214 (s), 1186 (s), 1176 (s), 1159 (s), 1119 (s), 1110 (s), 1073 (s), 1017 (s), 972 
(m), 966 (m), 951 (m), 941 (m), 922 (w), 892 (s), 863 (s), 838 (s), 802 (s), 761 (s), 724 
(s), 709 (s), 697 (s), 675 (s), 649 (m), 628 (s), 615 (s), 573 (s), 543 (m), 535 (m); 
MS (GC, 70 eV) m/z (%): 354 (27), 353 ([M]+, 100), 325 (12), 324 (10), 309 
(20), 308 (64), 280 (32), 279 (15), 278 (18), 252 (23), 250 (15); 
HRMS (EI): calcd. for C24H19NO2 (M
+) 353.14103, found 353.14092. 
 
Ethyl 4,7-bis(4-(trifluoromethyl)phenyl)quinoline-3-carboxylate (6e): 
According to the general procedure compound 6e was isolated by column 
chromatography as white crystals (100 mg, 56 %), mp = 155-156 ºC; 
H NMR (300 MHz, CDCl3): δ = 1.04 (t, 
3J = 
7.1 Hz, 3H, CH2CH3), 4.16 (q, 
3J = 7.2 Hz, 2H, 
CH2CH3), 7.42 – 7.52 (m, 2H, CHAr), 7.58 (d, 
3J = 
8.8 Hz, 1H, CHAr), 7.72 – 7.90 (m, 7H, CHAr), 8.45 
(d, 4J = 1.8 Hz, 1H, CHAr), 9.46 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.7 
(CH2CH3), 61.6(CH2CH3), 123.0 (C), 124.2 (d,  
1JC-F = 272.2 Hz, C), 124.2 (d, 
1JC-F = 272.1 Hz, C), 125.3 (q, 
2JC-F = 3.7 Hz, CH), 
126.2 (q, 2JC-F = 3.7, CH), 126.3, 127.0 (CH), 127.95 (CH), 128.0 (CH), 128.1 (CH), 
129.4 (CH), 130.6 (d, 3JC-F = 32.7 Hz, C), 130.8 (d, 
3JC-F = 32.6 Hz, C), 140.5 (d,  
N
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5JC-F = 1.2 Hz), 142.6, 143.1 (d, 
5JC-F =  1.1 Hz), 148.5, 149.5 (C), 151.2 (CH), 165.9 
(C=O); 
19F NMR (282 MHz, CDCl3): δ = -62.55 (CF3), -62.60 (CF3); 
IR (ATR, cm-1): v~  = 3047 (w), 2994 (w), 2942 (w), 2908 (w), 1705 (s), 1614 
(m), 1568 (m), 1491 (w), 1477 (w), 1453 (w), 1443 (w), 1409 (m), 1400 (m), 1370 (m), 
1322 (s), 1299 (s), 1265 (m), 1245 (m), 1223 (m), 1191 (m), 1162 (s), 1155 (s), 1118 
(s), 1107 (s), 1066 (s), 1021 (s), 1011 (s), 993 (m), 956 (m), 949 (m), 931 (m), 887 
(m), 876 (m), 866 (m), 851 (s), 828 (s), 820 (s), 798 (s), 778 (m), 764 (s), 743 (m), 718 
(s), 676 (m), 652 (m), 642 (m), 631 (m), 598 (s), 575 (m), 537 (m); 
 MS (EI, 70 eV) m/z (%): 490 (29), 489 ([M]+, 100), 470 (14), 461 (29), 460 
(13), 445 (27), 444 (92), 417 (37), 416 (38), 415 (11), 396 (22), 346 (11), 320 (18), 69 
(12), 29 (33); 
HRMS (ESI-TOF): calcd. for C26H17F6NO2 (M+H
+) 490.12362, found 
490.12413. 
 
Ethyl 4,7-bis(4-ethylphenyl)quinoline-3-carboxylate (6f): 
According to the general procedure compound 6f was isolated by column 
chromatography as white crystals (126 mg, 83 %), mp = 122-123 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.02 (t, 
3J = 7.1 Hz, 3H, OCH2CH3), 1.30 (t, 
3J = 7.6 Hz, 3H, 
CH3), 1.34 (t, 
3J = 7.6 Hz, 3H, CH3), 2.73 (q, 
3J = 7.7 Hz, 2H, CH2), 2.79 (q, 
3J = 7.7 Hz, 2H, CH2), 
4.14 (q, 3J = 7.1 Hz, 2H, OCH2CH3), 7.24 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.35 (d, 
3J = 8.0 Hz, 4H, 
CHAr), 7.64–7.73 (m, 3H, CHAr), 7.76 (dd,  
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 8.40 (d, 
3J = 1.8 Hz, 1H, CHAr), 9.35(s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 13.8 (CH2CH3), 15.6 (CH3), 15.7 (CH3), 28.7 
(CH2), 28.9 (CH2), 61.27 (CH2CH3), 123.2 (C), 126.3 (C), 126.6 (CH), 126.9 (CH), 
127.55 (CH), 127.7 (CH), 128.2 (CH), 128.8 (CH), 128.96 (CH), 133.8 (C), 137.1 (C), 
143.8 (C), 144.45 (C), 144.8 (C), 149.45 (C), 150.2 (C), 150.5 (CH), 166.8 (C=O); 
 IR (ATR, cm-1): v~  = 3045 (w), 3019 (w), 2959 (w), 2924 (w), 2905 (w), 2864 
(w), 1910 (w), 1889 (w), 1704 (s), 1614 (m), 1571 (m), 1513 (m), 1488 (m), 1460 (m), 
1449 (m), 1411 (m), 1404 (m), 1366 (m), 1346 (m), 1321 (m), 1292 (m), 1274 (m), 
N
O
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12631249 (m), 1221 (s), 1184 (m), 1150 (m), 1121 (m), 1111 (s), 1063 (m), 1051 (m), 
1027 (m), 1017 (s), 963 (m), 946 (m), 927 (w), 909 (m), 868 (m), 848 (m), 824 (s), 816 
(s), 798 (s), 772 (s), 764 (s), 701 (m), 675 (m), 658 (m), 638 (w), 627 (w), 603 (m), 
580 (m), 564 (m), 549 (m); 
          MS (EI, 70 eV) m/z (%): 410 (34), 409 ([M]+, 100), 394 (14), 366 (14), 364 (20), 
336 (12), 29 (31); 
HRMS (EI): calcd. for C28H27NO2 (M
+) 409.20363, found 409.20284. 
 
Ethyl 4,7-dip-tolylquinoline-3-carboxylate (6g): 
According to the general procedure compound 6g was 
isolated by column chromatography as white crystals 
(123 mg, 87 %), mp = 118-119 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.07 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 2.43 (s, 3H, CH3), 2.48 (s, 
3H, CH3), 4.16 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.21 (d, 
3J = 8.0 Hz, 2H, CHAr), 7.34 (d, 
3J = 3.2 Hz, 2H, 
CHAr), 7.34 (d, 
3J = 3.2 Hz, 2H, CHAr), 7.7 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.7 (s, 1H, 
CHAr), 7.75 (dd, 
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 8.39 (d, 
4J = 1.9 Hz, 1H, CHAr), 
9.35 (s, 1H, CHAr);  
 13C NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH3), 21.3 (CH3), 21.5 (CH3), 61.35 
(CH2CH3), 123.1 (C), 126.3, 126.55 (CH), 126.9 (CH), 127.5 (CH), 128.2 (CH), 128.9 
(CH), 128.9 (CH), 130.0 (CH), 133.6 (C), 136.85 (C), 138.1 (C), 138.5 (C), 143.8 (C), 
149.45 (C), 150.3 (C), 150.5 (CH), 166.7(C=O); 
IR (ATR, cm-1): v~  = 3028 (w), 2989 (w), 2958 (w), 2918 (w), 2851 (w), 1911 
(w), 1804 (w), 1731 (s), 1614 (m), 1578 (m), 1561 (m), 1513 (w), 1488 (m), 1441 (m), 
1412 (w), 1379 (m), 1365 (m), 1349 (w), 1318 (w), 1289 (s), 1270 (m), 1258 (m), 1243 
(w), 1222 (s), 1210 (s), 1183 (s), 1170 (s), 1155 (s), 1110 (s), 1025 (s), 1020 (s), 968 
(w), 946 (m), 924 (m), 874 (w), 860 (w), 843 (s), 826 (s), 812 (s), 796 (s), 786 (s), 764 
(s), 722 (s), 693 (s), 675 (s), 654 (m), 627 (w), 601 (s), 571 (m), 543 (s), 531 (m); 
MS (GC, 70 eV) m/z (%): 382 (27), 381 (M+, 100), 353 (12), 352 (16), 337 
(15), 336 (52), 308 (18), 307 (11), 292 (11), 265 (11), 29 (31); 
HRMS (EI): calcd. for C26H23NO2 (M
+) 381.17233, found 381.17211. 
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Ethyl 4,7-bis(4-methoxyphenyl)quinoline-3-carboxylate (6h): 
 According to the general procedure compound 6h 
was isolated by column chromatography as white 
crystals (132 mg, 86 %), mp = 120-121 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.09 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 3.88 (s, 3H, OCH3), 3.91 
(s, 3H, OCH3), 4.18 (t, 
3J = 7.1 Hz, 2H, CH2CH3), 
7.05 (dd, 3J = 8.8 Hz, 4J = 3.9 Hz, 4H, CHAr), 7.25 
(d, 3J = 8.7 Hz, 2H, CHAr), 7.64 – 7.8 (m, 4H, CHAr), 8.35 (d, 
4J = 1.2 Hz, 1H, CHAr), 
9.32 (s, 1H, CHAr);  
13C NMR (75 MHz, CDCl3): δ = 13.8 (CH2CH3), 55.3 (OCH3), 55.4 (OCH3), 
61.2 (CH2CH3), 113.7 (CH), 114.7 (CH), 123.2, 126.0 (CH), 126.3 (C), 126.7 (CH), 
128.1 (CH), 128.7 (CH), 128.8 (C), 130.3 (CH), 132.1 (C), 143.4 (C), 149.5 (C), 149.9 
(C), 150.5 (CH), 159.8 (C), 160.2 (C), 166.8 (C=O); 
IR (ATR, cm-1): v~  = 3102 (w), 3065 (w), 3041 (w), 2991 (w), 2955 (w), 2928 
(w), 2897 (w), 2833 (w), 1895 (w), 1694 (s), 1608 (s), 1577 (m), 1510 (s), 1484 (m), 
1458 (m), 1450 (m), 1440 (m), 1415 (m), 1401 (m), 1381 (m), 1368 (m), 1345 (m), 
1328 (m), 1305 (m), 1285 (s), 1243 (s), 1176 (s), 1147 (s), 1109 (s), 1032 (s), 1022 (s), 
971 (m), 944 (m), 926 (m), 896 (m), 871 (m), 847 (m), 832 (s), 825 (s), 800 (s), 765 
(s), 730 (m), 700 (m), 676 (s), 660 (m), 632 (w), 621 (w), 600 (m), 582 (s), 558 (s), 
545 (s), 527 (s); 
MS (EI, 70 eV) m/z (%): 414 (28), 413 (M+, 100), 368 (28); 
HRMS (EI): calcd. for C26H23NO4 (M
+) 413.16216, found 413.16092. 
 
Ethyl 4,7-bis(4-tert-butylphenyl)quinoline-3-carboxylate (6i): 
According to the general procedure compound 6i was 
isolated by column chromatography as white crystals 
(136 mg, 86 %), mp = 205-206 ºC; 
1H NMR (300 MHz, CDCl3) δ = 0.94 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 1.39 (s, 9H, C(CH3)3), 
1.42 (s, 9H, C(CH3)3), 4.10 (q, 
3J = 7.2, 2H, 
CH2CH3), 7.26 (d, 
3J = 8.4 Hz, 2H, CHAr), 7.53 (d, 
3J = 8.4 Hz, 4H, CHAr), 7.72 (d, 
3J = 8.4 Hz, 2H, 
N
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CHAr), 7.73 (s, 1H, CHAr), 7.78 (dd, 
3J = 8.8 Hz, 4J = 1.8 Hz, 1H, CHAr), 8.41 (d, 
4J = 1.7 Hz, 1H, CHAr), 9.34 (s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3) δ = 13.7 (CH2CH3), 31.5 (C(CH3)), 31.6 (C(CH3)), 
34.8, 34.9, 61.2 (CH2CH3), 123.4 (C), 125.1 (CH), 126.2 (CH), 126.3 (C), 126.6 (CH), 
126.9 (CH), 127.3 (CH), 128.3 (CH), 128.8 (CH), 133.6 (C), 136.8 (C), 143.7 (C), 
149.4 (C), 150.5 (2*C, C+CH), 151.4 (C), 151.7 (C), 167.0 (C=O). 
IR (ATR, cm-1): v~  = 3036 (w), 2953 (m), 2902 (w), 2867 (w), 1913 (w), 1892 
(w), 1799 (w), 1760 (w), 1702 (s), 1614 (m), 1572 (m), 1513 (w), 1486 (w), 1476 (w), 
1461 (m), 1448 (m), 1403 (m), 1393 (m), 1365 (m), 1346 (w), 1322 (m), 1294 (m), 
1271 (s), 1248 (m), 1224 (s), 1202 (m), 1194 (m), 1185 (m), 1152 (s), 1126 (s), 1113 
(s), 1107 (s), 1017 (s), 993 (w), 963 (w), 944 (w), 929 (w), 907 (m), 879 (w), 866 (m), 
849 (m), 829 (m), 822 (s), 815 (s), 798 (s), 765 (m), 753 (m), 742 (m), 676 (m), 658 
(m), 638 (w), 625 (w), 598 (m), 563 (s), 551 (m), 540 (m); 
HRMS (EI): calcd. for C32H35NO2 (M
+) 465.26623, found 465.26571. 
 
Ethyl 4,7-bis(4-(trifluoromethoxy)phenyl)quinoline-3-carboxylate (6j): 
According to the general procedure compound 6j was isolated by column 
chromatography as white crystals (131 mg, 68 %), mp = 119-120 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.03 (t, 
3J = 7.1 Hz, 3H, CH2CH3), 4.15 (q, 
3J = 7.1 Hz, 2H, 
CH2CH3), 7.31 – 7.42 (m, 6H, CHAr), 7.61 (d, 
3J = 8.7 Hz, 1H, CHAr), 7.71 – 7.80 (m, 3H, CHAr), 
8.39 (d, 4J = 1.8 Hz, 1H, CHAr), 9.41 (s, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 13.7 
(CH2CH3), 61.6 (CH2CH3), 120.6 (d,  
1JC-F = 257.5 Hz), 120.7 (d, 
1JC-F = 257.6 Hz, C), 120.8 (CH), 121.7 (CH), 123.3 (C), 
126.3 (C), 127.0 (CH), 127.3 (CH), 128.1 (CH), 129.0 (CH), 130.5 (CH), 135.2 (C), 
138.2 (C), 142.7 (C), 148.6 (C), 149.4 (C), 149.4 (d, 3JC-F = 1.9 Hz), 149.6 (d, 
3JC-
F = 2.0 Hz, C), 150.9 (CH), 166.2 (C=O). 
19F NMR (282 MHz, CDCl3): δ = -57.78 (OCF3), -57.77 (OCF3); 
IR (ATR, cm–1):  = 3036 (w), 2993 (w), 2960 (w), 2925 (w), 2825 (w), 1710. 
(s), 1617 (w), 1588 (w), 1571 (w), 1508 (m), 1486 (w), 1475 (w), 1450 (w), 1410 (w), 
1400 (w), 1368 (m), 1346 (w), 1326 (w), 1294 (w), 1249 (s), 1219 (s), 1199 (s), 1159 
(s), 1145 (s), 1102 (s), 1025 (s), 1016 (s), 958 (w), 946 (w), 917 (s), 854 (s), 834 (s), 
~
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792 (s), 768 (s), 740 (m), 698 (m), 676 (s), 634 (m), 624 (m), 611 (m), 583 (m), 533 
(m); 
MS (EI, 70 eV) m/z (%): 522 (29), 521 (100), 493 (19), 477 (22), 476 (72), 448 
(20), 362 (10), 351 (12), 69 (58), 29 (28); 
HRMS (EI): calcd. for C26H17F6NO4 (M
+) 521.10563, found 521.10540. 
 
General procedure for synthesis of compound 9: 
To a toluene suspension (4 mL) of 3-(ethoxycarbonyl)-4-phenylquinoline 1-
oxide (100 mg, 2 equiv.), 3-bromotoluene (30 mg, 1.1 equiv.), Pd(OAc)2 (1.9 mg, 
5 mol%), PBu2Me·HBF4 (2.1 mg, 5 mol%) and K2CO3 (47 mg, 2.5 equiv.) were added 
under argon atmosphere. The reaction mixture was heated under argon atmosphere for 
24 h at 110 °C. After cooling to 20 °C, the solution was diluted with water and 
extracted with CH2Cl2 (3×25 mL). The combined organic layers were dried (Na2SO4), 
filtered, and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, heptane/EtOAc). 
 
3-(ethoxycarbonyl)-4-phenyl-2-(m-tolyl)quinoline 1-oxide (9): 
According to the general procedure compound 9 was isolated as 
a light yellow semisolid (66 mg, 98 %). 
1H NMR (300 MHz, CDCl3): δ = 0.7 (t, 
3J = 7.1 Hz, 3H, 
CH3), 2.4 (s, 3H, CH3), 3.8 (q, 
3J = 7.1 Hz, 2H, CH2CH3), 7.2 – 
7.3 (m, 1H, CHAr), 7.4 – 7.5 (m, 6H), 7.5 – 7.5 (m, 3H), 7.6 
(ddd, 3J = 8.3 Hz, 3J = 6.7 Hz, 4J = 1.2 Hz, 1H, CHAr), 7.7 
(ddd, 3J = 8.5 Hz, 4J = 1.6 Hz, 5J = 0.6 Hz, 1H, CHAr), 7.8 (ddd, 
3J = 8.6 Hz, 
3J = 6.7 Hz, 4J = 1.6 Hz, 1H, CHAr), 8.9 (dd, 
3J = 8.8 Hz, 5J = 0.9 Hz, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 13.4 (CH2CH3), 21.6 (CH3), 61.7 (CH2CH3), 
120.5 (CH), 126.6 (CH), 127.6 (CH), 128.5 (CH), 128.5 (CH), 128.7 (C), 128.9 (CH), 
129.0 (CH), 129.9 (C), 130.0 (CH), 130.1 (CH), 130.5 (CH), 131.4 (CH), 131.8 (C), 
134.8 (C), 135.6 (C), 138.1 (C), 141.9 (C), 143.5 (C), 165.6 (C=O); 
IR (ATR, cm-1): v~  = 3446 (w), 3055 (w), 3029 (w), 2954 (w), 2916 (w), 2848 
(w), 2728 (w), 1933 (w), 1825 (w), 1730 (s), 1605 (w), 1587 (w), 1574 (w), 1542 (m), 
1498 (w), 1484 (w), 1472 (w), 1461 (m), 1441 (m), 1364 (m), 1326 (s), 1296 (s), 1223 
N
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(s), 1213 (s), 1178 (s), 1136 (m), 1124 (m), 1094 (s), 1081 (s), 1035 (s), 1020 (s), 1000 
(w), 984 (w), 967 (w), 938 (w), 898 (w), 882 (w), 856 (w), 848 (w), 812 (w), 775 (s), 
763 (s), 742 (s), 730 (s), 711 (s), 701 (s), 692 (s), 667 (s), 638 (m), 617 (w), 604 (s), 
588 (s), 568 (m), 546 (m), 528 (m); 
MS (GC, 70 eV) m/z (%): 383 (41), 382 (62), 367 (14), 354 (240, 339 (29), 338 
(100), 336 (14), 322 (28), 310 (17), 308 (10), 294 (23), 292 (11), 291 (12), 283 (12), 
282 (20), 280 (13), 278 (16), 277 (12), 20 (11), 176 (11), 29 (46); 
HRMS (EI): calcd. for C25H21NO3 (M
+) 383,15214, found 383,15307. 
 
General procedure for synthesis of compounds 10a-n: 
 In a pressure tube or Schlenk flask corresponding 2-chloro-4-
(trifluoromethyl)quinoline 9 (1 equiv.), arylboronic acid (1.1-1.5 equiv.), Pd(PPh3)4  
(3 mol %) and anhydrous potassium carbonate (2 equiv.) in 5 mL extra dry 
dimethylformamide were added under argon atmosphere. The reaction mixture was 
stirred at 130 °C for about 12 h. The solvent was evaporated under reduced pressure 
and residue was purified by column chromatography (silica gel, heptane/ethyl acetate). 
 
2-(2,3-dimethoxyphenyl)-4-(trifluoromethyl)quinoline (10a): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline (100 mg, 0.43 mmol), 2,3-
dimethoxyphenylboronic acid (94.3 mg, 0.52 mmol), 
potassium carbonate (96 mg, 0.69 mmol) and Pd(PPh3)4 
(15 mg, 0.01 mmol), the product 10a was isolated as a white 
solid (136 mg, 95 %); mp = 85 – 87 °C. 
 1H NMR (500 MHz, CDCl3): δ = 3.75 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 7.07 
(dd, 3J = 8.2 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.23 (t, 
3J = 8.0 Hz, 1H, CHAr), 7.50 (dd, 
3J = 7.8 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.68 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 4J = 1.3 Hz, 
1H, CHAr), 7.81 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 4J = 1.4 Hz, 1H, CHAr), 8.17 (dt, 
3J = 8.5 Hz, 4J = 2.0 Hz, 1H, CHAr), 8.27 (dd, 
3J = 8.5 Hz, 4J = 0.6 Hz, 1H, CHAr), 8.30 
(s, 1H, CHAr). 
  13C NMR (126 MHz, CDCl3): δ = 56.2 (OCH3), 61.4 (OCH3), 114.0 (CH), 120.5 
(q, 3JC-F = 5.5 Hz, CH), 122.0 (C), 122.9 (CH), 123.8 (d, 
1JC-F = 274.9 Hz, C), 124.0 (q,  
3JC-F = 2.3 Hz, CH), 124.8 (CH), 128.1 (CH), 130.1 (CH), 130.8 (CH), 133.8 (C), 133.9 
(q, 2JC-F = 31.6 Hz), 147.8 (C), 149.1 (C), 153.3 (C), 156.4 (C); 
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 19F NMR (300 MHz, CDCl3): δ = -61.43 (CF3);  
 IR (ATR, cm-1): ṽ = 3069 (w), 3007 (w), 2964 (m), 2937 (w), 2840 (w), 1555 
(m), 1476 (s), 1371 (s), 1371 (s), 1262 (s), 1132 (s), 999 (s), 764 (s), 683 (s), 593 (m).  
 MS (GC-MS) m/z (%): 334 ([M+H]+, 19), 333 ([M]+, 100), 332 (39), 318 (49), 
314 (18), 304 (37), 302 (33), 290 (39), 287 (27), 274 (16), 273 (23), 272 (37), 264 
(26), 261 (12), 247 (14), 246 (40), 221 (10), 204 (22), 198 (65), 196 (12), 191 (14), 
178 (15), 176 (22), 159 (18).  
 HRMS (EI): calcd for C18 F3H14NO2 ([M]
+) 333.09711 found 333.09671. 
 
2-(5-fluoro-2-methoxyphenyl)-4-(trifluoromethyl)quinoline (10b): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline (100 mg, 0.43 
mmol), 5-fluoro-2-methoxyphenylboronic acid (150 mg, 0.65 
mmol), potassium carbonate (144 mg, 1.04 mmol) and Pd(PPh3)4 
(23 mg, 0.02 mmol), the product 10b was isolated as a white solid 
(153 mg, 73 %); mp = 105 – 107 °C. 
1H NMR (250 MHz, CDCl3): δ = 3.89 (s, 3H, OCH3), 6.99 
(dd, 3J = 9.1 Hz, 3J = 4.3 Hz, 1H, CHAr), 7.15 (ddd, 
3J = 9.0 Hz, 3J = 7.6 Hz, 
4J = 3.2 Hz, 1H, CHAr), 7.69 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 4J = 1.4 Hz, 1H, CHAr), 
7.73 (dd, 3J = 9.1 Hz, 3J = 3.2 Hz, 1H, CHAr), 7.81 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 
4J = 1.4 Hz, 1H, CHAr), 8.16 (dt, 
3J = 8.6 Hz, 4J = 2.1 Hz, 1H, CHAr), 8.26 (ddd, 
3J = 8.5 Hz, 4J = 1.2 Hz, 5J = 0.5 Hz, 1H, CHAr), 8.32 (s, 1H, CHAr). 
  13C NMR (65 MHz, CDCl3): δ = 56.4 (OCH3), 112.9 (d, 
3JC-F = 8.0 Hz, CH), 
117.3 (d, 2JC-F = 23.2 Hz, CH), 118.0 (d, 
2JC-F = 24.5 Hz, CH), 120.4 (q, 
4JC-F = 5.6 Hz, 
CH), 122.0 (C), 123.8 (d, 1JC-F = 274.6 Hz, CH), 123.9 (q, 
4JC-F = 2.1 Hz), 128.2 (CH), 
129.5 (d, 3JC-F = 7.4 Hz), 130.2 (CH), 130.7 (CH), 133.7 (q, 
2JC-F = 31.5 Hz, C), 149.1, 
153.8 (d,4JC-F = 2.1 Hz, C),155.2 (d, 
4JC-F = 2.0 Hz, C), 157.6 (d, 
1JC-F = 239.4 Hz, C).
 19F NMR (300 MHz, CDCl3): δ = -61.51 (CF3), -112.18 (CF); 
 IR (ATR, cm-1): ṽ = 3080 (w), 3017 (w), 2929 (w), 2840 (w), 1610 (w), 1493 (s), 
1431 (m), 1352 (m), 1251 (s), 1166 (s), 1117 (s), 1032 (m), 881 (m), 809 (m), 751 (s), 
692 (m), 643 (m), 545 (w).  
 MS (GC-MS) m/z (%): 322 ([M+H]+, 16), 321 ([M]+, 86), 320 (50), 292 (38), 291 
(24), 290 (31), 252 (34), 237 (11), 223 (10), 222 (59), 221 (12), 208 (19), 199 (12), 
198 (100), 176 (12).  
 HRMS (EI): calcd for C17F4H11NO ([M]
+) 321.07713, found 321.07666. 
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2-(3-fluorophenyl)-4-(trifluoromethyl)quinoline (10c): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline (100 mg, 0.43 
mmol), 3-fluorophenylboronic acid (73 mg, 0.52 mmol), 
potassium carbonate (196 mg, 0.69 mmol) and Pd(PPh3)4 (3 
mol %, 15 mg, 0.01 mmol), the product 10c was isolated as a 
white solid (115 mg, 92 %); mp = 67 – 69 °C.  
1H NMR (300 MHz, CDCl3): δ = 7.21 (tdd, 
3J = 8.3 Hz,4J = 2.6 Hz, 
4J = 1.0 Hz, 1H, CHAr), 7.48-7.58 (m, 1H, CHAr), 7.69 (ddd, 
3J = 8.5 Hz, 4J = 7.4 Hz, 
4J = 1.4 Hz, 1H, CHAr), 7.85 (ddd, 
3J = 8.5 Hz, 3J = 7.0 Hz, 4J = 1.32 Hz, 1H, CHAr), 
7.91-8.02 (m, 2H, CHAr), 8.09-8.20 (m, 2H, CHAr), 8.28 (ddd, 
3J = 8.5 Hz, 4J = 1.4 Hz, 
4J = 0.7 Hz, 1H, CHAr). 
 13C NMR (75 MHz, CDCl3): δ = 114.6 (d, 
2JC-F = 23.0 Hz, CH), 115.9 (q,  
4JC-F = 5.4 Hz), 117.1 (d, 
2JC-F = 21.4 Hz, CH), 122.2 (q, 
4JC-F = 0.9 Hz), 123.2 (d,  
4JC-F = 3.0 Hz, CH), 123.6 (d, 
1JC-F = 274.8 Hz), 124.0 (q, 
4JC-F = 2.1 Hz, CH), 128.4 
(CH), 130.6 (CH), 130.7 (CH), 130.8 (CH), 135.4 (q, 2JC-F = 31.6 Hz, C), 140.8 (d,  
3JC-F = 7.6 Hz, C), 149.1 (C), 155.3 (d, 
4JC-F = 2.8 Hz, C), 163.6 (d, 
1JC-F = 246.4 Hz, 
C). 
  19F NMR (300 MHz, CDCl3): δ = -61.48 (CF3), -112.16 (CF); 
  IR (ATR, cm-1): ṽ = 3086 (w), 3053 (w), 2956 (w), 2924 (m), 2853 (w), 1933 
(w), 1853 (w), 1776 (w), 1613 (m), 1449 (s), 1356 (s), 1253 (s), 1115 (br, vs), 880 (s), 
762 (vs), 693 (m), 617 (m).  
  MS (GC-MS) m/z (%): 292 ([M+H]+, 17), 291 ([M]+ ,100), 290 (29), 222 (50), 
221(11);  
  HRMS (EI): calcd for C16F4H9N1 ([M]
+) 291.06656, found 291.06612. 
 
4-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)quinoline (10d): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline (100 mg, 
0.43 mmol), 4-(trifluoromethyl)phenylboronic acid (99 mg, 
0.52 mmol), potassium carbonate (196 mg, 0.69 mmol) and 
Pd(PPh3)4 (15 mg, 0.01 mmol), the product 10d was isolated as 
a white solid (61 mg, 41.5 %); mp = 81 – 83 °C. 
1H NMR (300 MHz, CDCl3): δ = 7.71 (ddd, 
3J = 8.5 Hz, 3J = 7.0 Hz, 
4J = 1.5 Hz, 1H, CHAr), 7.79-7.90 (m, 3H, CHAr), 8.14-8.22 (m, 2H, CHAr), 8.28-8.36 
(m, 3H, CHAr).  
N
CF3
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13C NMR (75 MHz, CDCl3): δ = 115.9 (q, 
3JC-F = 5.4 Hz, CH), 122.3 (d,  
4JC-F = 1.2 Hz), 123.6 (d, 
1JC-F = 275.0 Hz), 124.1 (d, 
4JC-F = 2.4 Hz, CH), 124.2 (d, 
1JC-F = 275.0 Hz), 126.1 (q, 
3JC-F = 3.8 Hz, CH), 128.0 (CH), 128.7 (CH), 130.9 (CH), 
130.9 (CH), 132.0 (q, 2JC-F = 32.7 Hz), 135.6 (q, 
2JC-F = 31.8 Hz), 141.7 (C), 149.2 
(C), 155.1 (C); 
19F NMR (300 MHz, CDCl3): δ = -61.46 (CF3), -62.71 (CF3); 
IR (ATR, cm-1): ṽ = 3101 (w), 3060 (w), 2961 (w), 2928 (w), 2852 (w), 1614 
(m), 1408 (m), 1322 (s), 1109 (vs), 1016 (s), 841 (s), 766 (s), 595 (m).  
MS (GC-MS) m/z (%): 342([M+H]+, 19), 341 ([M]+ 100), 340 (21), 322 (12), 
273 (11), 272 (59), 252 (11).  
HRMS (EI): calcd for C17F6H9N ([M]
+) 341.06337, found 341.06319. 
 
2-(2,3-dimethoxyphenyl)-6-methyl-4-(trifluoromethyl)quinoline (10e): 
Starting from 2-chloro-6-methyl-4-
(trifluoromethyl)quinoline (100 mg, 0.41 mmol), 2,3-
dimethoxyphenylboronic acid (89 mg, 0.49 mmol), 
potassium carbonate (109 mg, 0.78 mmol) and Pd(PPh3)4 
(14 mg, 0.01 mmol), the product 10e was isolated as a white solid (128 mg, 85.5 %); 
mp = 99 – 101 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.62 (s, 3H, CH3), 3.75 (s, 3H, OCH3), 3.96 (s, 
3H, OCH3), 7.06 (dd, 
3J = 8.1 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.23 (t, 
3J = 8.0 Hz, 1H, 
CHAr), 7.50 (dd, 
3J = 7.7 Hz, 3J = 1.5 Hz, 1H, CHAr), 7.65 (dd, 
3J = 8.6 Hz, 
4J = 1.8 Hz, 1H, CHAr), 7.92 (br. s., 1H, CHAr), 8.18 (d, 
3J = 8.7 Hz, 1H, CHAr), 8.28 
(s, 1H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 22.2(CH3), 56.2 (OCH3), 61.4 (OCH3), 113.8 
(CH), 120.4 (d, 3JC-F = 5.6 Hz, CH), 122.0 (C), 122.8 (CH), 122.9 (d, 
4JC-F = 2.1 Hz, 
CH), 123.9 (d, 1JC-F = 274.7 Hz, C), 124.8 (CH), 130.3 (CH), 132.4 (CH), 133.2 (q,  
2JC-F = 31.3 Hz, C), 133.7 (C), 138.4 (C), 147.6 (C), 147.7 (C), 153.3 (C), 155.3(C); 
19F NMR (300 MHz, CDCl3): δ = -61.49 (CF3); 
IR (ATR, cm-1): ṽ = 3088 (w), 3005 (w), 2973 (w), 2933 (m), 2868 (w), 2833 
(m), 1554 (m), 1469 (m), 1371 (s), 1264 (s), 1142 (s), 1113 (s), 1005 (s), 830 (m), 739 
(s), 680 (s), 572 (w). 
  MS (GC-MS) m/z (%): 348 ([M]+, 20), 347 ([M]
+ 100), 346 (37), 332 (49), 328 
(15), 318 (33), 304 (35), 301 (28), 288 (15), 287 (21), 286 (26), 278 (21), 260 (18), 
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246 (13), 212 (70), 190 (11), 166 (18). 
HRMS (EI): calcd for C19F3H16NO2 ([M]
+) 347.11276, found 347.11223. 
 
2-(2,5-dimethoxyphenyl)-6-methyl-4-(trifluoromethyl)quinoline (10f): 
Starting from 2-chloro-6-methyl-4-(trifluoromethyl)quinoline 
(100 mg, 0.41 mmol), 2,5-dimethoxyphenylboronic acid 
(73 mg, 0.52 mmol), potassium carbonate (109 mg, 0.78 
mmol) and Pd(PPh3)4 (14 mg, 0.01 mmol), the product 10f 
was isolated as a yellow solid (135 mg, 95 %);  
mp = 71 – 73 °C. 
1H NMR (250 MHz, CDCl3): δ = 2.60 (s, 3H, CH3), 3.86 (s, 3H, OCH3), 3.9 (s, 
3H, OCH3), 6.98 – 7.00 (m, 2H, CHAr), 7.52 (dd, 
4J = 2.1 Hz, 4J = 1.5 Hz, 1H, CHAr), 
7.63 (dd, 3J = 8.7 Hz, 4J = 1.9 Hz, 1H, CHAr), 7.9 (s, 1H, CHAr), 8.15 (d, 
3J = 8.6 Hz, 
1H, CHAr), 8.26 (s, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 22.2 (CH3), 56.0 (OCH3), 56.5 (OCH3), 113.3 
(CH), 116.2 (CH), 116.8 (CH), 120.6 (q, 3JC-F = 5.7 Hz, CH), 122.0 (d, 
4JC-F = 1.0 Hz), 
122.8 (d, 4JC-F = 2.3 Hz, CH), 124.0 (d, 
1JC-F = 274.6 Hz), 129.1 (C), 130.3 (CH), 
132.3 (CH), 132.8 (d, 2JC-F = 31.2 Hz, C), 138.1 (C), 147.8 (C), 151.8 (C), 154.3 (C), 
155.3 (C); 
19F NMR (300 MHz, CDCl3): δ = -61.45 (CF3); 
  IR (ATR, cm-1): ṽ = 3150 (w), 3014 (w), 2956 (w), 2840 (w), 1609 (w), 1501 (s), 
1415 (m), 1350 (s), 1255 (s), 1209 (s), 1139 (s), 1113 (s), 1038 (s), 916 (m), 879 (m), 
806 (m), 687 (m), 648 (m), 540 (w).  
MS (GC-MS) m/z (%): 348 ([M+H]+, 20), 347 ([M]+ 90), 346 (46), 332 (15), 318 
(34), 317 (13), 316 (27), 289 (11), 288 (11), 287 (15), 286 (16),278 (31), 261 (13), 260 
(22), 246 (11), 213 (15), 212 (100).  
HRMS (EI): calcd for C19F3H16NO2 ([M]
+) 347.11276, found 347.11221. 
 
2-(5-fluoro-2-methoxyphenyl)-6-methyl-4-(trifluoromethyl)quinoline (10g): 
Starting from 2-chloro-6-methyl-4-(trifluoromethyl)quinoline (100 mg, 0.41 mmol),  
5-fluoro-2-methoxyphenylboronic acid (83 mg, 0.49 mmol), potassium carbonate 
(109 mg, 0.78 mmol) and Pd(PPh3)4 (14 mg, 0.01 mmol), the product 10g was isolated 
as a white solid (134 mg, 97 %); mp = 103 – 105 °C. 
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1H NMR (300 MHz, CDCl3): δ = 2.62 (s, 3H, CH3), 
3.89 (s, 3H, OCH3), 6.99 (dd, 
3J = 9.0 Hz, 3J = 4.3 Hz, 1H, 
CHAr), 7.14 (ddd, 
3J = 9.0 Hz, 3J = 7.7 Hz, 4J = 3.0 Hz, 1H, 
CHAr), 7.65 (dd, 
3J = 8.7 Hz, 4J = 1. 9 Hz, 1H, CHAr), 7.73 
(dd, 3J = 9.0 Hz, 3J = 3.2 Hz, 1H, CHAr), 7.91 (br. s., 1H, 
CHAr), 8.16 (d, 
3J = 8.7 Hz, 1H, CHAr), 8.29 (s, 1H, CHAr). 
  13C NMR (75 MHz, CDCl3): δ = 22.3 (CH3), 56.4 (OCH3), 112.9 (d,  
3JC-F = 8.1 Hz, CH), 117.1 (d, 
2JC-F = 23.1 Hz, CH), 118.0 (d, 
2JC-F = 24.5 Hz, CH), 
120.3 (q, 3JC-F = 5.7 Hz, CH), 122.1 (C), 122.8 (q, 
4JC-F = 2.0 Hz, CH), 123.9 (d,  
1JC-F = 274.6 Hz, C), 129.5 (d, 
3JC-F = 7.3 Hz, C), 130.3 (CH), 132.5 (CH), 133.0 (q, 
2JC-F = 31.3 Hz, C), 138.5, 147.7 (C), 153.7 (d, 
4JC-F = 2.1 Hz, C), 154.1 (d,  
4JC-F = 1.9 Hz, C), 157.6 (d, 
1JC-F = 239.3 Hz, C). 
19F NMR (300 MHz, CDCl3): δ = -61.50 (CF3), -123.21 (CF); 
IR (ATR, cm-1): ṽ = 3145 (w), 3085 (w), 3022 (w), 2965 (w), 2921 (m), 2841 
(w), 1825 (w), 1603 (m), 1496 (m), 1348 (s), 1348 (s), 1250 (s), 1112 (vs), 1019 (s), 
901 (s), 824 (m), 799 (m), 742 (m), 690 (m), 657 (m), 539 (m).  
MS (GC-MS) m/z (%): 336 ([M+H]+,14), 335 ([M]+ 76), 334 (43), 306 (33), 305 
(33), 304 (22), 266 (26), 236 (20), 213 (13), 212 (100); 
HRMS (EI): calcd for C18F4H13NO ([M]
+) 335.09278, found 335.09228. 
 
2-(3-fluorophenyl)-6-methyl-4-(trifluoromethyl)quinoline (10h): 
Starting from 2-chloro-6-methyl-4-(trifluoromethyl)quinoline 
(100 mg, 0.41 mmol), 3-fluorophenylboronic acid (69 mg, 
0.49 mmol), potassium carbonate (109 mg, 0.78 mmol) and 
Pd(PPh3)4 (14 mg, 0.01 mmol), the product 10h was isolated 
as a white solid (117 mg, 93.7 %); mp = 126 – 128 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.61 (s, 3H, CH3), 7.19 (tdd, 
3J = 8.3 Hz, 
4J = 2.6 Hz, 4J = 0.9 Hz, 1H, CHAr), 7.46-7.56 (m, 1H, CHAr), 7.63-7.70 (m, 1H, 
CHAr), 7.87-7.99 (m, 3H, CHAr), 8.10 (s, 1H, CHAr), 8.15 (d, 
3J = 8.7 Hz, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 22.3 (CH3), 114.5 (d, 
2JC-F = 23.0 Hz, CH), 
115.8 (q, 3JC-F = 5.4 Hz, CH), 116.9 (d, 
2JC-F = 21.3 Hz, CH), 122.2 (d, 
4JC-F = 1.3 Hz, 
C), 122.9 (q, 4JC-F = 2.2 Hz, CH), 123.0 (d, 
4JC-F = 2.9 Hz, CH), 123.7 (d,  
1JC-F = 274.7 Hz, C), 130.5 (CH), 130.6 (d, 
3JC-F = 8.2 Hz, CH), 133.0 (CH), 134.6 (d, 
2JC-F = 31.6 Hz, C), 138.7, 140.9 (d, 
3JC-F = 7.6 Hz, C), 147.8, 154.3 (d, 
4JC-F = 2.7 Hz, 
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C), 163.6 (d, 1JC-F = 246.2 Hz, C). 
19F NMR (300 MHz, CDCl3): δ = -112.29 (CF), -61.54 (CF3); 
IR (ATR, cm-1): ṽ = 3080 (w), 2961 (w), 2923 (w), 2855 (w), 1611 (m), 1594 
(m), 1448 (m), 1354 (s), 1257 (s), 1187 (m), 1146 (s), 1114 (s), 878 (s), 777 (s), 688 
(m), 579 (w).  
MS (GC-MS) m/z (%): 306 ([M+H]+, 19), 305 ([M]+, 100), 304 (22), 236 (22);  
HRMS (EI): calcd for C17NF4H11 ([M]
+) 305.08221, found 305.08228. 
 
2-(4-fluorophenyl)-6-methyl-4-(trifluoromethyl)quinoline (10i): 
Starting from 2-chloro-6-methyl-4-(trifluoromethyl)quinoline 
(100 mg, 0.41 mmol), 4-fluorophenylboronic acid (73 mg, 
0.52 mmol), potassium carbonate (109 mg, 0.78 mmol) and 
Pd(PPh3)4 (14 mg, 0.01 mmol), the product 10i was isolated 
as a yellow solid (111 mg, 95 %); mp = 130 – 132 °C. 
1H NMR (250 MHz, CDCl3): δ = 2.61 (s, 3H, CH3), 7.23 (pseudo t, J = 8.7 Hz, 
2H, CHAr), 7.62-7.69 (m, 1H, CHAr), 7.89 (br. s., 1H, CHAr), 7.98-8.23 (m, 4H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 22.2 (CH3), 115.7 (q, 
3JC-F = 5.5 Hz, CH), 116.1 
(d, 2JC-F = 22.0 Hz, CH), 121.9 (d, 
3JC-F = 1.4 Hz, C), 122.9 (q, 
4JC-F = 2.3 Hz, CH), 
123.8 (q, 1JC-F = 274.2 Hz, C), 129.4 (d, 
3JC-F = 8.7 Hz, CH), 130.3 (CH), 132.9 (CH), 
134.5 (d, 2J = 31.3 Hz, C), 134.8 (q, 4JC-F = 3.3 Hz), 138.4 (C), 147.9 (C), 154.7 (C), 
164.2 (d, 1JC-F = 249.9 Hz, C).  
19F NMR (300 MHz, CDCl3): δ = -61.49 (CF3), -112.0 (CF); 
IR (ATR, cm-1): ṽ = 3061 (w), 2974 (w), 2959 (w), 2924 (m), 2859 (w) 1601 
(m), 1357 (s), 1321 (s), 1114 (s), 884 (m), 837 (s), 682 (m), 585 (m).  
MS (GC-MS) m/z (%): 306 ([M+H]+, 18), 305 ([M]+, 100), 304 (23), 236 (21). 
HRMS (EI): calcd for C17F4NH11 ([M]
+) 305.08221, found 305.08206. 
 
6-methyl-2-phenyl-4-(trifluoromethyl)quinoline (10j): 
Starting from 2-chloro-6-methyl-4-(trifluoromethyl)quinoline 
(100 mg, 0.41 mmol), phenylboronic acid (60 mg, 0.49 mmol), 
potassium carbonate (109 mg, 0.78 mmol) and Pd(PPh3)4 
(14 mg, 0.01 mmol), the product 10j was isolated as a yellow 
solid (110 mg, 94 %); mp = 100 – 102 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.62 (s, 3H, CH3), 7.46-7.61 (m, 3H, CHAr), 
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7.66 (dd, 3J = 8.7 Hz, 1H, CHAr), 7.84-7.94 (m, 1H, CHAr), 8.11-8.23 (m, 4H, CHAr). 
  13C NMR (75 MHz, CDCl3): δ = 22.2 (CH3), 116.1 (q, 
3JC-F = 5.5 Hz, CH), 122.0 
(q, 3JC-F = 1.5 Hz, C), 122.9 (q, 
4JC-F = 2.2 Hz, CH), 123.8 (q, 
1JC-F = 275.1 Hz), 127.5 
(CH), 129.1 (CH), 130.0 (CH), 130.4 (CH), 132.8 (CH), 134.4 (q, 2JC-F = 31.4 Hz, C), 
138.3 (C), 138.7 (C), 147.9 (C), 155.8 (C);  
19F NMR (300 MHz, CDCl3): δ = -61.45 (CF3); 
IR (ATR, cm-1): ṽ = 3068 (w), 3034 (w), 2979 (w), 2960 (w), 2924 (w), 2858 
(w), 2222 (m), 1966 (w), 1794 (w), 1700 (w), 1604 (m), 1494 (m), 1373 (s), 1259 (s), 
1146 (s), 1115 (s), 897 (s), 830 (m), 753 (s), 683 (s), 583 (m).  
MS (GC-MS) m/z (%): 288 ([M+H]+, 18), 287 ([M]+, 100), 286 (25), 218 (22). 
HRMS (EI): calcd for C17F3NH12 ([M]
+) 287.09147, found 287.09124. 
 
6-fluoro-4-(trifluoromethyl)-2-(2,3,4-trimethoxyphenyl)quinoline (10k): 
Starting from 2-chloro-6-fluoro-4-(trifluoromethyl)-
quinoline (100 mg, 0.40 mmol), 2,3,4-trimethoxyphenyl-
boronic acid (102 mg, 0.48 mmol), potassium carbonate 
(106 mg, 0.77 mmol) and Pd(PPh3)4 (14 mg, 0.01 mmol), 
the product 10k was isolated as a brown solid (132 mg, 
87 %); mp = 87 – 89 °C. 
1H NMR (250 MHz, CDCl3): δ = 3.85 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 3.96 
(s, 3H, OCH3), 6.87 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.57 (ddd, 
3J = 9.3 Hz, 3J = 8.0 Hz, 
4J = 2.7 Hz, 1H, CHAr), 7.69 (d, 
3J = 8.83 Hz, 1H, CHAr), 7.72-7.81 (m, 1H, CHAr), 
8.24 (ddd, 3J = 9.1 Hz, 3J = 5.5 Hz, 4J = 0.5 Hz, 1H, CHAr), 8.32 (s, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 56.3 (OCH3), 61.2 (OCH3), 61.6 (OCH3), 108.1 
(dq, 2JC-F = 24.5 Hz, 
4JC-F = 2.3 Hz, CH), 108.2 (CH), 120.4 (d, 
2JC-F = 25.6 Hz, CH), 
121.0 (d, 4JC-F = 5.5 Hz, CH), 122.5 (dd, 
3JC-F = 10.5 Hz, 
3JC-F = 1.0 Hz, C), 123.6 (d, 
1JC-F = 274.3 Hz), 125.8 (CH), 125.9 (C), 133.0 (d, 
3JC-F = 9.4 Hz, CH), 133.6 (dd,  
2JC-F = 31.7 Hz, 
4JC-F = 5.6 Hz, C), 142.6 (C), 146.3 (d, 
4JC-F = 0.5 Hz), 152.6, 155.4 
(d, 4JC-F = 2.9 Hz), 155.5 (C), 161.2 (d, 
1JC-F = 250.0 Hz, C). 
19F NMR (300 MHz, CDCl3): δ = -110.21 (CF), -62.07 (CF3); 
IR (ATR, cm-1): ṽ = 3165 (w), 3111 (w), 3074 (w), 3000 (w), 2967 (m), 2939 
(m), 2840 (w), 1593 (m), 1454 (m), 1357 (m), 1268 (m), 1163 (m), 1085 (s), 1019 (s), 
868 (m), 803 (m), 679 (m), 617 (w).  
MS (GC-MS) m/z (%): 382 ([M+H]+, 18), 381 ([M]+ 86), 380 (28), 367 (20), 366 
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(100), 362 (14), 352 (12), 350 (16), 348 (10), 338 (21), 336 (20), 335 (35), 323 (42), 
320 (20), 312 (15), 308 (20), 294 (10), 280 (26), 267 (11), 266 (36), 265 (10), 264 
(11), 253 (10), 252 (48), 216 (17), 194 (13), 183 (19), 182 (11); 
HRMS (EI): calcd for C19 F4NH15O3 ([M]
+) 381.09826, found 381.09796. 
 
2-(2,3-dimethoxyphenyl)-6-fluoro-4-(trifluoromethyl)quinoline (10l): 
Starting from 2-chloro-6-fluoro-4-
(trifluoromethyl)quinoline (100 mg, 0.40 mmol), 2,3-
dimethoxyphenylboronic acid (102 mg, 0.48 mmol), 
potassium carbonate (106 mg, 0.77 mmol) and Pd(PPh3)4 
(14 mg, 0.01 mmol), the product 10l was isolated as a white solid (124 mg, 88.9 %); 
mp = 96 – 99 °C. 
1H NMR (250 MHz, CDCl3): δ = 3.76 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 7.08 
(dd, 3J = 8.1 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.24 (t, 
3J = 8.0 Hz, 1H, CHAr), 7.50 (dd, 
3J = 7.8 Hz, 4J = 1.6 Hz, 1H, CHAr), 7.59 (ddd, 
3J = 9.2 Hz, 3J = 8.0 Hz, 3J = 2.7 Hz, 
1H, CHAr), 7.75-7.83 (m, 1H, CHAr), 8.29 (dd, 
3J = 9.2 Hz, 3J = 5.5 Hz, 1H, CHAr), 
8.34 (s, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 56.2 (OCH3), 61.4 (OCH3), 108.1 (dq,  
2JC-F = 24.7, 
4JC-F = 2.3 Hz, CH), 114.1 (CH), 120.5 (d, 
2JC-F = 25.6 Hz, CH), 121.3 (q, 
3JC-F = 5.4 Hz, CH), 122.7 (CH), 124.8 (CH), 125.8 (q, 
1JC-F = 274.2 Hz, C), 133.2 (d, 
3JC-F = 9.2 Hz, CH), 133.3 (C), 133.7 (dd, J = 31.8, 5.8 Hz, C), 146.2 (C), 147.7 (C), 
153.3 (C), 155.7 (d,4JC-F = 2.7 Hz, C), 161.4 (d, 
1JC-F = 249.9 Hz, C). 
19F NMR (300 MHz, CDCl3): δ = -62.09 (CF3), -109.72 (CF); 
IR (ATR, cm-1): ṽ = 3077 (w), 3019 (w), 2962 (w), 2938 (w); 2866 (w), 2839 
(w), 1628 (w), 1558 (m), 1473 (m), 1375 (m); 1273 (s), 1273 (br. s), 1127 (br. s), 1049 
(s), 1004 (s), 325 (m), 792 (m); 753 (s), 682 (m), 626 (w).  
MS (GC-MS) m/z (%): 352 ([M]+, 19), 351 ([M]+, 100) , 350 (41), 336 (37), 332 
(18), 322 (36), 320 (30), 308 (39), 305 (25), 292 (17), 291 (19), 290 (30), 282 (23), 
279 (10), 265 (13), 264 (38), 239 (12), 222 (16), 216 (59), 196 (12), 194 (16), 168 
(15).  
HRMS (EI): calcd for C18F4H13NO24 ([M]
+) 351.08769, found 351.08750. 
 
2-(2,5-dimethoxyphenyl)-6-fluoro-4-(trifluoromethyl)quinoline (10m): 
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Starting from (100 mg, 0.43 mmol), 2,5-
dimethoxyphenylboronic acid (87 mg, 0.48 mmol), potassium 
carbonate (106 mg, 0.77 mmol) and Pd(PPh3)4 (14 mg, 0.01 
mmol), the product 10m was isolated as a yellow solid (127 mg, 
92 %); mp = 82 – 84 °C. 
1H NMR (250 MHz, CDCl3): δ = 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 7.00-
7.04 (m, 2H), 7.51-7.63 (m, 2H, CHAr), 7.73-7.81 (m, 1H, CHAr), 8.27 (dd, 
3J = 9.2 Hz, 
3J = 5.60 Hz, 1H, CHAr), 8.35 (s, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 56.0 (OCH3), 56.5 (OCH3), 108.1 (dq,  
2JC-F = 24.3, 
4JC-F = 2.3 Hz, CH), 113.2 (CH), 116.2 (CH), 117.0 (CH), 120.4 (d,  
2JC-F = 25.6 Hz, CH), 121.5 (q, 
3JC-F = 5.5 Hz, CH), 122.7 (d, J = 10.8 Hz, C), 123.6 
(q, 2JC-F = 274.5 Hz, C), 128.6 (C), 133.2 (d, 
3JC-F = 9.2 Hz, CH), 133.2 (dd,  
2JC-F = 31.6 Hz, 
4JC-F = 5.9 Hz, C), 146.3 (d, J = 0.9 Hz, C), 151.8 (C), 154.3 (C), 
155.6 (d, 4JC-F = 3.2 Hz, C), 161.3 (d, 
1JC-F = 250.0 Hz, C).  
19F NMR (300 MHz, CDCl3): δ = -62.07 (CF3), -109.97 (CF); 
IR (ATR, cm-1): ṽ = 3073 (w), 3049 (w), 2948 (w), 2842 (w), 1626 (w), 1499 
(m), 1426 (m), 1348 (m); 1251 (m), 1216 (s), 1116 (s), 1025 (s), 798 (m), 646 (m), 
540(w).  
MS (GC-MS) m/z (%): 352 ([M+H]+, 15), 351 ([M]+ 94), 350 (47), 336 (16), 332 
(13), 322 (47), 320 (24), 308 (13), 293 (18), 292 (149; 291 (13), 290 (12), 282 (35), 
280 (11), 279 (14), 265 (22), 264 (40), 239 (17), 222 (10), 217 (12), 216 (100), 209 
(13), 196 (11), 194 (16), 54 (11).  
HRMS (EI): calcd for C18F4H13NO2 ([M]
+) 351.08769, found 351.08696. 
 
6-fluoro-2-(4-fluorophenyl)-4-(trifluoromethyl)quinoline (10n): 
Starting from 2-chloro-6-fluoro-4-(trifluoromethyl)quinoline 
(100 mg, 0.40 mmol), 4-fluorophenylboronic acid (67 mg, 0.48 
mmol), potassium carbonate (106 mg, 0.77 mmol) and 
Pd(PPh3)4 (14 mg, 0.01 mmol), the product 10n was isolated as 
a yellow solid (109 mg, 89 %); mp = 110 – 112 °C. 
1H NMR (250 MHz, CDCl3): δ = 7.19-7.33 (m, 2H, CHAr), 7.60 (ddd, 
3J = 9.3 Hz, 3J = 8.0, 4J = 2.7 Hz, 1H, CHAr), 7.71-7.80 (m, 1H, CHAr), 8.08-8.33 (m, 4 
H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 108.2 (dq, 
2JC-F = 24.3, 
4JC-F = 2.3 Hz, CH), 
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116.2 (d, 2JC-F = 22.0 Hz, CH), 116.3 (q, 
3JC-F = 5.5 Hz, CH), 121.0 (d,  
2JC-F = 25.6 Hz, CH), 122.6 (dq, 
3JC-F = 9.9 Hz, 
3JC-F = 1.1 Hz, C), 123.5 (q,  
1JC-F = 275.1 Hz, C), 129.5 (d, 
3JC-F = 8.7 Hz, CH), 133.2 (d, 
3JC-F = 9.2 Hz, CH), 
135.0 (q, 2JC-F = 31.6 Hz, C), 134.4 (d, 
4JC-F = 2.7 Hz, C), 146.4 (C), 155.0 (d,  
4JC-F = 3.2 Hz, C), 161.3 (d, 
1JC-F = 250.4 Hz, C), 164.4 (d, 
1JC-F = 250.0 Hz, C).  
19F NMR (300 MHz, CDCl3): δ = -62.16(CF3), -109.53 (CF), -110.87 (CF); 
IR (ATR, cm-1): ṽ = 2960 (w), 2920 (w), 2850 (w), 2359 (w), 1629 (w); 1600 
(w), 1557 (m), 1506 (m); 1375 (m), 1358 (br. m), 1225 (m); 1116 (br. s), 1106 (br. s), 
891 (m), 860 (m); 832 (s); 788 (m), 684 (m), 585 (m), 570 (m).  
MS (GC-MS) m/z (%): 310 ([M+H]+, 18), 309 ([M]+, 100), 308 (24), 240 (47), 
239 (10).  
HRMS (EI): calcd for C16F5NH8 ([M]
+) 309.05714, found 309.05679. 
 
General procedure for the synthesis of compounds 11a-f: 
To a Schlenk flask equipped with a magnetic stir bar PdCl2(PPh3)2 (0.02 equiv.), 
CuI (0.04 equiv.) and substituted 2-chloro-4-(trifluoromethyl)quinolines 9 (100 mg) 
were added. The flask was fitted with a rubber septum and then held under vacuum and 
backfilled with argon. Afterwards THF (6 mL), corresponding acetylene (1.2 equiv.) 
and triethylamine (1.5 equiv.) were added successively, the reaction mixture was 
stirred at room temperature for 15 - 24 h. After the reaction was completed (TLC 
control) to the reaction mixture was added distilled water and extracted with DCM 
(3x25 mL), the organic layers were collected, dried over Na2SO4 and evaporated to 
crude mass; the residue was purified by column chromatography over silica gel. 
 
2-(p-tolylethynyl)-4-(trifluoromethyl)quinoline (11a): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline 
(150 mg, 0.65 mmol), 4-methylphenylacetylene (90 mg, 
0.78 mmol), Pd(PPh3)2Cl2 (2 mol %, 9 mg, 0.01 mmol), 
CuI (5 mg, 0.04 equiv.), triethylamine (3 equiv., 196 mg, 
1.94 mmol), the product 11a was isolated as a brown solid 
(185 mg, 91 %); mp = 113 – 115 °C. 
1H NMR (250 MHz, CDCl3): δ = 2.39 (br. s., 3H, CH3), 7.21 (d, 
3J = 7.9 Hz, 2H, 
CHAr), 7.57 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.68 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 4J = 1.3Hz, 
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1H, CHAr), 7.82 (ddd, 
3J = 8.5 Hz, 3J = 6.9 Hz, 4J = 1.4 Hz, 1H, CHAr), 8.12 (d,  
3J = 8.5 Hz, 1H, CHAr), 8.22 (d, 
3J = 8.6 Hz, Hz, 1H, CHAr). 
13C NMR (65 MHz, CDCl3): δ = 21.8 (CH3), 88.8 (C≡C), 92.1 (C≡C), 118.6, 
121.6 (q, 3JC-F = 5.5 Hz, CH), 121.9 (q, 
3JC-F = 1.1 Hz, C), 123.3 (q, 
1JC-F = 275.1 Hz), 
124.0 (q, 4JC-F = 2.3 Hz, CH), 128.8 (CH), 129.4 (CH), 130.3 (CH), 130.9 (CH), 132.4 
(CH), 134.6 (q, 2JC-F = 31.6 Hz, ), 140.2 (C), 143.4 (C), 149.2 (C); 
19F NMR (300 MHz, CDCl3): δ = -61.61 (CF3); 
IR (ATR, cm-1): ṽ = 3058 (w), 3034 (w), 3012 (w), 2962 (w), 2921 (w), 2874 
(w), 2225 (m), 1941 (w), 1914 (w), 1826 (w),1767 (w),1726 (w), 1606 (m), 1512 (m), 
1374 (m), 1324 (m), 1250(s), 1129 (br. s), 1024 (s), 884 (s), 817 (br. s), 763 (s), 668 
(m), 539 (w).  
MS (GC-MS) m/z (%): 312 ([M+H]+, 20), 311 ([M]+, 100), 310 (17), 241 (11).  
HRMS (EI): calcd for C19F3H12N ([M]
+) 311.09164, found 311.09130. 
 
2-((4-tert-butylphenyl)ethynyl)-4-(trifluoromethyl)quinoline (11b): 
Starting from 2-chloro-4-(trifluoromethyl)quinoline 
(150 mg, 0.65 mmol), 1-tert-butyl-4-ethynylbenzene 
(123 mg, 0.78 mmol), Pd(PPh3)2Cl2 (2 mol %, 9 mg, 0.01 
mmol), CuI (5 mg, 0.04 equiv.), triethylamine (3 equiv., 
196 mg, 1.94 mmol), the product 11b was isolated as a 
brown solid (202 mg, 88 %); mp = 85 – 87 °C. 
1H NMR (250 MHz, CDCl3): δ = 1.36 (s, 9H, C(CH3)3), 7.40-7.48 (m, 2H), 7.59-
7.67 (m, 2H, CHAr), 7.67-7.73 (m, 1H, CHAr), 7.79 – 7.88 (m, 1H, CHAr), 7.90 (s, 1H, 
CHAr), 8.07-8.17 (m, 1H, CHAr), 8.20-8.27 (m, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 31.1 (3C, 3x(CH3)), 34.9, 88.2 (C≡C), 92.2 
(C≡C), 118.6 (C), 121.7 (q, 3JC-F = 5.5 Hz, CH), 121.9 (q, 
3JC-F = 1.4 Hz. C), 123.3 (q, 
1JC-F = 274.7 Hz, C), 124.0 (q, 
4JC-F = 2.3 Hz, CH), 125.7 (CH), 128.8 (CH), 130.3 
(CH), 130.9 (CH), 132.3 (CH), 134.6 (q, 2JC-F = 32.0 Hz, C), 143.4 (C), 149.2 (C), 
153.3 (C); 
19F NMR (300 MHz, CDCl3): δ = -61.60 (CF3); 
IR (ATR, cm-1): ṽ = 3068 (w), 2979 (w), 2932 (w), 2858 (w), 2222 (m), 2208 
(m), 1605 (m); 1549 (m), 1494 (m), 1374 (s), 1259 (s), 1146 (s), 1115 (vs), 897 (m), 
830 (m), 753 (s), 684 (s), 584 (m).  
MS (GC-MS) m/z (%): 353 ([M]+ 36), 339 (24), 338 (100), 310 (12), 155 (13).  
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HRMS (EI): calcd for C22FH18N ([M]
+) 353.13859, found 353.13821. 
 
6-methyl-2-(phenylethynyl)-4-(trifluoromethyl)quinoline (11c): 
Starting from 2-chloro-6-methyl-4-
(trifluoromethyl)quinoline (150 mg, 0.61 mmol), 
phenylacetylene (75 mg, 0.73 mmol), Pd(PPh3)2Cl2 (2 
mol %, 9 mg, 0.01 mmol), CuI (0.04 equiv., 5 mg), 
triethylamine (3 equiv., 185 mg, 1.83 mmol), the product 
11c was isolated as a brown solid (171 mg, 90 %); mp = 118 – 120 °C. 
 1H NMR (300 MHz, CDCl3): δ = 2.61 (s, CH3), 7.31-7.45 (m, 3H, CHAr), 7.63-
7.72 (m, 3H, CHAr), 7.81-7.91 (m, 2H, CHAr), 8.12 (d, 
3J = 8.7 Hz, 1H, CHAr). 
 13C NMR (65 MHz, CDCl3): δ = 22.3 (CH3), 88.7 (C≡C), 91.2 (C≡C), 123.4 (q, 
1JC-F = 274.7 Hz), 121.6 (q, 
3JC-F = 5.5 Hz, CH), 121.8 (C), 121.9 (q, 
3JC-F = 1.4 Hz), 
122.9 (q, 4JC-F = 2.0 Hz, CH), 128.6 (CH), 129.6 (CH), 130.0 (CH), 132.4 (CH), 133.2 
(CH), 133.9 (q, 2JC-F = 31.6 Hz, C), 139.4 (C), 142.1 (C), 147.9 (C). 
 19F NMR (300 MHz, CDCl3): δ = -61.67 (CF3); 
 IR (ATR, cm-1): ṽ = 3068 (w), 3034 (w), 2979 (w), 2924 (w), 2859 (w), 2221 
(m), 2209 (m), 1965 (vw), 1794 (vw), 1604 (m), 1494 (m), 1374 (s), 1274 (s), 1146 (s), 
1115 (br. vs), 897 (m), 753 (s), 689 (s), 583 (w). 
 MS (GC-MS) m/z (%): 312 ([M+H]+, 22), 311 ([M]
+ 100), 310 (19), 309 (8). 
 HRMS (EI): calcd for C19F3NH12 ([M+H]
+) 312.09946, found 312.09986. 
 
2-((4-tert-butylphenyl)ethynyl)-6-methyl-4-(trifluoromethyl)quinoline (11d): 
Starting from 2-chloro-6-methyl-4-
(trifluoromethyl)quinoline (150 mg, 0.61 mmol),  
1-tert-butyl-4-ethynylbenzene (116 mg, 0.73 mmol, 
1.2 equiv.), Pd(PPh3)2Cl2 (2 mol %, 9 mg,  
0.01 mmol), CuI (5 mg, 0.04 equiv.), triethylamine 
(185 mg, 1.83 mmol, 3 equiv.), the product 11d was 
isolated as a brown solid (184 mg, 82 %); mp = 116 – 118 °C. 
1H NMR (250 MHz, CDCl3): δ = 1.35 (s, 9H, C(CH3)3), 2.60 (s, 3H, CH3), 7.39-
7.47 (m, 2H, CHAr), 7.58-7.70 (m, 3H, CHAr), 7.87 (s, 2H, CHAr), 8.12 (d, 
3J = 8.7 Hz, 
1H, CHAr). 
13C NMR (65 MHz, CDCl3): δ = 22.3 (CH3), 31.3 (C, C(CH3)3), 35.1(C, 
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C(CH3)3), 88.3 (C≡C), 91.6 (C≡C), 118.8 (C), 121.7 (q, 
3JC-F = 5.5 Hz, CH), 121.9 (q, 
3JC-F = 1.0 Hz), 122.9 (q, 
4JC-F = 2.3 Hz, CH), 123.4 (q, 
1JC-F = 274.7 Hz), 125.7 (CH), 
130.0 (CH), 132.2 (CH), 133.1 (CH), 133.8 (q, 2JC-F = 31.6 Hz), 139.3 (C), 142.4 (C), 
147.9 (C), 153.1 (C); 
19F NMR (300 MHz, CDCl3): δ = -61.60 (CF3); 
IR (ATR, cm-1): ṽ = 3050 (vw), 2965 (m), 2949 (m), 2866 (w), 2201 (w), 1782 
(w), 1602 (w), 1550 (w), 1507 (w), 1371 (m), 1319 (m), 1282 (m), 1254 (s), 1165 (s), 
1139 (vs), 1105 (s), 825 (s), 693 (w), 648 (w), 566 (m). 
MS (GC-MS) m/z (%): 367 (39), 353 ([M+H-CH3]
+, 23), 352([M-CH3]
+
, 100), 
324 (10), 162 (10). 
HRMS (EI): calcd for C23F3NH20 ([M+H]
+) 368.16206, found 368.16233. 
 
6-methyl-2-(pent-1-ynyl)-4-(trifluoromethyl)quinoline (11e): 
Starting from 2-chloro-6-methyl-4-
(trifluoromethyl)quinoline (150 mg, 0.61 mmol), pent-1-yne 
(1.2 equiv., 50 mg, 0.73 mmol), Pd(PPh3)2Cl2 (2 mol %, 
9 mg, 0.01 mmol), CuI (5 mg, 0.04 equiv.), triethylamine  
 (3 equiv., 185 mg, 1.83 mmol), the product 11e was isolated 
as a yellow solid (155 mg, 91.6 %); mp = 118 – 120 °C. 
1H NMR (200 MHz, CDCl3): δ = 1.09 (t, 
3J = 7.3 Hz, 3H, CH2CH3), 1.71 (sxt, 
3J = 7.3 Hz, 2H, CH2CH2CH3), 2.49 (t, 
3J = 7.1 Hz, 2H, CH2, CH2CH2CH3), 2.58 (s, 
3H, CH3), 7.62 (dd, 
3J = 8.7 Hz, 4J = 1.8 Hz, 1H, CHAr), 7.71 (s, 1H, CHAr), 7.83 (br. 
s., 1H, CHAr), 8.06 (d, 
3J = 8.7 Hz, 1H, CHAr).  
13C NMR (65 MHz, CDCl3): δ = 13.8 (CH3), 21.6 (CH2CH2CH3), 21.9 
(CH2CH2CH3), 22.2 (Ar-CH3), 80.7 (C≡C), 93.3 (C≡C), 121.5 (q, 
3JC-F = 5.5 Hz, CH), 
121.7 (q, 3JC-F = 1.2 Hz, C), 122.8 (q, 
4JC-F = 2.0 Hz, CH), 123.4 (q, 
1JC-F = 274.7 Hz), 
129.9 (CH), 133.0 (CH), 133.7 (q, 2JC-F = 31.6 Hz, C), 138.9 (C), 142.6 (C), 147.7 (C). 
19F NMR (300 MHz, CDCl3): δ = -61.49 (CF3); 
IR (ATR, cm-1): ṽ = 3068 (w), 2979 (w), 2924 (w), 2858 (w), 2222 (m), 2208 
(m), 1605 (m), 1549 (m); 1494 (m), 1374 (s), 1361 (s), 1275 (s), 1259 (s), 1146 (s), 
1115 (vs), 596 (m), 830(m), 753 (s), 684 (s), 584 (m). 
MS (GC-MS) m/z (%): 278 ([M+H]+, 10), 277 ([M]
+
, 61), 276 (19), 262 (42), 250 
(16), 249 (100), 248 (27), 208 (10), 178 (15). 
HRMS (EI): calcd for C16F3H14N ([M]
+) 277.10729, found 277.10708. 
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6-fluoro-2-(hex-1-ynyl)-4-(trifluoromethyl)quinoline (11f): 
Starting from 2-chloro-6-fluoro-4-(trifluoromethyl)quinoline 
(150 mg, 0.61 mmol), hex-1-yne (60 mg, 0.73 mmol, 1.2 
equiv.), Pd(PPh3)2Cl2 (2 mol %, 9 mg, 0.01 mmol), CuI 
(0.04 equiv., 5 mg), triethylamine (185 mg, 1.82 mmol, 
3 equiv.), the product 11f was isolated as a brown solid 
(143 mg, 80 %), mp = 51 – 53 °C; 
1H NMR (250 MHz, CDCl3): δ = 0.97 (t, 
3J = 7.3 Hz, 3H, CH2CH3), 1.41-1.77 
(m, 4H, CH2CH2CH2), 2.53 (t, 
3J = 7.0 Hz, 2H, CH2), 7.57 (ddd, 
3J = 9.3 Hz, 
3J = 8.0 Hz, 4J = 2.8 Hz, 1H, CHAr), 7.66-7.74 (m, 1H, CHAr), 7.76 (s, 1H, CHAr), 8.17 
(dd, 3J = 9.3 Hz, 3J = 5.5 Hz, 1H, CHAr). 
13C NMR (200 MHz, CDCl3): δ = 13.6 (CH3), 19.2 (CH2), 22.1 (CH2), 30.2 
(CH2), 80.1 (C≡C), 94.3 (d, 
4J  C-F = 0.9 Hz), 108.2 (dq, 
2JC-F = 24.7 Hz, 
4JC-F = 2.7 Hz, 
CH), 121.1 (d, 2JC-F = 25.6 Hz, CH), 122.3 (q, 
3JC-F = 5.6 Hz, CH), 122.6 (dd,  
3JC-F = 10.5 Hz, 
3JC-F = 1.1 Hz, C), 123.1 (q, 
1JC-F = 274.2 Hz, C), 132.8 (d,  
3JC-F = 9.2 Hz, CH), 134.3 (q, 
2JC-F = 32.0 Hz, C), 143.0 (d, 
4JC-F = 3.2 Hz, C), 146.2 
(d, 4J = 0.9 Hz, C), 161.5 (d, 1JC-F = 252.2 Hz, C). 
19F NMR (300 MHz, CDCl3): δ = -108.56 (CF), -62.31 (CF3); 
IR (ATR, cm-1): ṽ = 3098 (w), 3062 (w), 2956 (m), 2930 (w), 2870 (w), 2229 
(m), 1626 (m), 1554 (m), 1373 (s), 1355 (s), 1250 (s), 1212 (s), 1162 (s), 1148 (s), 
1123 (s), 1029 (m), 904 (s), 834 (s), 685 (s), 570 (m). 
MS (GC-MS) m/z (%): 296 ([M+H]+, 14), 295 ([M]+, 75), 294 (37), 280 (59), 
267 (23), 266 (100), 254 (21), 253 (87), 252 (27), 239 (21), 229 (15), 226 (13), 203 
(13), 202 (18), 197 (13), 196 (18), 194 (19), 184 (12), 182 (19), 176 (13), 43 (11), 41 
(16). 
HRMS (EI): calcd for C16F4H13N ([M]
+) 295.09786, found 295.09735. 
 
General procedure for the synthesis of compounds 13a-r: 
In a Schlenk flask was prepared solution of aromatic amine (2.2 equiv.) in dry 
THF. Then 2.2 equiv. of n-BuLi (2.5 M solution in hexanes) was added at -78 °C under 
argon. To obtained lithium salt previously prepared solution of 6-chloro-1,3-
dialkyluracil (1 equiv.) in THF was added dropwise and afterward the reaction mixture 
N
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was allowed to warm to room temperature. The next day the solution was acidified with 
acetic acid and the solvent was evaporated. The solid rest was triturated with water and 
diethyl ether, filtered off with suction, washed twice and dried in a high vacuum or 
purified with column chromatography. 
 
6-(2-bromophenylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (13a): 
Starting with 6-chloro-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (200 mg, 1.14 mmol), 2-bromoaniline (430 mg, 
2.5 mmol) and n-BuLi (solution 2.5 M in hexanes) (1.2 mL, 
2.5 mmol) in dry THF (5 mL), the product 13a was isolated as 
a white solid (277 mg, 78 %), mp = 186-187 ºC; 
1H NMR (300 MHz, CDCl3): δ = 3.27 (s, 3H, CH3), 3.56 (s, 3H, CH3), 4.89 (s, 
1H, NH), 6.47 (s, 1H, CHAr), 7.12 (ddd, 
3J = 8.8 Hz, 3J = 6.5 Hz, 3J = 2.6 Hz, 1H, 
CHAr), 7.27 – 7.36 (m, 2H), 7.57 – 7.64 (m, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 27.9 (CH3), 29.4 (CH3), 79.8 (CH), 119.7 (C), 
126.7 (CH), 128.0 (CH), 128.7 (CH), 133.5 (CH), 135.6 (C), 151.80 (C), 151.9 (C), 
163.0 (C); 
IR (ATR, cm-1): v~  = 3271 (w), 2952 (w), 2916 (w), 1701 (s), 1631 (s), 1605 (s), 1580 (m), 
1527 (s), 1462 (s), 1435 (s), 1379 (m), 1359 (s), 1293 (m), 1265 (m), 1248 (m), 1191 (m), 1155 (w), 
1048 (m), 1025 (m), 1000 (m), 913 (w), 779 (s), 753 (s), 745 (s), 710 (w), 694 (w), 664 (m), 640 
(s), 595 (w), 534 (m), 496 (s), 426 (s); 
MS (GC, 70 eV) m/z (%): 311 ([M]+, 81Br, 36), 309 ([M]+, 79Br, 38), 230  
([M-Br]+, 100), 212 (12), 211 (13), 210 (13), 209 (12), 173 (43), 157 (13), 155 (12), 
145 (73), 130 (18), 127 (14), 117 (13), 90 (11), 82 (25), 75 (10), 55 (16), 42 (10); 
HRMS (EI): calcd. for C12H12
79BrN3O2 (M
+, 79Br) 309.01074, found 
309.01013; 
HRMS (EI): calcd. for C12H12
81BrN3O2 (M
+, 81Br) 311.00869, found 
311.00704; 
 
6-(2-bromo-4-methylphenylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 
(13b): 
Starting with 6-chloro-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (200 mg, 1.14 mmol) 
and 2-bromo-4-methylaniline (470 mg, 2.5 mmol) and n-butyl lithium (solution 2.5 M 
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in hexanes) (1.2 mL, 2.5 mmol) in dry THF (5 mL), the product 13b was isolated as a 
white solid (316 mg, 85 %), mp = 188-189 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.34 (s, 3H, CH3), 
3.28 (s, 3H, CH3), 3.57 (s, 3H, CH3), 4.87 (s, 1H, NH), 6.23 
(s, 1H, CHAr), 7.13 (dd, 
3J = 8.1 Hz, 4J =1.0 Hz, 1H, CHAr), 
7.19 (d, 3J = 8.1 Hz, 1H, CHAr), 7.45 (d, 
4J = 1.0 Hz, 1H, 
CHAr). 
13C NMR (75 MHz, CDCl3): δ = 20.7 (CH3), 27.9 (CH3), 29.3 (CH3), 79.3 (CH), 119.8 (C), 
126.8 (CH), 129.5 (CH), 132.7 (C), 133.8 (CH), 138.73 (C), 151.9 (C), 152.1 (C), 163.0 (C); 
IR (ATR, cm-1): v~  = 3266 (w), 2984 (w), 2919 (w), 1688 (m), 1638 (s), 1610 (s), 1510 (s), 
1462 (s), 1442 (s), 1424 (s), 1375 (s), 1359 (s), 1295 (s), 1283 (m), 1254 (m), 1208 (m), 1190 (m), 
1131 (w), 1047 (m), 998 (m), 919 (w), 908 (w), 894 (w), 881 (w), 871 (w), 843 (m), 814 (m), 782 
(s), 755 (s), 706 (m), 673 (m), 638 (s), 568 (m); 
MS (GC, 70 eV) m/z (%): 326 (11), 325 ([M]+, 81Br, 38), 324 (15), 323 ([M]+, 79Br, 43), 265 
(11), 245 (46), 244 ([M-Br]+, 88), 242 (11), 239 (10), 224 (16), 223 (12), 210 (11), 188 (11), 187 
(37), 183 (12), 160 (24), 159 (100), 146 (11), 145 (23), 144 (29), 132 (140, 131 (20), 130 (11), 127 
(17), 121 (14), 117 (17), 104 (12), 103 (21), 89 (11), 88 (25), 82 (38), 79 (10), 72 (13), 63 (13), 55 
(16), 41 (20);  
HRMS (EI): calcd. for C13H14BrN3O2 (M
+, 79Br) 323.02639, found 323.02616; 
HRMS (EI): calcd. for C13H14BrN3O2 (M
+, 81Br) 325.02434, found 325.02377. 
 
6-(2-bromo-4-isopropylphenylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 
(13c): 
Starting with 6-chloro-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione  (200 mg, 1.14 mmol) and 2-bromo-4-
isopropylaniline (540 mg, 2.5 mmol) and n-butyl lithium 
(solution 2.5 M in hexanes) (1.2 mL, 2.5 mmol) in dry 
THF (5 mL), the product 13c was isolated as a white solid 
(282 mg, 70 %), mp = 201-202 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.25 (d, 
3J = 6.92 Hz, 6H, CH(CH3)2), 2.89 (p, 
3J = 6.91 Hz, 1H, CH), 3.29 (s, 3H, CH3), 3.58 (s, 3H, CH3), 4.94 (s, 1H, NH), 6.14 (s, 
1H, CHAr), 7.15 – 7.25 (m, 2H, CHAr), 7.48 (d, 
4J = 1.73 Hz, 1H, CHAr); 
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13C NMR (63 MHz, CDCl3): δ = 23.9 (2*CH3), 28.1, 29.4, 33.7, 79.5 (CH), 
119.9 (C), 127.0 (CH), 127.05 (CH), 131.4 (CH), 132.9 (C), 149.8 (C), 152.0 (C), 
152.2 (C), 163.1 (C); 
IR (ATR, cm-1): v~  = 3210 (w), 3212 (w), 3143 (w), 3061 (w), 3001 (w), 2963 
(w), 2928 (w), 2874 (w), 1694 (s), 1614 (s), 1595 (s), 1575 (s), 1525 (s), 1514 (s), 
1471 (m), 1450 (m), 1412 (s), 1394 (s), 1377 (s), 1365 (s), 1349 (s), 1325 (m), 1287 
(s), 1236 (m), 1207 (m), 1183 (m), 1171 (m), 1156 (m), 1136 (m), 1123 (m), 1068 (m), 
1049 (m), 1032 (s), 930 (w), 885 (w), 862 (w), 818 (w), 780 (s), 767 (s), 747 (s), 709 
(w), 671 (m), 638 (m), 594 (m), 538 (m); 
MS (GC, 70 eV) m/z (%): 353 ([M]+, 81Br, 48), 351 ([M]+, 79Br, 49), 339 (11), 
338 (63), 337 (12), 336 (64), 273 (18), 272 ([M-Br]+, 100), 320 ([M-Br]+, 100), 239 
(12), 237 (13), 230 (45), 226 (14), 225 (13), 224 (21), 223 (15), 215 (14), 187 (55), 
172 (13), 171 (11), 158 (30), 157 (14), 145 (34), 144 (12), 143 (18), 130 (11), 127 
(14), 118 (13), 117 (21), 116 (17), 115 (17), 103 (19), 102 (15), 91 917), 90 (11), 89 
(15), 82 (59), 77 (17), 63 (10), 58 (31), 56 (24), 55 (34), 54 (21), 43 (18), 42 (56), 41 
(19), 39 (13), 29 (12); 
HRMS (EI): calcd. for C15H18BrN3O2 (M
+, 79Br) 351.05769, found 351.05766; 
HRMS (EI): calcd. for C15H18BrN3O2 (M
+, 81Br) 353.05564, found 353.05586. 
 
6-(2-bromo-4-chlorophenylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (13d): 
Starting with 6-chloro-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (200 mg, 1.14 mmol) and 2-bromo-4-chloroaniline 
(520 mg, 2.5 mmol) and n-butyl lithium (solution 2.5 M in 
hexanes) (1.2 mL, 2.5 mmol) in dry THF (5 mL), the product 
13d was isolated as a white solid (320 mg, 81 %), mp = 177-178 ºC; 
1H NMR (300 MHz, CDCl3): δ = 3.29 (s, 3H, CH3), 3.57 (s, 3H, CH3), 4.88 (s, 
1H, NH), 6.32 (s, 1H, CHAr), 7.25 (d, 
3J = 8.7 Hz, 1H, CHAr), 7.33 (dd, 
3J = 8.6 Hz, 
4J = 2.3 Hz, 1H, CHAr), 7.64 (d, 
4J = 2.3 Hz, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 28.1 (CH3), 29.7 (CH3), 80.2 (CH), 120.1 (C), 
127.3 (CH), 129.1 (CH), 132.9 (C), 133.3 (CH), 134.5 (C), 151.7 (C), 151.9 (C), 163.0 
(C); 
IR (ATR, cm-1): v~  = 3254 (w), 3085 (w), 2981 (w), 2951 (w), 1687 (s), 1603 
(s), 1565 (s), 1530 (s), 1470 (s), 1442 (s), 1425 (s), 1384 (s), 1365 (s), 1290 (s), 1267 
(m), 1255 (m), 1194 (m), 1166 (w), 1137 (w), 1096 (m), 1047 (m), 1005 (m), 915 (w), 
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875 (w), 862 (w), 820 (m), 782 (s), 767 (s), 734 (s), 709 (m), 698 (w), 682 (m), 671 
(w), 657 (m), 626 (m), 556 (s); 
MS (GC, 70 eV) m/z (%): 347 ([M]+, 81Br, 37Cl, 19), 346 (10), 345 ([M]+, 79Br, 43), 344 
(15), 343 (56), 266 (33), 265 (17), 264 ([M-Br]+,100), 246 (28), 245 (20), 244 (23), 243 (13), 231 
(20), 229 (18), 209 (17), 207 (48), 191 (15), 189 (10), 181 (29), 180 (12), 166 (11), 164 (16), 151 
(12), 127 (44), 124 (16), 82 (32), 75 (12), 55 (25), 54 (13), 42 (12); 
HRMS (EI): calcd. for C12H11BrClN3O2 (M
+, 81Br, 35Cl) 344.96972, found 344.96973; 
HRMS (EI): calcd. for C12H11BrClN3O2 (M
+, 81Br, 37Cl) 346.96677, found 
346.96720. 
 
6-(2-bromo-4-fluorophenylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (13e): 
Starting with 6-chloro-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (200 mg, 1.14 mmol) 
and 2-bromo-4-fluoroaniline (480 mg, 2.5 mmol) and n-butyl lithium (solution 2.5 M in 
hexanes) (1.2 mL, 2.5 mmol) in dry THF (5 mL), the product 13e was isolated as a 
white solid (338 mg, 90 %), mp = 160-161 ºC; 
1H NMR (300 MHz, CDCl3): δ = 3.27 (s, 3H, CH3), 3.57 (s, 
3H, CH3), 4.67 (s, 1H, NH), 6.45 (s, 1H, CHAr), 7.07 (ddd, 
3J = 8.8 Hz, 
3J = 7.7 Hz, 4J = 2.8 Hz, 1H, CHAr), 7.28 (dd, 
3J = 8.8 Hz, 4J = 4.7 Hz, 
1H, CHAr), 7.39 (dd, 
3J = 7.7 Hz, 4J = 2.8 Hz, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 28.1 (CH3), 29.6 (CH3), 79.2 (CH), 116.1 (d,  
2JC-F = 22.4 Hz, CH), 120.9 (d, 
2JC-F = 25.5 Hz, CH), 121.5 (d, 
3JC-F = 9.2 Hz, C), 129.1 (d, 
3J = 8.9 Hz, CH), 131.9 (C), 151.9, 152.5 (C), 160.8 (d, 1JC-F = 252.7 Hz), 163.1 (C);  
19F NMR (282 MHz, CDCl3): δ = -111.23 (CF); 
IR (ATR, cm-1): v~  = 3244 (w), 3114 (w), 3101 (w), 3071 (w), 3043 (w), 2945 (w), 2897 
(w), 1683 (s), 1603 (s), 1531 (s), 1480 (s), 1429 (s), 1379 (s), 1364 (s), 1295 (s), 1260 (s), 1226 (m), 
1197 (s), 1168 (m), 1120 (m), 1061 (w), 1041 (m), 1003 (m), 947 (w), 905 (m), 863 (m), 838 9m), 
811 (m), 786 (s), 759 (s), 752 (s), 716 (m), 688 (w), 670 (m), 636 (s), 579 (m), 558 (m); 
MS (GC, 70 eV) m/z (%): 329 ([M]+, 81Br, 36), 327 ([M]+, 79Br, 36), 248 ([M-
Br]+, 82), 230 (22), 229 (20), 228 (23), 227 (18), 215 (17), 213 (17), 191 (42), 175 
(14), 173 (12), 164 (11), 163 (100), 148 (19), 135 (20), 134 (13), 127 (22), 109 (10), 
108 (29), 107 (13), 94 (27), 82 (51), 81 (11), 58 (12), 57 (16), 56 (25), 55 (32), 54 
(22), 42 (37); 
HRMS (EI): calcd. for C12H11BrFN3O2 (M
+, 79Br) 327.00132, found 327.00072. 
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6-(2-bromophenylamino)-1,3-diethylpyrimidine-2,4(1H,3H)-dione (13f): 
Starting with 6-chloro-1,3-diethylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.98 mmol) and 2-bromoaniline 2 (370 mg, 2.15 mmol) 
and n-butyl lithium (solution 2.5 M in hexanes) (0.86 mL, 
2.15 mmol) in dry THF (5 mL), the product 13f was isolated as a 
white solid (304 mg, 91 %), mp = 174-176 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.20 (t, 
3J = 7.0 Hz, 3H, CH3), 1.44 (t, 
3J = 7.2 Hz, 3H, CH3), 3.96 (q, 
3J = 7.0 Hz, 2H, CH2), 4.12 (q, 
3J = 7.2 Hz, 2H, CH2), 
4.99 (s, 1H, NH), 6.21 (s, 1H, CHAr), 7.06 – 7.17 (m, 1H, CHAr), 7.29 – 7.40 (m, 2H, 
CHAr), 7.63 (d, 
3J = 8.0 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.2 (CH2CH3), 14.1 (CH2CH3), 36.5 (CH2CH3), 
38.1 (CH2CH3), 80.6 (CH), 119.1 (C), 126.3 (CH), 127.7 (CH), 128.8 (CH), 133.6 
(CH), 135.7 (C), 151.2 (C), 151.3 (C), 162.8 (C); 
IR (ATR, cm-1): v~  = 3101 (w), 2978 (w), 2932 (w), 2872 (w), 1689 (s), 1614 
(s), 1591 (s), 1574 (s), 1532 (s), 1479 (s), 1456 (s), 1435 (s), 1417 (s), 1396 (s), 1371 
(s), 1336 (s), 1315 (s), 1287 (s), 1250 (m), 1216 (m), 1178 (m), 1162 (m), 1119 (w), 
1094 (m), 1070 (m), 1049 (m), 1028 (m), 990 (m), 963 (w), 879 (w), 850 (w), 832 (w), 
803 (w), 791 (m), 779 (s), 762 (s), 739 (s), 701 (m), 686 (m), 665 (m), 639 (s), 592 
(m), 536 (m); 
MS (GC, 70 eV) m/z (%): 339 ([M]+, 81Br, 16), 337 ([M]+, 79Br, 17), 258 ([M-Br]+, 100), 
198 (14), 197 (11), 196 (14), 187 (34), 171 (11), 159 (47), 157 (13), 155 (12), 144 (12), 131 (13), 
117 (11), 68 (26), 29 (12);  
HRMS (EI): calcd. for C14H16BrN3O2 (M
+, 79Br) 337.04204, found 337.04223; 
HRMS (EI): calcd. for C14H16BrN3O2 (M
+, 81Br) 339.03999, found 339.04022. 
 
6-(2-bromo-4-methylphenylamino)-1,3-diethylpyrimidine-2,4(1H,3H)-dione (13g): 
Starting with 6-chloro-1,3-diethylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.98 mmol) and 2-bromo-4-methylaniline (400 mg, 
2.15 mmol) and n-butyl lithium (solution 2.5 M in hexanes) 
(0.86 mL, 2.15 mmol) in dry THF (5 mL), the product 13g was 
isolated as a white solid (320 mg, 92 %), mp = 180-181 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.20 (t, 
3J = 7.1 Hz, 3H, CH3), 1.43 (t, 
3J = 7.2 Hz, 3H, CH3), 2.34 (s, 3H, Ar-CH3), 3.95 (q, 
3J = 7.1 Hz, 2H, CH2), 4.11 (q, 
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3J = 7.2 Hz, 2H, CH2), 4.90 (s, 1H, NH), 6.10 (s, 1H, CHAr), 7.13 (dd, 
3J = 8.2 Hz, 
4J = 1.9 Hz, 1H, CHAr), 7.22 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.45 (d, 
4J = 1.9 Hz, 1H, 
CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.2 (CH2CH3), 14.0 (CH2CH3), 20.8 (Ar-CH3), 
36.4 (CH2CH3), 37.9 (CH2CH3), 80.0 (CH), 119.5, 126.7 (CH), 129.5 (CH), 132.9 (C), 
133.8 (CH), 138.5 (C), 151.3 (C), 151.6 (C), 162.8 (C); 
IR (ATR, cm-1): v~  = 3246 (w), 3056 (w), 2974 (w), 2932 (w), 2869 (w), 1688 
(s), 1604 (s), 1593 (s), 1531 (s), 1492 (s), 1480 (s), 1457 (s), 1435 (s), 1416 (s), 1393 
(s), 1373 (s), 1335 (m), 1312 (m), 1290 (s), 1267 (m), 1207 (m), 1178 (w), 1161 (w), 
1089 (m), 1068 (m), 1050 (m), 1033 (m), 987 (m), 963 (w), 894 (w), 863 (w), 837 (w), 
779 (s), 765 (s), 740 (s), 712 (w), 694 (w), 676 (w), 638 (m), 566 (m); 
MS (GC, 70 eV) m/z (%): 351 ([M]+, 79Br, 16), 273 (35), 272 ([M-Br]+, 100), 244 (13), 243 
(15), 238 (13), 237 (11), 236 (11), 213 (15), 212 (27), 211 (41), 210 (20), 209 (15), 201 (29), 198 
(12), 196 (12), 187 (18), 185 (18), 184 (12), 173 (74), 172 (21), 171 (11), 158 (13), 146 (17), 145 
(10), 141 (18), 140 (15), 132 (15), 131 (16), 130 (15), 117 (11), 104 (11), 90 (22), 89 (29), 88 (27), 
78 (16), 77 (10), 70 (12), 69 (17), 68 (13), 67 (55), 55 (19), 41 (15), 29 (16);  
HRMS (ESI): calcd. for C15H18BrN3O2 (M+H
+, 79Br) 352.06552, found 352.06541; 
HRMS (ESI): calcd. for C15H18BrN3O2 (M+H
+, 81Br) 354.06361, found 
354.06350. 
 
6-(2-bromo-4-isopropylphenylamino)-1,3-diethylpyrimidine-2,4(1H,3H)-dione (13h): 
Starting with 6-chloro-1,3-diethylpyrimidine-2,4(1H,3H)-
dione (200 mg, 0.98 mmol) and 2-bromo-4-isopropylaniline 
(460 mg, 2.15 mmol) and n-butyl lithium (solution 2.5 M in 
hexanes) (0.86 mL, 2.15 mmol) in dry THF (5 mL), the 
product 13h was isolated as a white solid (338 mg, 90 %), mp = 191-192 ºC; 
 1H NMR (300 MHz, CDCl3): δ = 1.2 (t, 
3J = 7.0 Hz, 3H, CH3), 1.2 (d, 
3J = 6.9 Hz, 6H, 
2*CH3), 1.41 (t, 
3J = 7.2 Hz, 3H, CH3), 2.90 (p, 
3J = 6.9 Hz, 1H), 3.94 (q, 3J = 7.0 Hz, 2H, CH2), 
4.11 (q, 3J = 7.2 Hz, 2H, CH2), 4.91 (s, 1H, NH), 6.19 (s, 1H, CHAr), 7.19 (dd, 
3J = 8.3 Hz, 
4J = 1.9 Hz, 1H, CHAr), 7.21 (d, 
3J = 8.2 Hz, 1H, CHAr), 7.48 (d, 
4J = 1.8 Hz, 1H, CHAr); 
 13C NMR (63 MHz, CDCl3): δ = 13.2 (CH2CH3), 14.0 (CH2CH3), 23.9 (CH3), 33.7 (CH), 
36.5 (CH2CH3), 38.0 (CH2CH3), 79.8 (CH), 119.8 (C), 126.9 (CH), 127.0 (CH), 131.4 (CH), 133.0 
(C), 149.5 (C), 151.3 (C), 151.7 (C), 162.8 (C); 
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IR (ATR, cm-1): v~  = 3202 (w), 2963 (w), 2931 (w), 2871 (w), 1686 (s), 1616 
(s), 1599 (s), 1587 (s), 1523 (s), 1481 (s), 1460 (m), 1452 (m), 1439 (s), 1417 (s), 1388 
(s), 1381 (s), 1351 (s), 1314 (s), 1281 (s), 1246 (m), 1216 (w), 1201 (w), 1183 (w), 
1169 (w), 1145 (w), 1092 (m), 1086 (m), 1068 (w), 1052 (m), 1047 (m), 1033 (m), 985 
(m), 960 (w), 923 (w), 898 (m), 863 (w), 838 (w), 807 (m), 788 (m), 779 (s), 763 (s), 
738 (m), 709 (m), 677 (m), 640 (m), 612 (w), 561 9m), 536 (m); 
MS (GC, 70 eV) m/z (%): 381 ([M]+, 81Br, 22), 381 ([M]+, 79Br, 21), 301 (22), 300 ([M-Br]+, 
100), 258 (13), 229 (15), 224 (12), 201 (36), 159 (11), 144 (15), 68 (20), 29 (12);  
HRMS (EI): calcd. for C17H22BrN3O2 (M
+, 79Br) 379.08899, found 379.08833; 
HRMS (EI): calcd. for C17H22BrN3O2 (M
+, 81Br) 381.08694, found 381.08656. 
 
6-(2-bromo-4-chlorophenylamino)-1,3-diethylpyrimidine-2,4(1H,3H)-dione (13i): 
Starting with 6-chloro-1,3-diethylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.98 mmol) and 2-bromo-4-chloroaniline (440 mg, 
2.15 mmol) and n-butyl lithium (solution 2.5 M in hexanes) 
(0.86 mL, 2.15 mmol) in dry THF (5 mL), the product 13i was 
isolated as a white solid (246 mg, 67 %), mp = 186-187 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.19 (t, 
3J = 7.0 Hz, 3H, CH3), 1.42 (t, 
3J = 7.2 Hz, 3H, CH3), 3.95 (q, 
3J = 7.0 Hz, 2H, CH2), 4.11 (q, 
3J = 7.2 Hz, 2H, CH2), 
4.89 (s, 1H, NH), 6.28 (s, 1H, CHAr), 7.27 (d, 
3J = 8.5 Hz, 1H, CHAr), 7.32 (dd, 
3J = 8.6 Hz, 4J = 2.2 Hz, 1H, CHAr), 7.64 (d, 
4J = 2.2 Hz, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 13.1 (CH2CH3), 14.0 (CH2CH3), 36.5 (CH2CH3), 
38.0 (CH2CH3), 80.7 (CH), 119.7 (C), 127.0 (CH), 129.1 (CH), 132.5 (C), 133.2 (CH), 
134.6 (C), 151.1 (C), 151.2 (C), 162.7 (C); 
IR (ATR, cm-1): v~  = 3235 (w), 3076 (w), 3052 (w), 2974 (w), 2933 (w), 2870 
(w), 1688 (s), 1613 (s), 1599 (s), 1563 (s), 1531 (s), 1475 (s), 1456 (s), 1435 (s), 1415 
(s), 1394 (s), 1373 (s), 1335 (s), 1312 (s), 1289 (s), 1261 (m), 1214 (m). 1197 (m), 
1177 9m), 1161 (w), 1136 (w), 1092 (s), 1068 (m), 1048 (s), 1033 (m), 988 (m), 963 
(m), 885 (w), 862 (m), 830 (w), 819 (w), 801 (m), 781 (s), 765 (s), 724 (s), 691 (m), 
674 (m), 628 (m), 622 (m), 556 (s), 526 (s); 
MS (GC, 70 eV) m/z (%): 373 ([M]+, 81Br, 35Cl, 28), 346 (10), 345 ([M]+, 79Br, 35Cl, 21), 
294 (33), 293 (16), 292 ([M-Br]+,100), 258 (11), 232 (25), 231 (21), 230 (22), 229 (13), 223 (13), 
221 (43), 207 (13), 205 915), 195 (17), 193 (51), 191 (12), 178 (11), 167 (20), 165 (14), 158 (10), 
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141 (27), 139 (13), 124 (15), 110 (10), 75 (13), 70 (18), 69 (13), 68 (45), 56 (14), 44 (12), 41 (17), 
29 (32); 
HRMS (EI): calcd. for C14H15BrClN3O2 (M
+, 79Br, 35Cl) 371.00307, found 371.00253; 
HRMS (EI): calcd. for C14H15BrClN3O2 (M
+, 79Br, 37Cl) 373.00012, found 373.00042; 
HRMS (EI): calcd. for C14H15BrClN3O2 (M
+, 81Br, 35Cl) 373.00102, found 373.00042; 
HRMS (EI): calcd. for C14H15BrClN3O2 (M
+, 81Br, 37Cl) 374.99807, found 374.99736. 
 
6-(2-bromo-4-fluorophenylamino)-1,3-diethylpyrimidine-2,4(1H,3H)-dione (13j): 
Starting with 6-chloro-1,3-diethylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.98 mmol) and 2-bromo-4-fluoroaniline (410 mg, 
2.15 mmol) and n-butyl lithium (solution 2.5 M in hexanes) 
(0.86 mL, 2.15 mmol) in dry THF (5 mL), the product 13j was 
isolated as a white solid (300 mg, 85 %), mp = 187-188 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.18 (t, 
3J = 7.0 Hz, 3H, CH3), 1.41 (t, 
3J = 7.2 Hz, 3H, CH3), 3.93 (q, 
3J = 7.0 Hz, 2H, CH2), 4.12 (q, 
3J = 7.2 Hz, 2H, CH2), 
4.68 (s, 1H, NH), 6.35 (s, 1H, CHAr), 7.07 (ddd, 
3J = 8.8 Hz, 3J = 7.7 Hz, 4J = 2.8 Hz, 
1H, CHAr), 7.29 (dd, 
3J = 8.8 Hz, 3J = 5.3 Hz, 1H, CHAr), 7.38 (dd, 
3J = 7.7 Hz, 
4J = 2.8 Hz, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 13.2 (CH2CH3), 14.0 (CH2CH3), 36.5 (CH2CH3), 38.0 
(CH2CH3), 79.5 (CH), 116.1 (d, 
2JC-F = 22.5 Hz, CH), 120.8 (d, 
2JC-F = 25.5 Hz, CH), 121.2 (d,  
3JC-F = 9.8 Hz, C), 128.9 (d, 
3JC-F = 8.6 Hz, CH), 132.0 (d, 
4JC-F = 6.1 Hz), 151.1 (C), 151.9 (C), 
160.7 (d, 1JC-F = 252.0 Hz), 162.8 (C); 
19F NMR (282 MHz, CDCl3): δ = -111.57 (CF); 
IR (ATR, cm-1): v~  = 3192 (br, w), 3060 (br, w), 2972 (br, w), 2934 (br, w), 1685 (s), 1614 
(s), 1532 (s), 1487 (s), 1417 (s), 1354 (m), 1254 (m), 1191 (m), 1085 (w), 1042 (w), 982 (w), 904 
(w), 787 (s), 763 (m), 696 (w), 638 (m); 
MS (GC, 70 eV) m/z (%): 357 ([M]+, 81Br, 19), 355 ([M]+, 79Br, 20), 276 ([M-
Br]+, 100), 242 (10), 216 (21), 215 (19), 214 (23), 213 (15), 205 (39), 189 (13), 177 
(56), 176 (10), 175 (12), 173 (10), 162 (14), 149 (15), 141 (11), 135 (14), 134 (11), 
108 (22), 107 (10), 94 (20), 70 (16), 69 (11), 68 (41), 56 (19) , 44 (12), 42 (25), 41 
(15), 29 (42); 
HRMS (EI): calcd. for C14H15BrFN3O2 (M
+, 79Br) 355.03262, found 355.03179; 
HRMS (EI): calcd. for C14H15BrFN3O2 (M
+, 81Br) 357.03057, found 357.03027. 
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6-(2-bromophenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-dione (13k): 
Starting with 6-chloro-1,3-dipropylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.86 mmol) and 2-bromoaniline (330 mg, 1.89 mmol) and 
n-butyl lithium (solution 2.5 M in hexanes) (0.75 mL, 1.89 mmol) 
in dry THF (5 mL), the product 13k was isolated as a white solid 
(289 mg, 91 %), mp = 139-140 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, 
3J = 7.4 Hz, 3H, CH3), 1.04 (t, 
3J = 7.4 Hz, 3H, CH3), 1.63 (h, 
3J = 7.5 Hz, 2H, CH2), 1.85 (h, 
3J = 7.4 Hz, 2H, CH2), 
3.85 (t, 3J = 7.6 Hz, 2H, CH2), 4.00 (t, 
3J = 7.6 Hz, 2H, CH2), 5.01 (s, 1H, NH), 6.21 
(s, 1H, CHAr), 7.10 (m, 1H, CHAr), 7.29-7.36 (m, 2H), 7.62 (d, 
3J = 8.1 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 11.3 (CH3), 11.4 (CH3), 21.2 (CH2), 22.2 (CH2), 
43.0 (CH2), 44.6 (CH2), 80.6 (CH), 119.0 (C), 126.0 (CH), 127.6 (CH), 128.8 (CH), 
133.6 (CH), 135.8 (C), 151.3 (C), 151.7 (C), 163.0 (C); 
IR (ATR, cm-1): v~  = 3271 (w), 3065 (w), 2962 (w), 2933 (w), 2874 (w), 1689 
(s), 1616 (s), 1600 (s), 1574 (s), 1523 (s), 1476 (s), 1437 (s), 1413 (s), 1389 (s), 1318 
(m), 1304 (m), 1287 (m), 1253 (m), 1198 (m), 1176 (w), 1157 (w), 1120 (w), 1081 (w), 
1055 (m), 1029 (m), 948 (w), 893 (w), 777 (s), 751 (s), 740 (s), 707 (m), 696 (w), 665 
(m), 639 (s), 602 (w), 547 (s); 
MS (GC, 70 eV) m/z (%): 367 ([M]+, 81Br, 31), 365 ([M]+, 79Br, 31), 324 (13), 
287 ([(M-Br)+H]+, 20), 286 ([M-Br]+, 100), 244 (45), 224 (12), 222 (10), 202 (35), 201 
(10), 198 (17), 197 (12), 196 (20), 195 (16), 173 (21), 171 (16), 158 (12), 157 (16), 
155 (19), 131 (38), 117 (14), 68 (13), 56 (16), 43 (26), 42 (28), 41 (44), 29 (19); 
HRMS (EI): calcd. for C16H20
79BrN3O2 ([M]
+) 365.07334, found 365.07306; 
HRMS (EI): calcd. for C17H22
81BrN3O2 ([M]
+) 367.07129, found 367.07148. 
 
6-(2-bromo-4-methylphenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-dione (13l): 
Starting with 6-chloro-1,3-dipropylpyrimidine-2,4(1H,3H)-
dione (200 mg, 0.86 mmol) and 2-bromo-4-methylaniline 
(350 mg 1.89 mmol) and n-butyl lithium (solution 2.5 M in 
hexanes) (0.75 mL, 1.89 mmol) in dry THF (5 mL), the 
product 13l was isolated as a white solid (290 mg, 88 %), 
mp = 119-120 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, 
3J = 7.5 Hz, 3H, CH3), 1.04 (t, 
3J = 7.4 Hz, 3H, CH3), 1.63 (h, 
3J = 7.4 Hz, 2H, CH2), 1.85 (h, 
3J = 7.5 Hz, 2H, CH2), 
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2.34 (s, 3H, CH3), 3.77 – 3.90 (m, 2H, CH2), 3.90 – 4.09 (m, 2H, CH2), 4.94 (s, 1H, 
NH), 6.04 (s, 1H, CHAr), 7.13 (dd, 
3J = 8.1 Hz, 4J = 1.0 Hz, 1H, CHAr), 7.22 (d, 
3J = 8.1 Hz, 1H, CHAr), 7.45 (d, 
4J = 1.0 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 11.4 (CH3), 11.5 (CH3), 20.8 (CH3), 21.2 (CH2), 
22.2 (CH2), 43.0 (CH2), 44.5 (CH2), 80.0 (CH), 119.3 (C), 126.4 (CH), 129.6 (CH), 
132.9 (C), 133.8 (CH), 138.4 (C), 151.7 (2*C, C), 163.0 (C); 
IR (ATR, cm-1): v~  = 3209 (w), 3032 (w), 2960 (w), 2927 (w), 2873 (w), 1691 
(s), 1614 (s), 1519 (s), 1492 (s), 1477 (s), 1435 (s), 1414 (s), 1392 (m), 1379 (m), 1358 
(m), 1340 (m), 1319 (m), 1286 (s), 1258 (m), 1205 (m), 1174 (w), 1138 (w), 1110 (w), 
1078 (w), 1053 (m), 1042 (m), 1000 (w), 947 (w), 892 (w), 869 (w), 804 (m), 783 (s), 
760 (s), 693 (w), 672 (m), 636 (m), 571 (m), 549 (m), 530 (m);  
MS (GC, 70 eV) m/z (%): 381 ([M]+, 81Br, 31), 380 ([M+H]+, 79Br, 11), 379 
([M]+, 79Br, 31), 338 (12), 301 ([(M-Br)+H]+, 20), 300 ([M-Br]+, 100), 259 (12), 258 
(68), 238 (12), 236 (11), 216 (34), 212 (19), 211 (17), 210 (24), 209 (13), 187 (39), 
185 (30), 173 (37), 172 (14), 171 (12), 158 (14), 146 (11), 145 (58), 131 (19), 130 
(14), 104 (10), 90 (21), 89 (20), 77 (13), 68 (17), 56 (20), 43 (38), 42 (37), 41 (55), 29 
(21); 
HRMS (EI): calcd. for C17H22
79BrN3O2 ([M]
+) 379.0899, found 379.08823; 
HRMS (EI): calcd. for C17H22
81BrN3O2 ([M]
+) 381.08694, found 381.08663. 
 
6-(2-bromo-4-isopropylphenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-dione 
(13m): 
Starting with 6-chloro-1,3-dipropylpyrimidine-
2,4(1H,3H)-dione (200 mg, 0.86 mmol) and 2-bromo-4-
isopropylaniline (410 mg, 1.89 mmol) and n-butyl 
lithium (solution 2.5 M in hexanes) (0.75 mL, 1.89 
mmol) in dry THF (5 mL), the product 13m was isolated 
as a white solid (283 mg, 80 %), mp = 160-161 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, 
3J = 7.4 Hz, 3H, CH3), 1.04 (t, 
3J = 7.4 Hz, 3H, CH3), 1.25 (d, 
3J = 6.9 Hz, 6H, CH3), 1.64 (h, 
3J = 7.4 Hz, 2H, CH2), 
1.85 (hept, 3J = 7.4 Hz, 2H, CH2), 2.89 (hept, 
3J = 6.9 Hz, 1H, CH), 3.71 – 3.92 (m, 
2H, CH2), 3.95 – 4.14 (m, 2H, CH2) 4.99 (s, 1H, NH), 6.10 (s, 1H, CHAr), 7.19 (dd, 
3J = 8.2 Hz, 4J = 1.7 Hz, 1H, CHAr), 7.26-7.32 (m, 1H, CHAr), 7.48 (d, 
4J = 1.7 Hz, 
1H, CHAr); 
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13C NMR (63 MHz, CDCl3) δ = 11.4 (CH3), 11.5 (CH3), 21.2 (CH2), 22.2 (CH2), 
23.9 (CH3), 33.7 (CH), 43.0 (CH2), 44.5 (CH2), 80.0 (CH), 119.4 (C), 126.5 (CH), 
127.0 (CH), 131.4 (C), 133.1 (CH), 149.4 (C), 151.7 (2*C, C), 163.0 (C); 
IR (ATR, cm-1): v~  = 3227 (w), 3045 (w), 2960 (w), 2930 (w), 2872 (w), 1686 
(m), 1616 (s), 1603 (s), 1588 (s), 1557 (m), 1523 (s), 1477 (m), 1461 (m), 1436 (m), 
1414 (m), 1390 (m), 1359 (m), 1341 (m), 1320 (m), 1305 (m), 1285 (m), 1257 (m), 
1206 (w), 1175 (w), 1106 (w), 1068 (w), 1053 (m), 1040 (m), 948 (w), 926 (w), 891 
(w), 878 (w), 833 (w), 780 (m), 766 (m), 736 (m), 708 (w), 676 (w), 665 (w), 636 (m), 
609 (w), 546 (m); 
MS (GC, 70 eV) m/z (%): 409 ([M]+, 81Br, 28), 408 ([M+H]+, 79Br, 10), 407 
([M]+, 79Br, 29), 329 ([(M-Br)+H]+, 23), 328 ([M-Br]+, 100), 287 (15), 286 (77), 244 
(27), 240 (10), 238 (11), 224 (14), 215 (24), 213 (18), 200 (14), 198 (13), 173 (45), 
159 (17), 158 (11), 144 (16), 143 (14), 117 (14), 115 (12), 103 (12), 91 (10), 68 (15), 
56 (21), 43 (52), 42 (45), 41 (57), 39 (13), 29 (19); 
HRMS (EI): calcd. for C19H26
79BrN3O2 ([M]
+) 407.12029, found 407.12057; 
HRMS (EI): calcd. for C19H26
81BrN3O2 ([M]
+) 409.11824, found 409.11873. 
 
6-(2-bromo-4-chlorophenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-dione (13n): 
Starting with 6-chloro-1,3-dipropylpyrimidine-2,4(1H,3H)-
dione (200 mg, 0.86 mmol) and 2-bromo-4-chloroaniline (390 
mg, 1.89 mmol) and n-butyl lithium (solution 2.5 M in 
hexanes) (0.75 mL, 1.89 mmol) in dry THF (5 mL), the 
product 13n was isolated as a white solid (222 mg, 64 %), 
mp = 153 - 155 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.93 (t, 
3J = 7.4 Hz, 3H, CH3), 1.05 (t, 
3J = 7.4 Hz, 3H, CH3), 1.54-1.71 (m, 2H, CH2), 1.84 (q, 
3J = 7.6 Hz, 2H, CH2), 3.86 (t, 
3J = 7.9 Hz, 2H, CH2), 4.00 (t, 
3J = 7.9 Hz, 2H, CH2), 4.99 (s, 1H, NH), 6.14 (s, 1H, 
CHAr), 7.27-7.35 (m, 2H, CHAr), 7.61-7.66 (m, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 11.4 (CH3), 11.5 (CH3), 21.2 (CH2), 22.3 (CH2), 
43.1 (CH2), 44.7 (CH2), 81.0 (CH), 126.5 (CH), 129.1 (CH), 132.3 (CH), 133.1 (C), 
134.6, 151.0, 151.6, 162.9 (C); 
IR (ATR, cm-1): v~  = 3240 (w), 3072 (w), 3054 (w), 2962 (w), 2932 (w), 2873 
(w), 1687 (s), 1610 (s), 1593 (s), 1563 (m), 1520 (s), 1477 (s), 1436 (s), 1415 (m), 
1392 (m), 1376 (m), 1359 (m), 1335 (m), 1320 (m), 1305 (m), 1276 (m), 1251 (m), 
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1205 (w), 1174 (w), 1142 (w), 1093 (m), 1053 (m), 1042 (m), 949 (w), 891 (m), 880 
(w), 848 (w), 832 (w), 783 (s), 767 (s), 745 (w), 720 (m), 687 (w), 658 (w), 626 (m), 
569 (m), 553 (m), 532 (m); 
MS (GC, 70 eV) m/z (%): 401 ([M]+, 81Br, 35), 400 (([M+H]+, 79Br, 11), 399 
([M]+, 79Br, 26), 360 (15), 358 (17), 322 (34), 321 ([(M-Br)+H]+, 20), 320 ([M-Br]+, 
100), 280 (17), 278 (51), 259 (12), 258 (16), 256 (11), 245 (12), 236 (30), 235 (14), 
233 (12), 232 (34), 231 (24), 230 (30), 229 (14), 207 (29), 205 (19), 195 (32), 193 
(38), 192 (11), 191 (16), 189 (11), 167 (14), 165 (41), 158 (14), 153 (18), 151 (11), 
124 (12), 111 (17), 110 (13), 70 (10), 68 (21), 56 (29), 43 (45), 42 (47), 41 (75), 39 
(20), 29 (30);  
HRMS (ESI) calcd. for C16H19
79BrClN3O2 ([M+H]
+) 400.04219, found 
400.04248; 
HRMS (ESI) calcd. for C16H19
81BrClN3O2 ([M+H]
+) 402.04005, found 
402.04006. 
 
6-(2-bromo-4-fluorophenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-dione (13o): 
Starting with 6-chloro-1,3-dipropylpyrimidine-2,4(1H,3H)-dione 
(200 mg, 0.86 mmol) and 2-bromo-4-fluoroaniline (360 mg, 1.89 
mmol) and n-butyl lithium (solution 2.5 M in hexanes) (0.75 mL, 
1.89 mmol) in dry THF (5 mL), the product 13o was isolated as a 
white solid (303 mg, 91 %), mp = 135-136 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, 
3J = 7.4 Hz, 3H, CH3), 1.05 (t, 
3J = 7.4 Hz, 3H, CH3), 1.63 (q, 
3J = 7.6 Hz, 2H, CH2), 1.84 (q, 
3J = 7.6 Hz, 2H, CH2), 
3.85 (t, 3J = 7.8 Hz, 2H, CH2), 4.01 (t, 
3J = 7.8 Hz, 2H, CH2), 4.82 (s, 1H, NH), 6.06 
(s, 1H, CHAr), 7.08 (ddd, 
3J = 9.1 Hz, 3J = 7.6 Hz, 4J = 2.9 Hz, 1H, CHAr), 7.27-7.38 
(m, 1H, CHAr), 7.39 (dd, 
3J = 7.7 Hz, 4J = 2.8 Hz, 1H, CHAr); 
 13C NMR (63 MHz, CDCl3): δ = 11.3 (CH3), 11.4 (CH3), 21.2 (CH2), 22.1 
(CH2), 43.0 (CH2), 44.5 (CH2), 79.8 (CH), 116.1 (d, 
2JC-F = 22.4 Hz, CH), 120.7 (d, 
3JC-
F = 8.2 Hz, C), 120.8 (d, 
2JC-F = 25.6 Hz, CH), 128.5 (d, 
3JC-F = 8.8 Hz, CH), 132.0 (d, 
4JC-F = 3.7 Hz, C), 160.6 (d, 
1JC-F = 252.1 Hz, C). 
19F NMR (282 MHz, CDCl3): δ = -111.86 (CF); 
IR (ATR, cm-1): v~  = 3224 (w), 3098 (w), 3068 (w), 3044 (w), 2961 (w), 2931 
(w), 2873 (w), 1689 (s), 1614 (s), 1599 (s), 1521 (s), 1477 (s), 1435 (s), 1414 (m), 
1387 (m), 1359 (m), 1338 (m), 1319 (m), 1288 (m), 1250 (s), 1190 (m), 1107 (w), 1076 
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(w), 1034 (m), 947 (w), 896 (m), 858 (w), 839 (w), 812 (m), 781 (s), 759 (m), 709 (w), 
688 (w), 674 (w), 633 (m), 586 (w), 549 (m); 
MS (GC, 70 eV) m/z (%): 385 ([M]+, 81Br, 23), 383 ([M]+, 79Br, 23), 344 (10), 
342 (17), 305 ([(M-Br)+H]+, 23), 304 ([M-Br]+, 100), 262 (46), 243 (10), 242 (15), 241 
(11), 240 (14), 229 (11), 227 (11), 220 (33), 219 (13), 216 (24), 215 (21), 214 (29), 
213 (16), 195 (15), 189 (19), 177 (50), 176 (12), 175 (14), 173 (12), 162 (11), 149 
(42), 135 (17), 134 (14), 111 (11), 108 (17), 107 (11), 94 (19), 82 (13), 68 (20), 56 
(25), 43 (37), 42 (39), 41 (63), 39 (18), 29 (27); 
HRMS (ESI) calcd. for C16H19
79BrFN3O2 ([M+H]
+) 384.07174, found 384.07166; 
HRMS (ESI) calcd. for C16H19
81BrFN3O2 ([M+H]
+) 386.06986, found 386.06982. 
 
6-(2-bromophenylamino)-1,3-dibutylpyrimidine-2,4(1H, 3H)-dione (13p): 
Starting with 1,3-dibutyl-6-chloropyrimidine-2,4(1H,3H)-
dione (200 mg, 0.77 mmol) and 2-bromoaniline (290 mg, 1.69 
mmol) and n-butyl lithium (solution 2.5 M in hexanes) (0.68 
mL, 1.69 mmol) in dry THF (5 mL), the product 13p was 
isolated as a white solid (280 mg, 92 %), mp = 132 - 133 ºC; 
 1H NMR (300 MHz, CDCl3): δ = 0.91 (t, 
3J = 7.3 Hz, 
3H, CH3), 0.98 (t, 
3J = 7.3 Hz, 3H, CH3), 1.33 (q, 
3J = 7.5 Hz, 2H, CH2), 1.44 (q, 
3J = 7.5 Hz, 2H, CH2), 1.56 (h, 
3J = 7.3 Hz, 2H, CH2), 1.78 (h, 
3J = 7.3 Hz, 2H, CH2), 
3.86 (t, 3J = 7.3 Hz, 2H, CH2), 4.03 (t, 
3J = 7.3 Hz, 2H, CH2), 4.95 (s, 1H, NH), 6.35 
(s, 1H, CHAr), 6.98 – 7.17 (m, 1H, CHAr), 7.28 – 7.35 (m, 2H, CHAr), 7.61 (d, 
3J = 8.4 Hz, 1H, CHAr); 
 13C NMR (63 MHz, CDCl3): δ = 13.88 (CH3), 13.92 (CH3), 20.2 (CH2), 20.3 
(CH2), 30.0 (CH2), 30.9 (CH2), 41.3 (CH2), 42.9 (CH2), 80.5 (CH), 119.1 (C), 126.2 
(CH), 127.6 (CH), 128.7 (CH), 133.5 (CH), 135.8 (C), 151.3 (C), 151.6 (C), 162.9 (C); 
IR (ATR, cm-1): v~  = 3233 (w), 2955 (w), 2929 (w), 2869 (w), 1686 (m), 1619 
(s), 1597 (s), 1580 (m), 1524 (s), 1497 (m), 1463 (m), 1437 (m), 1412 (m), 1391 (m), 
1353 (m), 1330 (m), 1318 (m), 1290 (m), 1269 (w), 1243 (w), 1224 (w), 1190 (w), 
1167 (w), 1154 (w), 1113 (w), 1081 (w), 1045 (m), 1028 (m), 949 (w), 932 (w), 910 
(w), 880 (w), 812 (w), 796 (w), 779 (m), 764 (m), 739 (m), 673 (w), 665 (w), 637 (m), 
602 (w), 551 (m); 
 MS (GC, 70 eV) m/z (%): 395 ([M]+, 81Br, 12), 393 ([M]+, 79Br, 12), 378 (29), 
376 (27), 340 (28), 338 (36), 315 (23), 314 ([M-Br]+, 100), 272 (33), 258 (46), 225 
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(13), 224 (25), 223 (50), 222 (20), 216 (13), 211 (12), 209 (12), 202 (45), 198 (17), 
197 (18), 196 (20), 195 (13), 173 (32), 171 (31), 159 (40), 158 (13), 157 (21), 155 
(18), 145 (11), 144 (12), 117 (16), 90 (10), 77 (10), 68 (14), 57 (16), 56 (32), 55 (25), 
43 (19), 42 (15), 41 (80), 39 (21), 29 (53); 
 HRMS (EI) calcd. for C18H24
79BrN3O2 ([M]
+) 393.10464, found 393.10385; 
HRMS (EI) calcd. for C18H24
81BrN3O2 ([M]
+) 395.10259, found 395.10284. 
 
6-(2-bromo-4-methylphenylamino)-1,3-dibutylpyrimidine-2,4(1H,3H)-dione (13q): 
Starting with 1,3-dibutyl-6-chloropyrimidine-
2,4(1H,3H)-dione (200 mg, 0.77 mmol) and 2-bromo-4-
methylaniline (310 mg, 1.69 mmol) and n-butyl lithium 
(solution 2.5 M in hexanes) (0.68 mL, 1.69 mmol) in 
dry THF (5 mL), the product 13q was isolated as a 
white solid (221 mg, 70 %), mp = 157-158 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.91 (t, 
3J = 7.3 Hz, 3H, CH3), 0.99 (t, 
3J = 7.3 Hz, 3H, CH3), 1.33 (h, 
3J = 7.3 Hz, 2H, CH2), 1.45 (h, 
3J = 7.3 Hz, 2H, CH2), 
1.57 (p, 3J = 7.3 Hz, 2H, CH2), 1.79 (p, 
3J = 7.7 Hz, 2H, CH2), 2.34 (s, 3H, CH3), 3.86 
(t, 3J = 7.3 Hz, 2H, CH2), 4.02 (t, 
3J = 7.3 Hz, 2H, CH2), 4.91 (s, 1H, NH), 6.15 (s, 1H, 
CHAr), 7.12 (dd, 
3J = 8.2 Hz, 4J = 1.0 Hz, 1H, CHAr), 7.21 (d, 
3J = 8.1 Hz, 1H, CHAr), 
7.44 (d, 4J = 0.9 Hz, 1H, CHAr); 
 13C NMR (63 MHz, CDCl3): δ = 13.9 (CH3), 13.9 (CH3), 20.2 (CH2), 20.3 (CH2), 
20.8 (CH3), 41.3 (CH2), 42.8 (CH2), 79.9 (CH), 119.3 (C), 126.5 (CH), 129.5 (CH), 
133.0 (C), 133.8 (CH), 138.3 (C), 151.7 (2*C), 162.9 (C); 
IR (ATR, cm-1): v~  = 3226 (w), 3042 (w), 2956 (w), 2929 (w), 2870 (w), 1690 
(s), 1616 (s), 1603 (s), 1590 (s), 1525 (s), 1489 (m), 1479 (m), 1437 (s), 1413 (m), 
1391 (m), 1361 (m), 1335 (m), 1318 (m), 1289 (m), 1277 (m), 1251 (m), 1228 (w), 
1192 (w), 1170 (w), 1129 (w), 1114 (w), 1080 (w), 1044 (m), 1011 (w), 950 (w), 931 
(w), 911 (w), 878 (w), 836 (w), 804 (w), 778 (s), 763 (m), 745 (m), 710 (w), 692 (w), 
674 (w), 634 (m), 554 (s), 526 (s); 
MS (GC, 70 eV) m/z (%): 409 ([M]+, 81Br, 24), 407 ([M]+, 79Br, 25), 392 (35), 
390 (33), 354 (18), 353 (10), 352 (24), 329 (18), 328 ([M-Br]+, 99), 286 (37), 273 (11), 
272 (75), 239 911), 238 (24), 236 (20), 230 (14), 225 (14), 224 (10), 223 (25), 216 
(57), 212 (15), 211 (25), 210 (26), 209 (17), 187 (49), 186 (15), 185 (43), 173 (37), 
172 (15), 171 (16), 169 (19), 158 (14), 145 (54), 144 (11), 131 (21), 130 (17), 103 
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(10), 91 (13), 90 (19), 89 (18), 77 (19), 68 (17), 57 (18), 56 (40), 55 (27), 43 (19), 42 
(22), 41 (100), 29 (57); 
HRMS (EI) calcd. for C19H26
79BrN3O2 ([M]
+) 407.12029, found 407.11962; 
HRMS (EI) calcd. for C19H26
81BrN3O2 ([M]
+) 409.11824, found 409.11832. 
 
6-(2-bromo-4-chlorophenylamino)-1,3-dibutylpyrimidine-2,4(1H,3H)-dione (13r): 
Starting with 1,3-dibutyl-6-chloropyrimidine-2,4(1H,3H)-
dione (200 mg, 0.77 mmol) and 2-bromo-4-chloroaniline 
(350 mg, 1.69 mmol) and n-butyl lithium (solution 2.5 M 
in hexanes) (0.68 mL, 1.69 mmol) in dry THF (5 mL), the 
product 13r was isolated as a white solid (298 mg, 
89.8 %), mp = 117-118 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.91 (t, 
3J = 7.3 Hz, 3H, CH3), 0.98 (t, 
3J = 7.3 Hz, 3H, CH3), 1.33 (p, 
3J = 7.3 Hz, 2H, CH3), 1.44 (p, 
3J = 7.3 Hz, 2H, CH3), 
1.57 (p, 3J = 7.4 Hz, 2H, CH2), 1.77 (p, 
3J = 7.7 Hz, 2H, CH2), 3.86 (t, 
3J = 7.8 Hz, 2H, 
CH2), 4.02 (t, 
3J = 7.8 Hz, 2H, CH2), 4.87 (s, 1H, NH), 6.38 (s, 1H, CHAr), 7.25 (d, 
3J = 8.6 Hz, 1H, CHAr)7.31 (dd, 
3J = 8.7 Hz, 4J = 2.2 Hz, 1H, CHAr), 7.63 (d, 
4J = 2.2 Hz, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 13.89 (CH3), 13.92 (CH3), 20.2 (CH2), 20.3 
(CH2), 30.0 (CH2), 30.9 (CH2), 41.3 (CH2), 43.0 (CH2), 80.7 (CH), 119.6 (C), 126.8 
(CH), 129.0 (CH), 132.4 (C), 133.2 (CH), 134.7 (C), 151.1, 151.5, 162.8 (C); 
IR (ATR, cm-1): v~  = 3211 (w), 2957 (w), 2929 (w), 2870 (w), 1694 (m), 1616 
(s), 1594 (s), 1523 (s), 1473 (m), 1464 (m), 1437 (s), 1414 (m), 1393 (m), 1362 (m), 
1335 (w), 1319 (w), 1303 (w), 1286 (m), 1259 (m), 1192 (w), 1169 (w), 1096 (m), 
1042 (m), 1016 (m), 930 (w), 911 (w), 872 (w), 778 (m), 763 (m), 741 (w), 728 (w), 
707 (w), 688 (w), 658 (w), 627 (w), 555 (m), 531 (m); 
MS (GC, 70 eV) m/z (%): 429 ([M]+, 81Br, 20), 427 ([M]+, 79Br, 15), 414(11), 
412 (28), 410 (24), 400 (10), 374 (43), 373 (11), 372 (35), 350 (30), 349 (17), 348 ([M-
Br]+, 88), 306 (21), 301 (11), 294 (15), 292 (48), 275 (11), 273 (11), 259 (17), 258 
(22), 257 (13), 256 (15), 245 (15), 243 (11), 236 (39), 233 (12), 232 (27), 231 (29), 
229 (19), 223 (65), 221 (11), 207 (35), 205 (26), 194 (11), 193 (31), 192 (11), 191 
(15), 189 (10), 179 (13), 178 (11), 169 (13), 167 (20), 158 (13), 151 (12), 150 (10), 
124 (17), 111 (15), 75 (11), 68 (16), 57 (21), 56 (42), 55 (31), 54 (11), 43 (24), 42 
(18), 41 (100), 29 (69);  
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HRMS (EI) calcd. for C18H23
79BrClN3O2 ([M]
+) 427.06567, found 427.06520; 
HRMS (EI) calcd. for C18H23
81BrClN3O2 ([M]
+) 429.06362, found 429.06429. 
 
General procedure for the synthesis of 1,3-dialkyl-1H-pyrimido[4,5-b]indole-
2,4(3H,9H)-diones 14a-r: 
To a 50 mL Schlenk flask, filled with 100 mg of corresponding 6-(2-
bromoarylamino)-1,3-dialkylpyrimidine-2,4(1H,3H)-dione 13 in extra dry DMA 
(3 mL), Pd(OAc)2 (10 mol. %), PCy3·HBF4 (10 mol. %), DBU (2 equiv.) was added. 
The flask was fitted with a septum, and then held under vacuum for 3 min, after that it 
was filled with argon. Holding under vacuum was repeated one more time, and after 
sequent filling with argon, the reaction mixture has been stirred for 3 hours at 145°C. 
After completing of the reaction (TLC control), the mixture was filtered through Celite 
pad and filtrate was evaporated to dryness and then purified by column 
chromatography (EtOAc:Heptane = 1:1) to give corresponding 1,3-dialkyl-1H-
pyrimido[4,5-b]indole-2,4(3H,9H)-diones 14. 
 
1,3-dimethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14a): 
Starting with 6-(2-bromophenylamino)-1,3-dimethylpyrimidine-
2,4(1H,3H)-dione 13a (100 mg, 0.32 mmol), Pd(OAc)2 (7.2 mg, 
10 mol %), PCy3·HBF4 (11.9 mg, 10 mol %), DBU (2 equiv.), the 
product 14a was isolated as a white solid (58 mg, 78 %), 
mp = 346-347 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 3.26 (s, 3H, CH3), 3.51 (s, 3H, CH3), 7.09 – 7.23 (m, 
2H, CHAr), 7.37 – 7.52 (m, 1H, CHAr), 7.72 – 7.91 (m, 1H, CHAr), 12.18 (s, 1H, NH); 
13C NMR (62.9 MHz, CDCl3):
 δ = 27.35 (CH3), 30.7 (CH3), 90.8 (C), 111.5 
(CH), 118.6 (CH), 121.7 (CH), 122.2 (CH), 123.5 (C), 134.5 (C), 145.2 (C), 151.0 (C), 
158.2 (C); 
IR (ATR, cm-1): v~  = 3170 (w), 3101 (w), 2959 (w), 2925 (w), 2852 (w), 1685 
(s), 1624 (s), 1605 (s), 1537 (s), 1495 (s), 1457 (s), 1441 (s), 1384 (m), 1328 (s), 1279 
(m), 1259 (s), 1232 (s), 1214 (m), 1098 (s), 1057 (s), 1019 (s), 995 (s), 966 (s), 934 
(w), 325 (w), 891 (w), 852 (w), 798 (s), 773 (s), 749 (s), 736 (s), 712 (s), 697 (s), 645 
(s), 605 (s), 572 (m), 546 (m); 
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MS (GC, 70 eV) m/z (%): 230 ([M+H]+, 13), 229 ([M]+, 100), 194 (14), 172 (75), 
171 (15), 162 (11), 157 (20), 144 (33), 73 (33), 57 (12), 55 (12), 44 (25), 43 (10), 42 
(10), 41 (11); 
HRMS (EI): calcd. for C12H11N3O2 (M
+) 229.08458, found 229.08486. 
 
1,3,6-trimethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14b): 
 Starting with 6-(2-bromo-4-methylphenylamino)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione 13b (100 mg, 
0.31 mmol), Pd(OAc)2 (6.9 mg, 10 mol %), PCy3·HBF4 
(11.4 mg, 10 mol %), DBU (2 equiv.), the product 14b was 
isolated as a white solid (67 mg, 89 %), mp = 347-348 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 2.39 (s, 3H, CH3), 3.25 (s, 3H, CH3), 3.4 
(br.s, 1H, NH), 3.5 (s, 3H, CH3, Ar-CH3), 7.0 (dd, 
3J = 8.2 Hz, 4J = 1.7 Hz, 1H, CHAr), 
7.29 (d, 3J = 8.1 Hz, 1H, CHAr), 7.63 (d, 
4J = 1.7 Hz, 1H, CHAr). 
13C NMR (63 MHz, DMSO-d6): δ = 21.2 (CH3), 27.3 (CH3), 30.6 (CH3), 90.6 
(C), 111.1 (CH), 118.6 (CH), 123.3 (CH), 123.8 (C), 130.4 (C), 132.8 (C), 145.2 (C), 
151.0 (C), 158.2 (C); 
IR (ATR, cm-1): v~  = 3408 (w), 3200 (w), 3043 (w), 2920 (w), 2855 (w), 1686 
(s), 1606 (s), 1552 (m), 1536 (s), 1478 (m), 1466 (s), 1434 (m), 1417 (m), 1372 (m), 
1328 (m), 1305 (m), 1282 (m), 1261 (m), 1235 (s), 1215 (m), 1201 (m), 1105 (m), 1058 
(m), 1010 (m), 990 (m), 973 (s), 950 (m), 879 (w), 839 (w), 815 (s), 775 (m), 762 (m), 
746 (s), 736 (m), 711 (s), 696 (s), 632 (m), 594 (m), 557 (s); 
MS (GC, 70 eV) m/z (%): 244 ([M+H]+, 16), 243 ([M]+, 100), 187 (10), 186 (75), 
171 (33), 158 (31), 157 (10), 116 (10); 
HRMS (EI): calcd. for C13H13N3O2 (M
+) 243.10023, found 243.09998. 
 
6-isopropyl-1,3-dimethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14c): 
 Starting with 6-(2-bromo-4-isopropylphenylamino)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione 13c (100 mg, 0.28 
mmol), Pd(OAc)2 (6.4 mg, 10 mol %), PCy3·HBF4 (10.5 mg, 
10 mol %), DBU (2 equiv.), the product 14c was isolated as a 
white solid (68 mg, 88 %), mp = 264-265 ºC; 
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1H NMR (300 MHz, CDCl3) δ = 1.14 (d, 
3J = 6.9 Hz, 6H), 2.85 (q, 3J = 6.9 Hz, 
1H, CH), 3.30 (s, 3H), 3.46 (s, 3H), 6.94 (dd, 3J = 8.3 Hz, 4J = 1.8 Hz, 1H, CHAr), 7.13 
(d, 3J = 8.3 Hz, 1H, CHAr), 7.75 (d, 
4J = 1.7 Hz, 1H, CHAr), 11.28 (s, 1H, NH); 
13C NMR (75 MHz, CDCl3): δ = 24.3 (CH3), 27.5 (CH3), 30.5, 34.0, 91.8 (C), 
110.7 (CH), 116.9 (CH), 121.2 (CH), 123.9 (C), 132.9 (C), 142.8 (C), 145.0 (C), 151.4 
(C), 159.0 (C); 
IR (ATR, cm-1): v~  = 3266 (w), 3211 (w), 2956 (w), 2929 (w), 2894 (w), 2864 
(w), 1702 (m), 1614 (s), 1536 (s), 1462 (s), 1436 (s), 1413 (m), 1384 (m), 1378 (m), 
1349 (m), 1337 (m), 1320 (m), 1279 (m), 1268 (m), 1255 (m), 1228 (m), 1207 (m), 
1154 (m), 1123 (w), 1101 (m), 1060 (m), 1045 (m), 1007 (m), 975 (s), 929 (w), 921 
(w), 876 (m), 830 (w), 802 (s), 771 (s), 746 (s), 737 (s), 706 (s), 689 (m), 640 (s), 604 
(m), 587 (m), 557 (m), 3536 (w); 
MS (GC, 70 eV) m/z (%): 272 ([M+H]+, 21), 271 ([M]+, 100), 214 (29), 199 (80), 
184 (11), 143 (12), 115 (10); 
HRMS (EI): calcd. for C15H17N3O2 (M
+) 271.13153, found 271.13146. 
 
6-chloro-1,3-dimethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14d): 
Starting with 6-(2-bromo-4-chlorophenylamino)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione 13d (100 mg, 0.29 mmol), 
Pd(OAc)2 (6.5 mg, 10 mol %), PCy3·HBF4 (10.7 mg, 10 mol %), 
DBU (2 equiv.), the product 14d was isolated as a white solid 
(69 mg, 90 %), mp = 374-375 ºC; 
1H NMR (250 MHz, DMSO-d6): δ = 3.28 (s, 3H, CH3), 3.52 (s, 3H, CH3), 7.18 
(dd, 3J = 8.5 Hz, 4J = 2.3 Hz, 1H, CHAr), 7.41 (d, 
3J = 8.5 Hz, 1H, CHAr), 7.77 (d, 
4J = 2.3 Hz, 1H, CHAr); 
13C NMR (63 MHz, DMSO-d6): δ = 26.9 (CH3), 30.3 (CH3), 90.4 (C), 112.6 
(CH), 117.4 (CH), 121.5 (CH), 124.8 (C), 125.9 (C), 132.9 (C), 145.8 (C), 150.6 (C), 
157.7 (C); 
IR (ATR, cm-1): v~  = 3263 (m), 3071 (w), 2939 (w), 1761 (w), 1695 (s), 1685 
(w), 1648 (s), 1622 (s), 1603 (s), 1578 (m), 1538 (s), 1495 (m), 1477 (m), 1453 (s), 
1411 (m), 1391 (m), 1369 (m), 1335 (m), 1298 (m), 1277 (m), 1253 (m), 1231 (m), 
1207 (m), 1151 (m), 1120 (m), 1060 (m), 1004 (m), 970 (s), 906 (m), 882 (s), 835 (m), 
802 (s), 766 (s), 747 (s), 713 (s), 699 (m), 682 (s), 642 (w), 603 (s), 535 (s); 
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MS (GC, 70 eV) m/z (%): 265 ([M]+, 37Cl, 16), 263 ([M]+, 100), 208 (25), 207 
(18), 206 (73), 205 (20), 191 (25), 180 (14), 178 (41), 177 (10); 
HRMS (EI): calcd. for C12H10ClN3O2 (M
+) 263.04561, found 263.04545; 
HRMS (EI): calcd. for C12H10ClN3O2 (M
+,37Cl) 265.04266, found 265.04273. 
 
6-fluoro-1,3-dimethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14e): 
 Starting with 6-(2-bromo-4-fluorophenylamino)-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione 13e (100 mg, 0.3 mmol), 
Pd(OAc)2 (6.8 mg, 10 mol %), PCy3·HBF4 (11.2 mg, 10 mol %), 
DBU (2 equiv.), the product 14e was isolated as a white solid 
(68 mg, 90 %), mp ˃ 360 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 3.23 (s, 3H, CH3), 3.47 (s, 3H, CH3), 6.99 
(td, 3J = 9.3 Hz, 4J = 2.6 Hz, 1H, CHAr), 7.37 (dd, 
3J = 8.7 Hz, 4J = 4.4 Hz, 1H, CHAr), 
7.44 (dd, 3J = 9.3, 4J = 2.6 Hz, 1H, CHAr), 12.21 (s, 1H, NH); 
13C NMR (126 MHz, CDCl3): δ = 27.3 (CH3), 30.7 (CH3), 91.1 (d, 
4JC-
F = 4.1 Hz), 104.0 (d, 
2JC-F = 25.1 Hz, CH), 109.5 (d, 
2JC-F = 25.5 Hz, CH), 112.6 (d, 
3JC-F = 9.7 Hz, CH), 124.3 (d, 
3JC-F = 11.2 Hz), 130.9 (C), 146.2 (C), 150.9 (C), 158.1 
(C), 158.3 (d, 1JC-F = 234.6 Hz); 
19F NMR (282 MHz, DMSO-d6): δ = -121.3 (CF); 
IR (ATR, cm-1): v~  = 3248 (m), 3089 (w), 3065 (w), 2922 (w), 1685 (s), 1644 
(s), 1627 (s), 1604 (s), 1548 (s), 1537 (s), 1469 (s), 1455 (s), 1442 (s), 1415 (m), 1394 
(m), 1371 (m), 1335 (m), 1308 (s), 1276 (m), 1253 (m), 1232 (m), 1209 (m), 1178 (s), 
1164 (m), 1122 (m), 1096 (m), 1059 (m), 1003 (m), 971 (s), 936 (w), 855 (s), 836 (w), 
807 (m), 788 (m), 766 (s), 746 (s), 707 (s), 686 (m), 624 (m), 560 (s); 
MS (GC, 70 eV) m/z (%): 248 ([M+H]+, 14), 247 ([M]+, 100), 190 (78), 189 (28), 
175 (28), 162 (62), 161 (18), 135 (15), 134 (14), 120 (13), 107 (14); 
HRMS (EI): calcd. for C14H14FN3O2 (M
+) 247.07516, found 247.07560. 
 
1,3-diethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14f): 
 Starting with 6-(2-bromophenylamino)-1,3-diethylpyrimidine-
2,4(1H,3H)-dione 13f (100 mg, 0.295 mmol), Pd(OAc)2 (6.6 mg, 10 
mol %), PCy3·HBF4 (0.0109 mg, 10 mol %), DBU (2 equiv.), the 
product 14f was isolated as a white solid (0.07g, 92 %),  
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mp = 305-306 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 1.14 (t, 
3J = 7.0 Hz, 3H, CH3), 1.2 (t, 
3J = 7.0 Hz, 3H, CH3), 4.0 (q, 
3J = 6.9 Hz, 2H, CH2), 4.1 (q, 
3J = 6.9 Hz, 2H, CH2), 
7.1–7.3 (m, 2H, CHAr), 7.4 (dd, 
3J = 6.2 Hz, 4J = 2.8 Hz, 1H, CHAr), 7.8 (dd, 
3J = 6.2 Hz, 4J = 2.8 Hz, 1H, CHAr); 
13C NMR (63 MHz, DMSO-d6): δ = 13.2 (CH3), 13.3 (CH3), 35.3 (CH2), 39.0 
(CH2), 91.1 (C), 111.6 (CH), 118.6 (CH), 121.6 (CH), 122.2 (CH), 123.7 (C), 134.8 
(C), 144.5 (C), 150.2 (C), 157.9 (C); 
IR (ATR, cm-1): v~  = 3455 (w), 3370 (w), 3160 (w), 3099 (w), 2979 (w), 2936 
(w), 2874 (w), 1683 (s), 1623 (s), 1605 (s), 1534 (s), 1497 (s), 1444 (s), 1386 (s), 1346 
(m), 1319 (s), 1298 (m), 1285 (m), 1269 (s), 1241 (s), 1204 (m), 1186 (m), 1153 (m), 
1141 (w), 1094 (m), 1075 (m), 1033 (m), 1015 (s), 967 (w), 922 (w), 899 (w), 875 (m), 
829 (m), 790 (w), 774 (s), 751 (m), 730 (s), 703 (s), 653 (m), 643 (m), 605 M), 557 
(w), 533 (m);  
MS (GC, 70 eV) m/z (%): 258 ([M+H]+, 31), 257 ([M]+, 92), 187 (12), 186 (44), 
185 (27), 171 (100), 169 (11), 159 (15), 158 (56), 145 (25), 144 (41), 143 (17), 130 
(28), 129 (16), 117 (11), 116 (13), 103 (25), 88 (11), 87 (14), 77 (11), 29 (15); 
HRMS (EI): calcd. for C14H15N3O2 (M
+) 257.11588, found 257.11636. 
 
1,3-diethyl-6-methyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14g): 
 Starting with 6-(2-bromo-4-methylphenylamino)-1,3-
diethylpyrimidine-2,4(1H,3H)-dione 13g (100 mg, 0.295 mmol), 
Pd(OAc)2 (6.4 mg, 10 mol %), PCy3·HBF4 (10.5 mg, 10 mol %), 
DBU (2 equiv.), the product 14g was isolated as a white solid 
(71 mg, 92 %), mp = 257-258 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 1.14 (t, 
3J = 6.9 Hz, 3H, CH3), 1.27 (t, 
3J = 7.0 Hz, 3H, CH3), 2.40 (s, 3H, CH3), 3.95 (q, 
3J = 6.9 Hz, 2H, CH2), 4.1 (q, 
3J = 7.0 Hz, 2H, CH2) 7.01 (dd, 
3J = 8.1 Hz, 4J = 1.7 Hz, 1H, CHAr), 7.31 (d, 
3J = 8.1 Hz, 1H, CHAr), 7.65 (s, 1H, CHAr), 12.06 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 13.2 (CH3), 13.3 (CH3), 21.2 (CH3), 35.3 
(CH2), 39.0 (CH2), 90.9 (C), 111.2 (CH), 118.7 (CH), 123.4 (CH), 123.8 (C), 130.5 
(C), 132.7 (C), 144.3 (C), 150.1 (C), 157.9 (C); 
N
N
N
H
O
O
CH3
 
 
156 
 
IR (ATR, cm-1): v~  = 3487 (w), 3388 (w), 3119 (w), 2974 (w), 2937 (w), 2873 
(w), 2806 (w), 1680 (s), 1623 (s), 1601 (s), 1534 (s), 1477 (m), 1453 (s), 1447 (s), 
1433 (s), 1393 (s), 1374 (m), 1352 (m), 1334 (m), 1304 (s), 1275 (s), 1249 (m), 1231 
(m), 1209 (m), 1189 (m), 1133 (w), 1093 (w), 1075 (m), 1036 (w), 1015 (m), 970 (w), 
929 (w), 876 (m), 847 (m), 804 (s), 787 (m), 777 (s), 750 (s), 701 (s), 677 (m), 654 
(m), 615 (m), 591 (m), 562 (m), 539 (s);  
MS (GC, 70 eV) m/z (%): 272 ([M+H]+, 18), 271 ([M]+, 100), 200 (41), 199 (21), 
185 (59), 172 (49), 171 (25), 159 (11), 158 (19), 143 (10), 117 (12), 116 (12), 89 (12), 
29 (17); 
HRMS (EI): calcd. for C15H17N3O2 (M
+) 271.13153, found 271.13153. 
 
1,3-diethyl-6-isopropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14h): 
 Starting with 6-(2-bromo-4-isopropylphenylamino)-1,3-
diethylpyrimidine-2,4(1H,3H)-dione 13h (100 mg, 
0.26 mmol), Pd(OAc)2 (5.9 mg, 10 mol %), PCy3·HBF4  
(9.7 mg, 10 mol %), DBU (2 equiv.), the product 14h was 
isolated as a white solid (78 mg, 99 %), mp = 124-126 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 1.14 (t, 
3J = 7.0 Hz, 3H, CH3), 1.25 (d,
 
3J = 6.9 Hz, 6H, CH3), 1.27 (t, 
3J = 6.9 Hz, 3H, CH3), 2.98 (p, 
3J = 6.9 Hz, 1H, CH), 
3.96 (q, 3J = 7.0 Hz, 2H, CH2), 4.09 (q, 
3J = 7.0 Hz, 2H, CH2), 7.08 (dd, 
3J = 8.3 Hz, 
4J = 1.8 Hz, 1H, CHAr), 7.34 (d, 
3J = 8.3 Hz, 1H, CHAr), 7.71 (d, 
4J = 1.8 Hz, 1H, 
CHAr), 12.08 (s, 1H, NH); 
13C NMR (75 MHz, DMSO-d6): δ = 13.2 (CH3), 13.3 (CH3), 24.5, 33.6, 35.3, 
38.75, 91.1 (C), 111.3 (CH), 115.9 (CH), 121.2 (CH), 123.8 (C), 133.0 (C), 142.0 (C), 
144.4 (C), 150.1 (C), 158.0 (C); 
IR (ATR, cm-1): v~  = 3154 (w), 3071 (w), 2957 (w), 2933 (w), 2868 (w), 1690 
(s), 1622 (s), 1599 (s), 1535 (s), 1470 (s), 1446 (s), 1392 (m), 1380 (m), 1344 (m), 
1327 (m), 1296 (m), 1276 (s), 1266 (s), 1244 (m), 1206 (m), 1183 (w), 1151 (w), 1110 
(w), 1084 (w), 1072 (m), 1030 9w), 1012 (m), 970 (w), 928 (w), 874 (w), 839 (w), 808 
(m), 775 (s), 754 (s), 729 (w), 700 (s), 671 (w), 640 (m), 584 (w), 555 (w), 531 (m);  
MS (GC, 70 eV) m/z (%): 300 ([M+H]+, 20), 299 ([M]+, 100), 284 (37), 228 (24), 
185 (28), 184 (11); 
HRMS (EI): calcd. for C17H21N3O2 (M
+) 299.16283, found 299.16332. 
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6-chloro-1,3-diethyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14i): 
 Starting with 6-(2-bromo-4-chlorophenylamino)-1,3-
diethylpyrimidine-2,4(1H,3H)-dione 13i (100 mg, 0.268 mmol), 
Pd(OAc)2 (6 mg, 10 mol %), PCy3·HBF4 (9.9 mg, 10 mol %), 
DBU (2 equiv.), the product 14i was isolated as a white solid 
(70 mg, 89 %), mp = 326-328 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 1.14 (t, 
3J = 6.9 Hz, 3H, CH3), 1.27 (t, 
3J = 7.0 Hz, 3H, CH3), 3.95 (q, 
3J = 7.0 Hz, 2H, CH2), 4.06 (q, 
3J = 7.0 Hz, 2H, CH2), 
7.20 (dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, CHAr), 7.43 (d, 
3J = 8.5 Hz, 1H, CHAr), 7.76 (d, 
4J = 2.2 Hz, 1H, CHAr), 12.39 (s, 1H, NH). 
13C NMR (63 MHz, DMSO-d6): δ = 13.1 (CH3), 13.2 (CH3), 35.4 (CH2), 39.2 
(CH2), 90.8 (C), 113.1 (CH), 117.7 (CH), 122.1 (CH), 124.9 (C), 126.2 (C), 133.2 (C), 
145.3 (C), 150.0 (C), 157.8 (C); 
IR (ATR, cm-1): v~  = 3480 (w), 3382 (w), 3232 (w), 3117 (w), 3060 (w), 2973 
(w), 2936 (w), 2872 (w), 2854 (w), 2806 (w), 1693 (s), 1674 (m), 1599 (s), 1530 (s), 
1503 (m), 1481 (m), 1447 (m), 1393 (s), 1352 (m), 1334 (m), 1292 (s), 1265 (m), 1247 
(s), 1230 (m), 1190 (m), 1144 (w), 1132 (w), 1116 (m), 1091 (m), 1064 (m), 1033 (w), 
1014 (m), 968 (m), 873 (m), 841 9m), 805 (s), 777 (s), 749 (s), 706 (s), 695 (s), 680 
(m), 664 (m), 589 (m), 555 (m), 535 (s); 
MS (GC, 70 eV) m/z (%): 293 ([M]+, 31), 291 ([M]+, 100), 263 (10), 222 (14), 
221 (14), 220 (40), 219 (21), 207 (17), 205 (53), 194 (16), 193 (10), 191 (13), 179 
(16), 178 (19), 164 (17), 137 (17), 129 (10), 100 (11), 29 (21); 
HRMS (EI): calcd. for C14H14ClN3O2 (M
+) 291.07691, found 291.07714; 
HRMS (EI): calcd. for C14H14ClN3O2 (M
+, 37Cl) 293.07396, found 293.07459. 
 
1,3-diethyl-6-fluoro-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14j): 
 Starting with 6-(2-bromo-4-fluorophenylamino)-1,3-
diethylpyrimidine-2,4(1H,3H)-dione 13j (100 mg, 0.28 mmol), 
Pd(OAc)2 (6.3 mg, 10 mol %), PCy3·HBF4 (10.3 mg, 10 mol %), 
DBU (2 equiv.), the product 14j was isolated as a white solid (73 
mg, 95 %), mp = 311-312 ºC; 
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1H NMR (300 MHz, DMSO-d6): δ = 1.17 (t, 
3J = 7.0 Hz, 3H, CH3), 1.28 (t, 
3J = 7.0 Hz, 3H, 
CH3), 4.03 (m, 4H, CH2), 6.8 (td, 
3J = 9.2 Hz, 4J = 2.6 Hz, 1H, CHAr), 7.20 (dd, 
3J = 8.5 Hz, 
3J = 4.2 Hz, 1H, CHAr), 7.54 (dd, 
3J = 9.2 Hz, 4J = 2.6 Hz, 1H, CHAr), 11.64 (s, 1H, NH); 
13C NMR (75 MHz, DMSO-d6): δ = 12.8 (CH3), 12.8 (CH3), 35.4 (CH2), 38.8 (CH2), 91.8 
(C), 104.7 (d, 2JC-F = 25.3 Hz, CH), 109.2 (d, 
2JC-F = 25.5 Hz, CH), 111.4 (d, 
3JC-F = 9.7 Hz, CH), 
124.3 (d, 3JC-F = 11.5 Hz), 130.6, 144.7 (C), 150.0 (C), 158.1 (C), 158.3 (d, 
1JC-F = 236.2 Hz, C); 
19F NMR (282 MHz, DMSO-d6): δ = -121.42 (CF); 
IR (ATR, cm-1): v~  = 3402 (w), 3176 (w), 2980 (w), 2964 (w), 2940 (w), 2893 (w), 2853 
(w), 2798 (w), 2709 (w), 1687 (s), 1625 (s), 1604 (s), 1535 (s), 1469 (s), 1451 (s), 1400 (m), 1389 
(m), 1376 (m), 1348 (m), 1333 (m), 1297 (s), 1259 (s), 1225 (m), 1205 (m), 1180 (m), 1119 (m), 
1095 (m), 1080 (m), 1072 (m), 1027 (m), 1011 (m), 972 (m), 937 (m), 901 (w), 878 (w), 856 (m), 
849 (m), 805 (m), 782 (s), 771 (s), 750 (m), 738 (m), 705 (s), 646 (m), 599 (m), 559 (m), 531 (s); 
MS (GC, 70 eV) m/z (%): 276 ([M+H]+, 16), 275 ([M]+, 100), 247 (11), 204 (34), 
203 (29), 189 (61), 176 (58), 175 (25), 163 (19), 162 (19), 148 (34), 147 (14), 134 
(12), 133 (12), 121 (25), 120 (21), 107 (11), 100 (11), 29 (32) ; 
HRMS (EI): calcd. for C14H14FN3O2 (M
+) 275,10646, found 275,10683. 
 
1,3-dipropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14k): 
 Starting with 6-(2-bromophenylamino)-1,3-dipropylpyrimidine-
2,4(1H,3H)-dione 13k (100 mg, 0.27 mmol), Pd(OAc)2 (6.1 mg, 
10 mol %), PCy3·HBF4 (10.1 mg, 10 mol %), DBU (2 equiv.), the 
product 14k was isolated as a white solid (58 mg, 78 %),  
mp = 133-134 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 0.93 (t, 
3J = 7.4 Hz, 3H, 
CH3), 0.99 (t, 
3J = 7.4 Hz, 3H, CH3), 1.64 (q, 
3J = 7.4 Hz, 2H), 1.75 (q, 3J = 7.4 Hz, 
2H), 3.93 (t, 3J = 7.4 Hz, 2H), 4.04 (t, 3J = 7.4 Hz, 2H), 7.19-7.34 (m, 2H, CHAr), 
7.34-7.56 (m, 1H, CHAr), 7.75-8.06 (m, 1H, CHAr), 12.17 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 10.7 (CH3), 11.2 (CH3), 20.8 (CH2), 20.9 
(CH2), 41.7 (CH2), 45.2 (CH2), 91.0 (C), 111.5 (CH), 118.7 (CH), 121.7 (CH), 122.3 
(CH), 123.5 (C), 134.5 (C), 144.6 (C), 150.6 (C), 158.1 (C); 
IR (ATR, cm-1): v~  = 3179 (w), 2963 (w), 2933 (w), 2871 (w), 1649 (s), 1622 
(s), 1601 (s), 1534 (s), 1498 (m), 1458 (m), 1444 (m), 1392 (m), 1383 (m), 1323 (m), 
1284 (m), 1266 (m), 1238 (m), 1185 (w), 1165 (w), 1155 (w), 1097 (w), 1074 (m), 
N
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1008 (m), 947 (w), 924 (w), 881 (w), 851 (w), 826 (w), 783 (m), 774 (m), 734 (s), 703 
(s), 692 (s), 647 (m), 606 (m), 570 (w), 544 (s), 526 (m);  
MS (GC, 70 eV) m/z (%): 386 ([M]+, 17), 385 ([M]+, 91), 243 (41), 201 (66), 
199 (14), 185 (39), 172 (27), 171 (100), 144 (14), 143 (20), 130 (16), 129 (13), 116 
(22), 115 (12), 103 (20), 102 (19), 89 (11), 43 (24), 42 (14), 41 (36), 39 (18), 29 (20); 
HRMS (EI): calcd. for C16H19N3O2 ([M]
+) 285.14718, found 285.14704. 
 
6-methyl-1,3-dipropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14l): 
Starting with 6-(2-bromo-4-methylphenylamino)-1,3-dipropylpyrimidine-2,4(1H,3H)-
dione 13l (100 mg, 0.26 mmol) and Pd(OAc)2 (6 mg, 10 mol %), PCy3·HBF4 (9.7 mg, 
10 mol %), DBU (2 equiv), the product 14l was isolated as a white solid (68 mg, 
87 %), mp = 218-219 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.95 (t, 
3J = 6.5 Hz, 3H, 
CH3), 1.00 (t, 
3J = 6.4 Hz, 3H, CH3), 1.74 (h, 
3J = 6.8 Hz, 2H), 
1.86 (h, 3J = 6.7 Hz, 2H), 2.35 (s, 3H, CH3), 4.08 (m, 4H), 7.00 
(d, 3J = 8.1 Hz, 1H, CHAr), 7.23 (d, 
3J = 8.2 Hz, 1H, CHAr), 
7.84 (s, 1H, CHAr), 9.56 (s, 1H, NH); 
13C NMR (75 MHz, CDCl3): δ = 11.1 (CH3), 11.4 (CH3), 
21.4, 21.4, 21.5, 43.0, 45.8, 92.5 (C), 110.7 (CH), 120.0 (CH), 124.1, 124.3 (CH), 
132.3 (C), 132.4 (C), 144.5 (C), 151.1 (C), 159.5 (C); 
IR (ATR, cm-1): v~  = 3217 (w), 3158 (w), 2958 (w), 2930 (w), 2869 (w), 1691 
(s), 1619 (s), 1604 (s), 1583 (s), 1550 (m), 1536 (s), 1474 (m), 1461 (m), 1428 (m), 
1393 (m), 1377 (m), 1361 (m), 1334 (m), 1305 (m), 1270 (m), 1238 (m), 1230 (m), 
1197 (m), 1183 (m), 1130 (w), 1108 (w), 1082 (m), 1038 (m), 979 (m), 943 (w), 932 
(w), 898 (w), 885 (w), 873 (m), 833 (m), 792 (s), 773 (s), 751 (m), 739 (m), 707 (s), 
654 (m), 574 (s), 526 (m); 
MS (GC, 70 eV) m/z (%): 300 ([M]+, 15), 299 ([M]+, 72), 257 (45), 215 (41), 
214 (14), 199 (25), 186 (24), 185 (100), 184 (12), 172 (32), 171 (22), 170 (11), 158 
(11), 144 (11), 142 (16), 117 (14), 116 (13), 89 (13), 43 (25), 42 (16), 41 (33), 39 (11), 
29 (16); 
HRMS (EI): calcd. for C17H21N3O2 ([M]
+) 299.16283, found 299.16231. 
 
6-isopropyl-1,3-dipropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14m): 
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Starting with 6-(2-bromo-4-isopropylphenylamino)-1,3-
dipropylpyrimidine-2,4(1H,3H)-dione 13m (100 mg, 
0.24 mmol), Pd(OAc)2 (5.5 mg, 10 mol %), PCy3·HBF4 
(9 mg, 10 mol %), DBU (2 equiv.), the product 14m was 
isolated as a white solid (75 mg, 93 %), mp = 89-90 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.97-1.01 (m, 6H, 
CH3), 1.12 (d, 
3J = 6.9 Hz, 6H, CH3), 1.69-1.93 (m, 4H), 2.86 (p, 
3J = 6.9 Hz, 1H), 
4.06-4.20 (m, 4H), 7.02 (dd, 3J = 8.4 Hz, 4J = 1.7 Hz, 1H, CHAr), 7.26 (d, 
3J = 8.4 Hz, 
1H, CHAr), 7.88 (d, 
4J = 1.6 Hz, 1H, CHAr), 10.31 (s, 1H, NH); 
13C NMR (75 MHz, CDCl3): δ = 11.0, 11.4, 21.5, 21.5, 24.3, 34.2, 43.0, 45.9, 
92.6 (C), 111.0 (CH), 117.1 (CH), 122.1 (CH), 124.0 (C), 132.8 (C), 143.7 (C), 144.8 
(C), 151.1 (C), 159.7 (C); 
IR (ATR, cm-1): v~  = 3155 (w), 3071 (w), 2958 (m), 2930 (w), 2871 (w), 1692 
(s), 1621 (s), 1598 (s), 1534 (s), 1470 (s), 1458 (s), 1430 (m), 1393 (m), 1381 (m), 
1361 (m), 1343 (m), 1327 (m), 1278 (m), 1260 (m), 1238 (m), 1197 (m), 1180 (m), 
1107 (m), 1078 (m), 1038 (m), 977 (w), 968 (w), 920 (w), 881 (m), 855 (w), 807 (m), 
776 (m), 752 (m), 702 (m), 640 (m), 572 (m), 533 (m); 
MS (GC, 70 eV) m/z (%): 328 ([M+H]+, 18), 327 ([M]+, 100), 326 (12), 312 (18), 
286 (12), 285 (53), 270 (34), 243 (27), 242 (15), 241 (10), 228 (18), 227 (22), 214 
(19), 213 (76), 211 (14), 199 (10), 197 (17), 185 (35), 184 (15), 171 (10), 158 (13), 
156 (12), 115 (18), 56 (10), 43 (39), 42 (29), 41 (46), 39 (10), 29 (11); 
HRMS (EI): calcd. for C19H25N3O2 ([M]
+) 327.19413, found 327.19367. 
 
6-chloro-1,3-dipropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14n): 
Starting with 6-(2-bromo-4-chlorophenylamino)-1,3-
dipropylpyrimidine-2,4(1H,3H)-dione 13n (100 mg, 0.25 mmol) 
and Pd(OAc)2 (5.6 mg, 10 mol %), PCy3·HBF4 (9.2 mg, 
10 mol %), DBU (2 equiv), the product 14n was isolated as a 
white solid (38 mg, 48 %), mp = 230-231 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 0.87 (t, 
3J = 7.5 Hz, 
3H, CH3), 0.93 (t, 
3J = 7.4 Hz, 3H, CH3), 1.58 (q, 
3J = 7.4 Hz, 2H), 1.70 (q, 
3J = 7.5 Hz, 2H), 3.86 (t, 3J = 7.5 Hz, 2H), 3.97 (t, 3J = 7.5 Hz, 2H), 7.20 (dd, 3J = 8.5 
Hz, 4J = 2.2 Hz, 1H, CHAr), 7.43 (d, 
3J = 8.5 Hz, 1H, CHAr), 7.76 (d, 
4J = 2.2 Hz, 1H, 
CHAr), 12.35 (s, 1H, NH); 
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13C NMR (63 MHz, DMSO-d6): δ = 10.7 (CH3), 11.1 (CH3), 20.7, 20.8, 41.7, 
45.3, 90.6 (C), 113.0 (CH), 117.7 (CH), 122.1 (CH), 124.8 (C), 126.1 (C), 133.1 (C), 
145.4 (C), 150.4 (C), 157.9 (C); 
IR (ATR, cm-1): v~  = 3501 (w), 2458 (w), 3121 (w), 3079 (w), 2956 (w), 2938 
(w), 2877 (w), 1680 (s), 1650 (s), 1620 (s), 1600 (s), 1553 (m), 1539 (s), 1463 (m), 
1449 (s), 1426 (w), 1389 (m), 1373 (w), 1365 (w), 1336 (m), 1291 (s), 1259 (m), 1244 
(m), 1199 (w), 1180 (w), 1143 (w), 1080 (s), 1042 (s), 976 (m), 929 (m), 893 (w), 873 
(m), 835 (w), 802 (s0, 771 (s), 748 (s), 732 (m), 709 (s), 678 (w), 652 (w), 576 (s), 559 
(s); 
MS (GC, 70 eV) m/z (%): 320 ([M+H]+, 18), 319 ([M]+, 100), 279 (13), 278 (13), 
277 (43), 237 (27), 235 (85), 233 (12), 221 (13), 219 (37), 218 (10), 207 (34), 206 
(30), 205 (90), 194 (18) 193 (10), 192 (47), 191 (17), 178 (14), 177 (11), 170 (12), 169 
(10), 164 (16), 142 (20), 137 (18), 129 (12), 102 (10), 56 (15), 43 (40), 42 (25), 41 
(60), 39 (21), 29 (22); 
HRMS (EI): calcd. for C19H25ClN3O2 ([M]
+) 319.10821, found 319.10770. 
 
6-fluoro-1,3-dipropyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14o): 
Starting with 6-(2-bromo-4-fluorophenylamino)-1,3-
dipropylpyrimidine-2,4(1H,3H)-dione 13o (100 mg, 0.26 mmol) 
and Pd(OAc)2 (5.8 mg, 10 mol %), PCy3·HBF4 (9.6 mg, 10 mol %), 
DBU (2 equiv.), the product 14o was isolated as a white solid 
(65 mg, 82 %), mp = 228-229 ºC; 
1H NMR (300 MHz, Acetone-d6): δ = 0.89 (t, 
3J = 7.5 Hz, 3H, 
CH3), 0.94 (t, 
3J = 7.5 Hz, 3H, CH3), 1.63 (h, 
3J = 7.5 Hz, 2H), 1.79 (h, 3J = 7.4 Hz, 
2H), 3.79 – 3.86 (m, 2H), 3.91 – 3.98 (m, 2H), 6.91 (ddd, 3J = 9.6 Hz, 3J = 8.8 Hz, 
4J = 2.6 Hz, 1H, CHAr), 7.33 (ddd, 
3J = 8.8 Hz, 3J = 4.3 Hz, 4J = 0.5 Hz, 1H, CHAr), 
7.56 (dd, 3J = 9.3 Hz, 4J = 2.6 Hz, 1H, CHAr), 11.11 (s, 1H, NH); 
13C NMR (63 MHz, Acetone-d6): δ = 11.3 (CH3), 11.7 (CH3), 22.1, 22.1, 43.0, 
46.4, 93.1 (d, 4JC-F = 4.0 Hz), 105.7 (d, 
2JC-F = 25.6 Hz, CH), 110.6 (d, 
2JC-F = 25.8 Hz, 
CH), 113.2 (d, 3JC-F = 9.7 Hz, CH), 126.2 (d, 
3JC-F = 11.2 Hz), 132.0 (C), 146.8 (C), 
151.9 (C), 159.3 (C), 160.1 (d, 1JC-F = 235.4 Hz); 
19F NMR (282 MHz, CDCl3): δ = -122.69 (CF); 
IR (ATR, cm-1): v~  = 3218 (w), 3194 (w), 2959 (w), 2932 (w), 2875 (w), 2851 
(w), 1693 (s), 1628 (s), 1601 (s), 1535 (s), 1468 (s), 1455 (s), 1429 (m), 1394 (m), 
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1363 (m), 1335 (w), 1302 (s), 1292 (s), 1257 (s), 1199 (w), 1179 (m), 1167 (m), 1097 
(m), 1077 (m), 1036 (s), 978 (m), 963 (m), 954 (m), 915 (w), 891 (w), 854 (m), 797 (s), 
771 (s), 750 (s), 698 (s), 668 (w), 636 (m), 568 (s), 526 (s); 
MS (GC, 70 eV) m/z (%): 304 ([M+H]+, 14), 303 ([M]+, 75), 261 (28), 219 (61), 
218 (10), 217 (11), 203 (28), 190 (24), 189 (100), 176 (37), 175 (15), 162 (12), 161 
(17), 148 (15), 147 (13), 134 (16), 133 (11), 121 (17), 120 (13), 107 (11), 43 (22), 42 
(16), 41 (32), 29 (14); 
HRMS (EI): calcd. for C16H18FN3O2 ([M]
+) 303.13776, found 303.13826. 
 
1,3-dibutyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14p): 
Starting with 6-(2-bromophenylamino)-1,3-dibutylpyrimidine-
2,4(1H,3H)-dione 13p (100 mg, 0.25 mmol) and Pd(OAc)2 
(5.7 mg, 10 mol %), PCy3·HBF4 (9.3 mg, 10 mol %), DBU (2 
equiv.), the product 14p was isolated as a white solid (66 mg, 
83 %), mp = 227-228 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 0.91 (t, 
3J = 7.3 Hz, 3H, CH3), 0.93 (t, 
3J = 7.3 Hz, 3H, CH3), 1.33 (m, 4H), 1.55 (p, 
3J = 7.2 Hz, 2H), 1.66 (p, 3J = 7.2 Hz, 
2H), 3.91 (t, 3J = 7.5 Hz, 2H), 4.03 (t, 3J = 7.5 Hz, 2H), 7.15 – 7.26 (m, 2H), 7.40 – 
7.48 (m, 1H, CHAr), 7.78 – 7.90 (m, 1H, CHAr), 12.14 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 13.6 (CH3), 13.7 (CH3), 19.3, 19.6, 29.6, 
29.7, 39.9, 43.6, 91.0 (C), 111.5 (CH), 118.6 (CH), 121.7 (CH), 122.2 (CH), 123.5 (C), 
134.5 (C), 144.5 (C), 150.4 (C), 158.0 (C); 
IR (ATR, cm-1): v~  = 3188 (w), 2957 (w), 2932 (w), 2865 (w), 1686 (s), 1626 
(s), 1601 (s), 1581 (w), 1535 (s), 1495 (m), 1459 (m), 1428 (w), 1408 (w), 1394 (w), 
1376 (w), 1323 (m), 1292 (w), 1269 (m), 1232 (m), 1190 (w), 1149 (w), 1115 (w), 
1084 (m), 1049 (w), 1018 (w), 1010 (w), 968 (w), 928 (m), 905 (w), 832 (w), 811 (w), 
775 (s), 751 (s), 738 (m), 703 (m), 645 (m), 605 (m), 5689 (m), 557 (m), 537 (m); 
MS (GC, 70 eV) m/z (%): 314 ([M+H]+, 17), 313 ([M]+, 79), 257 (29), 240 (28), 
215 (36), 201 (51), 185 (44), 172 (34), 171 (100), 158 (46), 157 (15), 130 (13), 116 
(16), 103 (14), 41 (12), 29 (10); 
HRMS (EI) calcd. for C18H23N3O2 ([M]
+) 313.17848, found 313.17862. 
 
1,3-dibutyl-6-methyl-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14q): 
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Starting with 6-(2-bromo-4-methylphenylamino)-1,3-
dibutylpyrimidine-2,4(1H,3H)-dione 13q (100 mg, 0.245 
mmol) and Pd(OAc)2 (5.5 mg, 10 mol %), PCy3·HBF4 
(9 mg, 10 mol %), DBU (2 equiv.), the product 14q was 
isolated as a white solid (69.7 mg, 87 %),  
mp = 175-176 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.91 (t, 
3J = 7.3 Hz, 3H, CH3), 0.92 (t, 
3J = 7.3 Hz, 3H, CH3), 1.28 – 1.51 (m, 4H), 1.61 – 1.72 (m, 2H), 1.74 – 1.91 (m, 2H), 
2.33 (s, 3H, CH3), 4.0 – 4.22 (m, 4H), 7.00 (dd, 
3J = 8.3 Hz, 4J = 1.6 Hz, 1H, CHAr), 
7.24 (d, 3J = 8.2 Hz, 1H, CHAr), 7.82 (s, 1H, CHAr), 9.85 (s, 1H, NH);  
13C NMR (63 MHz, CDCl3): δ = 13.7(CH3), 13.8(CH3), 20.0 (CH2), 20.3 (CH2), 
21.4(CH3), 30.3 (2*CH2), 41.3 (CH2), 44.3 (CH2), 92.5 (C), 110.8 (CH), 119.9 (CH), 
124.0, 124.3 (CH), 132.3 (C), 132.4 (C), 144.6 (C), 151.0 (C), 159.5 (C); 
IR (ATR, cm-1): v~  = 3220 (w), 3183 (w), 2953 (w), 2927 (w), 2869 (w), 1687 
(s), 1604 (s), 1537 (s), 1473 (m), 1463 (m), 1434 (m), 1393 (m), 1366 (m), 1335 (m), 
1301 (m), 1271 (m), 1234 (m), 1190 (w), 1175 (w), 1116 (w), 1084 (m), 1047 (w), 
1020 (w), 967 (w), 949 (w), 931 (w), 900 (w), 871 (w), 840 (w), 794 (s), 773 (s), 753 
(m), 735 (m), 701 (m), 641 (m), 566 (m); 
MS (GC, 70 eV) m/z (%): 328 ([M+H]+, 20), 327 ([M]+, 93), 311 (15), 310 (69), 
271 (34), 215 (42), 199 (42), 186 (35), 185 (100), 172 (46), 171 (24), 158 (11), 144 
(10), 142 (15), 117 (10); 
HRMS (EI) calcd. for C19H25N3O2 ([M]
+) 327.19413, found 327.19395. 
 
1,3-dibutyl-6-chloro-1H-pyrimido[4,5-b]indole-2,4(3H,9H)-dione (14r): 
Starting with 6-(2-bromo-4-chlorophenylamino)-1,3-
dibutylpyrimidine-2,4(1H,3H)-dione 13r (100 mg,  
0.23 mmol) and Pd(OAc)2 (5.2 mg, 10 mol %), PCy3·HBF4 
(8.6 mg, 10 mol. %), DBU (2 equiv), the product 14r was 
isolated as a white solid (35 mg, 43 %), mp = 225-226 ºC; 
1H NMR (300 MHz, CDCl3): δ = 0.82 – 0.99 (m, 6H), 1.27 – 1.49 (m, 4H), 1.56 
– 1.74 (m, 2H), 1.72 – 1.89 (m, 2H), 4.01 – 4.19 (m, 4H), 7.13 (dd, 3J = 8.5 Hz, 
4J = 1.9 Hz, 1H, CHAr), 7.24 (d, 
3J = 8.5 Hz, 1H, CHAr), 7.98 (d, 
4J = 1.9 Hz, 1H, 
CHAr), 9.88 (s, 1H, NH); 
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13C NMR (63 MHz, CDCl3): δ = 13.8 (CH3), 13.9 (CH3), 20.2 (CH2), 20.4 (CH2), 
30.4 (CH2), 30.4 (CH2), 41.5 (CH2), 44.6 (CH2), 92.6 (C), 112.3 (CH), 119.7 (CH), 
123.4 (CH), 125.2 (C), 128.6 (C), 132.8 (C), 145.3 (C), 151.0 (C), 159.4 (C);  
IR (ATR, cm-1): v~  = 3159 (w), 2956 (w), 2928 (w), 2870 (w), 2860 (w), 1695 
(s), 1626 (s), 1598 (s), 1550 (m), 1533 (s), 1478 (m), 1459 (m), 1446 (s), 1391 (ms), 
1369 (m), 1334 (m), 1287 (s), 1260 (s), 1232 (m), 1188 (w), 1173 (w), 1140 (w), 1113 
(w), 1084 (m), 1043 (m), 1020 (w), 954 (m), 944 (m), 931 (m), 908 (m), 865 (m), 842 
(m), 800 (m), 774 (s), 751 (m), 707 (m), 699 (m), 650 (m), 588 (m), 573 (m), 554 (m); 
MS (GC, 70 eV) m/z (%): 349 (28), 348 (17), 347 ([M]+, 85), 332 (30), 331 (18), 
330 (85), 305 (12), 293 (14), 292 (11), 291 (41), 276 (12), 274 (32), 251 (13), 249 
(40), 237 (21), 236 (11), 235 (63), 221 (17), 220 (10), 219 (47), 208 (13), 207 (36), 
206 (37), 205 (100), 194 (19), 193 (14), 192 (53), 191 (15), 178 (13), 164 (13), 142 
(22), 137 (11), 41 (24), 29 (19); 
HRMS (EI) calcd. for C18H22ClN3O2 [M]
+ 347.13951, found 347.13937. 
 
General procedures for the synthesis of 16a-r: 
 To a pressure tube equipped with stirrer bar, 100 mg of N-substituted 
aminopyrrole 15, corresponding amounts of bromoarene (1.1 equiv.), Pd(OAc)2  
 (5 mol. %), DPEphos (10 mol. %) and Cs2CO3 (2.5 equiv.) were dissolved in extra dry 
1,4-dioxane (4 mL) under inert atmosphere. The mixture was heated at 110 ºC for  
10-12h. Upon completion (TLC control), the reaction mixture was cooled to room 
temperature and concentrated under vacuum. The residue was purified by column 
chromatography. 
 
5-(2-bromophenylamino)-1-mesityl-1H-pyrrole-3-carbonitrile (16a): 
Starting with 15 (100 mg, 0.44 mmol), bromoarene (115 mg, 1.1 
equiv.), Pd(OAc)2 (4.9 mg, 5 mol. %), DPEphos (24 mg,  
10 mol. %), Cs2CO3 (361 mg, 2.5 equiv.), and 1,4-dioxane (4 mL), 
16a was isolated as a brown solid (113 mg, 67 %). mp = 64-65 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.0 (s, 6H, 2*CH3), 2.3 (s, 3H, CH3), 
5.5 (s, 1H, NH), 6.3 (dd, 4J = 1.9 Hz, 1H, CHAr), 6.7 (ddd, 
3J = 7.9 Hz, 
3J = 7.0 Hz, 3J = 1.9 Hz, 1H, CHAr), 6.9 (d,
 4J = 1.9 Hz, 1H, CHAr), 7.0 (s, 2H, 
N
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CHAr), 7.1 (dd, 
3J = 8.2 Hz, 4J = 1.9 Hz, 1H, CHAr), 7.2 (ddd, 
3J = 8.4 Hz, 3J = 6.9 Hz, 4J = 1.4 Hz, 
1H, CHAr), 7.4 (dd, 
3J = 8.0 Hz, 4J = 1.4 Hz, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 17.6 (2*C, CH3), 21.2 (CH3), 92.6 (C), 100.8 (C), 110.7 
(CH), 114.6 (CH), 116.9 (C), 121.2 (CH), 124.7 (CH), 128.6 (CH), 129.5 (CH), 131.8 (C), 131.9 
(C), 132.7 (CH), 136.2 (C), 139.8 (C), 140.9 (C); 
IR (ATR, cm-1): v~  = 3742 (w), 3363 (w), 3129 (w), 3063 (w), 3021 (w), 2950 (w), 2919 
(w), 2856 (w), 2736 (w), 2596 (w), 2327 (w), 2223 (s), 2173 (w), 1898 (w), 1684 (w), 1592 (s), 
1580 (s), 1565 (s), 1511 (s), 1488 (s), 1455 (m), 1439 (s), 1375 (m), 1300 (s), 1238 (m), 1217 (m), 
1180 (m), 1157 (m), 1143 (m), 1118 (w), 1043 (m), 1022 (s), 977 (m), 948 (w), 932 (w), 852 (m), 
801 (m), 746 (s), 706 (w), 692 (w), 673 (w), 657 (w), 637 (m), 584 (m), 553 (m); 
MS (GC, 70 eV) m/z (%): 382 (23), 381 (M+, 81Br, 99), 380 (26), 379 (M+, 79Br, 100), 
364 (12), 300 (16), 209 (41), 193 (14), 182 (12), 155 (14), 120 (11), 119 (11), 105 (11), 91 (15), 77 
(15); 
HRMS (EI) calcd for C20H18N3Br (M
+, 79Br) 379.06786, found 379.06738; 
HRMS (EI) calcd for C20H18N3Br (M
+, 81Br) 381.06582, found 381.06555. 
 
5-(2-bromophenylamino)-1-(2, 4-dimethylphenyl)-1H-pyrrole-3-carbonitrile (16b): 
Starting with 15 (100 mg, 0.47 mmol), bromoarene (122 mg,  
1.1 equiv.), Pd(OAc)2 (5.3 mg, 5 mol%), DPEphos (25.4 mg,  
10 mol%), Cs2CO3 (385 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16b was isolated as a brown solid (156 mg, 90 %). 
mp = 83-84 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.02 (s, 3H, CH3), 2.35 (s, 3H, 
CH3), 5.63 (s, 1H, NH), 6.36 (dd, 
4J = 1.9 Hz, 5J = 0.9 Hz, 1H, CHAr), 6.67 (ddd, 
3J = 8.0 Hz, 
7.3 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.91 (dd, 
3J = 8.2 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.02-7.04 (m, 2H, 
CHAr), 7.09 (d, 
4J = 1.9 Hz, 1H, CHAr), 7.10 – 7.19 (m, 2H, CHAr), 7.36 (dd, 
3J = 8.0 Hz, 
4J = 1.5 Hz, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 17.4 (CH3), 21.3 (CH3), 92.3 (C), 103.5 (CH), 110.2 (C), 
114.3 (CH), 116.7 (C), 120.9 (CH), 126.1 (CH), 127.5 (CH), 127.8 (CH), 128.5 (CH), 131.8 (CH), 
132.0, 132.6 (CH), 132.9 (C), 135.3 (C), 139.9, 141.8 (C); 
IR (ATR, cm-1): v~  = 3364 (w), 3128 (w), 3060 (w), 3023 (w), 2954 (w), 2920 (w), 2855 
(w), 2223 (s), 1898 (w), 1762 (w), 1682 (m), 1581 (s), 1565 (s), 1514 (s), 1487 (s), 1449 (s), 1440 
(s), 1382 (s), 1358 (m), 1299 (s), 1261 (m), 1237 (m), 1218 (m), 1204 (m), 1181 (m), 1149 (m), 
CN
N NH Br
CH3
H3C
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1127 (m), 1118 (m), 1105 (m), 1042 (m), 1021 (s), 979 (m), 930 (w), 876 (w), 817 (s), 801 (s), 773 
(m), 742 (s), 693 (m), 653 (m), 635 (s), 598 (m), 579 (m), 549 (m); 
MS (GC, 70 eV) m/z (%): 368 (21), 367 ([M]+, 81Br, 99), 366 (26), 365 ([M]+, 
79Br, 100), 286 ([M-Br]+, 22), 271 (18), 270 (12), 180 (12), 155 (15), 103 (10), 77 (21); 
HRMS (EI): calcd. for C19H16BrN3 (M
+, 79Br) 365.05221, found 365.05212; 
HRMS (EI): calcd. for C19H16BrN3 (M
+, 81Br) 367.05017, found 367.05033. 
 
5-(2-bromo-4,5-dimethylphenylamino)-1-(2,4-dimethylphenyl)-1H-pyrrole-3-carbonitrile 
(16c): 
Starting with 15 (100 mg, 0.47 mmol), bromoarene (137 mg, 
1.1 equiv.), Pd(OAc)2 (5.3 mg, 5 mol. %), DPEphos (25.4 mg, 
10 mol. %), Cs2CO3 (385 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16c was isolated as a brown solid (103 mg, 55 %). 
mp = 124-125 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.03 (s, 3H, CH3), 2.12 (s, 
3H, CH3), 2.15 (s, 3H, CH3), 2.35 (s, 3H, CH3), 5.44 (s, 1H, NH), 6.29 
(d, 4J = 1.7 Hz, 1H, CHAr), 6.75 (s, 1H, CHAr), 7.0 – 7.07 (m, 3H, CHAr), 7.12 (m, 2H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 17.5 (CH3), 18.7 (CH3), 19.9 (CH3), 21.3 (CH3), 92.2 (C), 
102.0 (CH), 107.1 (C), 115.9 (CH), 116.9 (C), 125.7 (CH), 127.6 (CH), 127.8 (CH), 129.6 (C), 
132.1 (CH), 132.7 (C), 133.0 (C), 133.0 (CH), 135.4 (C), 137.1 (C), 139.2 (C), 139.8 (C); 
IR (ATR, cm-1): v~  = 3355 (w), 3120 (w), 2919 (w), 2855 (w), 2217 (s), 1609 
(w), 1507 (s), 1514 (s), 1496 (s), 1444 (s), 1389 (s), 1381 (s), 1368 (m), 1286 (m), 
1272 (s), 1222 (m), 1193 (w), 1175 (s), 1147 (m), 1127 (m), 1021 (m), 1008 (m), 973 
(s), 866 (s), 830 (s), 809 (s), 724 (m), 694 (m), 676 (w), 637 (s), 546 (m), 528 (m), 510 
(m), 436 (s), 419 (s); 
MS (GC, 70 eV) m/z (%): 396 (23), 395 (M+, 81Br, 100), 394 (28), 393 (M+, 
79Br, 99), 314 (25), 299 (21), 298 (14), 208 (10), 103 (15), 77 (18); 
HRMS (EI): calcd. for C21H20BrN3 (M
+, 79Br) 393.08351, found 393.0832; 
HRMS (EI): calcd. for C21H20BrN3 (M
+, 81Br) 395.08147, found 395.08211. 
 
5-(2-bromo-4-chlorophenylamino)-1-(2,4-dimethylphenyl)-1H-pyrrole-3-carbo-
nitrile (16d): 
N NH
NC
H3C
CH3
H3C
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Starting with 15 (100 mg, 0.47 mmol), bromoarene (165 mg, 
1.1 equiv.), Pd(OAc)2 (5.3 mg, 5 mol. %), DPEphos (25 mg, 
10 mol. %), Cs2CO3 (385 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16d was isolated as a brown solid (133 mg, 70 %). 
mp = 127-128 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.01 (s, 3H CH3), 
2.35 (s, 3H CH3), 5.57 (s, 1H, NH), 6.36 (dd, 
4J = 1.8 Hz, 
4J = 0.7 Hz, 1H, CHAr), 6.80 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.00 (d, 
3J = 8.0 Hz, 1H, 
CHAr), 7.03 (dd, 
3J = 8.1 Hz, 4J = 1.9 Hz, 1H, CHAr), 7.07-7.13 (m, 3H, CHAr), 7.35 (d, 
4J = 2.3 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 17.5 (CH3), 21.3 (CH3), 92.5 (C), 104.3 (CH), 110.0 (C), 
114.7 (CH), 116.5 (C), 124.7, 126.5 (CH), 127.5 (CH), 127.8 (CH), 128.5 (CH), 131.2 (C), 132.0 
(CH), 132.1 (CH), 132.8 (C), 135.2 (C), 140.0 (C), 140.8 (C); 
IR (ATR, cm-1): v~  = 3393 (w), 3129 (w), 3059 (w), 2921 (w), 2851 (w), 2224 (s), 1685 
(w), 1576 (m), 1561 (m), 1513 (s), 1481 (s), 1466 (s), 1384 (s), 1354 (m), 1309 (m), 1296 (s), 1265 
(s), 1237 (m), 1220 (m), 1186 (s), 1150 (m), 1127 (m), 1100 (m), 1035 (s), 1004 (w), 980 (w), 927 
(w), 869 (m), 836 (m), 818 (s), 798 (s), 782 (s), 721 (m), 692 (m), 664 (m), 640 (s), 601 (s), 567 
(m), 544 (s), 464 (m), 432 (m); 
MS (GC, 70 eV) m/z (%): 403 (26), 402 (23), 401 (M+, 100), 400 (20), 399 
(74), 320 (16), 285 (12), 195 (13), 77 (16); 
HRMS (EI): calcd. for C19H15BrClN3 (M
+, 79Br) 399.01324, found 399.01292; 
HRMS (EI): calcd. for C19H15BrClN3 (M
+, 81Br, 35Cl) 401.01119, found 
401.01103; 
 
5-(2-bromophenylamino)-1-(4-isopropylphenyl)-1H-pyrrole-3-carbonitrile (16e): 
Starting with 15 (100 mg, 0.44 mmol), bromoarene (115 mg, 1.1 
equiv.), Pd(OAc)2 (5 mg, 5 mol. %), DPEphos (24 mg, 10 mol. %), 
Cs2CO3 (361 mg, 2.5 equiv.), and 1,4-dioxane (4 mL), 16e was 
isolated as a brown solid (133 mg, 79 %). mp = 101-102ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.26 (d, 
3J = 6.9 Hz, 6H), 2.94 (p, 
3J = 6.9 Hz, 1H), 5.74 (s, 1H, NH), 6.41 (dd, 4J = 2.0 Hz, 4J = 0.9 Hz, 1H, 
N NH
NC
Br
CH3H3C
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CHAr), 6.69 (ddd, 
3J = 7.9 Hz, 3J = 7.3 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.76 (dd, 
3J = 8.2 Hz, 
4J = 1.5 Hz, 1H, CHAr), 7.09 – 7.21 (m, 3H, CHAr), 7.24 – 7.29 (m, 3H, CHAr), 7.41 (dd, 
3J = 8.0 Hz, 4J = 1.5 Hz, 1H, CHAr). 
13C NMR (63 MHz, CDCl3): δ = 24.0 (CH(CH3)2), 33.9 (CH(CH3)2), 92.6 (C), 106.8 (CH), 
109.8 (C), 114.2 (CH), 116.5 (C), 120.8 (CH), 125.3 (CH), 126.4 (CH), 127.7 (CH), 128.6 (CH), 
130.8 (C), 132.7 (CH), 134.5 (C), 142.7 (C), 149.7 (C); 
IR (ATR, cm-1): v~  = 3328 (w), 3123 (w), 3061 (w), 2956 (w), 2922 (w), 2867 (w), 2221 
(s), 1901 (w), 1666 (w), 1607 (w), 1586 (m), 1576 (m), 1563 (w), 1518 (s), 1506 (s), 1488 (s), 1451 
(m), 1419 (m), 1393 (m), 1362 (w), 1338 (w), 1301 (m), 1290 (m), 1246 (w), 1226 (w), 1179 (m), 
1158 (w), 1149 (w), 1117 (w), 1097 (w), 1055 (w), 1045 (w), 1021 (s), 979 (w), 943 (w), 932 (w), 
923 (w), 893 (w), 874 (w), 856 (w), 836 (s), 822 (s), 740 (s), 704 (w), 691 (w), 684 (w), 645 (s), 
628 (s), 602 (m), 584 (m), 544 (m); 
MS (GC, 70 eV) m/z (%): 382 (22), 381 (M+, 81Br, 96), 380 (25), 379 (M+, 
79Br, 100), 366 (18), 364 (18), 285 (10), 284 (12), 258 (22), 257 (27), 155 (15), 103 
(12), 77 (17); 
HRMS (EI): calcd. for C20H18BrN3 (M
+, 79Br) 379.06786, found 379.06758; 
HRMS (EI): calcd. for C20H18BrN3 (M
+, 81Br) 381.06582, found 381.06594. 
 
5-(2-bromo-4,5-dimethylphenylamino)-1-(4-isopropylphenyl)-1H-pyrrole-3-carbonitrile (16f): 
Starting with 15 (100 mg, 0.44 mmol), bromoarene (155 mg,  
1.1 equiv.), Pd(OAc)2 (5 mg, 5 mol. %), DPEphos (24 mg,  
10 mol. %), Cs2CO3 (361 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16f was isolated as a yellowish oil (133 mg, 72 %). 
1H NMR (300 MHz, CDCl3): δ = 1.25 (d, 
3J = 6.9 Hz, 6H, 2*CH3), 
2.92 (p, 3J = 6.9 Hz, 1H, CH), 5.69 (s, 1H, NH), 6.40 (dd, 4J = 1.9 Hz, 
4J = 0.9 Hz, 1H, CHAr), 6.64 (d, 
3J = 8.8 Hz, 1H, CHAr), 7.08 (dd, 
3J = 8.8 Hz, 4J = 2.3 Hz, 1H, CHAr), 7.13 (d, 
3J = 8.5 Hz, 2H), 7.2 – 7.3 (m, 3H, CHAr), 7.39 (d, 
4J = 2.3 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 24.0 (CH(CH3)2), 33.9 (CH(CH3)2), 92.7 (C), 107.4 (CH), 
109.7 (C), 114.7 (CH), 116.3 (C), 124.6 (C), 125.2 (CH), 126.7 (CH), 127.7 (CH), 128.6 (CH), 
130.2 (C), 132.0 (CH), 134.3 (C), 141.7 (C), 149.9 (C); 
IR (ATR, cm-1): v~  = 3368 (w), 3130 (w), 3063 (w), 3039 (w), 2958 (w), 2925 (w), 2868 
(w), 2224 (s), 1903 (w), 1764 (w), 1680 (w), 1586 (m), 1572 (m), 1561 (m), 1518 (s), 1481 (s), 
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1420 (w), 1383 (s), 1361 (m), 1315 (m), 1294 (s), 1263 (m), 1244 (w), 1223 (w), 1204 (w), 1180 
(m), 1152 (w), 1140 (w), 1100 (m), 1055 (w), 1032 (s), 1022 (m), 1003 (w), 979 (w), 945 (w), 921 
(w), 864 (m), 837 (s), 802 (s), 757 (w), 731 (m), 693 (w), 638 (s), 627 (m), 609 (m), 545 (s); 
MS (GC, 70 eV) m/z (%): 403 (26), 402 (23), 401 (M+, 100), 400 (20), 399 
(74), 320 (16), 285 (12), 195 (13), 77 (16); 
HRMS (EI): calcd. for C20H17BrClN3 (M
+, 79Br, 35Cl) 413.02889, found 
413.02795; 
HRMS (EI): calcd. for C20H17BrClN3 (M
+, 79Br, 37Cl) 415.02594, found 
415.02603; 
HRMS (EI): calcd. for C20H17BrClN3 (M
+, 81Br, 35Cl) 417.02389, found 
417.02313. 
 
5-(2-bromophenylamino)-1-(4-methoxyphenyl)-1H-pyrrole-3-carbonitrile (16g): 
Starting with 15 (100 mg, 0.468 mmol), bromoarene (121 mg, 1.1 
equiv.), Pd(OAc)2 (5.2 mg, 5 mol. %), DPEphos (25 mg,  
10 mol. %), Cs2CO3 (382 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16g was isolated as a light brown solid (159 mg, 92 %), 
mp = 125-126 °C. 
1H NMR (300 MHz, CDCl3): δ = 3.81 (s, 3H, OCH3), 5.72 
(s, 1H, NH), 6.39 (dd, 4J = 2.0 Hz, 4J = 0.9 Hz, 1H, CHAr), 6.61 – 
6.77 (m, 2H, CHAr), 6.90 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.08 – 7.20 (m, 3H, CHAr), 7.22 
(d, 4J = 1.9 Hz, 1H, CHAr), 7.39 (dd, 
3J = 7.9 Hz, 4J = 1.5 Hz, 1H, CHAr); 
13C NMR (75 MHz, CDCl3):
 δ =55.6 (OCH3), 92.3 (C), 106.6 (CH), 109.6 (C), 
113.9 (CH), 114.7 (CH), 116.4 (C), 120.6 (CH), 126.4 (CH), 126.6 (CH), 128.5 (CH), 
129.5 (C), 130.7 (C), 132.6 (CH), 142.5 (C), 159.6 (C); 
IR (ATR, cm-1): v~  = 3387 (w), 3321 (w), 3126 (w), 3066 (w), 3015 (w), 2961 
(w), 2929 (w), 2835 (w), 2227 (s), 1888 (w), 1681 (w), 1609 (w), 1587 (s), 1575 (s), 
1562 (s), 1518 (s), 1485 (s), 1452 (s), 1411 (m), 1397 (m), 1357 (w), 1316 (w), 1299 
(s), 1291 (s), 1251 (s), 1222 (m), 1178 (s), 1170 (s), 1152 (m), 1107 (m), 1022 (s), 979 
(m), 931 (w), 859 (w), 834 (s), 802 (s), 795 (s), 748 (s), 742 (s), 722 (m), 688 (m), 650 
(m), 628 (s), 616 (s), 601 (s), 585 (s), 557 (s), 530 (s); 
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MS (EI, 70eV): m/z (%) = 370 ([M+H]+, 81Br, 20), 369 ([M]+, 81Br, 98), 368 
([M+H]+, 79Br, 25), 367 ([M]+, 79Br, 100), 354 (23), 352 (24), 288 (22), 272 (13), 244 
(16), 155 (13), 138 (11), 77 (13), 76 (11); 
HRMS (EI): calcd. for C18H14BrN3O (M
+, 79Br) 367.03148, found 367.03086; 
HRMS (EI): calcd. for C18H14BrN3O (M
+, 81Br) 369.02943, found 369.02906. 
 
5-(2-bromo-4-chlorophenylamino)-1-(4-methoxyphenyl)-1H-pyrrole-3-carbonitrile 
(16h): 
Starting with 15 (100 mg, 0.468 mmol), bromoarene (163 mg, 
1.1 equiv.), Pd(OAc)2 (5.2 mg, 5 mol. %), DPEphos (25.2 mg, 
10 mol. %), Cs2CO3 (382 mg, 2.5 equiv.), and 1,4-dioxane 
(4 mL), 16h was isolated as a yellowish oil (119 mg, 63 %). 
1H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3H, OCH3), 
5.70 (s, 1H, NH), 6.38 (dd, 4J = 1.9 Hz, 4J = 0.9 Hz, 1H, 
CHAr), 6.60 (d, 
3J = 8.8 Hz, 1H, CHAr), 6.89 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.07 (dd, 
3J = 8.9 Hz, 4J = 2.3 Hz, 1H, CHAr), 7.13 (d, 
3J = 9.0 Hz, 2H, CHAr), 7.23 (d, 
4J = 2.0 Hz, 1H, CHAr), 7.38 (d, 
4J = 2.3 Hz, 1H, CHAr);  
13C NMR (63 MHz, CDCl3): δ = 55.55 (OCH3), 92.3 (C), 107.1 (CH), 109.4 (C), 
114.4 (CH), 114.7 (CH), 116.2 (C), 124.4 (C), 126.5 (CH), 126.8 (CH), 128.4 (CH), 
129.3 (C), 130.1 (C), 131.9 (CH), 141.5 (C), 159.6 (C); 
IR (ATR, cm–1):  = 3355 (w), 3123 (w), 3073 (w), 3058 (w), 2966 (w), 2914 (w), 2835 
(w), 2222 (s), 1875 (w), 1678 (w), 1608 (w), 1589 (m), 1574 (m), 1561 (m), 1517 (s), 1506 (s), 
1490 (s), 1467 (s), 1438 (m), 1395 (m), 1385 (m), 1362 (m), 1300 (s), 1284 (m), 1245 (s), 1223 (m), 
1180 (m), 1170 (s), 1159 (m), 1138 (m), 1118 (m), 1107 (m), 1030 (s), 979 (m), 949 (w), 872 (w), 
852 (m), 832 (s), 806 (s), 765 (m), 730 (s), 719 (m), 690 (m), 651 (m), 645 (m), 624 (s), 604 (m), 
563 (m), 532 (s); 
MS (EI, 70eV): m/z (%) = 405 (27), 404 ([M+H]+, 81Br, 21), 403 ([M]+, 81Br, 
100), 402 ([M+H]+, 79Br, 19), 401 ([M]+, 79Br, 80), 388 (23), 322 (13), 287 (13), 272 
(13), 189 (12), 143 (24), 134 (23), 108 (24), 92 (16), 77 (19), 64 (17), 63 (10); 
HRMS (ESI-TOF): calcd for C18H13BrClN3O (M
+, 79Br) 402.00033, found 401.99996; 
HRMS (ESI-TOF): calcd for C18H13BrClN3O (M
+, 81Br) 403.9982, found 403.99775. 
 
5-(2-bromophenylamino)-1-(3-chlorophenyl)-1H-pyrrole-3-carbonitrile (16i): 
~
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Starting with 15 (100 mg, 0.46 mmol), bromoarene (119 mg, 1.1 equiv.), Pd(OAc)2 
(5 mg, 5 mol. %), DPEphos (24.7 mg, 10 mol. %), Cs2CO3 (374 mg, 2.5 equiv.), and 
1,4-dioxane (4 mL), 16i was isolated as a brown solid (128 mg, 75 %),  
mp = 145-146 ºC; 
1H NMR (300 MHz, CDCl3): δ = 5.7 (s, 1H, NH), 6.4 (dd, 
4J = 1.8 Hz, 4J = 0.9 Hz, 1H, CHAr), 6.6 – 6.77 (m, 2H, CHAr), 7.08 – 7.13 
(m, 1H, CHAr), 7.13 – 7.18 (m, 1H, CHAr), 7.28 – 7.31 (m, 2H, CHAr), 7.36 – 
7.32 (m, 2H, CHAr), 7.41 (dd, 
3J = 7.9 Hz, 4J = 1.4 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 93.5 (C), 108.1 (CH), 109.8 (C), 
114.1 (CH), 116.0 (C), 121.1 (CH), 123.4 (CH), 125.6 (CH), 126.3 (CH), 
128.6 (CH), 128.9 (CH), 130.6 (C), 130.6 (CH), 132.8 (CH), 135.3 (C), 137.8 (C), 142.5 (C). 
IR (ATR, cm-1):  = 3339.1 (s), 3130.3 (w), 3087.5 (w), 3019.1 (w), 2956.2 (w), 2921.6 
(w), 2851.5 (w), 2221.7 (s), 1591.5 (m), 1575.6 (m), 1511.4 (m), 1488.1 (m), 1476.7 (m), 1449.1 
(m), 1434.1 (m), 1416.2 (m), 1388 (m), 1355.4 (w), 1293.9 (m), 1264.3 (w), 1182.5 (m), 1154.6 
(w), 1119 (w), 1095.8 (w), 1021.7 (m), 816.5 (m), 743.6 (s), 680.7 (m), 632.3 (m). 
MS (EI, 70eV): m/z (%) = 375 ([M]+, 81Br, 37Cl, 28), 374 ([M-1]+, 81Br, 37Cl, 
22), 373 ([M]+, 81Br, 100), 372 ([M]+, 79Br, 37Cl, 19), 371 ([M]+, 79Br, 35Cl, 80), 294 
(10), 292 (28), 291 (10), 258 (10), 257 (52), 256 (21), 229 (10), 181 (13), 155 (26), 
138 (11), 77 (11), 76 (15), 75 (26). 
HRMS (EI) calcd for C17H11N3BrCl ([M]
+) 370.98194, found 370.98148; 
HRMS (EI) calcd for C17H11N3Br
37Cl ([M]+) 372.97899, found 372.97931; 
HRMS (EI) calcd for C17H11N3
81Br37Cl ([M]+) 374.97694, found 374.97714. 
 
5-(2-bromo-4-chlorophenylamino)-1-(3-chlorophenyl)-1H-pyrrole-3-carbonitrile 
(16j): 
Starting with 15 (100 mg, 1.0 mmol), bromoarene (160 mg, 1.1 
equiv.), Pd(OAc)2 (5.1 mg, 5 mol. %), DPEphos (24.7 mg,  
10 mol. %), Cs2CO3 (374 mg, 2.5 equiv.), and 1,4-dioxane (4 mL), 
16j was isolated as a yellowish solid (118 mg, 63 %). 
 mp = 161-162 ºC; 
1H NMR (300 MHz, CDCl3): δ = 5.71 (s, 1H, NH), 6.44 (dd, 
4J = 1.9 Hz, 
4J = 1.0 Hz, 1H, CHAr), 6.55 (d, 
3J = 8.7 Hz, 1H, CHAr), 7.08 (dd, 
3J = 8.8 Hz, 
4J = 2.3 Hz, 1H, CHAr), 7.13 (dt, 
3J = 6.6 Hz, 4J = 2.2 Hz, 1H, CHAr), 7.27 – 7.30 (m, 
2H, CHAr), 7.33 – 7.37 (m, 2H, CHAr), 7.40 (d, 
4J = 2.3 Hz, 1H, CHAr); 
~
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13C NMR (63 MHz, CDCl3): δ = 93.6 (C), 108.5 (CH), 109.7 (C), 114.6 (CH), 
115.8 (C), 123.4 (CH), 125.0 (C), 125.6 (CH), 126.5 (CH), 128.7 (CH), 129.1 (CH), 
130.1 (C), 130.7 (CH), 132.1 (CH), 135.4 (C), 137.6 (C), 141.4 (C); 
IR (ATR, cm-1): v~  = 3381 (w), 3144 (w), 3065 (w), 2922 (w), 2226 (s), 1598 (m), 1587 
(m), 1528 (m), 1478 (s), 1458 (s), 1424 (m), 1396 (s), 1371 (m), 1351 (m), 1317 (s), 1240 (w), 1221 
(m), 1160 (s), 1095 (s), 1079 (m), 1032 (m), 1020 (m), 998 (w), 981 (w), 914 (w), 889 (m), 857 (s), 
793 (s), 776 (s), 739 (s), 711 (s), 695 (s), 683 (s), 656 (m), 633 (m), 615 (s), 538 (s), 502 (m), 488 
(s), 452 (s), 442 (s), 414 (s); 
MS (GC, 70 eV) m/z (%): 409 (48), 408 (21), 407 (100), 406 (16), 405 (65), 293 
(17), 292 (13), 291 (49), 290 (13), 256 (11), 189 (12), 138 (12), 111 (23), 75 (23); 
HRMS (EI): calcd. for C17H10BrCl2N3 (M
+, 81Br, 35Cl) 406.94092, found 
406.94079; 
HRMS (EI): calcd. for C19H15BrClN3 (M
+, 81Br, 35Cl, 37Cl) 408.93797, found 
408.93854. 
 
5-(2-bromophenylamino)-1-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile (16k): 
Starting with 15 (100 mg, 0.46 mmol), bromoarene (119 mg, 1.1 
equiv.), Pd(OAc)2 (5.1 mg, 5 mol. %), DPEphos (24.7 mg,  
10 mol. %), Cs2CO3 (374 mg, 2.5 equiv.), and 1,4-dioxane (4 mL), 
16k was isolated as a white solid (120 mg, 70 %),  
mp = 118-120 °C. 
1H NMR (300 MHz, CDCl3): δ = 5.71 (s, 1H, NH), 6.44 (dd, 
4J = 2.0 Hz, 4J = 1.0 Hz, 1H, CHAr), 6.64 (dd, 
3J = 8.1 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.7 
(ddd, 3J = 8.0 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.11 (ddd, 
3J = 8.5 Hz, 
3J = 7.5 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.20 (d, 
3J = 8.7 Hz, 2H, CHAr), 7.27 (d, 
4J = 2.0 Hz, 1H, CHAr), 7.38 (d, 
3J = 8.8 Hz, 2H), 7.41 (dd, 3J = 8.0 Hz, 4J = 1.4 Hz, 
1H, CHAr); 
13C NMR (75 MHz, CDCl3):
 δ = 93.4 (C), 108.1 (CH), 109.7 (C), 114.0 (CH), 
116.0 (C), 121.0 (CH), 126.3 (CH), 126.5 (CH), 128.7 (CH), 129.9 (CH), 130.6 (C), 
132.8 (CH), 134.7 (C), 135.3 (C), 142.6 (C); 
IR (ATR, cm-1): = 3384.5 (m), 3138.5 (w), 3111.4 (w), 2960.7 (w), 2919.1 (w), 
2849.8 (w), 2226.6 (s), 1585.1 (m), 1565.5 (m), 1514.7 (m), 1489.9 (s), 1452.6 (m), 
1424.6 (m), 1407.5 (m), 1387.2 (w), 1359.3 (w), 1301.9 (m), 1292.5 (m), 1260.7 (w), 
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1151 (w), 1093.2 (m), 1023.2 (m), 1018.2 (m), 930.9 (w), 832.3 (m), 804.2 (m), 740 
(s), 638 (m), 608.4 (m). 
MS (EI, 70eV): m/z (%) = 375 (24), 374 (20), 373 ([M]+, 100), 372 (19), 371 
(74), 292 (27), 257 (47), 256 (20), 181 (10), 155 (23), 138 (12), 111 (21), 77 (10), 76 
(14), 75 (24). 
HRMS (EI) calcd for C17H11N3BrCl ([M]
+) 370.98194, found 370.98136; 
HRMS (EI) calcd for C17H11N3Br
37Cl ([M]+) 372.97939, found 372.97899; 
HRMS (EI) calcd for C17H11N3
81BrCl ([M]+) 372.97939, found 372.97989; 
HRMS (EI) calcd for C17H11N3
81Br37Cl ([M]+) 374.97694, found 374.97792. 
 
5-(2-bromo-4-chlorophenylamino)-1-(4-chlorophenyl)-1H-pyrrole-3-carbonitrile 
(16l): 
Starting with 15 (100 mg, 1.0 mmol), bromoarene (160 mg, 1.1 equiv.), Pd(OAc)2 
(5.1 mg, 5 mol. %), DPEphos (24.7 mg, 10 mol. %), Cs2CO3 (374 mg, 2.5 equiv.), and 
1,4-dioxane (4 mL), 16l was isolated as a brownish solid (140 mg, 75 %),  
mp = 93-94 ºC; 
1H NMR (300 MHz, CDCl3): δ = 5.67 (s, 1H, NH),  
6.41 – 6.47 (m, 1H, CHAr), 6.54 (d, 
3J = 8.7 Hz, 1H, CHAr), 7.08 
(dd, 3J = 8.7 Hz, 4J = 2.4 Hz, 1H, CHAr), 7.18 (d, 
3J = 8.7 Hz, 2H, 
CHAr), 7.27 (d, 
4J = 2.0 Hz, 1H, CHAr), 7.39 (d, 
3J = 8.8 Hz, 2H, 
CHAr), 7.4 (d, 
4J = 2.4 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 93.5 (C), 108.5 (CH), 
109.6 (C), 114.5 (CH), 115.9 (C), 125.0 (C), 126.5 (CH), 126.6 (CH), 128.7 (CH), 
130.0 (CH), 130.03 (C), 132.2 (CH), 134.9 (C), 135.2 (C), 141.5 (C); 
IR (ATR, cm-1): v~  = 3388 (w), 3130 (w), 2922 (w), 2852 (w), 2227 (s), 1676 
(w), 1586 (w), 1570 (w), 1558 (w), 1511 (s), 1491 (s), 1480 (s), 1472 (s), 1392 (s), 
1381 (s), 1352 (m), 1312 (m), 1288 (s), 1267 (s), 1220 (w), 1178 (s), 1143 (m), 1092 
(s), 1031 (s), 1020 (s), 1001 (w), 978 (w), 859 (s), 832 (s), 817 (s), 801 (s), 785 (s), 
732 (m), 708 (m), 665 (m), 639 (s), 601 (m), 588 (w), 542 (m), 530 (s), 490 (s), 459 
(s), 434 (m), 419 (s); 
MS (EI, 70eV): m/z (%) = 409 ([M]+, 81Br, 37Cl, 44), 407 ([M]+, 81Br, 35Cl, 100), 
406 (15), 405 (60), 326 (11), 293 (15), 292 (13), 291 (45), 290 (14), 256 (11), 189 
(13), 138 (13), 111 (25), 75 (26); 
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HRMS (EI): calcd. for C17H10BrCl2N3 (M
+, 81Br, 35Cl) 406.94092, found 
406.94116; 
HRMS (EI): calcd. for C17H10BrCl2N3 (M
+, 79Br, 35Cl, 37Cl) 406.94002, found 
406.94116; 
HRMS (EI): calcd. for C17H10BrCl2N3 (M
+, 81Br, 35Cl, 37Cl) 408.93797, found 
408.93889; 
HRMS (EI): calcd. for C17H10BrCl2N3 (M
+, 81Br, 37Cl) 408.93707, found 
408.93889. 
 
1-benzyl-5-(2-bromophenylamino)-1H-pyrrole-3-carbonitrile (16m): 
Starting with 15 (100 mg, 0.5 mmol), bromoarene (131 mg, 1.1 
equiv.), Pd(OAc)2 (5.6 mg, 5 mol. %), DPEphos (27.3 mg,  
10 mol. %), Cs2CO3 (412 mg, 2.5 equiv.), and 1,4-dioxane 
(4 mL), 16m was isolated as a yellowish oil (107 mg, 60 %). 
1H NMR (300 MHz, CDCl3): δ = 4.91 (s, 2H, CH2), 5.58 (s, 
1H, NH), 6.33 (dd, 4J = 1.9 Hz, 4J = 1.0 Hz, 1H, CHAr), 6.47 (dd, 
3J = 8.2 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.70 (td, 
3J = 7.6 Hz, 4J = 1.5 Hz, 1H, CHAr), 
7.05–7.13 (m, 3H, CHAr), 7.15 (d, 
4J = 1.9 Hz, 1H, CHAr), 7.29 – 7.37 (m, 3H, CHAr), 
7.46 (dd, 3J = 7.9 Hz, 3J = 1.5 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3):
 δ = 50.3 (CH2), 91.9 (C), 108.4 (CH), 109.5 (C), 
113.8 (CH), 116.6, 120.8 (CH), 126.3 (CH), 127.6 (CH), 128.5 (CH), 128.7 (CH), 
129.2 (CH), 130.1 (C), 132.8 (CH), 135.7 (C), 143.1 (C); 
IR (ATR, cm-1): v~  = 3369 (w), 3126 (w), 3063 (w), 3029 (w), 2930 (w), 2220 
(s), 1677 (w), 1591 (s), 1577 (s), 1563 (s), 1514 (s), 1485 (s), 1451 (s), 1395 (m), 1373 
(m), 1346 (m), 1297 (s), 1285 (s), 1238 (m), 1204 (m), 1184 (m), 1076 (w), 1043 (w), 
1021 (s), 1003 (w), 978 (m), 930 (w), 866 (w), 804 (m), 743 (s), 719 (s), 695 (s), 632 
(s), 587 (m), 567 (m), 541 (m); 
MS (EI, 70eV): m/z (%) = 353 ([M]+, 81Br, 33), 351 ([M]+, 79Br, 34), 181 (45), 
91 (100), 65 (13); 
HRMS (EI): calcd. for C18H14BrN3 (M
+, 79Br) 351.03656, found 351.03583; 
HRMS (EI): calcd. for C18H14BrN3 (M
+, 81Br) 353.03452, found 353.03377. 
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5-(2-bromophenylamino)-1-(3,4-dimethoxyphenethyl)-1H-pyrrole-3-carbonitrile 
(16n): 
Starting with 15 (100 mg, 0.37 mmol), bromoarene (96 mg, 1.1 
equiv.), Pd(OAc)2 (4 mg, 5 mol. %), DPEphos (19.8 mg,  
10 mol. %), Cs2CO3 (300 mg, 2.5 equiv.), and 1,4-dioxane 
(4 mL), 16n was isolated as a yellowish oil (86 mg, 55 %). 
1H NMR (300 MHz, CDCl3): δ = 2.87 (t, 
3J = 6.7 Hz, 2H, CH2), 
3.77 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.0 (t, 
3J = 6.7 Hz, 2H, CH2), 
5.10 (s, 1H, NH), 6.22 (dd, 4J = 1.9 Hz, 4J = 1.0 Hz, 1H, CHAr),  
6.29 – 6.40 (m, 2H, CHAr), 6.49 (dd, 
3J = 8.1 Hz, 4J = 2.0 Hz, 1H, CHAr), 
6.67 (td, 3J = 7.9 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.8 (d, 
3J = 8.1 Hz, 1H, CHAr), 7.1 (ddd, 
3J = 8.5 Hz, 
3J = 7.4 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.1 (d, 
4J = 1.9 Hz, 1H, CHAr), 7.4 (dd, 
3J = 8.0 Hz, 
4J = 1.5 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 37.7 (CH2), 47.8 (CH2), 55.9 (OCH3), 56.0 (OCH3), 91.7 
(C), 108.1 (CH), 109.1 (C), 111.6 (CH), 111.7 (CH), 113.7 (CH), 116.7, 120.6 (CH), 120.8 (CH), 
125.6 (CH), 128.6 (CH), 129.6 (C), 130.2 (C), 132.7 (CH), 143.2 (C), 148.3 (C), 149.2 (C); 
IR (ATR, cm-1): v~  = 3359 (w), 3123 (w), 3058 (w), 2997 (w), 2926 (w), 2850 (w), 2833 
(w), 2219 (w), 1673 (w), 1589 (m), 1577 (m), 1564 (m), 1513 (s), 1487 (s), 1462 (m), 1448 (s), 
1437 (s), 1417 (s), 1397 (m), 1375 (m), 1353 (m), 1298 (m), 1259 (s), 1234 (s), 1186 (m), 1154 (s), 
1138 (m), 1122 (s), 1021 (s), 979 (m), 937 (w), 852 (m), 803 (s), 743 (s), 694 (s), 631 (s), 542 (s); 
MS (GC, 70 eV) m/z (%): 427 ([M]+, 81Br, 38), 425 ([M]+, 79Br, 39), 194 (14), 166 (12), 165 
(100), 164 (70), 151 (77), 150 (17), 149 (10), 107 (12), 91 (13), 77 (14); 
HRMS (EI): calcd. for C21H20BrN3O2 (M
+, 79Br) 425.07334, found 425.07294; 
HRMS (EI): calcd. for C21H20BrN3O2 (M
+, 81Br) 427.07129, found 427.07155. 
 
5-(2-bromophenylamino)-1-cyclopentyl-1H-pyrrole-3-carbonitrile (16o): 
Starting with 15 (100 mg, 0.56 mmol), bromoarene (146 mg, 1.1 
equiv.), Pd(OAc)2 (6.3 mg, 5 mol. %), DPEphos (30 mg,  
10 mol. %), Cs2CO3 (460 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16o was isolated as a white solid (141 mg, 75 %); 
mp = 109-110 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.54 – 1.78 (m, 4H), 1.84 
– 1.9 (m, 2H), 2.0 – 2.1 (m, 2H), 4.41 (p, 3J = 7.1 Hz, 1H, CHAr), 5.67 (s, 1H, NH), 
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6.28 (dd, 4J = 2.0 Hz, 4J = 0.9 Hz, 1H, CHAr), 6.40 (dd, 
3J = 8.2 Hz, 4J = 1.5 Hz, 1H, 
CHAr), 6.70 (td, 
3J = 7.6 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.11 (ddd, 
3J = 8.5 Hz, 
3J = 7.4 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.19 (d, 
4J = 1.9 Hz, 1H, CHAr), 7.47 (dd, 
3J = 7.9 Hz, 4J = 1.5 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 24.3, 33.9, 56.4, 91.6 (C), 108.4 (CH), 109.3 
(C), 113.7 (CH), 116.9, 120.6 (CH), 123.1 (CH), 128.7 (CH), 129.9 (C), 132.7 (CH), 
143.7 (C); 
IR (ATR, cm-1): = 3401 (w), 3362 (m), 3116 (w), 3059 (w), 2962 (w), 2870 (w), 
2219 (s), 1674 (w), 1592 (m), 1578 (m), 1562 (m), 1513 (m), 1484 (s), 1450 (m), 1373 
(m), 1356 (m), 1297 (m), 1197 (m), 1154 (w), 1123 (w), 1045 (w), 1021 (s), 819 (s), 
742.5 (s), 639 (s). 
MS (EI, 70eV): m/z (%) = 332 ([M+H]+, 81Br, 12), 331 (M+, 81Br, 64), 330 
([M+H]+, 79Br, 12), 329 (M+, 79Br, 63), 263 (59), 262 (13), 261 (58), 183 (14), 182  
 ([M-Br]+, 100), 181 (57), 155 (24), 154 (11), 77 (11), 41 (28); 
HRMS (EI) calcd for C16H16BrN3 ([M]
+) 329.05221, found 329.05124; 
HRMS (EI) calcd for C16H16
81BrN3 ([M]
+) 331.05017, found 331.04950. 
 
5-(2-bromophenylamino)-1-pentyl-1H-pyrrole-3-carbonitrile (16p): 
Starting with 15 (100 mg, 0.56 mmol), bromoarene (146 mg, 1.1 
equiv.), Pd(OAc)2 (6.3 mg, 5 mol. %), DPEphos (30.3 mg,  
10 mol. %), Cs2CO3 (459 mg, 2.5 equiv.), and 1,4-dioxane (4 mL), 
16p was isolated as a yellowish oil (141 mg, 76 %). 
 1H NMR (300 MHz, CDCl3): δ = 0.85 (t, 
3J = 7.0 Hz, 3H, 
CH3), 1.33 – 1.16 (m, 2H, CH2), 1.67 (p, 
3J = 7.4 Hz, 2H, CH2), 3.73 
(t, 3J = 7.3 Hz, 2H, CH2), 5.65 (s, 1H, NH), 6.29 (dd, 
4J = 1.9 Hz, 4J = 0.9 Hz, 1H, 
CHAr), 6.42 (dd, 
3J = 8.2 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.71 (ddd, 
3J = 7.9 Hz, 
3J = 7.4 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.06 – 7.20 (m, 2H, CHAr), 7.47 (dd, 
3J = 8.0 Hz, 
4J = 1.4 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 13.95 (CH3), 22.2 (CH2), 28.74 (CH2), 30.6 
(CH2), 46.2 (CH2), 91.4 (C), 108.3 (CH), 109.45 (C), 113.8 (CH), 116.8 (C), 120.7 
(CH), 125.9 (CH), 128.7 (CH), 128.7 (C), 129.8 (C), 132.75 (CH), 133.9 (C), 143.5 
(C); 
IR (ATR, cm-1):  = 3340 (w), 3126 (w), 3068 (w), 2955 (w), 2928 (m), 2858 
(w), 2221 (s), 1721 (w), 1673 (w), 1646 (w), 1619 (w), 1591 (m), 1577 (m), 1563 (m), 
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1516 (s), 1487 (s), 1463 (m), 1450 (s), 1397 (m), 1377 (m), 1352 (m), 1297 (s), 1284 
(s), 1187 (m), 1157 (w), 1130 (m), 1118 (m), 1073 (w), 1043 (w), 1021 (s), 979 (w), 
931 (w), 864 (w), 802 (m), 742 (s), 706 (w), 633 (s), 537 (w); 
MS (EI, 70eV): m/z (%) = 333 ([M]+, 81Br, 33), 331 ([M]+, 79Br, 38), 252 (11), 
210 (10), 197 (14), 196 (99), 194 (13), 182 (40), 181 (30), 155 (13); 
HRMS (EI) calcd for C16H18BrN3 ([M, 
79Br]+)331.06786, found 331.06755; 
HRMS (EI) calcd for C16H18BrN3 ([M, 
81Br]+)333.06575, found 333.06582. 
 
5-(2-bromo-4,5-dimethoxyphenylamino)-1-tert-butyl-1H-pyrrole-3-carbonitrile (16q): 
Starting with 15 (100 mg, 0.61 mmol), bromoarene (199 mg, 1.1 
equiv.), Pd(OAc)2 (6.8 mg, 5 mol. %), DPEphos (33 mg,  
10 mol. %), Cs2CO3 (499 mg, 2.5 equiv.), and 1,4-dioxane  
 (4 mL), 16q was isolated by column chromatography as red 
crystals (156 mg, 68 %), mp = 133-134 ºC; 
1H NMR (300 MHz, CDCl3): δ = 1.58 (s, 9H, C(CH3)3), 3.67 (s, 3H, OCH3), 3.81 
(s, 3H, OCH3), 5.3 (s, 1H, NH), 6.1 (s, 1H, CHAr), 6.3 (dd, 
4J = 2.1 Hz, 4J = 1.1 Hz, 
1H, CHAr), 7.0 (s, 1H, CHAr), 7.2 (d, 
4J = 2.1 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 30.4 (C(CH3)3), 56.2 (OCH3), 56.9 (OCH3), 57.9 
(C(CH3)3), 90.1 (C), 98.5 (C), 99.1 (CH), 110.6 (CH), 116.1 (CH), 117.0 (C), 124.1 (CH), 131.5 
(C), 138.0 (C), 143.0 (C), 149.8 (C); 
IR (ATR, cm–1):  = 3372 (w), 3334 (w), 3153 (w), 2979 (w), 2957 (w), 2931 (w), 2827 
(w), 2214 (s), 1614 (w), 1586 (w), 1563 (w), 1507 (s), 1478 (m), 1462 (m), 1444 (m), 1432 (m), 
1396 (m), 1380 (m), 1371 (m), 1365 (m), 1357 (m), 1317 (m), 1275 (m), 1260 (m), 1231 (m), 1205 
(s), 1170 (s), 1149 (s), 1089 (m), 1033 (s), 985 (m), 929 (w), 871 (w), 832 (s), 806 (s), 789 (m), 748 
(m), 697 (m), 669 (m), 634 (s), 613 (m), 598 (m), 576 (m), 554 (m); 
MS (EI, 70 eV) m/z (%): 380 (12), 379 (64), 378 (12), 377 (M+, 64), 324 (16), 323 (100), 
322 (16), 321 (95), 308 (40), 306 (38), 243 (11), 242 (59), 241 (18), 226 (26), 211 (29), 198 (11), 
184 (12), 183 (10), 57 (28), 29 (11);  
HRMS (ESI): calcd for C17H20N3O2 (M
+, 79Br) 377.07334, found 377.07283;  
HRMS (ESI): calcd for C17H20N3O2 (M
+, 81Br) 379.07129, found 379.07124. 
 
5-(2-bromophenylamino)-1-tert-butyl-1H-pyrrole-3-carbonitrile (16r): 
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Starting with 15 (100 mg, 0.61 mmol), bromoarene (159 mg, 1.1 equiv.), Pd(OAc)2 
(6.8 mg, 5 mol. %), DPEphos (33 mg, 10 mol. %), Cs2CO3 (499 mg, 2.5 equiv.), and 
1,4-dioxane  (4 mL), 16r was isolated as a light yellow solid (166 mg, 85 %); 
mp = 140-141°C. 
1H NMR (300 MHz, CDCl3): δ = 1.57 (s, 9H, C(CH3)3), 5.62 (s, 
1H, NH), 6.30 (dd, 4J = 2.0 Hz, 4J = 1.1 Hz, 1H, CHAr), 6.50 (dd, 
3J = 8.2 Hz, 4J = 1.5 Hz, 1H, CHAr), 6.68 (ddd, 
3J = 7.9 Hz, 3J = 7.4 Hz, 
4J = 1.5 Hz, 1H, CHAr), 7.05 – 7.15 (m, 1H, CHAr), 7.24 (d, 
4J = 2.0 Hz, 
1H, CHAr), 7.46 (dd, 
3J = 8.0 Hz, 4J = 1.4 Hz, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 30.2 (C(CH3)3), 57.7 (C(CH3)3), 90.0 (C), 
109.34 (C), 111.0 (CH), 114.0 (CH), 116.8 (C), 120.3 (CH), 124.1 (CH), 128.5 (CH), 
130.50 (C), 132.5 (CH), 143.7 (C); 
IR (ATR, cm-1):  = 3381 (w), 3146 (w), 3104 (w), 3060 (w), 3001 (w), 2799 
(w), 3928 (w), 2219 (s), 1589 (m), 1560 (m), 1510 (m), 1488 (m), 1450 (m), 1415 (m), 
1337 (m), 1352 (m), 1314 (m), 1299.2 (m), 1207 (m), 1198 (m), 1157 (m), 1085 (m), 
1019.3 (m), 838 (m), 828.5 (m), 745 (s), 637 (s). 
MS (EI, 70eV): m/z (%) = 319 ([M]+, 81Br, 38), 317 ([M]+, 79Br, 38), 264 (13), 
263 (97), 261 (100), 183 (12), 182 (82), 181 (58), 155 (26), 154 (11), 76 (11), 57 (32), 
41 (23). 
HRMS (EI) calcd for C15H16N3Br ([M]
+) 317.05221, found 317.05299; 
HRMS (EI) calcd for C15H16N3 
81Br ([M]+) 319.05017, found 319.05095. 
 
General procedure for the synthesis of compounds 17a-s: 
To a Schlenk flask, corresponding compound 16 (100 mg), Pd(OAc)2 (5 mol %), 
PCy3·HBF4 (10 mol %), DBU (2.5 equiv.), and DMA (4-5 mL) were added under an 
inert atmosphere. The reaction mixture was refluxed at 145 °C for 3-4 h. The solvent 
was evaporated to dryness and the residue was purified by column chromatography to 
give compound 16. 
 
1-mesityl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17a): 
Starting from compound 16a (100 mg, 0.31 mmol), the product 17a was isolated as 
yellow solid (68 mg, 71 %); mp = 281-282 °C; 
~
N
NH
N
H3C
Br
CH3
CH3
179 
 
1H NMR (250 MHz, DMSO-d6): δ = 1.97 (s, 6H, CH3), 2.35 (s, 3H, CH3), 7.04 – 
7.21 (m, 4H, CHAr), 7.2 – 7.4 (m, 1H, CHAr), 7.61 (s, 1H, CHAr), 7.63– 7.75 (m, 1H, 
CHAr), 11.48 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 17.0 (CH3), 20.5 
(CH3), 83.2 (C), 105.7 (C), 112.3 (CH), 117.0, 117.6 (CH), 119.4 
(CH), 119.5 (C), 121.3 (CH), 128.8 (CH), 129.0 (CH), 132.5 (C), 
135.5 (C), 138.79 (C), 138.81 (C), 139.5 (C); 
IR (ATR, cm-1): v~  = 3240 (w), 3124 (w), 3055 (w), 2953 
(w), 2919 (w), 2855 (w), 2223 (m), 1894 (w), 1827 (w), 1781 (w), 
1727 (w), 1619 (w), 1577 (m), 1553 (s), 1516 (m), 1490 (m), 1464 (m), 1451 (s), 1376 
(w), 1317 (m), 1295 (m), 1261 (m), 1253 (m), 1209 (m), 1176 (m), 1123 (w), 1072 (m), 
1047 (m), 989 (m), 957 (m), 913 (w), 883 (w), 851 (m), 835 (m), 767 (s), 737 (s), 710 
(s), 700 (m), 662 (m), 637 (m), 603 (s), 594 (s), 548 (s); 
MS (GC, 70 eV) m/z (%): 300 (20), 299 (M+, 100), 298 (35), 284 (27), 247 
(23), 232 (11), 231 (11), 91 (15), 77 (14); 
HRMS (EI): calcd. for C29H37N3 (M 
+) 299.14170, found 299.14155. 
 
1-(2,4-dimethylphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17b): 
Starting from compound 16b (100 mg, 0.27 mmol), the product 17b was isolated as 
yellow solid (66 mg, 85 %); mp = 223-224 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 2.12 (s, 3H, CH3), 
2.39 (s, 3H, CH3), 7.09 – 7.20 (m, 2H, CHAr), 7.23 (dd, 
3J = 8.0 Hz, 4J = 2.0 Hz, 1H, CHAr), 7.31 (s, 1H, CHAr),  
7.33 – 7.40 (m, 2H, CHAr), 7.63 – 7.69 (m, 1H, CHAr), 7.70 (s, 
1H, CHAr), 11.53 (s, 1H, NH);
 
13C NMR (63 MHz, DMSO-d6): δ = 17.2 (CH3), 20.6 
(CH3), 83.3 (C), 105.7 (C), 112.3 (CH), 117.0 (C), 117.6 (CH), 119.4 (CH), 119.5 (C), 
121.4 (CH), 126.7 (CH), 127.7 (CH), 129.2 (CH), 131.9 (CH), 133.5 (C), 134.0 (C), 
138.8 (C), 139.0 (C), 139.5 (C); 
IR (ATR, cm-1): v~  = 3286 (w), 3131 (w), 3057 (w), 2919 (w), 2852 (w), 2220 
(s), 1621 (w), 1581 (m), 1555 (m), 1520 (m), 1496 (s), 1451 (m), 1375 (w), 1325 (w), 
1313 (m), 1251 (m), 1210 (m), 1170 (s), 1133 (m), 1111 (w), 1045 (s), 993 (w), 952 
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(w), 925 (w), 882 (w), 847 (w), 822 (s), 752 (s), 735 (s), 711 (s), 703 (s), 664 (m), 630 
(m), 595 (s), 555 (s), 535 (s), 500 (s), 451 (s), 433 (s); 
MS (GC, 70 eV) m/z (%): 286 (20), 285 (100), 284 (50), 270 (29), 233 (16); 
HRMS (EI): calcd. for C19H15N3 (M
+) 285.12605, found 285.12596. 
 
1-(2,4-dimethylphenyl)-5,6-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbo-
nitrile (17c): 
Starting from compound 16c (100 mg, 0.25 mmol), the 
product 17c was isolated as yellow solid (64 mg, 81 %); 
mp = 214-216 ºC; 
1H NMR (300 MHz, CDCl3): δ = 2.13 (s, 3H, CH3), 
2.36 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.41 (s, 3H, CH3), 7.06 
(s, 1H, CHAr), 7.09 (s, 1H, CHAr), 7.14 (dd, 
3J = 7.9 Hz, 
4J = 2.0 Hz, 1H, CHAr), 7.18 (d, 
4J = 1.8 Hz, 1H, CHAr), 7.21 
(d, 3J = 8.0 Hz, 1H, CHAr), 7.49 (s, 1H), 7.66 (s, 1H, CHAr); 
13C NMR (63 MHz, CDCl3): δ = 17.6 (CH3), 20.1 (CH3), 20.6 (CH3), 21.3 (CH3), 
85.2 (C), 107.9 (C), 112.6 (CH), 117.2 (C), 119.2 (C), 119.8 (CH), 126.6 (CH), 127.4 
(CH), 128.1 (CH), 129.4 (C), 131.3 (C), 132.5 (CH), 133.6 (C), 134.5 (C), 138.3 (C), 
138.3 (C), 139.7 (C); 
IR (ATR, cm-1): v
~
 =3254 (w), 3150 (w), 3126 (w), 3015 (w), 2957 (w), 2919 
(w), 2854 (w), 2222 (s), 1681 (w), 1568 (w), 1544 (m), 1519 (m), 1501 (s), 1456 (s), 
1371 (m), 1346 (w), 1324 (m), 1277 (m), 1235 (m), 1211 (m), 1168 (s), 1132 (m), 1115 
(m), 1042 (m), 1022 (m), 1001 (m), 953 (m), 866 (m), 853 (s), 812 (s), 764 (w), 752 
(m), 732 (m), 720 (m), 714 (m), 689 (m), 638 (m), 581 (s), 567 (m), 549 (s); 
MS (GC, 70 eV) m/z (%): 314 (21), 313 (M+, 100), 312 (39), 298 (28), 261 
(10); 
HRMS (EI): calcd. for C21H19N3 (M
+) 313.15735, found 313.15678. 
 
5-chloro-1-(2,4-dimethylphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile 
(17d): 
Starting from compound 16d (100 mg, 0.25 mmol), the product 17d was isolated as 
brown solid (60 mg, 75 %); mp = 246-247 °C. 
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1H NMR (300 MHz, CDCl3): δ = 2.09 (s, 3H, CH3), 2.34 
(s, 3H, CH3), 6.99 – 7.42 (m, 6H, CHAr). 7.69-7.71 (m, 1H, 
CHAr), 10.63 (s, 1H, NH); 
13C NMR (63 MHz, CDCl3): δ = 17.4 
(CH3), 20.9 (CH3), 84.7 (C), 106.2 (C), 113.0 (CH), 116.5 (C), 
118.0 (CH), 120.9 (C), 121.4 (CH), 124.8 (C), 126.6 (CH), 
127.6 (CH), 128.0 (CH), 131.9 (CH), 133.5 (C), 134.4 (C), 
138.0 (C), 139.1 (C), 139.7 (C);  
IR (ATR, cm-1): v~  = 3259 (w), 3131 (w), 2850 (w), 2223 (s), 1617 (w), 1576 
(s), 1558 (w), 1521 (s), 1498 (s), 1441 (s), 1377 (w), 1325 (w), 1285 (m), 1248 (m), 
1240 (m), 1206 (m), 1171 (s), 1137 (w), 1070 (m), 1043 (s), 864 (s), 837 (m), 824 (s), 
799 (s), 745 (s), 732 (s), 713 (m), 679 (w), 657 (w), 591 (s), 579 (s), 526 (s), 510 (s), 
449 (s), 431 (s), 424 (m), 408 (m); 
MS (GC, 70 eV) m/z (%): 321 (31), 320 (32), 319 (M+) 100), 318 (39), 304 
(26), 284 (19), 267 (17); 
HRMS (EI): calcd. for C19H14ClN3 (M
+) 319.08708, found 319.08741. 
 
1-(4-isopropylphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17e): 
Starting from compound 16e (100 mg, 0.26 mmol), the product 17e was isolated as 
brown solid (65 mg, 82 %); mp = 221-222 °C; 
1H NMR (300 MHz, DMSO-d6): δ = 1.27 (d, 
3J = 6.9 Hz, 
6H, CH(CH3)2), 3.01 (p, 
3J = 6.9 Hz, 1H, CH(CH3)2), 7.1 (td, 
3J = 7.5 Hz, 4J =1.4 Hz, 1H, CHAr), 7.2 (td, 
3J = 7.6 Hz, 1.6 Hz, 
1H, CHAr), 7.43 – 7.48 (m, 1H, CHAr), 7.49 (d, 
3J = 8.5 Hz, 2H, 
CHAr), 7.68 (d, 
3J = 8.6 Hz, (2+1) H, CHAr), 8.02 (s, 1H, CHAr), 
11.79 (s, 1H, NH); 
13C NMR (75 MHz, DMSO-d6): δ = 23.8 (CH(CH3)2), 33.1 (CH(CH3)2), 84.2 (C), 
107.1 (C), 112.6 (CH), 116.8 (C), 117.6 (CH), 119.2 (C), 119.7 (CH), 121.3 (CH), 
121.8 (CH), 127.0 (CH), 127.9 (CH), 135.0 (C), 137.0 (C), 139.6 (C), 147.6 (C); 
IR (ATR, cm-1):  = 3253.2 (m), 3146.5 (w), 3056 (w), 2955.8 (m), 2923 (m), 
2923 (w), 2863.9 (w), 2224.8 (s), 1909.2 (w), 1871.4 (w), 1835.3 (w), 1794.8 (w), 1755 
(w), 1613 (w), 1591 (w), 1544 (m), 1521 (m), 1507 (m), 1451 (m), 1417 (m), 1321(m), 
1322 (m), 1258 (m), 1252 (m), 1213 (m), 1176 (m), 1149.9 (m), 1110 (m), 1057.3 (m), 
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1012.9 (m), 991.8 (m), 918 (m), 818.7 s), 750.9 (m), 736 (s), 721.5 (s), 707.5 (s), 679.8 
(m), 613 (m), 577 (m), 536 (s).  
MS (EI, 70eV): m/z (%) = 300 (21), 299 (100), 284 (35), 257 (19), 256 (51), 127 
(17). 
HRMS (EI): calcd. for C18H12ClN3O (M
+) 321.06634, found 321.06619. 
 
5-chloro-1-(4-isopropylphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile 
(17f): 
Starting from compound 16f (100 mg, 0.24 mmol), the product 
17f was isolated as brown solid (63 mg, 80 %);  
mp = 254-255°C; 
1H NMR (300 MHz, CDCl3): δ = 1.23 (d, 
3J = 6.9 Hz, 6H, 
CH(CH3)2), 2.93 (p, 
3J = 6.9 Hz, 1H, CH(CH3)2), 7.05 (dd, 
3J = 8.6 Hz, 4J = 2.1 Hz, 1H, CHAr), 7.26 (d, 
3J = 8.6 Hz, 2H), 
7.31 (d, 3J = 8.5 Hz, 2H, CHAr), 7.43 (d, 
3J = 8.5 Hz, 2H, CHAr), 7.69 (d, 
4J = 2.1 Hz, 
1H, CHAr), 10.82 (s, 1H, NH). 
13C NMR (63 MHz, CDCl3): δ = 23.9 (CH(CH3)2), 33.7 (CH(CH3)2), 85.7 (C), 107.6 (C), 
113.2 (CH), 116.5 (C), 118.1 (CH), 120.9, 121.6 (CH), 121.8 (CH), 125.2 (C), 125.95 (CH), 128.0 
(CH), 135.2 (C), 138.06 (2*С), 148.4 (C);  
IR (ATR, cm-1): v~  = 3238 (w), 3135 (w), 3080 (w), 3049 (w), 2958 (w), 2935 (w), 2888 
(w), 2863 (w), 2230 (s), 1901 (w), 1835 (w), 1709 (w), 1693 (w), 1618 (w), 1590 (w), 1575 (m), 
1550 (m), 1520 (s), 1510 (s), 1441 (m), 1427 (m), 1405 (w), 1380 (w), 1361 (w), 1332 (w), 1309 
(w), 1287 (m), 1251 (m), 1220 (w), 1209 (m), 1169 (s), 1117 (w), 1096 (w), 1069 (w), 1057 (s), 
1013 (m), 961 (w), 942 (w), 920 (w), 883 (w), 856 (m), 834 (s), 825 (m), 792 (s), 762 (m), 744 (s), 
730 (s), 711 (w), 690 (w), 663 (w), 638 (w), 613 (w), 587 (s), 571 (m), 557 (m); 
MS (GC, 70 eV) m/z (%): 335 (M+, 37Cl, 34), 334 (22), 333 (M+, 35Cl, 100), 
318 (29), 293 (10), 292 (18), 291 (300, 290 (42), 283 (13), 161 (13); 
HRMS (EI): calcd. for C20H16ClN3 (M
+, 35Cl) 333.10273, found 333.10252; 
HRMS (EI): calcd. for C19H15ClN3 (M
+, 37Cl) 335.09978, found 335.09925. 
 
1-(4-methoxyphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17g): 
Starting from compound 16g (100 mg, 0.27 mmol), the product 17g was isolated as 
brown solid (47 mg, 60 %); mp = 195-196 °C; 
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 1H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3H, OCH3), 
6.98 (d, 3J = 8.8 Hz, 2H, CHAr), 7.07 – 7.19 (m, 2H, CHAr), 
7.21-7.26 (m, 1H, CHAr), 7.33 – 7.40 (m, 1H, CHAr), 7.44 (d, 
3J = 8.8 Hz, 2H, CHAr), 7.8 (d, 
3J = 7.1 Hz, 1H, CHAr), 10.43 
(s, 1H, NH); 
13C NMR (75 MHz, CDCl3): δ = 55.5 (OCH3), 85.3 (C), 
108.1 (C), 112.2 (CH), 115.0 (CH), 116.9 (C), 118.5 (CH), 119.8 (CH), 120.0 (C), 
121.8 (CH), 123.1 (CH), 125.5 (CH), 130.6 (C), 137.4 (C), 139.7 (C), 158.6 (C);  
IR (ATR, cm-1): v~  = 3257 (w), 3135 (w), 2998 (w), 2958 (w), 2929 (w), 2834 
(w), 2754 (w), 2225 (m), 2040 (w), 1619 (w), 1594 (w), 1579 (m), 1553 (m), 1519 (s), 
1504 (s), 1451 (s), 1440 (m), 1420 (m), 1379 (w), 1322 (m), 1307 (w), 1296 (m), 1249 
(s), 1211 (m), 1172 (s), 1111 (m), 1056 (m), 1033 (s), 1008 (m), 990 (m), 954 (m), 921 
(m), 885 (w), 834 (s), 813 (m), 790 (m), 750 (s), 743 (s), 732 (s), 721 (s), 703 (s), 677 
(w), 643 (w), 625 (w), 597 (s), 581 (s), 546 (s), 531 (s); 
MS (GC, 70 eV) m/z (%): 288 ([M+H]+, 20), 287 ([M]+, 100), 286 (19), 273 (12), 
272 (64), 244 (31), 243 (19), 154 (10), 127 (18); 
HRMS (EI): calcd. for C18H13N3O (M
+) 287.10531, found 287.10513. 
 
5-chloro-1-(4-methoxyphenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile 
(17h): 
Starting from compound 16h (100 mg, 0.25 mmol), the product 17h was isolated as 
brown solid (69 mg, 87 %); mp = 263-265 ºC; 
1H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3H, OCH3), 
7.00 (d, 3J = 8.9 Hz, 2H, CHAr), 7.05 (dd, 
3J = 8.6 Hz, 
4J = 2.0 Hz, 1H, CHAr), 7.36 (s, 1H, CHAr), 7.47 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.58 (s, 1H, CHAr), 7.62 (d, 
4J = 1.9 Hz, 1H, CHAr), 11.34 (s, 1H, NH); 
13C NMR (63 MHz, CDCl3): δ = 54.9 (OCH3), 84.2 (C), 
106.4, 112.7 (CH), 114.3 (CH), 115.8 (C), 116.9 (CH), 120.0 
(C), 120.8 (CH), 122.5 (CH), 124.0 (C), 125.7 (CH), 129.6, 
137.4 (C), 137.6 (C), 158.0 (C); 
IR (ATR, cm-1): v~  = 3229 (w), 3141 (w), 3079 (w), 3014 (w), 3970 (w), 2927 (w), 2835 
(w), 2228 (s), 1884 (w), 1854 (w), 1755 (w), 1715 (w), 1621 (w), 1595 (w), 1577 (m), 1551 (w), 
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1508 (s), 1441 (s), 1302 (w), 1285 (m), 1245 (s), 1209 (m), 1168 (s), 1112 (m), 1068 (w), 1052 (m), 
1028 (s), 1005 (m), 952 (w), 933 (w), 885 (w), 858 (m), 831 (s), 813 (m), 802 (s), 753 (s), 742 (m), 
725 (s), 686 (w), 662 (w), 637 (w), 614 (m), 589 (s), 563 (s); 
MS (GC, 70 eV) m/z (%): 323 (33), 322 (29), 321 (100), 320 915), 308 (19), 307 
(11), 306 (54), 286 (12), 278 (20), 243 (21), 161 (15); 
HRMS (EI): calcd. for C18H12ClN3O (M
+) 321.06688, found 321.06693. 
 
1-(3-chlorophenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17i): 
Starting from compound 16i (100 mg, 0.27 mmol), the product 17i 
was isolated as yellow solid (59 mg, 76 %); mp = 233-235 °C. 
1H NMR(300 MHz, DMSO-d6): δ = 7.17 (td, 
3J = 7.4 Hz, 
4J = 1.3 Hz, 1H, CHAr), 7.22 (td, 
3J = 7.6 Hz, 4J = 1.5 Hz, 1H, CHAr), 7.45 – 
7.56 (m, 2H, CHAr), 7.64 (d, 
3J = 8.1 Hz, 1H, CHAr), 7.65 – 7.71 (m, 1H, 
CHAr), 7.75 – 7.80 (m, 1H, CHAr), 7.90 (t, 
4J = 2.1 Hz, 1H, CHAr), 8.14 (s, 
1H, CHAr), 11.95 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 85.2 (C), 107.4 (C), 112.7 (CH), 116.5 (C), 117.7 (CH), 
119.0 (C), 119.7 (CH), 119.9 (CH), 121.0 (CH), 122.0 (CH), 127.0 (CH), 127.1 (CH), 131.6 (CH), 
134.4 (C), 136.7 (C), 138.3 (C), 139.6 (C); 
IR (ATR, cm-1): v~  = 3242 (w), 3135 (w), 3070 (w), 2922 (w), 2853 (w), 2757 (w), 2224 
(s), 1621 (w), 1595 (s), 1585 (s), 1551 (s), 1521 (s), 1508 (m), 1484 (s), 1453 (s), 1434 (m), 1424 
(m), 1380 (m), 1333 (m), 1317 (m), 1209 (m), 1170 (m), 1153 (m), 1099 (s), 1078 (m), 1060 (m), 
992 (m), 922 (m), 904 (m), 880 (m), 842 (w), 794 (m), 784 (s), 732 (s), 714 (s), 703 (s), 689 (s), 672 
(s), 619 (s), 606 (m), 584 (s), 544 (s); 
MS (GC, 70 eV) m/z (%): 293 (33), 292 (24), 291 (100), 290 (14), 257 (11), 256 (57), 229 
(10), 154 (25), 145 (10), 128 (11), 127 (36), 75 (11); 
HRMS (ESI-TOF): calcd. for C17H10ClN3 (M+H
+) 292.0636, found 292.06345; 
HRMS (ESI-TOF): calcd. for C17H10
39ClN3 (M+Na
+) 316.04308, found 
316.04307. 
 
1-(3-chlorophenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17j): 
Starting from compound 16j (100 mg, 0.24 mmol), the product 17j was isolated as 
yellow solid (58 mg, 72 %); mp = 285-286 °C; 
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1H NMR (300 MHz, DMSO-d6): δ = 7.23 (dd, 
3J = 8.7, 
3J = 2.2 Hz, 1H, CHAr), 7.49 (d, 
3J = 8.7 Hz, 1H, CHAr), 7.52 
(ddd, 3J = 8.1 Hz, 4J = 2.0 Hz, 4J = 1.1 Hz, 1H, CHAr), 7.62 
(d, 4J = 2.0 Hz, 1H, CHAr), 7.66 (d, 
3J = 8.0 Hz, 1H, CHAr), 
7.74 (ddd, 3J = 8.1 Hz, 4J = 2.2 Hz, 4J = 1.1 Hz, 1H, CHAr), 
7.88 (t, 4J = 2.1 Hz, 1H, CHAr), 8.17 (s, 1H, CHAr), 12.15 (s, 1H, NH); 
13C NMR (75 MHz, DMSO-d6): δ = 85.1 (C), 106.6 (C), 114.1 (CH), 116.1 (C), 
116.9 (CH), 119.9 (CH), 119.9 (C), 121.2 (CH), 121.7 (CH), 124.2 (C), 127.2 (CH), 
128.1 (CH), 131.6 (CH), 134.4 (C), 137.6 (C), 138.0 (C), 138.0 (C); 
IR (ATR, cm-1): v~  = 3216 (w), 3136 (w), 2919 (w), 2234 (m), 1622 (w), 1593 
(s), 1586 (m), 1574 (m), 1548 (m), 1507 (s), 1483 (m), 1444 (m), 1407 (w), 1328 (w), 
1291 (m), 1273 (w), 1251 (w), 1208 (m), 1188 (w), 1168 (s), 1095 (m), 1071 (w), 1053 
(s), 997 (w), 905 (m), 874 (m), 863 (m), 844 (m), 802 (s), 783 (s), 761 (s), 746 (s), 732 
(s), 713 (w), 699 (s), 676 (m), 662 (m), 605 (w), 593 (s), 536 (s), 501 (s), 443 (s), 432 
(m); 
MS (EI, 70eV): m/z (%) = 329 (11), 328 (13), 327 (66), 325 (100), 324 (110), 
292 (19), 291 (13), 290 (61), 188 (18), 161 (19), 111 (11), 75 (18); 
HRMS (EI) calcd for C17H9N3Cl2 ([M]
+) 325.01680, found 325.01651; 
HRMS (EI) calcd for C17H9N3Cl
37Cl ([M]+) 327.01385, found 327.01398. 
 
1-(4-chlorophenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17k): 
Starting from compound 16k (100 mg, 0.27 mmol), the product 
17k was isolated as yellow solid (55 mg, 70 %);  
mp = 259-260 ºC; 
1H NMR (300 MHz, DMSO-d6): δ = 7.16 (td, 
3J = 7.5 Hz, 
4J = 1.4 Hz, 1H, CHAr), 7.22 (td, 
3J = 7.5 Hz, 4J = 1.4 Hz, 1H, 
CHAr), 7.48 (d, 
3J = 7.6 Hz, 1H, CHAr), 7.68 (d, 
3J = 8.9 Hz, (2+1) H, CHAr), 7.81 (d, 
3J = 8.9 Hz, 2H, CHAr), 8.08 (s, 1H, CHAr), 11.87 (s, 1H, NH); 
13C NMR (75 MHz, DMSO-d6): δ = 85.0 (C), 107.4 (C), 112.6 (CH), 116.5 (C), 
117.7 (CH), 119.1 (C), 119.9 (CH), 121.9 (CH), 122.9 (C), 127.0 (CH), 129.9 (CH), 
131.4 (C), 135.9 (C), 136.8 (C), 139.6 (C); 
IR (ATR, cm-1): v~  = 3290 (w), 3141 (w), 3058 (w), 2957 (w), 2926 (w), 2858 
(w), 2753 (w), 2226 (m), 1922 (w), 1877 (w), 1841 (w), 1806 (w), 1723 (w), 1621 (w), 
1596 (m), 1587 (w), 1581 (w), 1542 (m), 1518 (s), 1495 (s), 1450 (s), 1431 (m), 1409 
N N
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(m), 1377 (m), 1335 (m), 1322 (m), 1278 (m), 1258 (s), 1227 (m), 1210 (m), 1171 (s), 
1121 (m), 1094 (s), 1072 (m), 1051 (m), 1012 (m), 992 (m), 965 (w), 926 (w), 918 (w), 
886 (w), 825 (s), 811 (s), 749 (s), 743 (s), 726 (s), 707 (s), 700 (s), 678 (m), 651 (w), 
638 (w), 621 (m), 605 (m), 577 (s), 535 (m); 
MS (GC, 70 eV) m/z (%): 293 (34), 292 (25), 291 (100), 290 (16), 257 (14), 256 (68), 229 
(10), 154 (22), 146 (11), 127 (35), 126 (10), 75 (17); 
HRMS (EI) calcd for C17H10ClN3 (M
+, 35Cl) 291.05578, found 291.05606; 
HRMS (EI) calcd for C17H10ClN3 (M
+, 37Cl) 293.05283, found 293.05368; 
 
5-chloro-1-(4-chlorophenyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17l): 
Starting from compound 16l (100 mg, 0.24 mmol), the product 17l 
was isolated as yellow solid (45 mg, 56 %); mp = 297-299 ºC; 
1H NMR (250 MHz, DMSO-d6): δ = 7.27 (dd, 
3J = 8.7 Hz, 
4J = 1.0 Hz, 1H, CHAr), 7.53 (d, 
3J = 8.6 Hz, 1H, CHAr), 7.7 – 7.8 
(m, 1H, CHAr), 7.74 (d, 
3J = 8.4 Hz, 2H, CHAr), 7.85 (d, 
3J = 8.7 Hz, 2H, CHAr), 8.18 (s, 1H, CHAr), 12.14 (s, 1H, NH); 
13C NMR (63 MHz, DMSO-d6): δ = 84.9 (C), 106.6 (C), 114.0 (CH), 116.1 (C), 
116.8 (CH), 119.9 (C), 121.6 (CH), 123.0 (CH), 124.1 (C), 127.9 (CH), 129.9 (CH), 
131.5 (C), 135.7 (C), 137.7 (C), 138.0 (C);  
IR (ATR, cm-1): v~ = 3233 (w), 3142 (w), 2956 (m), 2924 (m), 2855 (m), 2235 
(m), 1884 (w), 1841 (w), 1725 (m), 1645 (w), 1618 (w), 1595 (w), 1587 (w), 1511 (s), 
1490 (s), 1451 (m), 1441 (m), 1398 (w), 1378 (w), 1332 (w), 1285 (s), 1276 (s), 1209 
(m), 1171 (m), 1121 (m), 1108 (m), 1091 (s), 1069 (s), 1046 (m), 1010 (m), 952 (w), 
885 (m), 854 (m), 824 (s), 794 (s), 746 (s), 737 (s), 721 (m), 708 (m), 661 (m), 588 (s), 
545 (s); 
MS (GC, 70 eV) m/z (%): 328 (13), 327 (66), 326 (27), 325 (100), 292 (35), 291 (16), 290 
(84), 254 (12), 214 (11), 188 (24), 187 (13), 163 (14), 161 (29), 152 (15), 151 (15), 137 (11), 125 
(13), 124 (25), 113 (15), 111 (36), 102 (11), 100 (13), 99 (17), 85 (13), 76 (18), 75 (76), 74 (26), 51 
(13), 50 (28); 
HRMS (EI) calcd for C17H9Cl2N3 (M
+, 35Cl) 325.01680, found 325.01622; 
HRMS (EI) calcd for C17H10ClN3 (M
+, 37Cl) 327.01385, found 327.01445. 
 
1-benzyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17m): 
N
H
N
NC
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Starting from compound 16m (100 mg, 0.28 mmol), the product 17m 
was isolated as beige solid (48 mg, 62 %); mp = 181-182 °C; 
1H NMR (300 MHz, CDCl3): δ = 5.22 (s, 2H, CH2), 7.04 – 7.20 
(m, 4H, CHAr), 7.2 – 7.35 (m, 5H), 7.7 – 7.8 (m, 1H, CHAr), 10.2  
 (s, 1H, NH); 
13C NMR (75 MHz, CDCl3): δ = 51.1 (CH2), 84.0 (C), 107.7 
(C), 111.9 (CH), 117.3 (C), 118.6 (CH), 119.7 (CH), 120.4 (C), 121.6 (CH), 126.8 
(CH), 127.1 (CH), 128.3 (CH), 129.0 (CH), 135.8 (C), 138.9 (C), 139.7 (C);  
IR (ATR, cm-1): v~  = 3269 (w), 3108 (w), 3062 (w), 3029 (w), 2919 (w), 2850 
(w), 2219 (s), 1639 (w), 1621 (w), 1580 (m), 1563 (m), 1521 (m), 1493 (m), 1453 (m), 
1317 (m), 1245 (s), 1210 (m), 1174 (m), 1132 (m), 1111 (m), 1077 (m), 1029 (w), 1013 
(m), 998 (m), 947 (m), 919 (w), 837 (w), 817 (w), 736 (s), 710 (s), 695 (s), 666 (s), 647 
(m), 618 (s), 589 (s), 534 (s), 509 (s), 491 (s), 450 (s), 433 (s); 
MS (GC, 70 eV) m/z (%): 272 (12), 271 (59), 180 (13), 91 (100), 65 (12); 
HRMS (EI) calcd for C18H13N3 (M
+) 271.11040, found 271.11062; 
 
1-(3,4-dimethoxyphenethyl)-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17n): 
Starting from compound 16n (100 mg, 0.23 mmol), the 
product 17n was isolated as brown solid (49 mg, 60 %); 
mp = 175-176 °C; 
1H NMR (300 MHz, CDCl3): δ = 3.05 (t, 
3J = 6.4 Hz, 2H, CH2), 3.66 (s, 3H, OCH3), 3.81 (s, 3H, 
OCH3), 4.23 (t, 
3J = 6.4 Hz, 2H, CH2), 6.43 (d, 
4J = 2.0 Hz, 1H, CHAr), 6.56 (dd, 
3J = 8.1 Hz, 4J = 2.0 Hz, 
1H, CHAr), 6.72 (d, 
3J = 8.2 Hz, 1H, CHAr), 6.90 (s, 1H, CHAr), 7.11 – 7.22 (m, 3H, 
CHAr), 7.32 (broad s, 1H, CHAr/NH), 7.75 – 7.80 (m, 1H, CHAr); 
13C NMR (75 MHz, CDCl3) δ = 36.6 (CH2), 50.1 (CH2), 55.9 (OCH3), 56.0 
(OCH3), 83.7 (C), 108.5 (C), 111.6 (CH), 111.8 (CH), 112.0 (CH), 117.1, 118.9 (CH), 
120.6 (CH), 120.8, 120.9 (CH), 122.1 (CH), 126.9 (CH), 130.0 (C), 138.2 (C), 139.8 
(C), 148.3 (C), 149.2 (C).  
IR (ATR, cm-1):  = 3253 (w), 3158 (w), 3122 (w), 3064 (w), 2994 (w), 2954 
(w), 2929 (w), 2850 (w), 2833 (w), 2219 (s), 1615 (w), 1607 (w), 1582 (m), 1565 (m), 
1513 (s), 1492 (m), 1462 (s), 1451 (s), 1440 (m), 1420 (m), 1337 (m), 1320 (m), 1293 
(w), 1280 (w), 1259 (s), 1232 (s), 1174 (m), 1144 (s), 1113 (m), 1027 (s), 996 (m), 944 
~
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(m), 921 (w), 844 (m), 839 (m), 813 (m), 747 (s), 710 (s), 652 (m), 622 (m), 602 (m), 
586 (s), 562 (m), 532 (s); 
MS (GC, 70 eV) m/z (%): 346 (M+H+, 24), 345 (M+, 100), 165 (62), 164 (70), 
151 (76), 150 (14), 149 (11); 
HRMS (ESI-TOF): calcd. for C21H19N3O2 (M+H
+) 346.155, found 346.15511. 
 
1-cyclopentyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17o): 
Starting from compound 16o (100 mg, 0.3 mmol), the product 17o 
was isolated as beige solid (49 mg, 65 %); mp = 225-226 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.57 – 1.78 (m, 2H), 1.81 – 
2.01 (m, 4H), 2.10 – 2.28 (m, 2H), 4.55 (p, 3J = 7.1 Hz, 1H),  
6.97 – 7.14 (m, 3H, CHAr), 7.27 – 7.37 (m, 1H, CHAr), 7.59 – 7.82 
(m, 1H, CHAr), 10.28 (s, 1H, CHAr);  
 13C NMR (63 MHz, CDCl3): δ = 23.5, 32.1, 58.9, 82.6 (C), 107.45 (C), 111.75 (CH), 117.4 
(C), 118.3 (CH), 119.4 (CH), 120.0 (C), 121.2 (CH), 124.3 (CH), 138.2 (C), 139.6 (C);  
IR (ATR, cm-1): v~  = 3260 (w), 3111 (w), 2952 (w), 2923 (w), 2869 (w), 2853 (w), 2220 
(m), 1619 (w), 1580 (m), 1558 (m), 1525 (m), 1515 (m), 1491 (m), 1452 (m), 1435 (m), 1395 (m), 
1376 (m), 1324 (m), 1295 (w), 1251 (m), 1177 (m), 1144 (m), 1110 (m), 1091 (m), 1035 (m), 1012 
(m), 1002 (m), 955 (m), 921 (m), 889 (w), 876 (w), 843 (w), 802 (w), 759 (m), 743 (s), 711 (s), 688 
(m), 665 (m), 615 (m), 588 (s), 545 (s); 
MS (GC, 70 eV) m/z (%): 249 (M+, 54), 182 (14), 181 (100), 180 (25), 154 917), 127 (13), 
41 (12); 
HRMS (EI) calcd for C16H15N3 (M
+) 249.12605, found 249.12553. 
 
1-pentyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17p): 
Starting from compound 16p (100 mg, 0.3 mmol), the product 
17p was isolated as brown solid (40 mg, 53 %); mp = 171-172 
°C. 
1H NMR (300 MHz, CDCl3): δ = 0.89 (t, 
3J = 6.7 Hz, 
3H), 1.23 – 1.43 (m, 4H, 2*CH2), 1.86 (p, 
3J = 7.1 Hz, 2H, 
CH2), 4.03 (t, 
3J = 7.1 Hz, 2H, CH2), 7.01 (s, 1H, CHAr), 7.16 – 7.23 (m, 2H, CHAr),  
7.34 – 7.42 (m, 1H, CHAr), 7.78 – 7.86 (m, 1H, CHAr), 8.06 (s, 1H, NH); 
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13C NMR (75 MHz, CDCl3): δ = 14.0 (CH3), 22.3 (CH2), 28.9 (CH2), 29.8 (CH2), 48.1 
(CH2), 83.7 (C), 108.7 (C), 112.1 (CH), 117.4 (C), 119.1 (CH), 120.7 (CH), 121.0 (C), 122.2 (CH), 
127.0 (CH), 138.0 (C), 139.7 (C);  
IR (ATR, cm-1): v~  = 3268 (w), 3124 (w), 3058 (w), 2951 (w), 2923 (w), 2867 (w), 2851 
(w), 2214 (s), 1921 (w), 1882 (w), 1845 (w), 1619 (w), 1580 (m), 1563 (m), 1520 (m), 1491 (s), 
1452 (m), 1397 (w), 1357 (w), 1318 (m), 1247 (m), 1209 (w), 1176 (m), 1152 (w), 1106 (m), 1040 
(w), 1013 (w), 996 (m), 940 (w), 922 (w), 897 (w), 849 (w), 803 (w), 772 (m), 749 (s), 740 (s), 727 
(s), 711 (s), 614 (m), 584 (s), 533 (m); 
MS (GC, 70 eV) m/z (%): 252 (15), 251 (84), 250 (21), 236 (21), 222 (12), 195 
(61), 194 (100), 193 (11), 181 (38), 180 (29), 154 (18), 153 (12), 127 (15), 126 (11), 
41 (12); 
HRMS (EI): calcd. for C16H17N3 (M
+) 251.14170, found 251.14156. 
 
1-tert-butyl-5,6-dimethoxy-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17q): 
Starting from compound 16q (100 mg, 0.26 mmol), the 
product 17q was isolated as brown solid (35 mg, 45 %); 
mp = 263-264 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.7 (s, 9H, C(CH3)3), 
3.9 (s, 3H, OCH3), 3.9 (s, 3H, OCH3), 7.0 (s, 1H, CHAr), 7.1 
(s, 1H, CHAr), 7.3 (s, 1H, CHAr), 8.0 (s, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 29.7 (C(CH3)3), 56.5 (OCH3), 56.6 (OCH3), 
57.0 (C(CH3)3), 82.3 (C), 96.6 (CH), 101.7 (CH), 110.2 (C), 113.3 (C), 117.8 (C), 
123.9 (CH), 134.0 (C), 136.3 (C), 145.1 (C), 146.4 (C);  
IR (ATR, cm-1):  = 3353 (w), 3148 (w), 2966 (w), 2931 (w), 2871 (w), 2832 
(w), 2210 (w), 1633 (w), 1577 (m), 1546 (m), 1494 (m), 1467 (s), 1452 (s), 1427 (m), 
1411 (m), 1403 (m), 1373 (m), 1342 (w), 1309 (s), 1294 (s), 1247 (m), 1193 (s), 1178 
(s), 1163 (s), 1137 (s), 1121 (s), 1093 (m), 1029 (s), 996 (s), 954 (m), 908 (m), 872 (s), 
842 (s), 800 (m), 756 (s), 745 (s), 737 (m), 696 (s), 633 (m), 604 (s), 578 (m), 534 (m); 
MS (GC, 70 eV) m/z (%): 298 (M+H+, 17), 297 (M+, 89), 242 (14), 241 (100), 
240 (26), 227 (13), 226 (92), 198 (11), 183 (11), 170 (10), 154 (10), 57 (11); 
HRMS (ESI-TOF): calcd. for C17H19N3O2 (M+H
+) 298.1550, found 298.15519. 
 
1-tert-butyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17r): 
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Starting from compound 16r (100 mg, 0.31 mmol), the product 17r 
was isolated as brown solid (52 mg, 70 %); Beige solid, yield 
80 %; mp = 142 - 143 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.65 (s, 9H, C(CH3)3), 
7.07-7.16 (m, 3H, CHAr), 7.33-7.39 (m, 1H, CHAr), 7.71-7.78 (m, 
1H, CHAr), 9.71 (s, 1H, NH). 
13C NMR (63 MHz, CDCl3):
 δ = 29.9, 57.4, 89.7, 109.0, 
110.7, 113.7, 116.4, 119.9, 123.7, 128.4, 130.0, 132.6, 142.9; 
IR (ATR, cm-1):  = 3381.1 (s), 3146 (s), 3000.8 (s), 2978.9 (s), 2219.0 (s), 
1589.3 (s), 1560.4 (s), 1510 (s), 1487.9 (s), 1450 (s), 1373.1 (s), 1299.1 (s), 1206.6 (s), 
1197.6 (s), 1156.9 (s), 1085.2 (s), 1019.2 (s), 823.3, 744.6 (s), 637.4 (s); 
MS (GC, 70 eV) m/z (%): 237 (M+, 35), 182 (13), 181 (100), 180 (26), 154 
(14), 127 (11);HRMS (EI): calcd. for C15H15N3 (M
+) 237.12605, found 237.12604. 
 
1-mesityl-5,6-dimethyl-1,8-dihydropyrrolo[2,3-b]indole-3-carbonitrile (17s): 
Starting from 5-amino-1-mesityl-1H-pyrrole-3-carbonitrile (100 mg, 0.44 mmol), the 
product 17s was isolated as brown solid (65 mg, 82 %); mp = 285-286°C. 
1H NMR (300 MHz, CDCl3): δ = 2.00 (s, 6H, CH3), 
2.37 (s, 6H, CH3), 2.40 (s, 3H, CH3), 6.96 (s, 1H, CHAr), 
7.02 (s, 2H, CHAr), 7.08 (s, 1H, CHAr), 7.42 (s, 1H, NH), 
7.67 (s, 1H, CHAr); 
13C NMR (75 MHz, CDCl3): δ = 17.4 (CH3), 20.0 
(CH3), 20.4 (CH3), 21.1 (CH3), 85.1 (C), 107.9 (C), 112.5 
(CH), 117.1 (C), 119.2 (C), 119.65 (CH), 126.8 (CH), 129.3 
(C), 129.4 (CH), 131.1 (C), 132.4 (C), 136.1 (C), 137.8 (C), 138.2 (C), 139.7 (C); 
IR (ATR, cm-1): v~  = 3257 (w), 3129 (w), 3017 (w), 2918 (w), 2855 (w), 2222 
(s), 1633 (w), 1610 (w), 1572 (s), 1553 (s), 1524 (m), 1486 (s), 1457 (s), 1384 (w), 
1376 (w), 1324 (m), 1291 (s), 1274 (m), 1244 (w), 1210 (m), 1176 (s), 1115 (m), 1046 
(s), 1021 (m), 1004 (m), 954 (w), 856 (m), 845 (s), 803 (m), 749 (s), 736 (m), 714 (m), 
686 (m), 664 (w), 636 (m), 586 (m), 547 (s); 
MS (GC, 70 eV) m/z (%): 328 (25), 327 (M+, 100), 326 (33), 312 (28), 275 
(15); 
HRMS (ESI-TOF): calcd. for C19H14ClN3 (M+H
+) 328.18082, found 
328.18081.  
~
N
N
H
N
CH3H3C
H3C
N
H
N
NC
H3C
H3C
CH3
CH3
CH3
191 
 
Supplement 2: Crystallographic data 
Crystal data and structure refinement for compound 2h: 
 
Identification Code  is_mc6me234 
Empirical formula     C22H23NO5 
Formula weight     381.41 
Temperature      123(2) K 
Wavelength      0.71073 Å 
Crystal system     triclinic 
Space group (H.-M.)    P -1 
Space group (Hall)     -P 1 
Unit cell dimensions  a = 9.0845(2) Å   α = 93.9180(10)° 
     b = 10.1018(2) Å   β = 94.2530(10)° 
     c = 11.4606(2) Å   γ = 113.9650(10)° 
Volume      952.81(3) Å3 
Z       2 
Calculated density     1.329 mg/m3 
Absorption coefficient    0.094 mm-1 
F(000)      404 
Crystal size      0.200 x 0.190 x 0.110 mm 
Θ range for data collection   2.469 to 32.499° 
Index ranges    -13 ≤ h ≤ 13, -15 ≤ k ≤ 15, -17 ≤ l ≤ 17 
Reflections collected    31328 
Independent reflections    6845 [R(int) = 0.0332] 
Absorption correction    Multi-scan 
Max. and min. transmission   0.7464 and 0.7160 
Refinement method    Full-matrix least-squares on F2 
Data/restraints/parameters   4687/0/258 
Goodness-of-fit on F2    1.023 
Final R indices [I>2σ(I)]    R1 = 0.0455, wR2 = 0.1036 
R indices (all data)     R1 = 0.0778, wR2 = 0.1199 
  
 
 
192 
 
Crystal data and structure refinement for compound 5c: 
 
Identification Code    is_mcsr10 
Empirical formula     C27H25NO2 
Formula weight     395.48 
Temperature      123(2) K 
Wavelength      0.71073 Å 
Crystal system     monoclinic 
Space group (H.-M.)    P 21/c 
Space group (Hall)     -P 2ybc 
Unit cell dimensions  a = 11.2788(13) Å   α = 90° 
     b = 7.5335(8) Å   β = 100.062(3)° 
     c = 25.535(3) Å   γ = 90° 
Volume      2136.3(4) Å3 
Z       4 
Calculated density     1.230 mg/m3 
Absorption coefficient    0.077 mm-1 
F(000)      840 
Crystal size      0.320 x 0.070 x 0.050 mm 
Θ range for data collection   2.651 to 25.042° 
Index ranges    -13 ≤ h ≤ 13, -8 ≤ k ≤ 8, -30 ≤ l ≤ 23 
Reflections collected    16778 
Independent reflections    3756 [R(int) = 0.0822] 
Absorption correction    Multi-scan 
Max. and min. transmission   0.7452 and 0.6558 
Refinement method    Full-matrix least-squares on F2 
Data/restraints/parameters   1951/0/274 
Goodness-of-fit on F2    1.016 
Final R indices [I>2σ(I)]    R1 = 0.0561, wR2 = 0.1030 
R indices (all data)     R1 = 0.1415, wR2 = 0.1362 
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Crystal data and structure refinement for compound 6i: 
 
Identification Code     is_mcs1tbu 
Empirical formula      C32H35NO2 
Formula weight      465.61 
Temperature       123(2) K 
Wavelength       0.71073 Å 
Crystal system triclinic 
Space group (H.-M.) P -1 
Space group (Hall) -P 1 
Unit cell dimensions   a = 7.7489(2) Å   α = 83.9050(10)° 
      b = 12.5424(3) Å   β = 80.8950(10)° 
      c = 13.8544(3) Å   γ = 86.0430(10)° 
Volume       1320.15(5) Å3 
Z        2 
Calculated density      1.171 mg/m3 
Absorption coefficient     0.072 mm-1 
F(000)       500 
Crystal size       0.900 x 0.130 x 0.130 mm 
Θ range for data collection    2.321 to 31.000° 
Index ranges     -11 ≤ h ≤ 11, -18 ≤ k ≤ 18, -20 ≤ l ≤ 20 
Reflections collected     41500 
Independent reflections     8425 [R(int) = 0.0271] 
Absorption correction     Multi-scan 
Max. and min. transmission    0.7464 and 0.7145 
Refinement method     Full-matrix least-squares on F2 
Data/restraints/parameters    6204/3/351 
Goodness-of-fit on F2     1.014 
Final R indices [I>2σ(I)]     R1 = 0.0499, wR2 = 0.1274 
R indices (all data)      R1 = 0.0745, wR2 = 0.1463 
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Crystal data and structure refinement for compound 10a: 
 
Identification Code     is_mc_q6m23ome 
Empirical formula      C18H14F3NO2 
Formula weight      333.30 
Temperature       123(2) K 
Wavelength       0.71073 Å 
Crystal system      monoclinic 
Space group (H.-M.)     P 21/c 
Space group (Hall)      -P 2ybc 
Unit cell dimensions    a = 8.4267(6) Å   α = 90° 
       b = 21.8222(13) Å   β= 92.672(4)° 
       c = 16.9030(11) Å   γ = 90° 
Volume       3104.9(4) Å3 
Z        8 
Calculated density      1.426 mg/m3 
Absorption coefficient     0.117 mm-1 
F(000)       1376 
Crystal size       0.420 x 0.160 x 0.070 mm 
Θ range for data collection    2.222 to 28.998° 
Index ranges     -13 ≤ h ≤ 13, -15 ≤ k ≤ 15, -17≤ l ≤ 17 
Reflections collected     8417 
Independent reflections     7714 [R(int) = 0.0456] 
Absorption correction     Multi-scan 
Max. and min. transmission    0.745979 and 0.703927 
Refinement method     Full-matrix least-squares on F2 
Data/restraints/parameters    3625/0/437 
Final R indices [I>2σ(I)]     R1 = 0.0691, wR2 = 0.1091 
R indices (all data)      R1 = 0.1795, wR2 = 0.1307 
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Crystal data and structure refinement for compound 11e: 
 
Identification Code     ah_mc_qme4tbu 
Empirical formula      C23H20F3N 
Formula weight      367.40 
Temperature       123(2) K 
Wavelength       0.71073 Å 
Crystal system      triclinic 
Space group (H.-M.)     P -1 
Space group (Hall)      -P 1 
Unit cell dimensions   a = 8.6097(3) Å   α = 87.457(2)° 
      b = 9.9849(3) Å   β = 85.216(2)° 
      c = 11.4832(4) Å   γ = 70.471(1)° 
Volume       927.00(5) Å3 
Z        2 
Calculated density      1.316 mg/m3 
Absorption coefficient     0.097 mm-1 
F(000)       384 
Crystal size       0.280 x 0.200 x 0.100 mm 
Θ range for data collection    2.164 to 32.495° 
Index ranges    -12 ≤ h ≤ 12, -15 ≤ k ≤ 14, -17 ≤ l ≤ 17 
Reflections collected     29319 
Independent reflections     6674 [R(int) = 0.0321] 
Absorption correction     Multi-scan 
Max. and min. transmission    0.7464 and 0.6933 
Refinement method     Full-matrix least-squares on F2 
Data/restraints/parameters    5272/0/248 
Goodness-of-fit on F2     1.031 
Final R indices [I>2σ(I)]     R1 = 0.0431, wR2 = 0.1175 
R indices (all data)      R1 = 0.0566, wR2 = 0.1282 
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Crystal data and structure refinement for compound 14e: 
 
Identification Code     is_mcme4fpr 
Empirical formula      C14H16F N3O3S 
Formula weight      325.36 
Temperature       123(2) K 
Wavelength       0.71073 Å 
Crystal system      triclinic 
Space group (H.-M.)     P -1 
Space group (Hall )     -P 1 
Unit cell dimensions   a = 7.2249(2) Å   α = 114.1390(10)° 
      b = 10.8280(2) Å   β = 99.738(2)° 
      c = 10.9017(3) Å   γ = 102.4460(10)° 
Volume       727.62(3) Å3 
Z        2 
Calculated density      1.485 mg/m3 
Absorption coefficient     0.250 mm-1 
F(000)       340 
Crystal size       0.260 x 0.100 x 0.090 mm 
Θ range for data collection    3.016 to 31.497° 
Index ranges     -10 ≤ h ≤ 10, -15 ≤ k ≤ 15, -16 ≤ l ≤ 16 
Reflections collected     21574 
Independent reflections     4767 [R(int) = 0.0359] 
Absorption correction     Multi-scan 
Max. and min. transmission    0.7463 and 0.7040 
Refinement method     Full-matrix least-squares on F2 
Data/restraints/parameters    3468/0/207 
Goodness-of-fit on F2     1.011 
Final R indices [I>2σ(I)]     R1 = 0.0426, wR2 = 0.0920 
R indices (all data)      R1 = 0.0709, wR2 = 0.1050 
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List of abbreviations 
Ac Acetyl 
AChE Acetylcholinesterase 
Ar Aryl 
AP Alkaline Phosphatase 
ATR Attenuated total reflection 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
Bn Benzyl 
Bu Butyl 
Cy Cyclohexyl 
Cp Cyclopentyl 
DCM Dichloromethane 
DMA N, N-dimethylacetamide 
DMF N, N-dimethylformamide 
DMSO Dimethylsulphoxide 
DPEphos Bis[(2-diphenylphosphino)phenyl] ether 
dppf 1,1′-Bis(diphenylphosphino)ferrocene 
DNA Deoxyribonucleic acid 
EA Ethyl acetate 
EI Electron ionization 
ESI Electron spray ionization 
Et Ethyl 
Et3N Triethylamine 
EWG Electron withdrawing group 
GS Gas chromatography 
h Hours 
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HRMS High-resolution mass spectroscopy 
Hz Herz 
IC50 Half-maximal inhibitory concentration 
i-Pr Isopropyl 
IR Infrared 
J Coupling constant 
λ Wavelength 
Me Methyl 
MCPBA meta-Chloroperoxybenzoic acid 
min Minutes 
mp Melting point 
MS Mass spectroscopy 
n-BuLi n-Butyllithium 
NMR Nuclear magnetic resonance 
NPP Nucleotide pyrophosphatases/phosphodiesterase 
Ph Phenyl 
R Organic moiety 
t-Bu tert-Butyl 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
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